

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 11 April 2002 (11.04.2002)

PCT

(10) International Publication Number WO 02/29103 A2

(51) International Patent Classification⁷: C12Q 1/68, G06F 19/00

(21) International Application Number: PCT/US01/30589

(22) International Filing Date: 2 October 2001 (02.10.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/237,054

2 October 2000 (02.10.2000) US


- (71) Applicant (for all designated States except US): GENE LOGIC, INC. [US/US]; 708 Quince Orchard Road, Gaithersburg, MD 20878 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): HORNE, Darci

[US/US]; 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). ALVARES, Christopher [US/US]; 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). PERES-DA-SILVA, Supriya [US/US]; 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). VOCKLEY, Joseph, G. [US/US]; 708 Quince Orchard Road, Gaithersburg, MD 20878 (US).

- (74) Agents: CARROLL, Lawrence, J. et al.; Morgan, Lewis & Bockius LLP, 1800 M Street, NW, Washington, DC 20036-5869 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,

[Continued on next page]

(54) Title: GENE EXPRESSION PROFILES IN LIVER CANCER



(57) Abstract: The present invention identifies the global changes in gene expression associated with liver cancer by examining gene expression in tissue from normal liver, metastatic malignant liver and hepatocellular carcinoma. The present invention also identifies expression profiles which serve as useful diagnostic markers as well as markers that can be used to monitor disease states, disease progession, drug toxicity, druge efficacy and drug metabolism.

WO 02/29103 A2

SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, Published: ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

GENE EXPRESSION PROFILES IN LIVER CANCER

INVENTORS

5

25

Darci Horne, Christopher Alvares, Supriya Peres-da-Silva and Joseph Vockley

RELATED APPLICATIONS

This application is related to U.S. Provisional Application 60/211,379, filed on June 14, 2000, and is related to U.S. Provisional Application 60/237,054, filed October 2, 2000, and is related to U.S. Application 09/880,107, filed June 14, 2001, each of which is herein incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

Primary hepatocellular carcinoma (HCC) is a widespread cancer throughout the 10 world, especially prevalent where the incidence of chronic hepatitis B (HBV) and hepatitis C (HCV) viral infections are endemic (Groen, (1999) Semin. Oncol. Nurs. 15, 48-57; Idilman et al., (1998) J. Viral. Hepat. 5, 110-117; Di Bisceglie et al., (1998) Hepatol. 28, 1161-1165; Johnson, (1997) Hepatogastroenerology 44, 307-312; Sheu, (1997) J. Gastroeneterol. Hepatol. 12, S309-313). Hepatocellular carcinomas are very malignant 15 tumors that generally offer a poor prognosis, dependent on the size of the tumor, the effect on normal liver functions, and the involvement of metastases. They are best treated by surgical resection, when the tumors are diagnosed at a stage where this is a viable possibility, but the recurrence rate for these cancers remains high (Johnson, (1997) Hepatogastroenterology 44, 307-312; Schafer & Sorrell, (1999) Lancet 353, 1253-1257; 20 Groen, (1999) Semin. Oncol. Nurs. 15, 48-57; Sitzman, (1995) World. J. Surg. 19, 790-794; DiCarlo, (1995) Hepato-Gastroenterol. 42, 222-259; Tanaka et al., (1996) Hepato-Gastroenterol. 43, 1172-1181; El-Assal et al., (1997) Surgery 122, 571-577).

Numerous risk factors for the development of HCC have been identified: cirrhosis, HBV or HCV infection, being male, alcohol-related liver disease, exposure to aflatoxins, vinyl chloride and radioactive thorium dioxide, cigarette smoking, ingestion of inorganic arsenic, the use of oral contraceptives and anabolic steroids, iron accumulation, and various inherited metabolic disorders (hemochromatosis, glycogen storage disease, porphyria,

5

10

WO 02/29103 PCT/US01/30589

-2-

tyrosinemia, α-1-antitrypsin deficiency) (Di Bisceglie *et al.*, (1998) Hepatol. 28, 1161-1165; Chen *et al.*, (1997) J. Gastroenterol. Hepatol. 12, S294-308; Schafer & Sorrell (1999) Lancet 353, 1253-1257; Groen, (1999) Semin. Oncol. Nurs. 15, 48-57; Idilman *et al.*, (1998) J. Viral. Hepat. 5, 110-117; Johnson, (1997) Hepato-Gastroenterol. 44, 307-312).

In addition to liver tumors attributed to hepatocellular carcinoma, there are liver tumors that arise as metastases from primary tumors in other parts of the body. These tumors most often metastasize from the gastrointestinal organs, primarily the colon and rectum, but it is possible for metastatic liver cancers to occur from primary cancers throughout the body (Sitzman, (1990) Hepatic Neoplasia, in Bayless (editor) Current Therapy in Gastroenterology and Liver Disease, Marcel Dekker; Groen, (1999) Semin. Oncol. Nurs. 15, 48-57). These cancers can be treated using the routine therapies such as chemotherapy, radiotherapy, surgical resection, liver transplantation, chemoembolization, cryosurgery, or a combination of therapies (Sitzman 1990, Groen 1999).

The characterization of genes that are differentially expressed in tumorigenesis is an 15 important step in identifying those that are intimately involved in the details of a cell's transformation from normal to cancerous. Little is known about the molecular changes that take place in the liver during the course of tumor progression. While changes in the expression level of individual genes has been reported, for example, galectin-3 (Hsu et al., (1999) Int. J. Cancer 81: 519-526; Iurisci et al., (2000) Clin. Cancer Res. 6: 1389-1393; Nakamura et al., (1999) Int. J. Oncol. 15: 143-148) and pancreatic secretory trypsin 20 inhibitor (PTSI, Ohmachi et al., (1994) Int. J. Cancer 55: 728-734) the investigation of the global changes in gene expression which occur in liver have not been documented. The identification of genes that are expressed in tumor tissue at differing levels, but not expressed at any level in normal liver tissue will be very valuable for monitoring tumor 25 progression. The identification of genes and ESTs that are expressed in both types of tumors, i. e., primary hepatocellular carcinomas as well as metastatic tumors of a different origin, and not in normal liver cells would be extremely valuable for the diagnosis of liver cancer. Thus there exists a need in the art for the identification of new genes and ESTs to serve as molecular markers to monitor the onset and development of liver cancer. These 30 and other needs are met by the present invention.

SUMMARY OF THE INVENTION

WO 02/29103 PCT/US01/30589
-3-

The present invention identifies the global changes in gene expression associated with liver cancer by examining gene expression in tissue from normal liver, metastatic malignant liver and hepatocellular carcinoma. The present invention also identifies expression profiles which serve as useful diagnostic markers as well as markers that can be used to monitor disease states, disease progression, drug toxicity, drug efficacy and drug metabolism.

5

10

15

20

25

30

The invention includes methods of diagnosing the presence or absence of liver cancer in a patient comprising the step of detecting the level of expression in a tissue sample of two or more genes from Tables 3-9; wherein differential expression of the genes in Tables 3-9 is indicative of liver cancer. In some preferred embodiments, one or more genes may be selected from a group consisting of the genes listed in Tables 3-5. In some preferred embodiments, the method may include detecting the expression level of one or more genes selected from a group consisting Tetraspan NET-6 protein; collagen, type V, alpha; and glypican 3.

The invention also includes methods of detecting the progression of liver cancer and/or differentiating nonmetastatic from metastatic disease. For instance, methods of the invention include detecting the progression of liver cancer in a patient comprising the step of detecting the level of expression in a tissue sample of two or more genes from 3-9; wherein differential expression of the genes in Tables 3-9 is indicative of liver cancer progression. In some preferred embodiments, one or more genes may be selected from a group consisting of the genes listed in Tables 3-5.

In some aspects, the present invention provides a method of monitoring the treatment of a patient with liver cancer, comprising administering a pharmaceutical composition to the patient and preparing a gene expression profile from a cell or tissue sample from the patient and comparing the patient gene expression profile to a gene expression from a cell population comprising normal liver cells or to a gene expression profile from a cell population comprising liver cancer cells or to both. In some preferred embodiments, the gene profile will include the expression level of one or more genes in Tables 3-9. In other preferred embodiments, one or more genes may be selected from a group consisting of the genes listed in Tables 3-5.

In another aspect, the present invention provides a method of treating a patient with liver cancer, comprising administering to the patient a pharmaceutical composition, wherein

-4-

the composition alters the expression of at least one gene in Tables 3-9, preparing a gene expression profile from a cell or tissue sample from the patient comprising tumor cells and comparing the patient expression profile to a gene expression profile from an untreated cell population comprising liver cancer cells. In some preferred embodiments, one or more genes may be selected from a group consisting of the genes listed in Tables 3-5.

5

10

15

20

25

30

In one aspect, the present invention provides a method of diagnosing hepatocellular carcinoma in a patient, comprising detecting the level of expression in a tissue sample of two or more genes from Tables 3-9, wherein differential expression of the genes in Tables 3-9 is indicative of hepatocellular carcinoma. In some preferred embodiments, one or more genes may be selected from a group consisting of the genes listed in Tables 3 or 5.

In another aspect, the present invention provides a method of detecting the progression of hepatocellular carcinoma in a patient, comprising detecting the level of expression in a tissue sample of two or more genes from Tables 3-9; wherein differential expression of the genes in Tables 3-9 is indicative of hepatocellular carcinoma progression. In some preferred embodiments, one or more genes may be selected from a group consisting of the genes listed in Tables 3 or 5.

The present invention also provides materials and methods for monitoring the treatment of a patient with a hepatocellular caricnoma. The present invention provides a method of monitoring the treatment of a patient with hepatocellular carcinoma, comprising administering a pharmaceutical composition to the patient, preparing a gene expression profile from a cell or tissue sample from the patient and comparing the patient gene expression profile to a gene expression from a cell population comprising normal liver cells or to a gene expression profile from a cell population comprising hepatocellular carcinoma cells or to both. In some preferred embodiments, the method may include detecting the level of expression of one or more genes from the genes listed in Tables 3-9. In some preferred embodiments, one or more genes may be selected from a group consisting of the genes listed in Tables 3 or 5.

In a related aspect, the present invention provides a method of treating a patient with hepatocellular carcinoma, comprising administering to the patient a pharmaceutical composition, wherein the composition alters the expression of at least one gene in Tables 3-9, preparing a gene expression profile from a cell or tissue sample from the patient comprising hepatocellular carcinoma cells and comparing the patient expression profile to a

-5-

gene expression profile from an untreated cell population comprising hepatocellular carcinoma cells. In some preferred embodiments, one or more genes may be selected from a group consisting of the genes listed in Tables 3 or 5.

The present invention provides a method of diagnosing a metastatic liver tumor in a patient, comprising detecting the level of expression in a tissue sample of two or more genes from Tables 3-9, wherein differential expression of the genes in Tables 3-9 is indicative of a metastatic liver tumor. In some preferred embodiments, one or more genes may be selected from a group consisting of the genes listed in Tables 4 or 5.

5

10

15

20

25

30

The present invention provides a method of detecting the progression of a metastatic liver tumor in a patient, comprising detecting the level of expression in a tissue sample of two or more genes from Tables 3-9, wherein differential expression of the genes in Tables 3-9 is indicative of a metastatic liver tumor progression. In some preferred embodiments, one or more genes may be selected from a group consisting of the genes listed in Tables 4 or 5.

In a related aspect, the present invention provides a method of monitoring the treatment of a patient with a metastatic liver tumor, comprising administering a pharmaceutical composition to the patient, preparing a gene expression profile from a cell or tissue sample from the patient and comparing the patient gene expression profile to a gene expression from a cell population comprising normal liver cells or to a gene expression profile from a cell population comprising metastatic liver tumor cells or to both. In some preferred embodiments, the method of the present invention may include detecting the expression level of one or more genes selected from the genes listed in Tables 3-9. In some preferred embodiments, one or more genes may be selected from a group consisting of the genes listed in Tables 4 or 5.

In some preferred embodiments, the present invention provides a method of treating a patient with a metastatic liver tumor, comprising administering to the patient a pharmaceutical composition, wherein the composition alters the expression of at least one gene in Tables 3-9, preparing a gene expression profile from a cell or tissue sample from the patient comprising metastatic liver tumor cells and comparing the patient expression profile to a gene expression profile from an untreated cell population comprising metastatic liver tumor cells. In some preferred embodiments, one or more genes may be selected from a group consisting of the genes listed in Tables 4 or 5.

WO 02/29103 PCT/US01/30589
-6-

The invention also includes methods of differentiating metastatic liver cancer from hepatocellular carcinoma in a patient comprising the step of detecting the level of expression in a tissue sample of two or more genes from Tables 3-9; wherein differential expression of the genes in Tables 3-9 is indicative of metastatic liver cancer rather than hepatocellular carcinoma.

5

10

15

20

25

30

The invention further includes methods of screening for an agent capable of modulating the onset or progression of liver cancer, comprising the steps of exposing a cell to the agent; and detecting the expression level of two or more genes from Tables 3-9. In some preferred embodiments, one or more genes may be selected from a group consisting of the genes listed in Tables 3-5.

Any of the methods of the invention described above may include the detection of at least 2 genes from the tables. Preferred methods may detect all or nearly all of the genes in the tables. In some preferred embodiments, one or more genes may be selected from a group consisting of the genes listed in Tables 3-5.

The invention further includes compositions comprising at least two oligonucleotides, wherein each of the oligonucleotides comprises a sequence that specifically hybridizes to a gene in Tables 3-9 as well as solid supports comprising at least two probes, wherein each of the probes comprises a sequence that specifically hybridizes to a gene in Tables 3-9. In some preferred embodiments, one or more genes may be selected from a group consisting of the genes listed in Tables 3-5.

The invention further includes computer systems comprising a database containing information identifying the expression level in liver tissue of a set of genes comprising at least two genes in Tables 3-9; and a user interface to view the information. In some preferred embodiments, one or more genes may be selected from a group consisting of the genes listed in Tables 3-5. The database may further include sequence information for the genes, information identifying the expression level for the set of genes in normal liver tissue and malignant tissue (metastatic and nonmetastatic) and may contain links to external databases such as GenBank.

Lastly, the invention includes methods of using the databases, such as methods of using the disclosed computer systems to present information identifying the expression level in a tissue or cell of at least one gene in Tables 3-9, comprising the step of comparing the expression level of at least one gene in Tables 3-9 in the tissue or cell to the level of

-7-

expression of the gene in the database. In some preferred embodiments, one or more genes may be selected from a group consisting of the genes listed in Tables 3-5.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a flow chart showing a schematic representation of the experimental protocol.

Figures 2A-2C are graphs of the number of genes present in all samples as a function of the number of samples for the second sample set.

10 DETAILED DESCRIPTION

15

20

25

30

Many biological functions are accomplished by altering the expression of various genes through transcriptional (e.g., through control of initiation, provision of RNA precursors, RNA processing, etc.) and/or translational control. For example, fundamental biological processes such as cell cycle, cell differentiation and cell death, are often characterized by the variations in the expression levels of groups of genes.

Changes in gene expression also are associated with pathogenesis. For example, the lack of sufficient expression of functional tumor suppressor genes and/or the over expression of oncogene/protooncogenes could lead to tumorgenesis or hyperplastic growth of cells (Marshall, (1991) Cell, 64, 313-326; Weinberg, (1991) Science, 254, 1138-1146). Thus, changes in the expression levels of particular genes (e.g., oncogenes or tumor suppressors) serve as signposts for the presence and progression of various diseases.

Monitoring changes in gene expression may also provide certain advantages during drug screening development. Often drugs are screened and prescreened for the ability to interact with a major target without regard to other effects the drugs have on cells. Often such other effects cause toxicity in the whole animal, which prevent the development and use of the potential drug.

The present inventors have examined tissue samples from normal liver, metastatic malignant liver and hepatocellular carcinoma to identify the global changes in gene expression associated with liver cancer. The protocol used is schematically represented in Figure 1. These global changes in gene expression, also referred to as expression profiles, provide useful markers for diagnostic uses as well as markers that can be used to monitor disease states, disease progression, drug toxicity, drug efficacy and drug metabolism.

Definitions

5

10

15

20

25

30

In the description that follows, numerous terms and phrases known to those skilled in the art are used. In the interests of clarity and consistency of interpretation, the definitions of certain terms and phrases are provided.

The present invention provides compositions and methods to detect the level of expression of genes that may be differentially expressed dependent upon the state of the cell, *i.e.*, normal versus cancerous. As used herein, the phrase "detecting the level of expression" includes methods that quantitate expression levels as well as methods that determine whether a gene of interest is expressed at all. Thus, an assay which provides a yes or no result without necessarily providing quantification of an amount of expression is an assay that requires "detecting the level of expression" as that phrase is used herein.

As used herein, oligonucleotide sequences that are complementary to one or more of the genes described herein, refers to oligonucleotides that are capable of hybridizing under stringent conditions to at least part of the nucleotide sequence of said genes. Such hybridizable oligonucleotides will typically exhibit at least about 75% sequence identity at the nucleotide level to said genes, preferably about 80% or 85% sequence identity or more preferably about 90% or 95% or more sequence identity to said genes.

"Bind(s) substantially" refers to complementary hybridization between a probe nucleic acid and a target nucleic acid and embraces minor mismatches that can be accommodated by reducing the stringency of the hybridization media to achieve the desired detection of the target polynucleotide sequence.

The terms "background" or "background signal intensity" refer to hybridization signals resulting from non-specific binding, or other interactions, between the labeled target nucleic acids and components of the oligonucleotide array (e.g., the oligonucleotide probes, control probes, the array substrate, etc.). Background signals may also be produced by intrinsic fluorescence of the array components themselves. A single background signal can be calculated for the entire array, or a different background signal may be calculated for each target nucleic acid. In a preferred embodiment, background is calculated as the average hybridization signal intensity for the lowest 5% to 10% of the probes in the array, or, where a different background signal is calculated for each target gene, for the lowest 5% to 10% of the probes for each gene. Of course, one of skill in the art will appreciate that

-9-

where the probes to a particular gene hybridize well and thus appear to be specifically binding to a target sequence, they should not be used in a background signal calculation. Alternatively, background may be calculated as the average hybridization signal intensity produced by hybridization to probes that are not complementary to any sequence found in the sample (e.g., probes directed to nucleic acids of the opposite sense or to genes not found in the sample such as bacterial genes where the sample is mammalian nucleic acids). Background can also be calculated as the average signal intensity produced by regions of the array that lack any probes at all.

The phrase "hybridizing specifically to" refers to the binding, duplexing or hybridizing of a molecule substantially to or only to a particular nucleotide sequence or sequences under stringent conditions when that sequence is present in a complex mixture (e.g., total cellular) DNA or RNA.

10

15

20

25

30

The term "mismatch control" or "mismatch probe" refer to a probe whose sequence is deliberately selected not to be perfectly complementary to a particular target sequence. For each mismatch (MM) control in a high-density array there typically exists a corresponding perfect match (PM) probe that is perfectly complementary to the same particular target sequence. The mismatch may comprise one or more bases.

While the mismatch(s) may be located anywhere in the mismatch probe, terminal mismatches are less desirable as a terminal mismatch is less likely to prevent hybridization of the target sequence. In a particularly preferred embodiment, the mismatch is located at or near the center of the probe such that the mismatch is most likely to destabilize the duplex with the target sequence under the test hybridization conditions.

The term "perfect match probe" refers to a probe that has a sequence that is perfectly complementary to a particular target sequence. The test probe is typically perfectly complementary to a portion (subsequence) of the target sequence. The perfect match (PM) probe can be a "test probe", a "normalization control" probe, an expression level control probe and the like. A perfect match control or perfect match probe is, however, distinguished from a "mismatch control" or "mismatch probe."

As used herein a "probe" is defined as a nucleic acid, capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e., A, G, U, C or T) or modified bases (7-

-10-

deazaguanosine, inosine, etc.). In addition, the bases in probes may be joined by a linkage other than a phosphodiester bond, so long as it does not interfere with hybridization. Thus, probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages.

5

10

15

20

25

30

The term "stringent conditions" refers to conditions under which a probe will hybridize to its target subsequence, but with only insubstantial hybridization to other sequences or to other sequences such that the difference may be identified. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH.

Typically, stringent conditions will be those in which the salt concentration is at least about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotide). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.

The "percentage of sequence identity" or "sequence identity" is determined by comparing two optimally aligned sequences or subsequences over a comparison window or span, wherein the portion of the polynucleotide sequence in the comparison window may optionally comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical monomer unit (e.g., nucleic acid base or amino acid residue) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Percentage sequence identity when calculated using the programs GAP or BESTFIT (see below) is calculated using default gap weights.

Homology or identity may be determined by BLAST (Basic Local Alignment Search Tool) analysis using the algorithm employed by the programs blastp, blastn, blastx, tblastn and tblastx (Karlin et al., (1990) Proc. Natl. Acad. Sci. USA 87, 2264-2268 and Altschul, (1993) J. Mol. Evol. 36, 290-300, fully incorporated by reference) which are

-11-

tailored for sequence similarity searching. The approach used by the BLAST program is to first consider similar segments between a query sequence and a database sequence, then to evaluate the statistical significance of all matches that are identified and finally to summarize only those matches which satisfy a preselected threshold of significance. For a discussion of basic issues in similarity searching of sequence databases, see Altschul et al., (1994) Nature Genet. 6, 119-129) which is fully incorporated by reference. The search parameters for histogram, descriptions, alignments, expect (i.e., the statistical significance threshold for reporting matches against database sequences), cutoff, matrix and filter are at the default settings. The default scoring matrix used by blastp, blastx, tblastn, and tblastx is the BLOSUM62 matrix (Henikoff et al., (1992) Proc. Natl. Acad. Sci. USA 89, 10915-10919, fully incorporated by reference). Four blastn parameters were adjusted as follows: Q=10 (gap creation penalty); R=10 (gap extension penalty); wink=1 (generates word hits at every winkth position along the query); and gapw=16 (sets the window width within which gapped alignments are generated). The equivalent Blastp parameter settings were Q=9; R=2; wink=1; and gapw=32. A Bestfit comparison between sequences, available in the GCG package version 10.0, uses DNA parameters GAP=50 (gap creation penalty) and LEN=3 (gap extension penalty) and the equivalent settings in protein comparisons are GAP=8 and LEN=2.

20 Uses for the Liver Cancer Markers as Diagnostics

10

15

25

30

As described herein, the genes and gene expression information provided in Tables 3-9 may be used as diagnostic markers for the prediction or identification of the malignant state of the liver tissue. For instance, a liver tissue sample or other sample from a patient may be assayed by any of the methods described herein or by any other method known to those skilled in the art, and the expression levels from a gene or genes from the Tables, in particular the genes in Tables 3-5, may be compared to the expression levels found in normal liver tissue, tissue from metastatic liver cancer or hepatocellular carcinoma tissue. Expression profiles generated from the tissue or other sample that substantially resemble an expression profile from normal or diseased liver tissue may be used, for instance, to aid in disease diagnosis. Comparison of the expression data, as well as available sequence or other information may be done by researcher or diagnostician or may be done with the aid of a computer and databases as described above.

5

10

15

20

25

30

Use of the Liver Cancer Markers for Monitoring Disease Progression

As described above, the genes and gene expression information provided in Tables 3-9 may also be used as markers for the monitoring of disease progression, for instance, the development of liver cancer. For instance, a liver tissue sample or other sample from a patient may be assayed by any of the methods described above, and the expression levels in the sample from a gene or genes from or 3-9 may be compared to the expression levels found in normal liver tissue, tissue from metastatic liver cancer or hepatocellular carcinoma tissue. Comparison of the expression data, as well as available sequence or other information may be done by researcher or diagnostician or may be done with the aid of a computer and databases as described above.

Use of the Liver Cancer Markers for Drug Screening

According to the present invention, the genes identified in Tables 3-9 may be used as markers to evaluate the effects of a candidate drug or agent on a cell, particularly a cell undergoing malignant transformation, for instance, a liver cancer cell or tissue sample. A candidate drug or agent can be screened for the ability to stimulate the transcription or expression of a given marker or markers (drug targets) or to down-regulate or counteract the transcription or expression of a marker or markers. According to the present invention, one can also compare the specificity of drugs' effects by looking at the number of markers affected by different drugs and comparing them. More specific drugs will affect fewer transcriptional targets. Similar sets of markers identified for two drugs indicates a similarity of effects.

Agents that are assayed in the above methods can be randomly selected or rationally selected or designed. As used herein, an agent is said to be randomly selected when the agent is chosen randomly without considering the specific sequences involved in the association of the a protein of the invention alone or with its associated substrates, binding partners, etc. An example of randomly selected agents is the use a chemical library or a peptide combinatorial library, or a growth broth of an organism.

As used herein, an agent is said to be rationally selected or designed when the agent is chosen on a nonrandom basis which takes into account the sequence of the target site and/or its conformation in connection with the agents action. Agents can be rationally

-13-

selected or rationally designed by utilizing the peptide sequences that make up these sites. For example, a rationally selected peptide agent can be a peptide whose amino acid sequence is identical to or a derivative of any functional consensus site.

The agents of the present invention can be, as examples, peptides, small molecules, vitamin derivatives, as well as carbohydrates. Dominant negative proteins, DNA encoding these proteins, antibodies to these proteins, peptide fragments of these proteins or mimics of these proteins may be introduced into cells to affect function. "Mimic" as used herein refers to the modification of a region or several regions of a peptide molecule to provide a structure chemically different from the parent peptide but topographically and functionally similar to the parent peptide (see Grant, (1995) in Molecular Biology and Biotechnology Meyers (editor) VCH Publishers). A skilled artisan can readily recognize that there is no limit as to the structural nature of the agents of the present invention.

Assay Formats

5

10

15

20

25

30

The genes identified as being differentially expressed in liver cancer may be used in a variety of nucleic acid detection assays to detect or quantititate the expression level of a gene or multiple genes in a given sample. Any hybridization assay format may be used, including solution-based and solid support-based assay formats, for example, traditional Northern blotting. Other suitable assay formats that may be used for detecting gene expression levels include, but are not limited to, nuclease protection, RT-PCR and differential display methods. These methods are useful for some embodiments of the invention; however, methods and assays of the invention are most efficiently designed with array or chip hybridization-based methods for detecting the expression of a large number of genes. Assays and methods of the invention may utilize available formats to simultaneously screen at least about 100, preferably about 1000, more preferably about 10,000 and most preferably about 1,000,000 or more different nucleic acid hybridizations.

Assays to monitor the expression of a marker or markers as defined in Tables 3-9 may utilize any available means of monitoring for changes in the expression level of the nucleic acids of the invention. As used herein, an agent is said to modulate the expression of a nucleic acid of the invention if it is capable of up- or down-regulating expression of the nucleic acid in a cell.

In one assay format, gene chips containing probes to at least two genes from Tables

-14-

3-9 may be used to directly monitor or detect changes in gene expression in the treated or exposed cell as described in more detail above. In another format, cell lines that contain reporter gene fusions between the open reading frame and/or the 3' or 5' regulatory regions of a gene in Tables 3-9 and any assayable fusion partner may be prepared. Numerous assayable fusion partners are known and readily available including the firefly luciferase gene and the gene encoding chloramphenicol acetyltransferase (Alam *et al.*, (1990) Anal. Biochem. 188, 245-254). Cell lines containing the reporter gene fusions are then exposed to the agent to be tested under appropriate conditions and time. Differential expression of the reporter gene between samples exposed to the agent and control samples identifies agents which modulate the expression of the nucleic acid.

5

10

15

20

25

30

Additional assay formats may be used to monitor the ability of the agent to modulate the expression of one or more genes identified in Tables 3-9. For instance, as described above, mRNA expression may be monitored directly by hybridization of probes to the nucleic acids of the invention. Cell lines are exposed to the agent to be tested under appropriate conditions and time and total RNA or mRNA is isolated by standard procedures such those disclosed in Sambrook *et al.*, (1989) Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratory Press).

In another assay format, cells or cell lines are first identified which express the gene products of the invention physiologically. Cell and/or cell lines so identified would be expected to comprise the necessary cellular machinery such that the fidelity of modulation of the transcriptional apparatus is maintained with regard to exogenous contact of agent with appropriate surface transduction mechanisms and/or the cytosolic cascades. Such cell lines may be, but are not required to be, derived from liver tissue. Further, such cells or cell lines may be transduced or transfected with an expression vehicle (e.g., a plasmid or viral vector) construct comprising an operable non-translated 5'-promoter containing end of the structural gene encoding the instant gene products fused to one or more antigenic fragments, which are peculiar to the instant gene products, wherein said fragments are under the transcriptional control of said promoter and are expressed as polypeptides whose molecular weight can be distinguished from the naturally occurring polypeptides or may further comprise an immunologically distinct tag. Such a process is well known in the art (see Sambrook et al., (1989) Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratory Press).

5

10

15

20

25

30

ı

Cells or cell lines transduced or transfected as outlined above are then contacted with agents under appropriate conditions; for example, the agent comprises a pharmaceutically acceptable excipient and is contacted with cells comprised in an aqueous physiological buffer such as phosphate buffered saline (PBS) at physiological pH, Eagles balanced salt solution (BSS) at physiological pH, PBS or BSS comprising serum or conditioned media comprising PBS or BSS and serum incubated at 37°C. Said conditions may be modulated as deemed necessary by one of skill in the art. Subsequent to contacting the cells with the agent, said cells will be disrupted and the polypeptides of the lysate are fractionated such that a polypeptide fraction is pooled and contacted with an antibody to be further processed by immunological assay (e.g., ELISA, immunoprecipitation or Western blot). The pool of proteins isolated from the "agent-contacted" sample will be compared with a control sample where only the excipient is contacted with the cells and an increase or decrease in the immunologically generated signal from the "agent-contacted" sample compared to the control will be used to distinguish the effectiveness of the agent.

Another embodiment of the present invention provides methods for identifying agents that modulate the levels, concentration or at least one activity of a protein(s) encoded by the genes in Tables 3-9. Such methods or assays may utilize any means of monitoring or detecting the desired activity.

In one format, the relative amounts of a protein of the invention between a cell population that has been exposed to the agent to be tested compared to an un-exposed control cell population may be assayed. In this format, probes such as specific antibodies are used to monitor the differential expression of the protein in the different cell populations. Cell lines or populations are exposed to the agent to be tested under appropriate conditions and time. Cellular lysates may be prepared from the exposed cell line or population and a control, unexposed cell line or population. The cellular lysates are then analyzed with the probe, such as a specific antibody.

The genes which are assayed according to the present invention are typically in the form of mRNA or reverse transcribed mRNA. The genes may be cloned or not and the genes may be amplified or not. The cloning itself does not appear to bias the representation of genes within a population. However, it may be preferable to use polyA+RNA as a source, as it can be used with less processing steps.

-16-

The sequences of the expression marker genes are in the public databases. Tables 3-9 provide the Affymetrix gene ID and GenBank accession number for each marker identified. The nucleotide sequence for each marker has been provided in electronic format with this application and these sequences are incorporated herein by reference as are equivalent and related sequences present in the public databases.

Probes based on the sequences of the genes described herein may be prepared by any commonly available method. Oligonucleotide probes for assaying the tissue or cell sample are preferably of sufficient length to specifically hybridize only to appropriate, complementary genes or transcripts. Typically the oligonucleotide probes will be at least 10, 12, 14, 16, 18, 20 or 25 nucleotides in length. In some cases longer probes of at least 30, 40, or 50 nucleotides will be desirable.

Probe design

5

15

20

25

30

One of skill in the art will appreciate that an enormous number of array designs are suitable for the practice of this invention. The high density array will typically include a number of probes that specifically hybridize to the sequences of interest. See WO 99/32660 for methods of producing probes for a given gene or genes. In addition, in a preferred embodiment, the array will include one or more control probes.

High density array chips of the invention include "test probes." Test probes may be oligonucleotides that range from about 5 to about 500 or about 5 to about 50 nucleotides, more preferably from about 10 to about 40 nucleotides and most preferably from about 15 to about 40 nucleotides in length. In other particularly preferred embodiments the probes are about 20 or 25 nucleotides in length. In another preferred embodiment, test probes are double or single strand DNA sequences. DNA sequences are isolated or cloned from natural sources or amplified from natural sources using natural nucleic acid as templates. These probes have sequences complementary to particular subsequences of the genes whose expression they are designed to detect. Thus, the test probes are capable of specifically hybridizing to the target nucleic acid they are to detect.

In addition to test probes that bind the target nucleic acid(s) of interest, the high density array can contain a number of control probes. The control probes fall into three categories referred to herein as (1) normalization controls; (2) expression level controls; and (3) mismatch controls.

Normalization controls are oligonucleotide or other nucleic acid probes that are complementary to labeled reference oligonucleotides or other nucleic acid sequences that are added to the nucleic acid sample. The signals obtained from the normalization controls after hybridization provide a control for variations in hybridization conditions, label intensity, "reading" efficiency and other factors that may cause the signal of a perfect hybridization to vary between arrays. In a preferred embodiment, signals (e.g., fluorescence intensity) read from all other probes in the array are divided by the signal (e.g., fluorescence intensity) from the control probes thereby normalizing the measurements.

5

10

15

20

25

30

Virtually any probe may serve as a normalization control. However, it is recognized that hybridization efficiency varies with base composition and probe length. Preferred normalization probes are selected to reflect the average length of the other probes present in the array, however, they can be selected to cover a range of lengths. The normalization control(s) can also be selected to reflect the (average) base composition of the other probes in the array, however in a preferred embodiment, only one or a few probes are used and they are selected such that they hybridize well (i.e., no secondary structure) and do not match any target-specific probes.

Expression level controls are probes that hybridize specifically with constitutively expressed genes in the biological sample. Virtually any constitutively expressed gene provides a suitable target for expression level controls. Typical expression level control probes have sequences complementary to subsequences of constitutively expressed "housekeeping genes" including, but not limited to the β-actin gene, the transferrin receptor gene, the GAPDH gene, and the like.

Mismatch controls may also be provided for the probes to the target genes, for expression level controls or for normalization controls. Mismatch controls are oligonucleotide probes or other nucleic acid probes identical to their corresponding test or control probes except for the presence of one or more mismatched bases. A mismatched base is a base selected so that it is not complementary to the corresponding base in the target sequence to which the probe would otherwise specifically hybridize. One or more mismatches are selected such that under appropriate hybridization conditions (e.g., stringent conditions) the test or control probe would be expected to hybridize with its target sequence, but the mismatch probe would not hybridize (or would hybridize to a significantly lesser extent). Preferred mismatch probes contain a central mismatch. Thus, for example, where a

5

10

15

20

25

30

probe is a twenty-mer, a corresponding mismatch probe will have the identical sequence except for a single base mismatch (e.g., substituting a G, a C or a T for an A) at any of positions 6 through 14 (the central mismatch).

Mismatch probes thus provide a control for non-specific binding or cross hybridization to a nucleic acid in the sample other than the target to which the probe is directed. Mismatch probes also indicate whether a hybridization is specific or not. For example, if the target is present the perfect match probes should be consistently brighter than the mismatch probes. In addition, if all central mismatches are present, the mismatch probes can be used to detect a mutation. The difference in intensity between the perfect match and the mismatch probe (I(PM) - I(MM)) provides a good measure of the concentration of the hybridized material.

Nucleic Acid Samples

As is apparent to one of ordinary skill in the art, nucleic acid samples used in the methods and assays of the invention may be prepared by any available method or process. Methods of isolating total mRNA are also well known to those of skill in the art. For example, methods of isolation and purification of nucleic acids are described in detail in Chapter 3 of Laboratory Techniques in Biochemistry and Molecular Biology: Hybridization With Nucleic Acid Probes, Part I Theory and Nucleic Acid Preparation, Tijssen, (1993) (editor) Elsevier Press. Such samples include RNA samples, but also include cDNA synthesized from a mRNA sample isolated from a cell or tissue of interest. Such samples also include DNA amplified from the cDNA, and an RNA transcribed from the amplified DNA. One of skill in the art would appreciate that it is desirable to inhibit or destroy RNase present in homogenates before homogenates can be used.

Biological samples may be of any biological tissue or fluid or cells from any organism as well as cells raised *in vitro*, such as cell lines and tissue culture cells. Frequently the sample will be a "clinical sample" which is a sample derived from a patient. Typical clinical samples include, but are not limited to, sputum, blood, blood-cells (e.g., white cells), tissue or fine needle biopsy samples, urine, peritoneal fluid, and pleural fluid, or cells therefrom.

Biological samples may also include sections of tissues, such as frozen sections or formalin fixed sections taken for histological purposes.

Solid Supports

5

10

15

20

25

30

Solid supports containing oligonucleotide probes for differentially expressed genes of the invention can be filters, polyvinyl chloride dishes, silicon or glass based chips, etc. Such wafers and hybridization methods are widely available, for example, those disclosed by Beattie (WO 95/11755). Any solid surface to which oligonucleotides can be bound, either directly or indirectly, either covalently or non-covalently, can be used. A preferred solid support is a high density array or DNA chip. These contain a particular oligonucleotide probe in a predetermined location on the array. Each predetermined location may contain more than one molecule of the probe, but each molecule within the predetermined location has an identical sequence. Such predetermined locations are termed features. There may be, for example, about 2, 10, 100, 1000 to 10,000; 100,000 or 400,000 of such features on a single solid support. The solid support, or the area within which the probes are attached may be on the order of a square centimeter.

Oligonucleotide probe arrays for expression monitoring can be made and used according to any techniques known in the art (see for example, Lockhart *et al.*, (1996) Nat. Biotechnol. 14, 1675-1680; McGall *et al.*, (1996) Proc. Nat. Acad. Sci. USA 93, 13555-13460). Such probe arrays may contain at least two or more oligonucleotides that are complementary to or hybridize to two or more of the genes described herein. Such arrays may also contain oligonucleotides that are complementary or hybridize to at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50, 70, 100 or or more the genes described herein.

Methods of forming high density arrays of oligonucleotides with a minimal number of synthetic steps are known. The oligonucleotide analogue array can be synthesized on a solid substrate by a variety of methods, including, but not limited to, light-directed chemical coupling, and mechanically directed coupling (see Pirrung et al., (1992) U.S. Patent No. 5,143, 854; Fodor et al., (1998) U.S. Patent No. 5,800,992; Chee et al., (1998) 5,837,832.

In brief, the light-directed combinatorial synthesis of oligonucleotide arrays on a glass surface proceeds using automated phosphoramidite chemistry and chip masking techniques. In one specific implementation, a glass surface is derivatized with a silane reagent containing a functional group, e.g., a hydroxyl or amine group blocked by a photolabile protecting group. Photolysis through a photolithogaphic mask is used selectively to expose functional groups which are then ready to react with incoming 5'

-20-

photoprotected nucleoside phosphoramidites. The phosphoramidites react only with those sites which are illuminated (and thus exposed by removal of the photolabile blocking group). Thus, the phosphoramidites only add to those areas selectively exposed from the preceding step. These steps are repeated until the desired array of sequences have been synthesized on the solid surface. Combinatorial synthesis of different oligonucleotide analogues at different locations on the array is determined by the pattern of illumination

during synthesis and the order of addition of coupling reagents.

In addition to the foregoing, additional methods which can be used to generate an array of oligonucleotides on a single substrate are described in Fodor *et al.*, (1993). WO 93/09668. High density nucleic acid arrays can also be fabricated by depositing premade or natural nucleic acids in predetermined positions. Synthesized or natural nucleic acids are deposited on specific locations of a substrate by light directed targeting and oligonucleotide directed targeting. Another embodiment uses a dispenser that moves from region to region to deposit nucleic acids in specific spots.

15

20

25

30

10

Hybridization

Nucleic acid hybridization simply involves contacting a probe and target nucleic acid under conditions where the probe and its complementary target can form stable hybrid duplexes through complementary base pairing (see Lockhart et al., (1999) WO 99/32660). The nucleic acids that do not form hybrid duplexes are then washed away leaving the hybridized nucleic acids to be detected, typically through detection of an attached detectable label. It is generally recognized that nucleic acids are denatured by increasing the temperature or decreasing the salt concentration of the buffer containing the nucleic acids.

Under low stringency conditions (e.g., low temperature and/or high salt) hybrid duplexes (e.g., DNA-DNA, RNA-RNA or RNA-DNA) will form even where the annealed sequences are not perfectly complementary.

Thus specificity of hybridization is reduced at lower stringency. Conversely, at higher stringency (e.g., higher temperature or lower salt) successful hybridization requires fewer mismatches. One of skill in the art will appreciate that hybridization conditions may be selected to provide any degree of stringency. In a preferred embodiment, hybridization is performed at low stringency, in this case in 6× SSPE-T at 37°C (0.005% Triton x-100) to ensure hybridization and then subsequent washes are performed at higher stringency (e.g.,

-21-

1× SSPE-T at 37°C) to eliminate mismatched hybrid duplexes. Successive washes may be performed at increasingly higher stringency (e.g., down to as low as 0.25× SSPET at 37°C to 50°C) until a desired level of hybridization specificity is obtained. Stringency can also be increased by addition of agents such as formamide. Hybridization specificity may be evaluated by comparison of hybridization to the test probes with hybridization to the various controls that can be present (e.g., expression level control, normalization control, mismatch controls, etc.).

In general, there is a tradeoff between hybridization specificity (stringency) and signal intensity. Thus, in a preferred embodiment, the wash is performed at the highest stringency that produces consistent results and that provides a signal intensity greater than approximately 10% of the background intensity. Thus, in a preferred embodiment, the hybridized array may be washed at successively higher stringency solutions and read between each wash. Analysis of the data sets thus produced will reveal a wash stringency above which the hybridization pattern is not appreciably altered and which provides adequate signal for the particular oligonucleotide probes of interest.

Signal Detection

5

10

15

20

25

30

The hybridized nucleic acids are typically detected by detecting one or more labels attached to the sample nucleic acids. The labels may be incorporated by any of a number of means well known to those of skill in the art (see Lockhart et al., (1999) WO 99/32660).

Databases

The present invention includes relational databases containing sequence information, for instance for the genes of Tables 3-9, as well as gene expression information in various liver tissue samples. Databases may also contain information associated with a given sequence or tissue sample such as descriptive information about the gene associated with the sequence information, or descriptive information concerning the clinical status of the tissue sample, or the patient from which the sample was derived. The database may be designed to include different parts, for instance a sequences database and a gene expression database. Methods for the configuration and construction of such databases are widely available, for instance, see Akerblom *et al.*, (1999) U.S. Patent 5,953,727, which is herein incorporated by reference in its entirety.

-22-

The databases of the invention may be linked to an outside or external database. In a preferred embodiment, as described in Tables 3-9, the external database is GenBank and the associated databases maintained by the National Center for Biotechnology Information (NCBI).

Any appropriate computer platform may be used to perform the necessary comparisons between sequence information, gene expression information and any other information in the database or provided as an input. For example, a large number of computer workstations are available from a variety of manufacturers, such has those available from Silicon Graphics. Client-server environments, database servers and networks are also widely available and appropriate platforms for the databases of the invention.

The databases of the invention may be used to produce, among other things, electronic Northerns to allow the user to determine the cell type or tissue in which a given gene is expressed and to allow determination of the abundance or expression level of a given gene in a particular tissue or cell.

The databases of the invention may also be used to present information identifying the expression level in a tissue or cell of a set of genes comprising at least one gene in Tables 3-9 comprising the step of comparing the expression level of at least one gene in Tables 3-9 in the tissue to the level of expression of the gene in the database. Such methods may be used to predict the physiological state of a given tissue by comparing the level of expression of a gene or genes in Tables 3-9 from a sample to the expression levels found in tissue from normal liver, malignant liver or hepatocellular carcinoma. Such methods may also be used in the drug or agent screening assays as described below.

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples therefore, specifically point out the preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.

EXAMPLES

5

10

15

20

25

30 Example 1: Tissue Sample Acquisition and Preparation

Figure 1 outlines the experimental protocol used. Liver tissue samples were excised and snap frozen in liquid nitrogen. The clinical data for each of the samples included in this

5

10

15

20

25

30

study are outlined in Table 1. The sample set was composed of eight samples of normal liver tissue (N1-N8), five samples of metastatic adenocarcinoma arising from rectum (designated M1 and M3) and colon (M2, M4 and M5) tissues and six samples of primary hepatocellular carcinomas. Samples were named according to type of tissue:

HCC=hepatocellular carcinoma, M=metastatic, N=normal. Table 1 includes the TNM classification (the American Joint Committee on Cancer's system of classifying cancers) of the tissues used as samples where T refers to the extent of the primary tumor, N refers to the absence or presence and extent of regional lymph node metastasis, and M refers to the absence or presence of distant metastasis. Numbers following T, N, and M refer to the size of the primary tumor and the amount of vascular invasion, where 0=no evidence of tumor, lymph node involvement or metastasis, 4=multiple tumors involved, and x=cannot be assessed. Histopathologic grade (Table 1) is a qualitative assessment of differentiation of a tumor, where G1=most differentiated and G4=undifferentiated. Clinical stage (Table 1) characterizes the anatomic extent of disease in the patient from whom the sample was taken, where I and II are early stages, III and IV are late stages.

With minor modifications, the sample preparation protocol followed the Affymetrix GeneChip Expression Analysis Manual. Frozen tissue was first ground to powder using the Spex Certiprep 6800 Freezer Mill. Total RNA was then extracted using Trizol (Life Technologies). The total RNA yield for each sample (average tissue weight of 300 mg) was 200-500 μ g. Next, mRNA was isolated using the Oligotex mRNA Midi kit (Qiagen). Since the mRNA was eluted in a final volume of 400 μ l, an ethanol precipitation step was required to bring the concentration to 1 μ g/ μ l. Using 1-5 μ g of mRNA, double stranded cDNA was created using the SuperScript Choice system (Gibco-BRL). First strand cDNA synthesis was primed with a T7-(dT₂₄) oligonucleotide. The cDNA was then phenol-chloroform extracted and ethanol precipitated to a final concentration of 1 μ g/ μ l.

From 2 µg of cDNA, cRNA was synthesized according to standard procedures. To biotin label the cRNA, nucleotides Bio-11-CTP and Bio-16-UTP (Enzo Diagnostics) were added to the reaction. After a 37°C incubation for six hours, the labeled cRNA was cleaned up according to the Rneasy Mini kit protocol (Qiagen). The cRNA was then fragmented (5× fragmentation buffer: 200 mM Tris-Acetate (pH 8.1), 500 mM KOAc, 150 mM MgOAc) for thirty-five minutes at 94°C.

55 μg of fragmented cRNA was hybridized on the human Hu35k set and the

WO 02/29103 PCT/US01/30589
-24-

HuGeneFL array for twenty-four hours at 60 rpm in a 45°C hybridization oven The chips were washed and stained with Streptavidin Phycoerythrin (SAPE) (Molecular Probes) in Affymetrix fluidics stations. To amplify staining, SAPE solution was added twice with an anti-streptavidin biotinylated antibody (Vector Laboratories) staining step in between.

Hybridization to the probe arrays was detected by fluorometric scanning (Hewlett Packard Gene Array Scanner). Following hybridization and scanning, the microarray images were analyzed for quality control, looking for major chip defects or abnormalities in hybridization signal. After all chips passed QC, the data was analyzed using Affymetrix GeneChip software (v3.0), and Experimental Data Mining Tool (EDMT) software (v1.0).

10

15

20

25

30

5

Example 2: Gene Expression Analysis

All samples were prepared as described and hybridized onto the Affymetrix HuGeneFL array and the Human Hu35k set of arrays. Each chip contains 16-20 oligonucleotide probe pairs per gene or cDNA clone. These probe pairs include perfectly matched sets and mismatched sets, both of which are necessary for the calculation of the average difference. The average difference is a measure of the intensity difference for each probe pair, calculated by subtracting the intensity of the mismatch from the intensity of the perfect match. This takes into consideration variability in hybridization among probe pairs and other hybridization artifacts that could affect the fluorescence intensities. Using the average difference value that has been calculated, the GeneChip software then makes an absolute call for each gene or EST.

The absolute call of present, absent or marginal is used to generate a Gene Signature, a tool used to identify those genes that are commonly present or commonly absent in a given sample set, according to the absolute call. For each set of samples, a median average difference was figured using the average differences of each individual sample within the set. The median average difference must be greater than 150 to assure that the expression level is well above the background noise of the hybridization. For the purposes of this study, only the genes and ESTs with a median average difference greater than 150 have been further studied in detail.

The Gene Signature for one set of samples is compared to the Gene Signature of another set of samples to determine the Gene Signature Differential. This comparison identifies the genes that are consistently present in one set of samples and consistently

WO 02/29103 PCT/US01/30589 -25-

absent in the second set of samples.

The Gene Signature Curve is a graphic view of the number of genes consistently present in a given set of samples as the sample size increases, taking into account the genes commonly expressed among a particular set of samples, and discounting those genes whose expression is variable among those samples. The curve is also indicative of the number of samples necessary to generate an accurate Gene Signature. As the sample number increases, the number of genes common to the sample set decreases. The curve is generated using the positive Gene Signatures of the samples in question, determined by adding one sample at a time to the Gene Signature, beginning with the sample with the smallest number of present genes and adding samples in ascending order. The curve displays the sample size required for the most consistency and the least amount of expression variability from sample to sample. The point where this curve begins to level off represents the minimum number of samples required for the Gene Signature. Graphed on the x-axis is the number of samples in the set, and on the y-axis is the number of genes in the positive Gene Signature.

15

20

25

30

10

Example 3: Gene Expression Analysis of Normal Liver Tissue

The gene expression patterns and Gene Signature were individually determined for each sample set: eight samples with normal liver pathology, six samples whose pathology indicated the primary malignancy to be hepatocellular carcinoma, and five samples whose primary colorectal adenocarcinoma had metastasized to the liver. The Gene Signatures obtained for the normal sample set is shown in Figure 2A, the metastatic liver cancer set in Figure 2B and the hepatocellular carcinoma set in Figure 2C.

The Gene Signature considers the present and absent genes alone, and does not take into consideration those that have been called marginal. Table 2 shows the numbers of present genes, called the positive Gene Signature, and the number of absent genes, called the negative Gene Signature, for each of the three sets of samples.

The Gene Signature is the set of genes that are commonly present or commonly absent in N-1 samples of a given sample set. The positive Gene Signature for the normal liver tissues contains 6,213 genes and ESTs. This same set of normal samples did not show any detectable level of expression of 24,900 genes. Many of the genes and ESTs in this positive Gene Signature are housekeeping genes or structural genes that are not only expressed in the liver, but are ubiquitously expressed in tissues throughout the body. Within

5

10

15

20

30

this positive Gene Signature are also those genes whose expression is specifically restricted to normal liver tissue and those genes required for the liver to function at its normal capacities. It is the group of genes unique to the liver whose expression levels are most likely to change during tumorigenesis. Whether up-regulated or down-regulated or turned completely on or turned completely off, the changes in expression of these vital genes very likely contributes to the drastic changes in liver function caused by the transformation of normal liver cells into cancerous cells.

Example 4: Gene Expression Analysis of Malignant Liver Tissue

There are 8,479 genes and ESTs in the positive Gene Signature for the HCC tumors, and a total of 23,233 genes and ESTs are included in the negative Gene Signature of the HCC samples. This negative Gene Signature includes all the genes that have been completely turned off during tumorigenesis, as well as those genes that are not usually expressed in liver tissue. These results include a number of genes and ESTs that are not regularly expressed in liver tissues, but through the process of tumor production, their expression patterns have been dramatically altered from no detectable level of expression to some significant level of expression in comparison with the normal liver.

The colorectal metastases in the liver commonly express 5,102 genes and ESTs, and do not show expression of 30,455 additional genes and ESTs. As with the negative Gene Signature for the HCC sample set, the genes included in this data set are generally not expressed in liver tissue, whether tumor or normal tissue. The 5,102 in the sample set of metastatic tumors also identify those genes with expression levels that have been changed from off to on as a result of tumor formation.

25 Example 5: Analysis of Gene Expression Profiles

A differential comparison of the genes and ESTs expressed in the normals and the two different types of liver tumors identifies a subset of the genes included in the positive Gene Signatures that are uniquely expressed in each sample set. This Gene Signature Differential highlights genes whose expression profiles have most dramatically changed in the transformation from normal to diseased liver cells. The parameters for these analyses were set to accommodate variation in expression of one of eight normal samples and one of the six HCC samples or one of the 5 metastatic tumor samples, such that the genes

categorized as unique to normal were called present by the software in seven of eight (87%) normal liver samples and were also called absent in five of six HCC (83%) or four of five (80%) metastatic liver tumor. Conversely, the genes categorized as unique to each set of tumors as compared to the normal livers were called present in five of six HCC (83%) or four of five (80%) metastatic tumor samples and absent in seven of eight normal livers (87%).

5

10

15

20

25

30

The Gene Signature Differential comparing the normal livers to those with metastatic tumors identified a total of 903 sequences expressed only in normal liver tissue. The number of genes or ESTs that meet the median average difference minimum of 150 is 449, of which 289 are genes and the number of ESTs is 160. The remaining ESTs and genes may be indistinguishable from the background noise of the hybridization. The same comparison of normals versus metastatic tumors demonstrates that in the metastatic tumor samples there are 296 uniquely expressed sequences. Those that meet the median average difference minimum requirement are 83 genes and 72 ESTs. Those genes and ESTs expressed in metastatic and not in normal liver tissue are shown in Table 9A and those present in normal liver tissue and not metastatic tissue Table 9B. Numerous genes with differing expression levels in metastatic liver tumor tissue compared to normal tissue were identified. The fifteen genes whose expression level was most different in metastatic as compared to normal tissue are shown in Table 4. Those with the most increased expression are in Table 4A and those with the most decreased expression are in Table 4B. Expression levels were determined by comparing the mean expression values of individual genes in tumor and normal liver samples. Fold change was calculated as a ratio with a p value given as a measure of statistical significance. Fold change is considered significant for a given gene or EST when it is greater than 3.0 with a p value <0.05. Only the characterized genes have been listed; the ESTs with similar fold changes are not presented here. Asterisk (*) in Table 4 denotes those genes that were also identified in the Gene Signature differential between metastatic liver carcinoma and normal liver tissue. A complete listing of all the genes and ESTs with at least a three-fold change in expression is shown in Table 6. Table 6A contains those genes and ESTs whose expression level increased in metastatic tissue relative to normal tissue and Table 6B contains those genes and ESTs whose expression level decreased.

The Gene Signature Differential between the normal liver samples and the HCC

-28-

samples identifies a total of 47 unique expressers in the normals, 23 with an median average difference of 150,13 of which are named gene and 10 of which are ESTs. When comparing the expression of the HCC samples with the normal livers, there are 243 genes and ESTs only expressed in the HCC samples.

5

10

15

20

25

30

Those genes and ESTs expressed in HCC and not in normal liver tissue are shown in Table 8A and those present in normal liver tissue and not HCC tissue in Table 8B. Numerous genes with differing expression levels in HCC compared to normal tissue were identified. The fifteen genes whose expression level was most different in HCC as compared to normal tissue are shown in Table 3. Those with the most increased expression are in Table 3A and those with the most decreased expression are in Table 3B. Expression levels were determined by comparing the mean expression values of individual genes in tumor and normal liver samples. Fold change was calculated as a ratio with a p value given as a measure of statistical significance. Fold change is considered significant for a given gene or EST when it is greater than 3.0 with a p value <0.05. Only the characterized genes have been listed; the ESTs with similar fold changes are not presented here. Asterisk (*) denotes those genes that were also identified in the Gene Signature differential between hepatocellular carcinoma and normal liver tissue. A complete listing of all the genes and ESTs with at least a three-fold change in expression is shown in Table 7. Table 7A contains those genes and ESTs whose expression level increased in hepatocellular carcinoma tissue relative to normal tissue and Table 7B contains those genes and ESTs whose expression level decreased.

Analysis of sample set identified 24 ESTs and 42 genes that are expressed in both metastatic liver tumors and hepatocellular carcinomas, but not in normal liver tissues. The fifteen genes with the most increase in expression level in both types of cancer are shown in Table 5. Expression levels were determined by comparing the mean expression values of individual genes in tumor and normal liver samples. The mean expression value for HCC and metastatic carcinomas was greater than 250, and included only those genes that showed a fold change greater than 3 with significant p values for both sets of tumors. No detectable level of expression was found in the normal liver tissues for these genes. Only the characterized genes have been listed; the ESTs with similar fold changes that are unique to the tumors are not presented here.

Differential gene expression patterns between normal liver samples and

-29-

hepatocellular carcinomas and between normal livers and metastatic liver tumors were examined. Genes uniquely expressed by each of the groups individually were identified, as well as those genes that are commonly expressed among liver tumors, whether primary hepatocellular carcinomas or metastatic liver tumors.

5

10

15

20

25

30

Example 6: Association of Liver Cancer with Specific Gene Expression

The present inventors have closely examined a number of the tumor-expressing genes to determine if their expression patterns correlate with previous reports published in the literature, and to define a logical relationship between the gene and hepatocarcinogenesis. A number of genes that have previously been associated with either liver cancer or other types of cancers were identified, as well as numerous genes that have not been linked to cancers in any previous studies.

842 genes and ESTs that are up-regulated in hepatocellular carcinomas were identified when compared with normal liver tissue. One such gene is PTTG1, pituitary tumor-transforming gene 1, or securin, an oncogene that inhibits sister chromatid separation during anaphase. Normal tissues show little or no PTTG1 expression, but high levels of expression have been associated with various tumors, including liver tumors, and carcinoma cell lines. Overexpression in NIH3T3 cells resulted in transformation, and these cells caused the formation of tumors when injected into mice. The mechanism by which this tumorigenic activity takes place is postulated to be through the missegregation of sister chromatids, resulting in aneuploidy and, therefore, genetic instability. Our data further support this overexpression of PTTG1 in hepatocellular carcinoma, with a fold change of 10.7 (P=0.00052), and no detectable level of expression in normal tissues, as identified by the differential comparison of the consensus patterns of gene expression of these two sample sets.

Galectin 3, LGALS3, one of a family of beta-galactoside-binding animal lectins, is significantly overexpressed both in primary hepatocellular carcinoma and metastatic liver carcinomas with fold changes of 6.8 (P=0.00103) and 27.1 (P=0.00001), respectively. Expression of LGALS3 has been associated with tumor growth, progression, and metastasis, as well as cell-cell and cell-matrix interactions and inflammatory processes. Although expression studies by Hsu *et al.* revealed no detectable level of galectin-3 in normal liver cells, samples from patients with hepatocellular carcinoma revealed considerable levels of

-30-

LGALS3 expression. The abnormal expression of this lectin may be an early event in the process of transformation of normal cells to tumor cells, or it may impart an increased capacity for these tumor cells to survive and proliferate. Consistent with the reports by Iurisci et al and Nakamura et al, an increased expression level was found in both types of tumor, but higher concentrations of galectin-3 were observed in liver metastates from colorectal tumors than in the primary HCC tumors.

Another gene that is overexpressed in both hepatocellular carcinoma and metastatic colorectal adenocarcinomas with fold changes of 12.2 (P=0.00169) and 58.0 (P=0.00063), respectively, is solute carrier family 2, member 3, or glucose transporter 3 (GLUT3). It is one of a family of transmembrane proteins that function as facilitative glucose transporters, which has a unique specificity for brain and neuronal tissues. Glucose uptake and metabolism are known to be increased in carcinoma cells compared to normal cells. Glucose transporter expression may be elevated in response to the increase in glucose utilization seen in actively proliferating cells, like those of tumors. Conversely, the high levels of glucose transporter expression may be responsible for the enhanced influx of glucose into the tumor cells. Various reports have indicated increased expression of one or more of the family of glucose transporters in malignancies, including those of the brain, esophagus, colon, pancreas, liver, breast, lung, bladder, ovary, testis, skin, head and neck, kidney, and gastric tumors. Kurata et al. (Jpn J Cancer Res 1999 Nov;90(11):1238-43) specifically report that metastatic liver carcinomas have even higher levels of GLUT3 expression than primary tumors. Consistent with previous studies, the current data confirm the significant overexpression of GLUT3 both in primary liver cancer, hepatocellular carcinoma, and in tumors that have metastasized from the colon and rectum.

10

15

20

25

30

One of the significantly underexpressed genes identified by comparing the expression profiles of hepatocellular carcinomas and metastatic liver tumors with that of normal liver tissue is metallothionein 1L. The expression level in HCC is 26.9 fold lower than that of normal (P=0.00999), and in metastatic colorectal adenocarcinomas it is down-regulated 66.5 fold (P=0.00415). Metallothioneins are heavy metal binding proteins that are involved in detoxification of metals, zinc and copper metabolism cellular adaptation mechanisms, and may be involved in regulating apoptosis. Colorectal adenocarcinoma that has metastasized to the liver has been specifically reported to express less metallothionein than normal liver tissue. Comparison of the consensus patterns of gene expression between

-31-

metastatic liver samples and normal liver samples show no significant level of MT1L expression in the tumors. Furthermore, additional work has determined that human hepatocellular carcinomas contain much lower levels of metallothioneins than normal liver tissue, and that this decrease correlates with the degree of differentiation and concentrations of copper and zinc in the cells. By comparing the expression profiles of hepatocellular carcinoma and normal liver tissue, this significant reduction in MT1L expression in HCC was confirmed.

5

10

15

20

25

30

A number of enzymes belonging to the family of cytochrome P450s are drastically underexpressed in the two sets of liver tumors in comparison with the normal liver tissue. For example, expression of CYP2A6 is decreased in HCC with a fold change of 14.2 (P=0.0307), and in metastatic tumors with a fold change of 69.9 (P=0). CYP8B1 is down-regulated 19.3 fold (P=0.00807) in HCC and 65.1 fold (P=0.0039) in liver metastases. In addition to these commonly down-regulated cytochrome P450s, in HCC samples CYP2B is underexpressed 17.9 fold (P=0.01469), and in the metastatic liver tumors CYP2C9 and CYP2A7 are underexpressed 84.7 fold (P=0.00327) and 72.0 fold (P=0), respectively. Several of these genes are also identified by the differential comparison between expression profiles of tumor and normal, confirming the significant decrease in expression in tumor tissues. Many of these P450 enzymes are critical players in the metabolism of carcinogens, drugs, and other chemical compounds, that are expressed in normal liver.

In addition to genes that are underexpressed in metastatic adenocarcinomas in the liver, more than 1000 genes and ESTs that are overexpressed specifically in these tumors were identified. Two of the most highly up-regulated are claudin 4, also known as clostridium perfringens enterotoxin receptor 1 (fold change 84.4, P=0) and occludin (fold change 43.1, P=0). Both of these genes are tight junction proteins, responsible for the formation and maintenance of continuous seals around epithelial cells to form a physical barrier that blocks the free passage of water and solutes through the paracellular space. More specifically, claudin-4 is one member of a family of transmembrane proteins that comprise tight junction strands, and occludin is a cell adhesion molecule (Morita $et\ al.$, (1999) Proc. Natl. Acad. Sci. U.S.A. 96: 511-516). Claudins likely function as paracellular channels, regulating the flow of ions and solutes into and out of the paracellular space (Simon $et\ al.$, (1999) Science 235: 103-106; Wong & Goodenough (1999) Science 285: 62; Anderson & Van Itallie (1999) Curr. Biol. 9: R922-924). Tight junction proteins also

WO 02/29103 PCT/US01/30589 -32-

contribute to the regulation of the cellular processes of cell growth and differentiation (Matter & Balda (1999) Int. Rev. Cytol. 186: 117-146). Permeability of tight junctions has been associated with tumor formation, where a breakdown in the barrier function of tight junctions allows an increase in the cellular permeability. This breakdown then opens the tight junction barrier, permitting invasion by tumor cells (Zak et al., (2000) Pflugers Arch. 440: 179-183; Mullin (1997) J. Exp. Zool. 279: 484-489). It has been reported that tight junctions of colon tumors leak more than do the tight junctions of normal colon (Soler et al., (1999) Carcinogenesis 20: 1425-1431). A complete loss of tight junction function and a loss of cell-cell contact growth control was seen in cells that had been transfected with oncogenic Raf-1, and expression levels of occludin and another claudin are lower in these cells (Li & Mrsny (2000) J. Cell Biol. 148: 791-800). Occludin expression has been upregulated in vitro by the addition of various fatty acids that have anti-cancer effects, decreasing the paracellular permeability (Jiang et al., (1998) Biochem. Biophys. Res. Commun. 244: 414-420). The extreme down-regulation of occludin and claudin-4 in metastatic liver tumors is strongly supported by the reports of tight junction breakdown in tumor tissues.

5

10

15

20

25

The present study identified 93 significantly up-regulated genes in both primary HCC and metastatic liver tumors that were not found to have any detectable level of expression in the normal samples. Serine protease inhibitor, Kazal type I (SPINK1), also called pancreatic secretory trypsin inhibitor (PSTI) or tumor-associated trypsin inhibitor (TATI), is one such gene. It is highly expressed in the cells of normal pancreas and in the mucosa of the gastrointestinal tract where it offers protection from proteolytic breakdown. A marked increase in expression is seen in various pancreatic diseases and in tumors of different tissues, including gastric carcinomas, colorectal cancers, and other neoplastic tissues. This increase is presumably due to the elevated expression of trypsin in the tumors, and not related to amplification or rearrangements within the gene. SPINK1 is also considered a valuable marker for a number of solid tumors. A drastic elevation of SPINK1 in the blood of patients with hepatocellular carcinoma has been seen (see Ohmachi et al.). Furthermore, it has been suggested that the level of expression correlates with the extent of tumor, such that this heightened expression level could be indicative of HCC under certain conditions. In keeping with this report of overexpression in these tumors, the present expression data show the levels of expression of this gene in HCC samples to be 28.9 times

-33-

higher than normal (P=0.00003), and in metastatic liver tumors the expression level is 9.8 times higher than normal (P=0.03697).

Midkine is one of a family of heparin-binding growth factors, inducible by retinoic acid, and is actively involved in cell-cell interactions and angiogenesis. The expression pattern of midkine is highly restricted in normal adult tissues, and no expression has been reported in normal adult liver, although its expression is required during embryogenesis for normal development. However, it is expressed in moderate to high levels in many tumors, including Wilm's tumors of the kidney, stomach, colon, pancreas, lung, esophagus, breast, and liver tumors. The present data confirm these reports, showing a significant overexpression of midkine in hepatocellular carcinoma samples (fold change 9.9, P=0.02104) and in liver metastases (fold change 10.4, P=0.01818), but no noticeable expression in normal liver.

5

10

15

20

25

30

Stathmin, leukemia-associated phosphoprotein 18, is a phosphoprotein whose expression pattern and phosphorylation status are controlled by extracellular signals responsible for the regulation of the processes of cell proliferation and differentiation. It is also involved in the regulation of cell division via the destabilization of microtubules. When comparing expression levels between non-malignant tissues and malignant tissues, the tumors generally show a significant up-regulation of this phosphoprotein, specifically lymphomas, leukemias, breast and prostate tumors. One reason proposed for this elevated expression in cancer cells is the dissimilarity in the rates of cell proliferation and states of differentiation between normal and tumor cells. In both HCC samples and metastatic adenocarcinomas, significant up-regulation of stathmin, 9.4 fold in HCC (P=0.00015) and 4.8 fold in metastatic tumors (P=0.00514) was seen.

Both the genes and ESTs described here will provide valuable information for the identification of new drug targets against liver carcinomas, and that information may be extended for use in the study of carcinogenesis in other tissues.

Although the present invention has been described in detail with reference to examples above, it is understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims. All cited patents, applications and publications referred to in this application are herein incorporated by reference in their entirety.

Table 1. Clinical Information for Hepatocellular Carcinoma, Metastatic Liver Tumor, and Normal Liver Samples Included in this Study

Table 2. Summary of Genes and ESTs Expressed in HCC, Metastatic Liver Tumors, and Normal Livers

	Hepatocellular Carcinoma	Colorectal Metastases	Normal Livers
I. Fingerprint of Gene Expression			
Genes and ESTs commonly expressed in sample set	8479	5102	6213
Genes and ESTs commonly unexpressed in sample set	23233	30455	24900
II. Fold Change			
Genes and ESTs overexpressed in tumors (fold change >3 and p<0.05)	842	1044	
Number of Genes	430	603	
Number of ESTs	412	441	
Genes and ESTs underexpressed in tumors (fold change >3 and p<0.05)	393	1867	
Number of Genes	235	1016	
Number of ESTs	158	851	
III. Differential Comparison between Normal and Tumor Expression			
Genes and ESTs turned ON in turnors	243	296	
Genes and ESTs with expression level above threshold in tumor	11	155	
Number of Genes	38	88	
Number of ESTs	39	72	
Genes and ESTs turned OFF in turnors	47	803	
Genes and ESTs with expression level above threshold in normal	23	449	
Number of Genes	13	289	
Number of ESTs	10	160	

Table 3A. Top fifteen genes overexpressed in hepatocellular carcinoma.

Genbank	Seq ID	Unigene Cluster	Comp Nama		
AAOSSBOR	125	10 446400	Colle Nalle	Fold Change Pvalue	Pvalue
Decorat	3	ns. 140420	collagen, type V, alpha 1	40 OF	70000
AA156187	339	Hs.81634	ATP synthase. H+ transporting mitochondrial F0 complex subjust to include		
AA428172	986	Hs 8546	Notch (Proceedings In the Complete Statement of Section 1)		9.4 0.02007
000000		20000	The companied from the companied of the	9.0 _*	0.00195
7500054-0-	8001	HS.25258/	pituitary tumor-transforming 1	10.7*	64000
AA505133	1417	Hs.279905	solute carrier family 2 (facilitated durose transported) momber 2		0.00022
AA610116	.1499	He 102737	**************************************	.7.	12.2 0.00169
7000000		13.10273	renaspan NET-0 protein	16.4	4 0.00249
AAOZU881	1510	Hs.21858	trinucleotide repeat containing 3	č	•
D31094	1630	He 100708		Ď	29000'n c.e
		113.1037.90		46	4 00048
U512/6	1678	Hs.81915	leukemia-associated nhosphoprotein n18 (etathmin)	i (
103464	7000	Us 170572	the state of the s	<u>ந்</u>	9.4 0.00015
10000	1007	113.1737.3	collagen, type I, alpha Z	10.4	4 0.00979
M84250	2426	Hs.82045	midkine (neurite growth-promoting factor 2)	*	
N33920	2493	He 44532		D.	0.02104
307770	2 6	7004		50,3	0
VV453ZU	3523	Hs.228059	KRAB-associated protein 1	** 07	٠
Y00705	3850	Hs.181286	serine professe inhibitor Kozal tana 4		0.00002
737987	2882	Uo 440664	the state of the s	28.	28.9 0.00003
201001	2002	ns.118051	giypican 3	107	7 0 02304

Table 3B. Top fifteen genes underexpressed in hepatocellular carcinoma.

Genbank	Seg ID	Unigene Cluster			
AAOO7305	ţ		Gene Name	Fold Change Pvalue	Pvalue
000000	-	US.1218	alcohol dehydrogenase 4 (class II) ni notwontida		
AA010605	92	He 2899	philodical id it is a second of the second o	37.	37.8 0.00939
	ì	0001:01		שכ	11000
AA448002	1113	Hs.23759	Dutative time II membrane arration		20.0 U.UU800
H58692	1080			14.1*	0
70001	200		Tormyltetrahydrofolate dehydrogenase	0	
H80901	2005		ficolin (collection (fibrillation	Z0.	20.2 0.00485
H81070	2000	U. 076F	Comagentinogen domain-containing) 3 (Hakata antigen)	18.6	0
	4000		KNA nelicase-related profein		
K03192	2127		Atohrom DAFO COLECTION COLOR	39.	39.6 0.00002
1420072			Syloculouse F450, sublamily IIA (phenobarbital-inducible), polypeptide 6	14	142 00207
WZ36/3	2318		Cytochrome P450 subfamily IIB (phonohorhita) in distillation	Ė	70000
N80129	2703		Control of	17.9	9 0.01469
077	3	13:34200	meranomionen 1L	90	
K9/419	3004		Cytochrome D450 subfamilia / will father and an area of a subfamilia / will be father and a subfamilia / will be father and a subfamilia / will be father and a subfamilia / will be father as a subfa	6.02	9 0.00999
TARN75	2420		concentration of the second of	19.3	3 0.00807
	200		nemoglobin, alpha 1	1	
167931	3184		fibringen B beta nationalists	35.8	8 0.00471
T95813	3262	g	Services of a polybehilde	17.3	3 0.00128
	2020		NAA1051 protein	6	•
U56814	3393	Hs.88646	deoxyribonicleses Like 3	4.02	4 0.01361
W88946	3639			17.7	7 0.00007
			purative glyciffe-n-acyltransferase	25.	25.3 0 00221

Table 4A. Top fifteen genes overexpressed in metastatic carcinomas of the liver.

Genbank	Sea ID	Uniciano Clustor			
AA400740		Inchio allaguro	Gene Name	Fold Chanc	Fold Change Pyalue
81 /0015	717	Hs.73848	Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific	50 9*	0.0004
			cross reacting antigen)		0.000
AA156243	340	Hs.154737	Serine professe umbilical and other in	:	
AA335191	741	He 173724		41.4*	0.00139
A A 404 FOO		13:11.0124	Cleaurie Kinase, Drain	47 4*	0.00440
A442 1302	934	Hs.91011	Anterior gradient 2 (Xenopus teasis) homolog		0.400.0
AA427468	973	Hs.5372	Clardin A	20.3	0.0041
AA429009	700	ç		84.4*	0
	1		Serine protease inhibitor. Kunitz type 1	*0.0%	7000
AA610116	1499	Hs. 102737	Tetrosmon NET & motolic		0.0000
H58873	1001			SS	33.7 0.00171
	- CB	HS.16990Z	Solute carrier family 2 (facilitated olucese transporter) momber 2		
H94471	2042	Hs 171952	Oost talis		0.00063
UOESSS	! 6	1	Occidani	43	43.1
L80233	2048	Hs.31439	Serine protease inhibitor Krinitz tyne o	? !	·
HG2788-HT2896			Calablin hinding southing	47.1	o -:
AADORAO	1700	,	Carcyclin billioning protein	33.2	0
INC8340	2317	Hs.220529	Carcinoembryonic antinen-related cell adhesion motoride E		
M35252	2343		Transmembrane 4 emperantition of the contraction of	36.6	0.0116
N92934	2725		constitution of a supervaluity member 3	39.1	.1
	217	ns. 17409	Cysteine-rich protein 1 (intestinal)	30	
X93036	3830	Hs.92323	EXVD domain-containing its fermion		20.0 0.002
				** ~	0.000

Table 4B. Top fifteen genes underexpressed in metastatic carcinoma of the liver.

Genbank	Seq ID	Unigene Cluster			
A A 2 5 6 3 6 7	670	11-407000		Fold Change Pvalue	Pvalue
100000	B / C	HS. 107906	Paraoxonase 3	70.3	703 0 00102
H28692	1960	Hs.9520	Formvitetrahydrofate dehydronenase		20.00
K03192	2127	Hs 183584	Cutochrome D4EO surface in the contract of the	4.10	0
16883	2468	Ho 467500	Optioning 1930, sublatifility IIA (phenobarbital-inducible), polypeptide 6	6 0.0*	0
200011	200	US. 10/329	Cytochrome P450, subtamily IIC (mephenytoin 4-hydroxylase), polypentide 9	84.7	84 7 0 00327
M15656	2268	Hs.234234	Aldolase B. fructose-bisphosphate		0.0002
M16594	2272	Hs.89552	distribute S-transferace A2		Э
M81340	2405	LIO 40EE	A Deal of the state of the stat	73.2*	0
	2047	US. 1833	Serum amyloid A4. constitutive	26.07	700000 0 007
N53031	2556	Hs.89691	IID alvocaltransferace 2 formity not mountain not	7.0.7	0.000.0
NEAAAA	1000	10100	ery elycody wai sie as a faithly, polybepide by	92.6	97.6 0.00022
	/007	HS.90/65	Fibrinogen, A alpha polypeptide	6 00	0000
R43174	2848	Hs. 1898	Paranyonasa 1		88.3 0.00001
R40450	2000	U. 60750	- 000 -	74.0*	0.00038
20101	7007	18.03/30	i ransferrin receptor 2	9 196	95 0 00010
T48039	3129	Hs.2351	Protein C (inactivator of coorgination forters \(\text{\contract} \)	0.00	0.00040
T59148	3158	He 50966	Certamond absorbate according to a city of a c	84.4	0.00112
000001	0 0		Carbarroy-Priospirate synthetase 1, mitochondrial	88.0*	0
022023	332/	HS.250615	Cytochrome P450, subfamily IIA (phenoparhital-inducible), polypertide 7	72.04	•
X55283	3734	Hs.1259	Asialoglycoprotein recentor 2		
				20	85 0.00084

Table 5. Top fifteen genes expressed in both hepatocellular carcinomas and metastatic liver tumors ad not in normal livers.

Genbank	Seq ID	Unigene Cluster	Gene Name	HCC Fold	HCC p	Metastatics Metastatic	Metastatic
				Change	value	Fold	p value
AA055896	135	He 148428				Change	
AA204927	125	Us 77000	collagell, type V, alpha 1	10.9	0.00907	18.2	0.00146
AA225404	74.5	6607.80	tropomyosin 1 (alpha)	6.1	0.0014	7.1	0.00074
181000A	741	HS.173724	creatine kinase, brain	C.	0.01462	7.77	0.000
AA428472	266	Hs.236522	DKEZP434P106 protein	9 6	20110.0	ŧ.	0.00418
AA434418	1036	He 72172		8. 8.	0.00063	დ ფ	0.00208
AA5272A	7	115.721.72	nied cities and cities	6.8	0.0032	5.1	0.00498
1704174	24	HS. 166468	programmed cell death 5	7.7	20000	7	
AA610116	1499	Hs. 102737	letrasnan NET-6 protein	: ;	0.0000	7.	0.00908
AA620881	1510			16.4	0.00249	33.7	0.00171
D26120	1635		increoude repeat containing 3	9.5	0.00062	8.7	0.00735
020120	000		ribonuclease, RNase A family, 1 (pancreatic)	6.9	80000	7.7	70000
D31094	1639	Hs.109798	G8 profein)	00000	Š	0.03027
D51276	1678	Hs 81915		4.0	0.0048	4.4	0.04845
H27188	100		leuneillia-associated phosphoprotein p18 (stathmin)	9.4	0.00015	4.8	0.00514
103464	200	;	collagen-binding protein 2 (colligen 2)	5.8	0.01826	4.2	0.02073
10100	2034	77	collagen, type I, alpha 2	10.4	0.0000	0	00000
M94250	2426	Hs.82045	midking (neurite growth promoting foots: 2)	<u>.</u>	0.000.0	0.0	0.00028
Y00705	3850	He 181286	יייייייי לייייייייט פוסטייייייט פוסטייייייט פוסטיייייייט פוסטיייייייט פוסטיייייייט פוסטיייייייט פוסטיייייייט פוסטייייייט פוסטייייייט פוסטיייייייט פוסטייייייט פוסטיייייט פוסטיייייט פוסטיייייט פוסטיייייט פוסטיייייט פוסטיייייט פוסטייייט פוסטיייט פוסטייט פוסטיייט פוסטיייט פוסטייט פוטטייט פוסטייט פוסטייט פוטטייט פוטטייט פוסטייט פוטט פוטטייט פוטטייט פוטטייט פוטטייט פוטט פוט	G.	0.02104	10.4	0.01818
			serine protease innibitor, Kazal type 1	28.9	0.00003	80	0.03697

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	or levid
rc_AA001409_i_at	AA001409	-	EST	3.35	1-	O OAOOO
rc_AA001504_f_at	AA001504	7	EST	000 000	a 5	0.04032
Ψ,	AA007158	15	EST	3.05	} ≦	0.00330
rc_AA007160_at	AA007160	16	EST	9	g. ≦	0.01904
rc_AA010065_s_at	AA010065	22	CDC28 protein kinase 2	30	g 5	0.01033
rc_AA011134_at	AA011134	58	EST	28.70	g (0.027.32
rc_AA011383_at	AA011383	31	EST	5.17	3 5	200000
rc_AA025166_s_at	AA025166	20	fusion, derived from t(12:16) malignant liposarcoma	3.74	}	0.0000
rc_AA025277_at	AA025277	.51	EST	4.56	음 달	0.0032
rc_AA026030_at	AA026030	23	EST	11.01)	0.01649
rc_AA026092_at	AA026092	24	EST	3.83) 9	0.04596
rc_AA026150_at	AA026150	22	EST	5.14	- 9	0.01072
rc_AA026356_at	AA026356	22	EST	4.1	ġ,	0.00133
rc_AA027946_at	AA027946	9	EST	3.22	- 9	0.00098
rc_AA028103_at	AA028103	61	EST	3.52	- 9	0.01142
rc_AA028132_s_at	AA028132	62	EST	6.25	+ 9	0.00646
rc_AA029215_at	AA029215	.04	adaptor-related protein complex 2, beta 1 subunit	3.65	t 9	0.00037
	AA029356	99	EST	3.68	9	0.01545
rc_AA033790_f_at	AA033790	74	apolipoprotein D	4.21	- 8	0.03247
rc_AA034378_f_at	AA034378	11	endogenous retroviral protease	4.01	9	0.00974
rc_AA034499_s_at	AA034499	78	zinc finger protein 198	3.7	- an	0.02143
rc_AA040465_at	AA040465	92	EST	3.25	g.	0.00146
יוס	AA043959	5	tropomyosin 4	8.54	g	0.00222
rc_AA053007_t_at	AA053007	123	putative receptor protein	6.76	- 9	0.00061
rc_AAU53U33_at	AA053033	124	EST	7.83	g	0.00379
rc_AA053102_s_at	AA053102	125	cadherin 17, Ll cadherin (liver-intestine)	26.63	ď	0.01745
	AA053248	126	EST	7.01	음	0.00003
10_AA03246_1_at	AA053248	126	EST	6.16	음	0.00191
1c_A4033424_at	AA053424	127	EST	8.76	g.	0.01775
α _,	AA053660	128	ESI	15.98	dn	0.00003
18_2_CUOCCUAY_21	AAUSSBUS	132	EG.	42.83	đ	0.00142

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name		- 1	
rc_AA055811_s_at	AA055811	133	glycoprotein A33 (tran	rold Change		Pvalue
æ	AA055896	135	Colladen type // place 1	0.80	ᅀ	0.02152
AA056361 at	AAOSBS	\$ 5	informal moments and a second	18.16	ф	0.00146
rc AA062721 at	AAA65551	2 4	inegral memorane protein 2C	3.53	dn	0.02983
	AA070706	140	iluciear lactor (erythroid-derived 2)-like 1	6.2	dn	0.00024
rc AA070827 24	A A 0 2 0 2 0 5		100	4.26	ď	0.00018
rc AA074544 c+	0 0 0 7 0 F 4 1	/c.		4.41	an	0.01902
10_A071000	AAU/4514	160	EST	7.69	. 9	
rc_AAU/5289_at	AA075299	1 64	EST	34.27	<u> </u>	
rc_AA075580_f_at	AA075580	165	EST	7.5	<u> </u>	0.00002
rc_AA075722_at	AA075722	166	nuclear transport factor 2 (placental protein 45)	4.30	Q.	0.02083
AA078862_s_at	AA078862	173	EST	4.14	S	0.00374
rc_AA084901 at	AA084901	181	rithosomal protein OS blood 70kD anti-	6.52	ᅀ	0.00025
rc AA084921 f at	AA084921	, 6 2 2 3	ribosomal profeir SO Milase, 7 UND, polypeptide 2	9.13	ф	0.00003
	70000	70	Trousonial protein 310	3.29	Qn	0.04872
			Kangai 1 (suppression of tumorigenicity 6, prostate; CD82		_	1
			antigen (R2 leukocyte antigen, antigen detected by monoclonal			
rc_AA086232_f_at	AA086232	186	and antibody IA4))	7 4 4	•	0.00
AA093497_s_at	AA093497	199	DEK oncodene (DNA hinding)	<u>.</u>	<u>a</u>	0.01916
AA094517 at	AA094517	202	EST EST	0.0	d	0.02551
AA094752_at	AA094752	203	throthofical 42 of 12 desired	3.52	đ	0.04805
rc AA099404 s at	7070000	3 6	iiybaiieiidal 43.2 na protein	4.47	đ	0.00243
	+0+660V	202	-23	29.07	gn	C
0710077			carcinoembryonic antigen-related cell adhesion molecule 6 (non-		ŀ)
rc_AATUU/19_s_at	AA100719	212	specific cross reacting antigen)	50 88	9	*0000
rc_AA101551_at	AA101551	216	EST	20.00	<u>ਜ</u> ੇ :	0.00081
rc_AA113149 s at	AA113149	226	filmor elipproceipp elibropoforable actual de constituent	24.78	g.	0
l i		ì	amos adplicasing submensionable candidate 3	10.58	ф	0.00543
rc_AA113303_at	AA113303	227	transmembrane 4 superfamily member (fetrasnan NET-2)	7		
rc_AA116036 at	AA116036	233	Chromosome 20 once to the form of the last	5.73	<u>a</u>	0.00084
rc_AA121315_at	AA121315	237	KINA1077 postale	8.81	d,	0.00133
rc AA12238R at	AA422286	3 6		4.86	g n	0.02438
rc_AA126044_et	AA126044	228	collagen, type v, alpha 2 Fox	4.28	dn	0.005
20 A A 20 A 20 D C C C C C C C C C C C C C C C C C C	4400444	240		11.23	g	0.00041
18 E2407 F3	AA126429	247	peroxisomal farnesylated protein	3.23	. 2	0.00478
)	<u>.</u>	2 7 7 7 7

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name		- 1	
rc_AA126459 s_at	AA126459	248	DKEZPSERR03 profe	roid Change	- 1	Pvalue
rc AA126719_at	AA126749	250		3.69	g.	0.00352
AA127712 at	AA127712	250	- 20	5.31	핰	0.00026
rc 44127851 at	AA4370E4	7 22		6.59	g	0.03706
	A4106407	/07		3.23	9	0.01943
rc AA128561 et	AA126407	607		3.78	9	0.01081
rc	AA126301	707	collagen, type XVII, alpha 1	60.9	g	0.0433
10_AA131004_BI	AA131084	265	procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3	4.74	đ	0.00427
10_AA131102_S_81	AA131162	266	EST	4.68	. <u>a</u>	0.00042
10_AA131584_at	AA131584	268	DKFZP56400463 protein	6.83	. gn	0.00025
C AA131684 at	AA131894	269	EST	3.76	. <u>a</u>	0.00384
_	AA131919	270	putative type II membrane protein	15.36	g	0.00027
16_AA132032_S_8t	AA132032	271	trinucleotide repeat containing 1	4.19	. S	0.00295
rc_AA132554_at	AA132554	273	EST	4.96	. g	0.02076
	AA132983	274	DKFZP586G1517 protein	3.31	e g	0.01155
rc_AA132986_at	AA132986	275	EST	9.72	t 9	0.00552
rc_AA133590_at	AA133590	282	EST	3.23	+ 5	0.03565
rc_AA133936_at	AA133936	284	EST	61.6	}	0.0000
rc_AA134052_s_at	AA134052	285	Rab geranylgeranyltransferase, alpha subunit	3.54	3 5	0.0000
rc_AA134158_s_at	AA134158	287	EST	3.42	3 5	0.0002
rc_AA134968_at	AA134968	289	EST	4 5	3 5	0.020
rc_AA134985_at	AA134985	290	EST	12.1	<u>6</u> :	0.00079
rc AA135407 f at	AA135407	292	Andorem straviral protesses	12.11	d n	0.00318
rc_AA135871_at	AA135871	294		3.64	g S	0.01086
rc_AA135894_at	AA135894	205	retionic soid induced 3	3.39	롸	0.01544
rc AA136547 at	A A 426547	3 6		14.27	ᅀ	0.00558
10 AA443403 ct	A 4 40 400	200		3.51	g	0.00308
m 00143763 at	AA143493	310	pleckstrin Z (mouse) homolog	4.58	d	0.01037
10 A440040	AA143/03	311	ESI	18.09	an	0.00347
rc_AA140619_at	AA146619	312	EST	4.87	9	0.00863
֝֟֟֟֡֟	AA147084	314	proliferation-assoclated 2G4, 38kD	4.4	. 2	0.0045
rc_AA147439_s_at	AA147439	315	EST	503	<u> </u>	95000
				5	}	0.000.0

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seq 1D	C Known Gene Name	Fold Change	Direction	Pyslite
10 0000 01	10000			B		
10 00140000 at	AA 146853	320	minichromosome maintenance deficient (S. cerevisiae) 4	6.39	dn	0.0125
10_A4108077_81	AA148977	322	EST	3.64	. <u>a</u>	0.02911
1c_AA149889_at	AA149889	326	neighbor of A-kinase anchoring protein 95	3.34	. 9	0.02054
rc_AA150053_at	AA150053	327	EST	3.71	- 9	0.00102
rc_AA151182_at	AA151182	332	EST	3.51	} =	0.000
rc_AA151428_s_at	AA151428	335	matrix metalloproteinase 23B	7.45	3 5	0.00045
rc_AA151778_at	AA151778	338	claudin 7	7.7	- -	0.00090
			ATP synthase. H+ transporting mitochondrial E0 complex	2.0	}	0.00002
rc_AA156187_at	AA156187	339	subunit b. isoform 1	70 00	;	
rc_AA156243_at	AA156243	340	Serine professe umbilical andothalium	43.24	3 .	0.00006
rc_AA156450_at	AA156450	342		47.44	ď	0.00139
rc AA157818 f at	AA157818	240		3.33	ᅀ	0.00587
rc AA158234 at	AA158224	2 2	GOT	25.99	롸	0.00153
Fo AA46070F of	44.70234	100		17.04	đ	0.00711
16 AA 1307 31	AA158/95	352	ESI	3.07	. <u>a</u>	0.00057
rc_AA159525_at	AA159525	354	EST	49.39	- 5	0.000
rc_AA161043_at	AA161043	356	tetraspan 1	78.8	<u> </u>	0.00002
rc_AA161292_s_at	AA161292	357	interferon, alpha-inducible protein 27	5.5	<u>.</u>	0.000.0
rc AA164252 f at	AA164252	250	Were some exempt feature industries	13.84	g	0.00004
	30350100	200	Vor herve growin ractor inducible	3.41	d	0.00154
			NADH dehydrogenase (ubiquinone) Fe-S protein 6 (13kD)		-	
rc_AA169837_at	AA169837	364	(NADH-coenzyme Q reductase)	3 17	<u> </u>	00000
rc_AA171760_at	AA171760	367	EST	17.05	3	0.03030
rc_AA171939_at	AA171939	368	EST	7.00	<u>d</u> :	0
rc AA172076 at	AA172076	369	EST	4.07	0	0.00104
rc_AA173430_at	AA173430	274	101	3.06	롸	0.00326
rc AA179298 et	A 4 4 50 000	- 6		4.32	dn	0.04362
rc AA170787 et	A A 4 70 70 7	ρ/ς ()	stomatin-like protein 2	3.72	g	0.00299
rc AA170846 of	A 4 4 20 4 F	200	polygiutamine binding protein 1	6.44	음	0.00208
20 A A 194600 - 4	AA174043	200		5.77	g,	0.01414
20 A A 19200 - 31	AA181600	384	EST	5.38	g	0.03316
1C_AA102001_1_81	AA182001	386	EST	3.56	. g	0.00945
18 00870 M	AA18/938	391	EST	3.86	B	0.00512

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gone Name	1070	1	
rc_AA188378_i_at	AA188378	392	EST	rold Change	DIrection	Pvalue
rc_AA188378_f_at	AA188378	392	EST	9.00	<u>a</u>	0.00277
rc_AA189015_at	AA189015	307	TOT I	5.54 40.0	g.	0.01359
rc AA191708 at	AA191708	5 6	בא	5.27	dn	0.00004
rc AA192755 at	AA192755	5 5	- 531	3.87	g.	0.01904
rc AA194237 at	A A 104227	7 8	5.5	3.13	요	0.00442
10 10101 Or	A 4 0 4 7 0 4	408 609		3.13	g.	0.00212
ro 04104724_80	AA194724	409	endonuclease G	3.09	ď	0.04011
18 08 79 71 71 71 71 71 71 71 71 71 71 71 71 71	AA196790	421	EST	7.64	g	0.00287
rc_AA20492/_at	AA204927	425	tropomyosin 1 (alpha)	7.09	- 9	0.00074
rc_AAZ11483_at	AA211483	435	EST	44.07	. <u>o</u>	0.00175
rc_AA211851_t_at	AA211851	436	EST	3.66	- 9	0.00789
rc_AA213696_at	AA213696	437	poly(A)-binding protein, cytoplasmic 1	24 65	<u>ء</u>	00000
AA215299_s_at	AA215299	439	U6 snRNA-associated Sm-like protein LSm7	15.84	3 5	0.0000
rc_AA215468_s_at	AA215468	4	ADP-ribosylation factor-related protein 1	0.00	<u> </u>	0.00001
rc_AA218663 at	AA218663	444	acid-inducible phosphorotein	S. C.	롸	0.04048
AA224502 at	AA224502	154		3.26	đ	0.03537
rc AA226932 at	A A 226022	÷ 4	F31	4.12	ф	0.00694
	A420332	504	URFZF364F09Z3 protein	6.84	đ	0.00405
16_A4221360_at	AA22/560	458	EST	12.81	9	0.01693
rc_AAZZ/9Z6_at	AA227926	460	EST	684		70770
				0.01	d n	10/100
rc_AA233886_s_at	AA233886	475	D site of albumin promoter (albumin D-box) binding protein	3 38	<u> </u>	0,000
rc_AA233959_i_at	AA233959	477	EST	40.50	S :	0.0210
rc_AA234096_at	AA234096	479	EST	19.09	S :	0.00101
rc AA234362 at	AA234362	481	EST	23.72 0.00	<u>a</u>	0.00018
rc_AA235707_at	A A 225707	2	101 101	3.89	유	0.03524
rc AA236037 of	A A 2 2 6 7 2 7		101 101	9.17	d	0.00005
rc AA236533 c ct	AA236633	200	101	5.74	g,	0.0091
rc AA236714 f at	AAZ30333	914	ecotropic viral integration site 1	4.01	d	0.02882
rc AA237047 24	AAK307 14	310	nuclear mitotic apparatus protein 1	4.35	d	0.00083
rc 402/3/32 of	AAKS/U1/	126	KIAA1068 protein	3.52	롸	0.00976
rc AA2//3/20	AAZ43133	272	Serine/threonine kinase 15	7.73	dn	0.04328
מייטראיין טי	AAK43173	970	ESI	8.75	đ	0.00003

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name	Eold Change		1
AA249819 s at	AA249819	535	EST	Fold Cilarige	- 1 -	Fvaiue
rc_AA251230 at	AA251230	540	EST	0.03 7.7	g :	0.00130
rc AA251299 s at	AA251299	541	KIDADO14 pene product	5 5	3	0.00034
įα	AA251909	240	EST SOLD POUNCE	16.86	d d	0.00046
rc AA252994 at	AA252004	5 7		3.35	ᅀ	0.03937
۰, ۳	A A 25 20 4 4	2 2	apopiosis irriibitor 4 (survivin)	3.55	ф	0.00075
A A DESCRIPTION OF THE	AAZ33011	ည်	KIAAU/13 protein	4.73	d	0.01944
AAZSSSSS sat	AA253330	262	adaptor-related protein complex 1, gamma 1 subunit	3.87	g	0.00708
rc_AA253473_at	AA253473	267	EST	15.23	. g	0.00171
rc_AA256273_at	AA256273	211	EST	4.13	<u> </u>	0.03874
rc_AA256642_at	AA256642	582	EST	11.17	.	0.00035
rc_AA258482_s_at	AA258482	296	zinc finger protein	3.17	h <u>S</u>	0.0000
rc_AA261907_at	AA261907	603	DKFZP566E144 protein	4 54	}	0.07280
rc_AA262477_at	AA262477	809	ribonuclease HI, large subunit	4.87	3 5	0.02203
rc_AA262887_at	AA262887	610	EST	5.4)	0.0000
rc_AA262943_at	AA262943	611	EST	13.42	}	0.047
rc_AA262969 f at	AA262969	613	ferritin, heavy polypeptide 1	7 40	g. <u>s</u>	0.00234
AA263044 s at	AA263044	615	H2A histone family member V)	3 :	0.00013
rc AA278817 at	AA278817	618	EST	÷ ÷	<u>d</u> !	0.00024
rc AA278838 e at	AA278838	000	F OF T	4.22	<u>G</u> .	0.00061
2 VA270477 04	A A 270477	020		ო	d d	0.02832
1C_AAZ/91//_81	A42/81//	624	lymphocyte antigen 75	6.05	d	0.01821
	AAZ/9840	632	titin-cap (telethonin)	5.58	dn	0.01253
ທຸ.	AA280283	637	EST	4.99	ᅀ	0.02644
rc_AAZ80/34_ at	AA280734	633	KIAA0618 gene product	9.64	9	0.00003
ಹೣ	AA280928	. 642	EST	3.27	. an	0.04625
rc_AAZ8Z149_s_at	AA282149	654	huntingtin interacting protein-1-related	4.19	g	0.00091
œ'	AA282247	657	EST	80	. g	0.00014
rc_AA283085_s_at	AA283085	299	EST	4.93	. an	0.00382
rc_AA284879_at	AA284879	629	EST	24.68	. an	0.00001
rc_AA284945_at	AA284945	089	EST	5.98	. 9	0.00026
rc_AA287022_s_at	AA287022	685	thymidine kinase 1, soluble	4.51	음	0.02582
rc_AA28/347_at	AA287347	687	EST	5.47	g G	0.00034

Ŷ

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name			
rc AA287393 at	AA287393	889	EST	Fold Change	e Direction	Pvalue
		3	3	5.68	dn	0.00062
rc_AA290674_s_at	AA290674	692	eukaryotic translation initiation factor 4F binding protain 1	11 60	1	
rc_AA291137_at	AA291137	694	EST	80.1 80.1	d d	0.00036
rc AA291139 at	AA291139	908	FOT	12.c	ᅀ	0.00685
rc_AA291168_at	AA291168	909		8.69	용	0.04573
AA291456 s at	AA201456	2 6		40.67	롸	0.00065
C AA291659 at	AA2046E0	3 5	-01 -01	3.96	g	0.03633
rc AA202370 at	AA202230	707		3.83	9	0.01934
rc AA292659 at	AA2823/9	2,5	1001	6.04	g	0.00568
rc AA292765 at	A A 20,28E	270	71112	3.48	g	0.00037
rc AA292788 s at	AA202760	717	ZVVTU Interactor	7.14	g.	0.02623
, <u>a</u>	AA202024	7.4	ונט – 1	4.69	dn	0.00967
rc AA293719 at	AA202740	2 6		3.97	dn	0.00067
AA295819 s at	AA205810	2 6	רט. האיז	4.69	g	0.02181
AA298786 at	AA208796	727		80	d	0.01793
AA306121 at	AA306131	7 20	L CO	4.65	ď	0.02821
AA307748 s at	0.00000	7 7 7	- CONTRACTOR IN THE CONTRACTOR	4.85	dn	0.00381
AA320369 s. at	AA320360	725	CO.	3.7	ď	0.00001
AA328993 s at	AA328003	720	Circinosome 19 open reading frame 3	4.33	dn	0.00554
rc AA331303 of	A A 224203	000		3.66	d	0.00146
rc_AA335091_at	AA331393	2 2 2	150-1	16.73	dn	0.00848
rc AA335191 f at	AA325101	44		5.28	dn	6000.0
rc AA338729 at	AA338720	147	creaine kinase, drain Est	47.35	d	0.00419
rc AA33889 f at	V V 2 2 8 8 9 0	3 1		3.33	g S	0.00046
-¦	AA330009	763	actin related protein 2/3 complex, subunit 4 (20 kD)	10.77	g	0.03782
rc AA370163 at	AA370163	707	- CT	5.01	롸	0.00255
rc AA372018 at	AA3720183	007	101 101	3.34	ᅀ	0.00643
AA372630 s at	0.0372620	00/		14.3	요	0.00178
AA384184 S at	AA384184	202	uniterentially expressed in hematopoletic lineages	25.49	dn	0.01743
rc AA394121 at	AA304104	170	DATZF 300 BU 31 B Protein	3.38	ᅀ	0.01209
15-1	171 +6600	0	raminin receptor 1 (6/kD, ribosomal protein SA)	23.78	9	0.00099

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name	10 77		
rc_AA397906 at	AA397906	782	DKF7P4341216 prote	rold Change	Direction	Pvalue
rc AA397916 f at	AA307016	707		3.2	<u>d</u>	0.00138
. 0	0 0 0 0 0 0 0	5 6	101	3.27	d	0.02895
r AA308761 s of	A A 200764	3 6	- POT	4.17	ф	0.00004
10 A 208000 24	10/06044	86 / 67 /		3.43	c,	0.00726
10_AA390900_81	AA398908	ည်		38.69	d d	0.01089
10_A4009420_81	AA399226	803	tight junction protein 3 (zona occludens 3)	3.59	d d	0.02002
1c_A4400271_at	AA4002/1	814	EST	3.51	음	0.00742
	AA401958	832	EST	3.62	. 9	0.01232
rc_AA402495_at	AA402495	838	EST	4.91	- 9	0.00235
AA402937_at	AA402937	843	EST	3.11	÷ 2	0.00182
rc_AA402968_at	AA402968	844	EST	3.1	9	0.00453
rc_AA403159_at	AA403159	842	Ste-20 related kinase	7.33	1 9	0.00187
rc_AA404338_at	AA404338	849	EST	10.9	.	0.000
rc_AA405310_at	AA405310	856	EST.	3.23) 9	0.0000
rc_AA405460_at	AA405460	857	EST	4 02	. <u>-</u>	0.03700
rc_AA405715_at	AA405715	862	hypothetical protein	4.68	}	0.03492
rc_AA405791_at	AA405791	864	EST	21.22	}	0.0000
rc_AA406145_f_at	AA406145	870	EST	A 74	<u> </u>	0 000 0
rc_AA406218_at	AA406218	872	EST	- 88 7	<u>-</u>	0.00047
rc_AA406385_at	AA406385	876	DKFZP564B0769 protein	4.00 2.00	c :	0.02194
rc_AA406542_at	AA406542	878	EST	3.21	g i	0.00724
rc AA410469 at	AA410469	883	FST	0.21	핰	0.00724
rc_AA410508_at	AA410508	885	EST	6.3	<u>Q</u> .	0.00103
rc AA410962 s at	AA410062	802		16.04	ф	0.02635
rc AA410972 2+	AA410072	3 6	peroxisorire promeranve activated receptor, delta	3.45	dn	0.04574
rc 00411502 at	A44 10972 A444500	200	ПО I	3.12	ф	0.00023
rc AA41695 of	A4411502	200	LO.	16.42	g S	0.00241
20 00411000 at	A4411085	088		3.83	dn	0.00417
20 AA412204 24	A4411813	863	postmetotic segregation increased 2-like 11	9.79	dn	0.03499
70 AA412401 at	A4412301	888	E&-	4.57	d	0.00026
70 AA412405 at	A44 12403	200		3.09	dn	0.00047
18 5 CO47 14 AV	AA412405	-DB	ESI	13.82	dn	0.01021

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Disposion	Displace
rc_AA412720_at	AA412720	902	EST	S G	- 1 -	O 04306
rc_AA416963_at	AA416963	911	EST	5. E	3 5	0.01395
rc_AA416973_at	AA416973	913	EST	3.61	3 5	0.0000
rc_AA419217_at	AA419217	923	DKFZP586E1422 protein	6.27	3 5	0.000
rc_AA421562_at	AA421562	934	anterior gradient 2 (Xenepus laevis) homolog	- 65 - 65 - 65 - 65 - 65 - 65 - 65 - 65	3 5	2,000
rc_AA421638_at	AA421638	935	EST	3.05	3 5	0.004
rc_AA422049_at	AA422049	937	EST	3.38	3 5	0.0067
rc_AA422086_at	AA422086	938	EST	10 74	3- <u>5</u>	0.000
rc_AA422150_at	AA422150	939	cytochrome P540 family member predicted from ESTs	17.14	당 달	0.03410
rc_AA424029_at	AA424029	943	EST	89.8	g 5	0.00100
rc_AA424487_at	AA424487	945	EST	38.41	3 5	0.000
rc_AA424881_at	AA424881	949	EST	83	} <u> </u>	0.00558
rc_AA425279_at	AA425279	951	quiescin Q6	6.15	} <u> </u>	0.00083
rc_AA425401_at	AA425401	954	serine/threonine kinase 24 (Ste20, yeast homolog)	3.22	3 5	0.0000
rc_AA425852_s_at	AA425852	928	EST	7.78	1 5	0.00020
- 1	AA425852	928	EST	8 4	3 5	0.00233
rc_AA426447_at	AA426447	965	EST	4 23	g. <u>s</u>	0.000
rc_AA426521_at	AA426521	296	Sjogren's syndrome nuclear autoantigen 1	3.47	}	0.0303
rc_AA427442_at	AA427442	971	quanine nucleotide regulatory factor	43°	3 5	0.01.00
AA427468 s at	AA427468	973	claudin 4	0.45 84.43	d :	0.01347
rc AA427636 at	AA427636	976	EST	£ 6	<u>a</u> . :	0 1
rc AA427825 at	AA427825	8 5	. FOR	19.23	ď	0.00145
rc aa427925 s at	AA427925	600	- N	3.32	ф	0.01615
rc AA427946 at	0.0727046	700	Complete Assessment Habitation to the contract of the contract	3.23	ф	0.01806
A A 428427 6 24	0461740	200	uyileliri, axonemai, lignt polypeptide 4	3.01	g	0.00001
	AA428172	986	Notch (Drosophila) homolog 3	9.53	dn	0.02562
1C_AA426904_8t	AA428964	983	kallikrein 10	21.83	g	0.02324
	AA429009	994	serine protease inhibitor, Kunitz type 1	30.04	g.	0.00001
	AA428470	966	EST	3.67	an	0.00782
rc_AA429472_at	AA429472	997	DKFZP434P106 protein	8.27	. an	0.00208
rc_AA429636_at	AA429636	100	hexokinase 2	10.43	. an	0.00597
AA428625_at	AA429825	1003	DKFZP566B023 protein	6.63	g.	0.00032

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seg ID	Known Gene Name		•	
rc AA429890 s at	AA429890	1001	cisplatin resistance as	rold Change	ł	Pvalue
rc AA430032 at	AA430032	1000	Diffultant fumor francforming 4	12.51	S	0.00053
rc AA430048 at	2000110V	5 5	VIA A DAGO	16.87	ᅀ	0.00659
CC 00430674 of	0 4 4 5 0 0 4 6 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	7101	NIAAU IOU protein	6.27	ф	0.00631
rc 00434740 of	A4430074	1018	101 101	15.11	dn	0.00293
10 AA434770 -	AA431719	1025	EST	4.25	đn	0.00015
	AA431776	1027	EST	3.24	an	0.01814
rc_AA431873_at	AA431873	1028	EST	4.03	1 5	0.00785
rc_AA432162_at	AA432162	1029	DKFZP586B2022 protein	3.48	} =	0.03851
rc_AA433930_at	AA433930	1032	chondroitin 4-sulfotransferase	2.48 7.68	g	0.03631
rc_AA434418_at	AA434418	1036	KIAA1115 protein	. u	<u>.</u>	0.02443
rc AA435526 s at	AA435526	1037	transferrin recentor (ngn CD74)	3. c	<u>d</u> :	0.00498
rc_AA435665_at	AA435665	1040	EST	3.09	g.	0.00139
	A A 436027	1050	- B - H	8.66	요	0.00001
, ,	A A 436473	000	100 I	3.71	ф	0.03676
	A A 436646	7007	_ N	3.03	dn	0.00133
10_A432366_24	A4430010	0001	בט <u>-</u>	3.18	dn	0.04402
10_AA437360_81	AA43/368	1063	EST	3.75	ď	0.01317
	AA43/38/	1064	EST	3.81	g	0.01478
rc_AA441911_at	AA441911	1066	EST	6.14	on.	0.00003
AA442054_s_at	AA442054	1067	phospholipase C, gamma 1 (formerly subtype 148)	16.89	. 9	0.0005
rc_AA442763_at	AA442763	1072	cyclin B2	5.09	}	0.00203
rc_AA443271_at	AA443271	1073	KIAA0546 protein) (}	0.02.100
rc_AA443316_s_at	AA443316	1075	v-Ha-ras Harvev rat sarcoma viral oncodene homolog	5 5	3. £	0.01220
rc AA443941 at	AA443941	1085	tumor suppressing subtransferable capadidate 4	÷ ¢	<u>-</u>	0.01729
rc_AA446949_at	AA446949	1008		3.57	d	0.01685
rc AA446069 24	0446060	2 6		3.41	ᅀ	0.03411
rc AAA7418 s of	A4440900	200	101	3.45	dn	0.02232
rc AA447687 of	AA447.1.0	200	F0-	3.03	dn	0.01702
rc AA447732 of	AA44/00/	4 0 6		11.42	dn	0.00362
re AA447004 et	A444732	001	ESI	3.2	d	0.00591
20 20440072 2 24	A444/991	71.1.		4.99	dn	0.00173
rc_884490/3_s_ar	AA449073	1117	EST	6.89	dn	0.01445
10_M4449122_81	AA449122	1119	EST	3.65	d n	0.00369

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	e Direction	Pvalue
rc_AA449456_at	AA449456	1126	EST	6.29	1 -	0.00087
rc_AA449458_at	AA449458	1127	EST	3.22	f 9	0.03098
rc_AA449475_at	AA449475	1128	EST	3.06	9	0.00291
rc_AA449479_at	AA449479	1129	EST	3,09	÷ 9	0.03495
rc_AA450247_at	AA450247	1133	EST	5.27	t 9	0.02833
rc_AA451676_at	AA451676	1135	EST	14.72	9	0.00056
			hepatocellular carcinoma associated protein; breast cancer		}	
rc_AA451680_at	AA451680	1136	associated gene 1	3.55	9	0.0000
rc_AA451877_at	AA451877	1138	EST	8.63	r =	0.00189
rc_AA452259_at	AA452259	1143	EST	3.49	+ 유	0.00114
rc_AA452536_at	AA452536	1145	v-ral simian leukemia viral oncogene homolog A (ras related)	r. G	9	0 00481
AA452724_at	AA452724	1149	programmed cell death 5	7.2	}	0.0000
rc_AA453477_at	AA453477	1153	X-prolyl aminopeptidase (aminopeptidase P)-like	4.23	}	0000
rc_AA453783_s_at	AA453783	1158	EST	6.16	r 9	0.00167
rc_AA454597_s_at	AA454597	1166	EST	3.63	- <u>G</u>	0.0067
rc_AA454710_at	AA454710	1168	EST	3.42	- 9	0.00653
AA454908_s_at	AA454908	1171	KIAA0144 gene product	6.3	en en	0.00539
rc_AA455521_s_at	AA455521	1178	E2F transcription factor 5, p130-binding	4.6	- Q n	0.00773
rc_AA455522_s_at	AA455522	1179	EST	3.83	. <u>a</u>	0.00017
rc_aa458852_f_at	AA458852	1203	KIAA0440 protein	3.2	- A	0.00038
rc_AA458890_at	AA458890	1206	EST	3.36	9	0.00303
rc_AA459254_at	AA459254	1211	EST	5.36	· 9	0.0259
rc_AA459310_r_at	AA459310	1214	EST	3.45	9	0.00179
rc_AA459388_s_at	AA459388	1215	copine I	5.23	유	0.00691
rc_AA459703_at	AA459703	1222	v-myc avian myelocytomatosis viral oncogene homolog	4.75	9	0.02413
rc_AA459961_at	AA459961	1223	EST	3.24	- 8	0.00316
rc_AA460017_i_at	AA460017	1225	EST	10.76	+ <u>9</u>	0.00106
rc_AA460017_f_at	AA460017	1225	EST	3,61	- 9	0.00109
rc_AA461187_at	AA461187	1236	EST	8.15	유	0.00068

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name	1010	- 1	
rc_AA461473_at	AA461473	1242	nebulette	rold Citarige		Fvalue
rc_AA461476_at	AA461476	1243		0.00	<u>-</u>	0.03855
rc AA463234 at	AA463234	1246		4.12	<u>s</u>	0.008/1
1		1		5.94	d S	0.01182
rc AA463725 at	AA463725	1249	acetylalicosemiodresponen	Ì		
rc AA463861_at	AA463864	4254	COT	4.7	g.	0.04715
rc AAA6444 1 24	A A 6 4 4 4 4	122	Hor	24.79	ᅀ	0.00096
10 141414 at	AA404414	8071	ES.	4.99	음	0.00529
rc_A4464698_at	AA464698	1262	EST	3.24	- 9	0.04854
rc_AA464963_at	AA464963	1265	EST	504	<u></u>	0.0000
			BUB3 (budding uninhibited by benzimidazoles 3, yeast)	5	}	20.00.0
AA471278_at	AA471278	1277	homolog	A 14	<u> </u>	0.0000
rc_AA476216_at	AA476216	1279	EST	5.5	<u>-</u>	0.00073
rc AA478017 at	AA478017	1295	zvxin	1 1	3	90000
	AA478300	120R	CD39-like 2	//·c	함	0.00484
rc AA478415 at	AA478415	1200	LST.	6.15	с	0.01625
rc AA78500 at	A A 479E00	200		4.56	д	0.00095
rc AAA70044 s st	AA410388	100	G protein-coupled receptor 56	3.31	g	0.00182
70 AA470777 5 24	A 4 4 7 0 2 0 4 4	7001	- COL	6.9	g	0.04668
20 AAAAAAA	A4479727	1315	ES.	90.9	dn	0.00389
10_A4419191_at	AA4/9/9/	1316	ESI	7.93	an	0.0000
rc_AA479945_s_at	AA479945	1319	plakophilin 3	3.17	÷ 9	0.01767
rc_AA482007_at	AA482007	1331	EST	3.49	- 9	0.00167
,			protein kinase related to S. cerevisiae STE20, effector for	}	<u>.</u>	
rc_AA482127_at	AA482127	1333	Cdc42Hs	4 88	<u> </u>	0.00017
rc_AA482224_f_at	AA482224	1334	putative type II membrane protein	50.4	3 5	0.000.0
AA482319 f at	AA482319	1335	nitative time II membrane eratein	, i	₹	0.0103
rc AA482546 s at	AAAROKAE	1226	Parative type II Institution protein	5.11	d	0.00177
rc AA482613 at	A A 40.264.9	200	NIAMOLE4 projein	4.41	슠	0.00604
TC AAABEADE 21	A A 495 405	1338	UKFZP434BZU3 protein	4.14	d	0.00186
20 AA485607 24	A4463403	540	101	5.35	d	0.03475
10_70463697_at	AA463587	1346		14.74	9	0.00102
10_A440090/_S_BI	AA488987	1365	synaptogyrin 2	3.24	g.	0.01444
ic_AA408/U/_at	AA489707	1371	EST	3.47	g.	0.03433

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seg ID	Known Gene Name	Fold Change	Direction	order d
rc_AA489712_at	AA489712	1372	EST	4 93		0.00728
rc_AA490212_at	AA490212	1375	H2A histone family, member Y	3.74	3 5	0.00720
rc_AA490494_at	AA490494	1377	EST	5.16	9	0.01696
rc_AA491223_at	AA491223	1389	EST	3.03	÷ 9	0.00557
rc_AA496204_at	AA496204	1397	EST	3.69	s o	0.01097
rc_AA496245_at	AA496245	1398	EST	3.96	- 2	0.0039
			v-erb-b2 avian erythroblastic leukemia viral oncogene homolog		 	
rc_AA496981_at	AA496981	1404	ന	4.93	9	0.01096
rc_AA497031_at	AA497031	1407	EST	11.05	3 5	0.01030
rc_AA504111_at	AA504111	1409	EST	3.2	£ 5	0.00544
rc_AA504264_at	AA504264	1410	EST	3.81	<u> </u>	0.00684
rc_AA504270_at	AA504270	1411	EST	4.96	3 5	0.0000
AA504413_at	AA504413	1413	EST .	3.35	1 5	0.000
rc_AA504806_at	AA504806	1416	EST	3.54		0.00221
rc_AA598405_at	AA598405	1424	membrane interacting protein of RGS16	4.69	÷ <u>=</u>	0.0122
rc_AA598506_s_at	AA598506	1430	KIAA0179 protein	3 17	<u> </u>	0.01604
rc AA598712 at	AA598712	1436	EST	5 6	<u>.</u>	0.000
rc_AA598988_at	AASORORA	1442	EG.L	0.00	g.	0.03656
rc A A 500244 ot	A E00344	7 7		4.32	ᅀ	0.00044
12 - N039244 at	A4389244	1448	NIAAUSSU protein	3.39	d	0.01246
rc_AA599522_f_at	AA599522	1452	squamous cell carcinoma antigen recognised by T cells	6.75	9	00000
rc_AA608579_s_at	AA608579	1464	paired-like homeodomain transcription factor 2	4.29	ਜੇ Ξ	0.04435
rc_AA608897_at	AA608897	1473	EST	6 6	} =	0.00087
rc_AA608965_at	AA608965	1474	Hermansky-Pudlak syndrome	3.19	r S	0.0000
rc_AA609008_at	AA609008	1475	EST	3.46	d an	0.02935
rc_AA609013_s_at	AA609013	1477	dipeptidase 1 (renal)	10.17	. dn	0.00109
rc_AA609614_at	AA609614	1487	EST	6.5	<u> </u>	0.00406
rc_AA609786_s_at	AA609786	1491	nucleolar protein 1 (120kD)	4.75	<u> </u>	0.00261
rc_A4610033_8t	AA610053	1496		7.01	dn	0.00003
12 A A620466 24	AA610116	1499	tetraspan NE I-6 protein	33.68	dn	0.00171
rc_A4020400_ar	AA620466	1502	EST	5.14	d	0.00004

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

881_at	Sed ID			
995_at AA620995 1512 80_at AA621277 1520 80_at AA62177 1520 80_at AA621780 1530 at AB0002533 1539 at AB0002781 1540 at AF001294 1544 AF001294 1544 AF001294 1544 at C01766 1559 at C01766 1559 at C01766 1569 at C14098 1568 at C14098 1569 at C14098 1569 at C14348 1589 at C14348 1589 at C14369 1607 at at D13413 1604 b14520 1613 b14657 1615 b	trinucleotide repeat containing 3			Pvalue
77_at AA621277 1520 80_at AA621277 1520 80_at AA621277 1530 at AB0002533 1539 s_at AB000584 1540 at AF001294 1544 at AF003521 1545 at C01766 1559 f_at C01766 1569 f_at C14098 1568 at C14098 1568 f_at C14098 1568 f_at C14348 1569 f_at C14348 1569 f_at C15324 1574 f_at C15324 1567 f_at C15339 1607 f_at D14530 1614 p_f15		0.00	g.	0.00735
## APO02533 1539 So_at		3.74	윤	0.03414
at AB000584 1533 S. at AB000584 1533 S. at AB000584 1533 S. at AB000584 1540 at AF001294 1544 at AF003521 1545 at C01766 1559 f. at C13992 1564 f. at C14098 1568 at C14098 1568 at C14412 1569 f. at C14348 1568 at C14348 1569 f. at C15324 1574 at D13413 1604 D14520 1613 1	_ `	3.81	d	0.00194
at AB002533 1539 -s_at AB002533 1539 -s_at AB006781 1540 at AF001294 1544 -at AF003521 1545 -f_at C01766 1559 -f_at C13992 1564 -f_at C14098 1568 -f_at C14098 1568 -f_at C14756 1574 -f_at C14756 1574 -f_at C14756 1579 -f_at C14348 1568 -f_at C14348 1568 -f_at C14348 1568 -f_at C14348 1568 -f_at C14348 1569 -f_at C14348 1569 -f_at C15324 1574 -f_at C14750 1613 -f_at C15324 1615 -f_at C1615 -f_at C161		3.65	dn	0.01582
at AB006781 1540 at AB006781 1540 at AF001294 1544 at AF001294 1544 at C01766 1559 at C01766 1559 at C01766 1569 at C14098 1568 at C14098 1568 at C1412 1569 at C14348 1568 at C14348 1568 at C14348 1568 at C14348 1569 at C15324 1574 at C15324 1574 at C21248 1585 at C15324 1574 at D13413 1604 b14520 1613 b14530 1614 p14657		4.7	g	0.00071
at AF001294 1544 at AF001294 1544 at AF001294 1544 at C01766 1559 fat C01766 1559 at C01766 1569 fat C14098 1566 at C14098 1568 at C1412 1569 fat C14756 1574 at C21248 1585 at C21248 1585 at D13413 1604 b14520 1613 b14530 1614 p	_ `	6.38	a	0.00003
at AF001294 1544 at AF003521 1545 at AF004709 1547 at C01766 1559 -f_at C01766 1569 -f_at C14098 1568 at C1412 1568 at C14756 1574 f_at C14756 1574 at C21248 1585 at C21248 1585 at D00017 1587 b14520 1614 b14520 1614 b14530 at D14530 1614 b		7.05	. 9	0.00913
at AF003521 1545 at AF004709 1547 at C00021 1551 at C01766 1559 -f_at C13992 1564 -f_at C14098 1568 at C14412 1569 at C14756 1574 at C21248 1585 at C21248 1585 at C21248 1585 at C21248 1585 at C21248 1587 at D13413 1604 at D13639 1607 b14520 1613 b b14530 1614 p	_	7.45	<u>}</u>	00000
at AF004709 1547 at C00021 1551 at C01766 1559 fat C13992 1564 fat C14098 1568 at C14348 1568 at C14412 1569 fat C14756 1570 fat C21248 1585 at C21248 1585 at D00017 1587 b14520 1604 b14520 1613 b14530 1614 b14657 1615	_	11.08	}	0,000
at C00021 1551 at C01766 1559 -f_at C13992 1564 -f_at C14051 1565 -f_at C14098 1566 at C14348 1568 at C14412 1569 -f_at C14756 1570 -f_at C21248 1585 at C21248 1587 at D13413 1604 at D13639 1607 at D14520 1613 b	_	3 62	}	0.0000
at C00021 1551 at C01766 1559 f_at C13992 1564 f_at C14051 1565 at C14038 1566 at C14348 1568 1568 f_at C1472 1569 f_at C14756 1570 f_at C21248 1585 at C21248 1585 D11086 1595 D13639 1607 D14520 1613 D14550 1614 D14657 1615	stress-associated endoplasmic reticulum protein 1: rihosome	5	<u>}</u> .	0.003
fat C01766 1559 fat C13992 1564 fat C14051 1565 at C14098 1568 at C14348 1568 fat C14412 1569 fat C14756 1570 fat C21248 1585 at C21248 1585 D00017 1587 D11086 1595 D13639 1604 D14520 1613 D14550 1615		2 22	:	7,000
fat C13992 1564 fat C14051 1565 at C14098 1568 at C14348 1568 at C14412 1569 fat C14756 1570 fat C21248 1585 at C21248 1585 at C21248 1585 D00017 1587 D11086 1595 D13639 1607 D14520 1613 D14530 1615		5.55 10.61	<u>a</u> .	0.00215
fat C14051 1565 fat C14098 1566 at C14348 1568 at C14412 1569 fat C14756 1570 fat C21248 1585 at C21248 1585 at C21248 1585 D00017 1587 D11086 1595 D13639 1607 D14520 1613 D14657 1615	_	13.6/	g.	0.00003
f at C14098 1568 at C14348 1568 at C14412 1569 f at C15324 1574 at C21248 1585 at C21248 1585 at C21248 1585 at D00017 1587 b11086 1595 b14520 1613 b14530 1614	_	6.39	음	0.00059
at C14030 1966 at C14348 1568 at C14756 1570 f at C21248 1585 at C21248 1585 at C21248 1585 at C21248 1585 at D00017 1587 b11086 1595 a1_s_at D13413 1604 b14520 1613 b14550 1615		3.68	음	0.01453
at C14348 1568 at C14412 1569 f_at C15324 1574 at C21248 1585 at C21248 1585 at D00017 1587 a1_s_at D13413 1604 b14520 1613 b14530 1614		3.53	dn	0.04401
at C14412 1569 f_at C14756 1570 f_at C15324 1574 at C21248 1585 D00017 1587 D11086 1595 a1_s_at D13413 1604 D14520 1613 D14550 1614 D14657 1615	_	4.08	2	0.00111
f_at C14756 1570 f_at C15324 1574 at C21248 1585 D00017 1587 a1_s_at D13413 1604 D14520 1613 D14550 1615	1569 HSPC038 protein	0 %	} <u> </u>	0.000
fet C15324 1574 24 C21248 1585 D00017 1587 D11086 1595 a1_s_at D13413 1604 D13639 1607 D14520 1613 D14550 1615		5	3	0.0000
at_s_at C21248 1585 D00017 1587 D11086 1595 at_s_at D13413 1604 D13639 1607 D14520 1613 D14530 1614 D14657 1615		0.30	d n	0.00001
a1_s_at D13413 1607 1607 1607 1607 1607 1607 1607 1607		5.22	ᅀ	0.00344
a1_s_at D13413 1604 1607 1607 1607 1607 1607 1613 1613 1614 1615 1615 1615 1615 1615 1615 1615		3.85	ď	0.00456
a1_s_at D13413 1604 1607 1607 1607 1607 1607 1613 1613 1614 1615 1615 1615 1615 1615 1615 1615		11.38	9	0
a1_s_at D13413 1604 a				
a1_s_at D13413 1604 D13639 1607 O14520 1613 D14530 1614 D14657 1615 D14657 1615 D14657 1615 D14657		5.61	9	0.00873
a1_s_at D13413 1604 a D13639 1607 a D14520 1613 a D14530 1614 a D14657 1615 a	heterogeneous nuclear ribonucleoprotein U (scaffold			
D13639 1607 D14520 1613 D14530 1614 D14657 1615		4 70	9	60000
D14520 1613 D14530 1614 D14657 1615			<u>2</u> :	0.00092
D14530 1614 D14657 1615		D 4.	<u>a</u> .	0.01641
D14657 1615		4.93	g	0.00004
6101		3.1	dn	0.00331
101070		3.7	dn	0.04079
ול_טופטונים שנים 1623 golgi autoantige	1623 golgi autoantigen, golgin subfamily a, 3	3.44	g.	0.02212

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name			
rc D20464 at	DODAGA	1625		rold Change	e Direction	Pvalue
rc D20906 at	D20404	1023	Diomognialit adjacent to zinc tinger domain, 2B	3.27	dn	0.04897
18-00003-0-1	070300	1701		5.18	9	0.02189
			_		•	
D21063_at	D21063	1628		3,83	2	0.00983
D21261_at	D21261	1629	transgelin 2	3.46	} <u> </u>	0.0000
D23660_at	D23660	1630	_		S :	0.00000
D25216_at	D25216	1631	_	3.22	<u>d</u>	0.00316
D25274 at	D25274	46.00		3.17	g	0.02125
D25328 04	17770	7007		3.39	珨	0.00238
	025328	1633		3.17	g	0.04925
rc_Uzəsəu_i_at	025560	1634		4.72	. <u>9</u>	0.00661
D26129_at	D26129	1635	ribonuclease, RNase A family, 1 (pancreatic)	5.68	. 9	0.03827
			neuroblastoma candidate region, suppression of tumoriaenicity) - 	L.	
D28124_at	D28124	1636		6.38	g	0.00045
D31094_at	D31094	1639	G8 protein	4.41	<u></u>	0.00010
D31417 at	D31417	1645	secreted protein of unknown function	- 1:1	<u>}</u> :	0.04040
1	• • •	2		4.56	d n	0.00014
D38073_at	D38073	1651	minichromosome maintenance deficient (S. cerevisiae) 3	3 65	9	0.0400
D38548 at	D38548	1655	KIAA0076 gene product	3 4	<u>.</u>	0.010.0
D38583_at	D38583	1656	S400 calcium-biodica acataia A44 (actains)	C.4.	d	0.00036
D42085 34	742000	5 6	Croc cardium Pumum protein Am (cargizzarin)	18.7	ᅀ	0.00003
742040	044000	0201	NIAAUUSS gene product	3.83	d	0.00036
D43050	D45848	1659	KIAA0082 protein	3.32	o n	0.0014
D45350_at	D43950	1660	chaperonin containing TCP1, subunit 5 (epsilon)	3.61	on.	0.00672
D49400_at	D49400	1667	ATPase, vacuolar, 14 kD	4.01	. 9	0.00287
D50663_at	D50663	1671	t-complex-associated-testis-expressed 1-like 1	4.09	- 9	0.000
D50913_at	D50913	1672	KIAA0123 protein	332	}	0.00200
D50914_at	D50914	1673	KIAA0124 protein	72.7	}	0.01202
rc_D51112_s_at	D51112	1675	collabsin response mediator protein 1	1.7	- :	20,000,0
rc_D51133_f_at	D51133	1676	tubulin, beta, 4	7 8 4	g :	0.00076
rc D51276 f at	D51276	1678	lettkemie-seconisted absorbanchasis 240 (24-44-26)	† ·	3 -	0.020.0
	764207	200	"Located and a feet bringbringhous process by the (statument)	4.81	ᅀ	0.00514
re D51203 f. of	754303	000	ribusornal protein 512	3.3	dn	0.02829
15_001332_1_at	001083	1681	ribosomai protein L4	5.64	đ	0.00074
			(•	

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Sed ID	Known Gene Name	Eold Change	- 1	21,016
rc D52632 f at	D52632	1683	ribosomal profein Se	rold Gilaily		Fvalue
rc D53130 f at	DE2420	2.0		3.12	ď	0.00498
100000	6000	100	noosomal protein SZ8	4.38	9	0.000
rc_D54296_f_at	D54296	1685	KIAA0255 gene product	3.8	- <u>s</u>	0.01059
D55716 at	D55716	1686	ministromomomorphism of the state of the sta			
rc D57/80 at	057700	2 6	minding modellie mannendialice deliciem (o. cerevisiae) /	9.9	음	0.00151
10 DE0222 & 04	00,400	800. 1000.	chaperonin containing TCP1, subunit 7 (eta)	4.08	음	0.00001
10_039322	D59322	1694	ESI	4.18	g	0.00006
₫,	D59847	1701	EST	3.09	. g	0.02206
rc_D60811_s_at	D60811	1704	EST	3.22	÷ 9	0.0098
			platelet-activating factor acetylhydrolase, isoform lb, gamma		<u>.</u>	
D63391_at	D63391	1710	subunit (29kD)	3.91	g	0.00062
D63486_at	D63486	1712	KIAA0152 gene product	6.33	. <u>a</u>	0.00078
Dos46/_at	D6348/	1713	KIAA0153 protein	5.4	d	0.00027
D63874 at	D62874	4744				
D62880 24	10000	± 1	iligir-mobility group (nonnistone chromosomal) protein 1	3.64	음	0.00228
מספפר שו	023880	CL/1	KIAA0159 gene product	4.26	g	0.00253
D/8301_at	D/8361	1718	EST	3.14	9	0.00023
D/86/6_at	D78676	1719	EST	3.2	. <u>s</u>	0.00635
D79205_at	D79205	1721	ribosomal protein L39	3.07	. 9	0.00021
rc_D80237_s_at	D80237	1729	actin related protein 2/3 complex, subunit 4 (20 kD)	3.27	+ 9	0.00137
rc_D80662_s_at	D80662	1733	adaptor-related protein complex 1, gamma 2 subunit	3.43	t 9	0.00108
rc_D80710_f_at	D80710	1734	integral type I protein	7.08	+ 9	0.00213
rc_D80917_f_at	D80917	1736	KIAA0670 protein/acinus	3.58	. 5	0 00007
rc_D80946_f_at	D80946	1737	SFRS protein kinase 1	8.53	<u>ב</u>	0.00455
			5-aminoimidazole-4-carboxamide ribonucleotide	}	<u>.</u>	2000
D82348_at	D82348	1744	formyltransferase/IMP cyclohydrolase	3.93	Ē	0.00037
D82558_at	D82558	1746	novel centrosomal protein RanBPM	5.94	} =	0.00257
D83735_at	D83735	1747	calponin 2	10.45	3 5	0.001.02
	1		trinucleotide repeat containing 11 (THR-associated protein, 230	74.0	3	0.000.0
D83783_at	D83783	1748	kDa subunit)	6.55	dn	0.00176

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Dispetion	B.co.la
			trinucleotide repeat containing 11 (THR-associated protein 230	in and		LAGING
D83783_at	D83783	1748	kDa subunit)	2 23	<u> </u>	0770
D86956_at	D86956	1753	heat shock 105kD		<u> </u>	0.00746
D86974_at	D86974	1756	KIA A0220 matein	4	읔	0.03013
D87735 at	D8772E	7	יייייייייייייייייייייייייייייייייייייי	3.85	롸	0.0161
D87053_0t	CS / 20	40/	ribosomai protein L14	3.92	g	0.00015
D00454_0t	D8/853	1765	N-myc downstream regulated	6.12	. g	0.00033
D00134 at	D88154	1766	villin-like	4.18	· 9	0.00051
rc_ro1444_r_at	F01444	1770	KIAA0440 protein	6.78	+ 9	0.000
rc_F01568_at	F01568	1772	EST	3.24	3 5	0.0020
rc_F02800_at	F02800	1780	EST	3.45	} <u> </u>	0.00.0
rc_F02863_at	F02863	1782	EST	20.4	3 5	0.03230
rc_F04320_s_at	F04320	1786	replication factor C (activator 1) 4 (37kD)	2.00	d :	0.01039
rc_F04444_at	F0444	1788	EST (Common) (Common)	5.03	S	0.01119
rc_F04531 s at	F04531	1791	Kell blood group precureor (Mel cod aboactate	4.07	g S	0.01132
, T	F04674	1703	KINANTAR STATES	7.79	G	0.03205
rc F09297 s at	F00207	2 6		8.2	g.	0.00028
TO E0000	100001	200		3.94	g	0.0016
100001	F09394	1803	KIAA0715 protein	22.89	. <u>9</u>	0.01753
rc_rusp64_at	F09684	1805	EST	3.78	. 9	0.0027
			procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-)	}	0.00211
rc_F09788_at	F09788	1808	hydroxylase), alpha polypentide II	**	!	00000
rc F13809 f at	F13809	1828	frontance (falaba)	4.14	d h	0.00003
rc H04753 f at	H04753	1830		7.62	음	0.00012
	H04700	1841		3.38	롸	0.02447
٠, ۴	706307	5 5		3.71	g.	0.04109
	10000	1040	KIAAUZ66 gene product	4.06	dn	0.0015
10 105025 S at	H05525	1846	hypothetical protein	4.6	g	0.0033
10 H00063 1 81	CZ9C0H	184	EST	5.17	9	0.04551
≅,	H08863	1829	hypothetical protein	3.48	- 5	0.000
rc_H09241_s_at	H09241	1861	EST	4.17	}	0.0020
rc_H09271_f_at	H09271	1862	EST	5.05	<u>.</u> <u>.</u>	0.00127
rc_H09281_at	H09281	1863	EST		} :	0.0010
rc H13532 f at	H13532	1881	ribosomal protein 1 18a	0 0	Q.	0.00966
1 		3		3.97	g	0.00061

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name	Fold Charge	- 1	
rc_H17476_at	H17476	1889	EST	Tota Citati	- 1	Pvalue 0.00470
rc_H18412_s_at	H18412	1890	isocitrate dehydrogenase 3 (NAD+) gamma	5.44	<u>-</u>	0.00479
rc H18442 f at	H18442	1891	Creating kings hadin	. t. č.	3	0.00202
rc H20989 s at	HOORD	9 9	Security Misses, pigni	17.42	ᅙ	0.02391
TO H24077 of	120903	1099	Pyluvate Kiliase, muscie	11.37	ф	0.0375
10_1124011_BI	77047	200		3.05	d	0.0324
rc_nz/188_r_at	H2/188	1908	collagen-binding protein 2 (colligen 2)	4.16	g	0.02073
rc_H28333_t_at	H28333	1912	melanoma adhesion molecule	3.11	. <u>e</u>	0.00172
rc_H29565_at	H29565	1913	EST	3.89	· =	0.01856
rc_H38240_s_at	H38240	1916	thrombospondin 2	4 28	3 E	0.0.0
rc_H38568_s_at	H38568	1918	EST	4 86	3 5	0.000
rc_H42321_f_at	H42321	1928	ribosomal protein L18a	20.6	}	0.000
H43286 s at	H43286	1929	Gamma-aminohuturic acid (GARA) B recentor 1	25.2	} !	0.01102
rc H43646 at	HA36A6	1030	HOA histone family, mamper V	20.c	<u>a</u>	0.01972
HARABE & of	146486	5 6		4.6	g	0.00147
יייייייייייייייייייייייייייייייייייייי	140400	1832	nesca protein	4.77	g	0.00421
10_H4903/_S_BI	H49637	1940	EST	3.79	. an	0.01092
rc_H52673_s_at	H52673	1943	BCL2-antagonist/killer 1	3 03	<u></u>	20200
H53657_s_at	H53657	1945	adenvlate cyclase 3	0000	} :	0.0333
H55437 at	H55437	1948	kraken-like	0.00	3	0.0045
rc H56345 r at	H56345	1050		5.53 5.53	읔	0.02344
	25001	200		4.15	9	0.00488
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			solute carrier family 2 (facilitated glucose transporter), member		•	
rc_H58873_s_at	H58873	1961		57.98	=	0.00083
rc_H59617_at	H59617	1964	EST	e e	1 =	0.0000
rc_H75933_f_at	H75933	1998	laminin receptor 1 (67kD, ribosomal protein SA)	5.83	<u></u>	0.000
rc_H78211_at	H78211	2001	EST	6.73	<u> </u>	0.00024
rc_H78323_at	H78323	2002	transcription factor Dn-1	0	} :	0.02400
l			high mobility group (non-kiefens als	9.ca	<u>a</u> .	0.00320
rc H84443 f of	U04445	1000	ingri-mobility group (nonnistone chromosomal) protein isoforms			
10 14 13 1 at	10001	7007	and Y	5.82	d	0.00769
10000/4_s_all	H880/4	2021	collagen, type I, alpha 2	5.06	đ	0.00866
H69551_s_at	H89551	2024	EST	9.94	9	0.00137
rc_H93021_at	H93021	2033	peptidylprolyl isomerase A (cyclophilin A)	3.31	- <u>9</u>	0.0183
rc_H93492_at	H93492	2037	EST	3.94	. g	0.01136

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change Direction Pyalus	Direction	Pyaliio
rc_H93652 f at	H93652	2039	ribosomal protein S5	3.34	10000	00000
rc H94471 at	H94471	2042			}	0.00.0
10 10 10 10 10 10 10 10 10 10 10 10 10 1	00000	2012		43.09	a	3
1C_1190235_S_BI	185233	2048	serine protease inhibitor, Kunitz type, 2	47.06	9	0
rc_H96975_at	H96975	2057	EST	3.22	. 🖺	0.0141
rc_H97013_at	H97013	2059	ephrin-A4	9 14	1 5	0.00346
rc H97809 at	H97809	2063	EST	- u	} !	0.00340
108037 of	7000077	0000		50.4	<u>a</u>	0.000
100324 81	47606L	7/07	criromatin assembly factor 1, subunit A (p150)	3.53	d d	0.02106
rc_H99473_s_at	H99473	2077	regulator of nonsense transcripts 1	5.37	ф	0.00177

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	e Direction	Pvalue
J03459_at	J03459	2093	leukotriene A4 hydrolase	3.03	9	0.04041
J03464_s_at	J03464	2094	collagen, type I, alpha 2	9.81	1 9	0.00028
			solute carrier family 25 (mitochondrial carrier; adenine		,	
J03592_at	J03592	2096	nucleotide translocator), member 6	10,05	Qn	0
J03827_at	J03827	2100	nuclease sensitive element binding protein 1	4.45	음	0.00015
			membrane component, chromosome 1, surface marker 1			
J04152_rna1_s_at	J04152	2107	(40kD glycoprotein, Identified by monoclonal antibody GA733)	5.26	Qn	0.02466
J04164_at	J04164	2108	interferon induced transmembrane protein 1 (9-27)	12.37	r on	0.00001
AFFX-BioDn-3_at	J04423	2109	EST	54.11	1 9	0.02774
AFFX-BloDn-3_at	J04423	2109	EST	48,05	19	0.02203
AFFX-BioDn-3_at	J04423	2109	EST	21.46	- <u>Q</u>	0.04283
AFFX-BioB-3_at	J04423	2109	EST	5.13	. <u>e</u>	0.02791
AFFX-BioB-5_at	J04423	2109	EST	4.47	. <u>a</u>	0.02754
AFFX-BioDn-3_st	J04423	2109	EST	4,35	9	0.01245
J04469_at	J04469	2111	creatine kinase, mitochondrial 1 (ublquitous)	7.9	- 9	0.00705
J04823_rna1_at	J04823	2115	cytochrome c oxidase subunit VIII	3.35	t 9	0.00075
J05257_at	J05257	2118	dipeptidase 1 (renal)	12.02	1 9	0.02099
J05582_s_at	J05582	2121	mucin 1, transmembrane	25.39	+ =	0.00056
			solute carrier family 2 (facilitated glucose transporter), member	8	<u>)</u>	
K03195_at	K03195	2128		10.73	9	0.00139
K03460_at	K03460	2129	tubulin, alpha 1 (testis specific)	7.5	}	0 0000
L03411_s_at	L03411	2134	RD RNA-binding protein	3 97	<u> </u>	0.0000
L04483 s at	L04483	2136	ribosomal profein S21	5 5	}	0.000
l l			NADH dehydrogenase (ubiquinone) 1 alpha subcomplex. 9	4 7	d n	0.0003
L04490_at	L04490	2137	(39KD)	5.22	g	0.02192
					•	

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pyalue
L06499_at	L06499	2141	ribosomal protein L37a	4.34	_	0.01103
L06505_at	T06505	2142	ribosomal protein L12	5.	5 9	0.00163
L08044_s_at	L08044	2149	trefoil factor 3 (intestinal)	21.42	: <u>a</u>	0.01674
L08044_s_at	L08044	2149	trefoil factor 3 (intestinal)	14.18	. an	0.02124
L09604_at	L09604	2151	proteolipid protein 2 (colonic epithelium-enriched)	8.68	g G	0
L11566_at	L11566	2156	ribosomal protein L18	4.29	. an	0.00014
L11669_at	L11669	2157	tetracycline transporter-like protein	6.75	. <u>a</u>	0.00101
L12350_at	L12350	2160	thrombospondin 2	3.78	9	0.00061
L12711_s_at	L12711	2161	transketolase (Wernicke-Korsakoff syndrome)	3.08	2	0.03362
			high-mobility group (nonhistone chromosomal) protein isoforms		-	
L17131_ma1_at	L17131	2168	l and Y	20.57	dn	0.00058
L19527_at	L19527	2169	ribosomal protein L27	3.54	g	0.00025
L19605_at	L19605	2170	annexin A11	6.38	. an	0.00017
			macrophage migration inhibitory factor (glycosylation-inhibiting		•	
L19686_rna1_at	L19686	2171	factor)	5.26	an	0.00562
L20591_at	L20591	2173	annexin A3	4.64	. <u>a</u>	0.00065
L20941_at	L20941	2174	ferritin, heavy polypeptide 1	3.3	. <u>2</u>	0.01172
L21954_at	L21954	2177	benzodiazapine receptor (peripheral)	8.53	a S	0.00001
L23808_at	L23808	2179	matrix metalloproteinase 12 (macrophage elastase)	6.18	. <u>a</u>	0.02195
L25081_at	L25081	2180	ras homolog gene family, member C	3.67	. <u>a</u>	0.00005
L33075_at	L33075	2195	IQ motif containing GTPase activating protein 1	3.83	- Q	0.00015
L33842_ma1_at	L33842	2197	IMP (inosine monophosphate) dehydrogenase 2	11.03	В	0.00001
L33930_s_at	L33930	2198	CD24 antigen (small cell lung carcinoma cluster 4 antigen)	9.16	9	0.01252
			transcription elongation factor B (SIII), polypeptide 1 (15kD,		•	
L34587_at	L34587	2200	elongin C)	4.32	d	0.00287
L36720_at	L36720	2205	bystin-like	3.46	g	0.00094
L38696_at	T38696	2208	RNA-binding protein (autoantigenic)	3.7	- d	0.00093
		;	thyroid receptor interacting protein 10 (CDC42-interacting			
L40379_at	L40379	2210	protein)	3.87	dn	0.00207
L40904_at	L40904	2212	peroxisome proliferative activated receptor, gamma	3.43	ф	0.03511

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Sed ID	Known Gene Name	Fold Change	Direction	Divalue
L41351_at	L41351	2214	protease, serine, 8 (pr	6.34	1 -	0 01132
L44538_at	L44538	2217	EST	4.34	f S	0.04319
L76191_at	L76191	2222	interleukin-1 receptor-associated kinase 1	5.66	}	0.000.0
L76200_at	L76200	2223		3.24	1	0.0097
AFFX-HUMRGE/M10098 M10098	09£ M10098	2231	EST	11.55	, 9	0.00099
AFFX-HUMRGE/M10098 M10098	09£ M10098	2231	EST	10.2	e an	0.00027
AFFX-HUMRGE/M10098 M10098	09£ M10098	2231	EST	5.62	. an	0.00251
AFFX-HUMRGE/M10098 M10098	09£ M10098	2231	EST	5.61	. <u>a</u>	0.01238
AFFX-HUMRGE/M10098 M10098	09£ M10098	2231	EST	5.35	. g	0.00186
AFFX-HUMRGE/M10098 M10098	09£ M10098	2231	EST	4.79	dn	0.00328
AFFX-HUMRGE/M10098 M10098	09£M10098	2231	EST	4.66	. g	0.00405
AFFX-HUMRGE/M1009EM1009B	09EM10098	2231	EST	3.73	dn dn	0.01794
M12125_at	M12125	2241	tropomyosin 2 (beta)	10.83	dn.	0.00191
M13934_cds2_at	M13934	2255	_	3.99	on on	0
M14199_s_at	M14199	2258	laminin receptor 1 (67kD, ribosomal protein SA)	7.01	. an	0
M14483_ma1_s_at	M14483	2261	prothymosin, alpha (gene sequence 28)	4.46	on On	0.00686
M14949_at	M14949	2264	related RAS viral (r-ras) oncogene homolog	3.11	. <u>a</u>	0.00013
M15205_at	M15205	2265	thymidine kinase 1, soluble	3.75	. an	0.00159
M16364_s_at	M16364	2269	creatine kinase, brain	12.69	. an	0.03633
M17733_at	M17733	2280	thymosin, beta 4, X chromosome	4.15	. <u>e</u>	0.0000
M17885_at	M17885	2281	ribosomal protein, large, P0	3.92	. an	0.00003
M17886_at	M17886	2282	ribosomal protein, large, P1	4.34	. <u>a</u>	0.00004
M18000_at	M18000	2283	ribosomal protein S17	3.79	. <u>a</u>	0.00004
			carcinoembryonic antigen-related cell adhesion molecule 6 (non-		•	
M18728_at	M18728	2285	specific cross reacting antigen)	44.82	gn	0.00291
M20471_at	M20471	2289	clathrin, light polypeptide (Lca)	5.32	. Q .	0.00344
M22960_at	M22960	2296	protective protein for beta-galactosidase (galactosialidosis)	4.49	유	0.00898
M23613_at	M23613	2301	nucleophosmin (nucleolar phosphoprotein B23, numatrin)	3.67	육	0.00977

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Sed ID	Known Gene Name	Fold Change	Direction	Dvalue
			guanine nucleotide bi	0		
M24194_at	M24194	2302	2-iike 1	4.55	qn	0.00017
M24485_s_at	M24485	2304	glutathione S-transferase pi	10.2	g	0.00003
M26708_s_at	M26708	2311	prothymosin, alpha (gene sequence 28)	3.35	- <u>e</u>	0.00064
	M27826	2313	endogenous retroviral protease	26.36	. <u>a</u>	0.00342
AFFX-M27830_5_at	M27830	2314	EST	15.53	9	0.00022
	M27830	2314	EST	14.86	- 9	0.00043
AFFX-M27830_5_at	M27830	2314	EST	10.64	g	0.00213
AFFX-M27830_M_at	M27830	2314	EST	88	ב ב	0.00041
AFFX-M27830_M_at	M27830	2314	EST	8.78	÷ 9	0 00003
AFFX-M27830_5_at	M27830	2314	EST	82	<u> </u>	0.00094
AFFX-M27830 M at	M27830	2314	EST	6.25 5.25	<u>.</u> .	0.000
AFFX-M27830 M at	M27830	2314	EST	5.78	g 5	0.00046
M29277_at	M29277	2316	melanoma adhesion molecule	3.91	}	0.00112
M29540_at	M29540	2317	carcinoembryonic antigen-related cell adhesion molecule 5	36.57	ф	0.0116
M30496_at	M30496	2324	ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase)	ю 80	g	0.00478
M31303_ma1_at	M31303	2327	leukemia-associated phosphoprotein p18 (stathmin)	7.48	÷ 9	0.00021
M31520_ma1_s_at	M31520	2328	ribosomal protein S24	3,37	9	0.00077
M31520_at	M31520	2328	ribosomal protein S24	3.13	- S	0.00014
M32405_at	M32405	2334	ribosomal protein S15	4.01	- <u>8</u>	0.00055
M32886_at	M32886	2335	sorcin	8.35	9	0.00215
AFFX-HUMGAPDH/M33 M33197	33 M33197	2337	glyceraldehyde-3-phosphate dehydrogenase	3.31	. <u>a</u>	600000
M34182_at	M34182	2340	protein kinase, cAMP-dependent, catalytic, gamma	4.51	g S	0.00043
M35252_at	M35252	2343	transmembrane 4 superfamily member 3	39.12	. g	0
M36072_at	M36072	2347	ribosomal protein L7a	3.1	.	0.00006
			S100 calcium-binding protein A10 (annexin II ligand, calpactin I,			
M38591 at	M38591	2350	light polypeptide (p11))	14.87	đ	0
M3869U_at	M38690	2351	CD9 antigen (p24)	808	9	0.00059
M55998_s_at	M55998	2356	collagen, type I, alpha 1	6.99	. g .	0.00103

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Sed ID	Known Gene Name	Fold Change	Direction	Pvalue
M57710_at	M57710	2357	lectin, galactoside-bin	27.12		00001
M60784_s_at	M60784	2366	small nuclear ribonucleoprotein polypeptide A	5.74	3 9	0.00126
M60854_at	M60854	2367	ribosomal protein S16	3.4	r an	0.00001
M62895_s_at	M62895	2375	annexin A2, annexin A2 pseudogene 2	6.11	- <u>S</u>	0.00013
M64716_at	M64716	2382	ribosomal protein S25	3.16	. <u>e</u>	0.00039
M68864_at	M68864	2389	ORF	3.1	. <u>a</u>	0.00603
M77232_ma1_at	M77232	2399	ribosomal protein S6	3.82	. <u>a</u>	0.00045
M77349_at	M77349	2400	transforming growth factor, beta-induced, 68kD	4.81	· 9	0.00546
M77836_at	M77836	2401	pyrroline-5-carboxylate reductase 1	3.43	. <u>a</u>	0.00759
M79463_s_at	M79463	2402	promyelocytic leukemia	4.88	9	0.01821
M81757_at	M81757	2406	ribosomal protein S19	5.46	. <u>e</u>	0
			tyrosine 3-monooxygenase/tryptophan 5-monooxygenase			
M86400_at	M86400	2410	activation protein, zeta polypeptide	5.62	g	0.00016
M86667_at	M86667	2411	nucleosome assembly protein 1-like 1	3.03	. <u>a</u>	0.04853
			stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing			
M86752_at	M86752	2412	protein)	7.32	g	0.00001
M87339_at	M87339	2415	replication factor C (activator 1) 4 (37kD)	4.07	. <u>a</u>	0.00316
M91083_at	M91083	2419	chromosome 11 open reading frame 13	3.3	. Q	0.00163
			membrane component, chromosomal 4, surface marker (35kD			
M93036_at	M93036	2422	glycoprotein)	16.45	a S	0.00308
M94250_at	M94250	2426	midkine (neurite growth-promoting factor 2)	10.39	. Q	0.01818
M94345_at	M94345	2427	capping protein (actin filament), gelsolin-like	22.38	g.	0.00003
M96739_at	M96739	2434	nescient helix loop helix 1	3.72	- - - -	0.00015
rc_N20198_s_at	N20198	2440	ubiquitin-conjugating enzyme E2 variant 1	5.17	g.	0.00508
rc_N21359_at	N21359	2442	EST	4.43	d	0.00078
rc_N22015_at	N22015	2448	EST	46.61	dn	0.00025
rc_N22107_at	N22107	2449	EST	6.88	d	0.04259
rc_N24899_at	N24899	2461	EST	3.06	g	0.00353
rc_N26186_at	N26186	2468	EST	6.15	g S	0.00135
rc_N27186_at	N27186	2470	EST	3.79	d	0.00112
rc_N27334_at	N27334	2471	EST	3.65	dn	0.03437

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pyalite
rc_N29888_at	N29888	2483	EST	3.7		0.00226
rc_N30436_f_at	N30436	2484	EST	3.45	t 9	0.02356
rc_N31570_at	N31570	2486	TNF receptor-associated factor 5	10.39	<u> </u>	0.00018
rc_N31597_s_at	N31597	2487	DKFZP564G2022 protein	4.44	en	0.00085
N36432_at	N36432	2507	erythrocyte membrane protein band 4.1-like 2	3.03	<u> </u>	0.03086
rc_N39099_at	N39099	2508	EST	4.42	. a	0.00643
rc_N39237_at	N39237	2511	EST	9.29	on On	0.00001
rc_N39254_s_at	N39254	2512	EST	4.42	. an	0.00478
rc_N46423_at	N46423	2521	EST	9.64	÷ 9	0.00027
			eukaryotic translation initiation factor 3, subunit 3 (gamma.	· !	<u> </u>	
rc_N47956_at	N47956	2524	40kD)	6.34	gn	0.00251
rc_N49284_s_at	N49284	2537	v-myb avian myeloblastosis viral oncogene homolog	11.82	19	0.01981
rc_N49738_at	N49738	2539	EST	3.81	- <u>a</u>	0.02479
rc_N50048_at	N50048	2542	EST	4.08	. <u>G</u>	0.00085
rc_N51053_s_at	N51053	2543	eukaryotic translation initiation factor 5	3.42	. an	0.01326
rc_N51342_at	N51342	2545	EST	3.56	g an	0.0001
rc_N52168_at	N52168	2551	EST	5.65	g G	0.00003
rc_N54841_at	N54841	2572	EST	42.96	on on	0.00002
rc_N56935_s_at	N56935	2575	EST	3.57	- an	0.00282
rc_N58463_at	N58463	2580	PCTAIRE protein kinase 1	3.18	g G	0.00649
rc_N62126_at	N62126	2589	EST	8.51	- a	0.00016
rc_N62675_s_at	N62675	2594	DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 16	3.61	g.	0.04034
rc_N62819_at	N62819	2595	EST	3.25	g	0.01137
rc_N64616_at	N64616	2611	EST	3.11	. <u>a</u>	0.0074
rc_N66139_s_at	N66139	2615	neurochondrin	4.03	. <u>a</u>	0.00118
			homolog of mouse quaking QKI (KH domain RNA binding		-	
rc_N66624_at	N66624	2618	protein)	6.25	gn	o
rc_N66951_at	N66951	2621	EST	5.54	+ 9	0.02442
rc_N67205_at	N67205	2625	EST	3.1	Ω	0.00626
					•	
rc_N68038_f_at	N68038	2632	phorbolin (similar to apolipoprotein B mRNA editing protein)	3.75	ф	0.01041

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_N68385_f_at	N68385	2635	ribosomal protein L13	3.57	1 "	0.00417
rc_N68921_at	N68921	2639	EST	4.4	1 9	0.00989
rc_N69252_f_at	N69252	2647	ferritin, light polypeptide	5.33	- 9	0.01554
rc_N69263_at	N69263	2648	EST	7.47	- <u>a</u>	0.00004
rc_N70577_at	N70577	2659	EST	3.07	. an	0.01975
rc_N70678_s_at	N70678	2660	TAR (HIV) RNA-binding protein 1	4.2	<u> </u>	0.00119
rc_N70903_at	N70903	2662	EST	4.41	. <u>a</u>	0.0078
rc_N71072_at	N71072	2664	EST	2.57	. <u>a</u>	0.03881
rc_N71781_at	N71781	2666	EST	7.01	+ <u>9</u>	0.02952
			solute carrier family 11 (proton-coupled divalent metal ton		L i	
rc_N72116_s_at	N72116	2668	transporters), member 2	9.01	9	0.00051
rc_N73762_f_at	N73762	2678	EST	8.65	+ 9	0.0023
rc_N73808_f_at	N73808	2679	EST	8.46) 9	0.01886
rc_N73846_at	N73846	2680	EST	3.27	r S	0.00012
rc_N77947_s_at	N77947	2698	EST	S	- <u>9</u>	0.00117
rc_N80703_at	N80703	2704	EST	90.9	- 9	0.00003
rc_N89670_at	N89670	2709	EST	4.26	. <u>a</u>	0.00002
rc_N89937_at	N89937	2711	LIM domain only 7	3.6	. g	0.00375
rc_N90238_i_at	N90238	2712	EST	3.06	2	0.00354
rc_N91023_at	N91023	2716	EST	3.87	- <u>o</u>	0.00008
			amyloid beta (A4) precursor protein-binding, family A, member	•	<u>.</u>	
rc_N92775_at	N92775	2723	3 (X11-like 2)	3.86	dn	0.00577
rc_N92915_at	N92915	2724	brefeldin A-inhibited guanine nucleotide-exchange protein 1		9	0.00807
rc_N92934_s_at	N92934	2725	cysteine-rich protein 1 (intestinal)	35,52	÷ 9	0.002
rc_N93105_f_at	N93105	2728	EST	3.77	9	0.02195
rc_N93798_at	N93798	2738	protein tyrosine phosphatase type IVA, member 3	4.65	- 9	0.00118
rc_N98464_s_at	N98464	2744	EST	15.95	· S	0.00004
rc_N98758_f_at	N98758	2745	EST	3.87	9	0.0074
N99505_at	N99505	2746	EST	3.6	an an	0.04499
rc_R02036_at	R02036	2754	EST	8.01	: 요	0.01012

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pyalue
rc_R06251_f_at	R06251	2764	tumor protein D52-like	5.57		0 00037
rc_R06254_f_at	R06254	2765	tumor protein D52-like 2	4.64	3	0.00039
rc_R06866_s_at	R06866	2774	EST	5.18	÷ 9	0.00187
rc_R06986_f_at	R06986	2776	peptidylprolyl isomerase B (cyclophilin B)	3.01	- 9	0.04418
rc_R22585_at	R22565	2800	EST	4.8	. a	0.0424
rc_R26706_s_at	R26706	2803	EST	3.21	. a	0.03858
rc_R26744_at	R26744	2804	midline 1 (Opitz/BBB syndrome)	4.32	. <u>a</u>	0.00532
rc_R27432_at	R27432	2808	EST	3.62	. 0	0.00014
			UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase.		È	
rc_R28636_at	R28636	2809	polypeptide 3	3.78	on.	0.00765
rc_R31107_at	R31107	2812	EST	4.12	÷ 9	0.00003
rc_R33498_s_at	R33498	2820	EST	41.34	÷ 9	0.00001
rc_R36947_s_at	R36947	2825	calcium channel, voltage-dependent, beta 3 subunit	4.11	- <u>9</u>	0.00006
rc_r38076_s_at	R38076	2828	EST	4.08	- 9	0.00374
rc_R38239_at	R38239	2830	EST	7.14	o n	0.00249
rc_R38280_at	R38280	2831	BCS1 (yeast homolog)-like	3.68	. <u>a</u>	0.000
rc_R38511_s_at	R38511	2832	protein similar to E.coli yhdg and R. capsulatus nifR3	5.19	. <u>q</u>	0.00015
rc_R39191_s_at	R39191	2834	KIAA1020 protein	4.69	. <u>a</u>	0.00456
rc_R40254_at	R40254	2840	EST	5.82	. a	0.00304
rc_R43952_at	R43952	2853	homeo box B5	4.11	. <u>a</u>	0.04316
rc_R44479_at	R44479	2855	KIAA0552 gene product	4.14	. an	0.0181
rc_R44538_at	R44538	2856	EST	5.73	. <u>a</u>	0.01015
rc_r45698_at	R45698	2866	EST	3.01	. <u>a</u>	0.04766
rc_R45994_f_at	R45994	2867	EST	7.81	ď	0.0018
rc_R48447_at	R48447	2871	EST	7.75	음	0.00049
rc_R48589_at	R48589	2874	EST	4.95	an	0.01346
rc_R49084_s_at	R49084	2879	KIAA0770 protein	3.57	ď	0.00447
rc_R49216_at	R49216	2880	EST	3.64	a S	0.0004
rc_R49395_s_at	R49395	2881	EST	4.38	. <u>a</u>	0.00112
rc_R49476_at	R49476	2883	EST	. 10,95	. <u>a</u>	0.00014
rc_R52161_at	R52161	2893	EST	5.84	- 음	0.03253

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_R53109_f_at	R53109	2899	dimethylarginine dimethylaminohydrolase 2	3.31	1-	0.02389
rc_R53109_r_at	R53109	2899		3.22	9	0.00724
rc_R54614_s_at	R54614	2902		3.24	g.	0.00526
rc_R55470_at	R55470	2904	EST	3.59	ď	0.00515
rc_R56095_s_at	R56095	2906	EST	8.16	g.	0.00023
R56678_at	R56678	2908	EST	3.81	Ω	0.02242
rc_R56880_at	R56880	2909	EST	6.82	on on	0.02559
rc_R58974_at	R58974	2910	EST	4.95	- 23	0.00498
rc_R59352_s_at	R59352	2915	KIAA0296 gene product	4.19	유	0.00393
rc_R61297_s_at	R61297	2920	eukaryotic translation initiation factor 3, subunit 6 (48kD)	6.42	9	0.00126
R69700_at	R69700	2943	EST	6.71	d an	0.0021
rc_R70005_at	R70005	2944	EST	4.61	9	0.00037
rc_R70801_s_at	R70801	2950	EST	6.36	. an	0.00563
rc_R71082_s_at	R71082	2951	programmed cell death 5	3.6	- <u>c</u>	0.01338
rc_R71395_at	R71395	2952	EST	10.42	. g	0.00422
rc_R73565_at	R73565	2959	EST	3.29	<u> </u>	0.03489
			O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-		-	
			acetylglucosamine:polypeptide-N-acetylglucosaminyl			
rc_R76782_s_at	R76782	2963	transferase)	5.83	dn	0.01126
rc_R77631_at	R77631	2967	EST	3.43	. <u>a</u>	0.0000
rc_R79580_at	R79580	2970	EST	6.25	. an	0.00593
rc_R87989_at	R87989	2979	centrosome associated protein	3.64	an	0.00008
rc_R91819_at	R91819	2984	EST	8.95	. g	0.0000
rc_R92994_s_at	R92994	2990	matrix metalloproteinase 12 (macrophage elastase)	11.05	. <u>a</u>	0.00248
rc_R95966_i_at	R95966	2997	EST	11.22	. an	0.00682
rc_R96924_s_at	R96924	3001	EST	6.18	. <u>a</u>	0.03417
rc_R97759_at	R97759	3006	serum/glucocorticoid regulated kinase	5.99	g.	0.00221
S54005_s_at	S54005	3020	thymosin, beta 10	7.03	. a	0.00334
S56151_s_at	S56151	3021	milk fat globule-EGF factor 8 protein	4.59	. d	0.0091
S69272_s_at	S69272	3028	protease inhibitor 6 (placental thrombin inhibitor)	5.15	g.	0.00003

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
S73885_s_at	S73885	3032	transcription factor AP-4 (activating enhancer-binding protein 4)	4.18	an	0.00005
S78187_at	S78187	3036	cell division cycle 25B	8.07	<u> </u>	0.0000
S81914_at	S81914	3038	immediate early response 3	5.46	. a	0.01798
rc_T03313_at	T03313	3042	dyskeratosis congenita 1, dyskerin	9.63	. g	0.00001
rc_T03438_s_at	T03438	3043	EST	8.18	g.	0.00032
rc_T03580_f_at	T03580	3046	pyruvate kinase, muscle	24.91	g.	0.0001
rc_T12599_f_at	T12599	3056	ribosomal protein L21	3.54	. a	0.01437
rc_T15442_f_at	T15442	3057	calpain, large polypeptide L1	5.01	9	0.00255
rc_T15473_at	T15473	3058	muscle specific gene	5.81	. <u>a</u>	0.02404
rc_T15477_at	T15477	3029	EST	3.61	o G	0.00005
rc_T15903_s_at	T15903	3063	EST	3.23	g	0.01377
rc_T16308_f_at	T16308	3069	EST	5.29	요.	0.00119
rc_T16983_s_at	T16983	3074	cleavage and polyadenylation specific factor 4, 30kD subunit	5.23	9	0.00075
rc_T23465_at	T23465	3081	EST	4.4	- 9	0.017
rc_T23490_i_at	T23490	3082	EST	11.86	- 9	0.03242
rc_T23516_f_at	T23516	3083	3-phosphoglycerate dehydrogenase	5.38	. a	0.00001
rc_T24068_s_at	T24068	3088	EST	15.26	- a	0.00046
rc_T25725_at	T25725	3091	EST	3.26	. a	0.00099
rc_T26366_f_at	T26366	3093	EST	30.43	. <u>G</u>	0.00153
rc_T26471_at	T26471	3094	EST	4.62	g	0.01091
			protein phosphatase 2 (formerly 2A), regulatory subunit A (PR		•	
rc_T26513_l_at	T26513	3092	65), alpha isoform	5.07	g	0.0016
rc_T26574_s_at	T26574	3096	catenin (cadherin-associated protein), delta 1	3.17	9	0.00828
rc_T30193_s_at	T30193	3098	protease, serine, 8 (prostasin)	8.39	. g	0.00043
rc_T32072_s_at	T32072	3102	EST	5.95	9	0.00029
rc_T32108_at	T32108	3103	EST	98.9	1 9	0.00723
rc_T33489_s_at	T33489	3105	EST	8.04	g G	0.00469
					•	
rc_T33508_s_at	T33508	3106	phosphatidylinositol-4-phosphate 5-kinase, type II, beta	3.31	<u>a</u>	0.00416

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	9 Direction	Pvalue
T35341_s_at	T35341	3112	EST	4.73	đ	0.00057
T35725_s_at	T35725	3113	EST	3.4	. a	0.00149
rc_T40849_s_at	T40849	3116	maternal G10 transcript	4.11	9	0.00449
rc_T47032_s_at	T47032	3124	partner of RAC1 (arfaptin 2)	3.27	d n	0.00503
rc_T47325_s_at	T47325	3125	EST	5.63	d d	0.01015
rc_T47601_at	T47601	3126	EST	4.05	- G	0.00878
			ceroid-lipofuscinosis, neuronal 3, juvenile (Batten, Spielmeyer-		•	
rc_T47969_s_at	T47969	3128	Vogt disease)	3.03	dn	0.03452
			eukaryotic translation initiation factor 3, subunit 3 (gamma,		•	
T48195_s_at	T48195	3131	40kD)	3.75	<u>a</u>	0.00012
rc_T48293_f_at	T48293	3133	EST	3.55	<u>a</u>	0.01355
rc_T53404_at	T53404	3143	EST	10.68	9	0.00582
rc_T55004_s_at	T55004	3146	EST	4.83	g.	0.00156
rc_T55196_at	T55196	3147	EST	4.04	. <u>a</u>	0.00012
rc_T58153_s_at	T58153	3154	heat shock 105kD	3.08	<u> </u>	0.01317
rc_T58607_at	T58607	3155	EST	3.52	g G	0.04102
rc_T59161_s_at	T59161	3159	thymosin, beta 10	3.41	g.	0.01885
rc_T59668_s_at	T59668	3160	lysyl oxidase	3.28	<u>α</u>	0.00588
rc_T66935_at	T66935	3179	EST	3.97	d d	0.00188
rc_T77733_s_at	T77733	3219	tubulin, gamma 1	4.42	ф	0.00049
rc_T78922_s_at	T78922	3222	stem cell growth factor; lymphocyte secreted C-type lectin	3.42	g	0.02419
rc_T91116_at	T91116	3252	EST	4.01	. G	0.02721
rc_T92935_at	T92935	3255	EST	3.48	d d	0.03578
rc_T95057_f_at	T95057	3259	EST	10.39	ġ.	0.00003
rc_T98284_at	T98284	3268	EST	4.47	g.	0.00054
U01062_at	U01062	3273	inositol 1,4,5-triphosphate receptor, type 3	7.41	음	0
U01147_at	U01147	3275	active BCR-related gene	3.22	ф	0.00103
U02493_at	U02493	3279	non-Pou domain-containing octamer (ATGCAAAT) binding protein	3.04	dn	0.0019

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Chang	Fold Change Direction	Pvalue
U03891 at	U03891	3283	phorholin (eimilar to analisospetia B mBNA calities	,		
U04313_at	U04313	3284	processe inhibitor 5 (maspin)	£ 4.54	을 음	0.000065
-					<u> </u>	
U05875_at	U05875	3286	interferon gamma receptor 2 (interferon gamma transducer 1)	3.09	g	0.00549
U07969_s_at	002969	3289	cadherin 17, Ll cadherin (liver-intestine)	10.78	- 9	0.02002
U09117_at	U09117	3294	phospholipase C, delta 1	7.96	t 9	0.0001
U09564_at	U09564	3295	SFRS protein kinase 1	3.79	÷	0.00265
U09770_at	027e0U	3296	cysteine-rich protein 1 (intestinal)	13.03	} <u> </u>	0.000
U11861_at	U11861	3298	maternal G10 transcript	3.8	1	0.000
U12404_at	U12404	3299	ribosomal protein L10a	4.18	1 9	0.00004
U12465_at	U12465	3300	ribosomal protein L35	4.69	. <u>S</u>	0.00001
U14968_at	U14968	3303	ribosomal protein L27a	4.01	2	0.00003
U14969_at	U14969 ·	3304	rlbosomal protein L28	4.63	9	0.00004
U14970_at	U14970	3305	ribosomal protein S5	3.45	} <u>{</u>	0.0003
U14971_at	U14971	3306	ribosomal protein S9	3 93	} <u></u>	0.000
U14972_at	U14972	3307	ribosomal protein S10	5.24	3 5	0.00020
U14973 at	U14973	3308	ribosomal protein S29	7.0	<u>}</u> !	0.000.0
I)		- -	d D	0.00028
U15008_at	U15008	3309	small nuclear ribonucleoprotein D2 polypeptide (16,5kD)	49	9	0.00396
U17077_at	U17077	3314	BENE protein	4.98	r G	0.00366
1117760 ms4 st	1147760	7760	laminin, beta 3 (nicein (125kD), kalinin (140kD), BM600			
מון המון המו	00710	33.13	(1zəku))	3.54	dn	0.01853
U20499_at	U20499	3321	sulfotransferase family 1A, phenol-preferring, member 3	5.5	9	0.00299
U20758_rna1_at	U20758	3323	secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1)	6,7	<u> </u>	0.02440
:			epithelial protein up-regulated in carcinoma, membrane	3	3	0.03
U21049_at	U21049	3325	associated protein 17	7.53	g	0.01667
112570_cdsz_s_all	0223/6	3328	v-myb avian myeloblastosis viral oncogene homolog	3.34	dn	0.03416
043769_81	68/670	3334	ribosomal protein L21	4.37	d	0.00045

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

hydroxysteroid (11-beta) dehydrogenase 2 fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase, Lewis blood group included) E2F transcription factor 5, p130-binding chromosome segregation 1 (yeast homolog)-like E2F transcription factor 5, p130-binding chromosome segregation 1 (yeast homolog)-like solute carrier family 6 (neurotransmitter transporter, creatine), member 8 potassium voltage-gated channel, KQT-like subfamily, member potassium voltage-gated channel, KQT-like subfamily, member ladinin 1 ladinin 2 ladinin 1 ladinin	Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	P Direction	Dvalue
Livesylfransferase 3 (galactoside 3(4)-L-fucosylfransferase, 1027328 Livesylfransferase 3 (galactoside 3(4)-L-fucosylfransferase, 3335 Lives blood group included) 305 up 4.14 up 6.0	U26726_at	U26726	3336		3.45	qn	0.02342
U27228 3338 Lewis blood group included) U37328 3338 Lewis blood group included) U37326 3346 E2F transcription factor 5, p130-binding U37326 3346 E2F transcription factor 5, p130-binding U37328 3346 E2F transcription factor 5, p130-binding U37328 3351 member 8 U40990 3359 up colubroarcane segregation 1 (yeast homolog)-like subfamily, member U40990 3359 laninin receptor 1 (67kD, ribosomal protein SA) 3.18 up colubroarcane gregation that subfamily, member U40990 3359 laninin receptor 1 (67kD, ribosomal protein SA) 3.18 up colubroarcane discotin domain receptor family, member 1 3.18 up colubroarcane discotin domain receptor family, member 1 5.54 up colubroarcane discotin domain receptor family, member 1 5.94 up colubroarcane discotin domain receptor family, member 1 5.94 up colubroarcane family 1 (neutral amino acid transporter), member 2.40 up colubroarcane family 1 (neutral amino acid transporter), member 3.38 discotin domain receptor family 3.39 up colubroarcane family 1 (neutral amino acid transporter), member 3.39 up colubroarcane family 1 (neutral amino acid transporter), member 3.39 up colubroarcane family 1 (neutral amino acid transporter), member 3.39 up colubroarcane family 1 (neutral amino acid transporter), member 3.39 up colubroarcane family 1 (neutral amino acid transporter), member 3.39 up colubroarcane family 1 (neutral amino acid transporter), member 3.39 up colubroarcane family 1 (neutral amino acid transporter), member 3.39 up colubroarcane family 1 (neutral amino acid transporter), member 3.39 up colubroarcane family 1 (neutral amino acid transporter), member 3.39 up colubroarcane family 1 (neutral amino acid transporter) and 9.30 up colubroarcane family 1 (neutral amino acid transporter) and 9.30 up colubroarcane family 1 (neutral amino acid transporter) and 9.30 up colubroarcane family 1 (neutral amino acid transporter) and 9.30 up colubroarcane family 1 (neutral amino acid transporter) and 9.30 up colubroarcane inhibitor 4 (survivin) and 9.30 up colubroarcane inhibitor 4 (survivin) and 9.30 u				fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase,) ;	ŀ	
U33286 3346 E2F transcription factor 5, p130-binding U33286 349 E2F transcription factor 5, p130-binding U33286 349 expension of lyeast homology-like 349 dynomenses egregation 1 (yeast homology-like 350 up colube carrier family 6 (neurotransmitter transporter, creatine), 350 up colube carrier family 6 (neurotransmitter transporter, creatine), 351 member 3355 polymerase (RNA) II (DNA directed) polypeptide H 352 up colube carrier family 6 (neurotransmitter transporter), member 3359 1 3352 laminin receptor 1 (67KD, ribosomal protein SA) 3.11 up colubes 2367 oystatin 8 (stefin B) 3362 laminin receptor 1 (67KD, ribosomal protein SA) 3.11 up colubes 2367 oystatin 8 (stefin B) 3370 discoloin domain receptor family, member 1 5.54 up colubes 2382 caudal type homeo box transcription factor 1 4.76 up colubes 2383 2382 caudal type homeo box transcription factor 1 5.75 up colube carrier family 1 (neutral amino acid transporter), member 5.75 up colube carrier family 1 (neutral amino acid transporter), member 3391 interferon regulatory factor 7 399 up colubes 2391 interferon regulatory factor 7 399 up colubes 2391 interferon regulatory factor 7 399 up colubes 2391 interferon regulatory factor 7 300 up colubes 2392 3403 21nc finger protein E2-C 3404 up colubes 242 apoptosis inhibitor 4 (survivin) 3408 342 Transcription factor) 342 Transcription factor) 3430 serine protease inhibitor, Kuniz type, 2 1885 up colubes 3430 serine protease inhibitor, Kuniz type, 2 1885 up colubes 242 poptosis inhibitor, Kuniz type, 2 1885 up colubes 242 poptosis inhibitor, Kuniz type, 2 1885 up colubes 242 poptosis inhibitor, Kuniz type, 2 1885 up colubes 242 poptosis inhibitor, Kuniz type, 2 1885 up colubes 242 poptosis inhibitor, Kuniz type, 2 1885 up colubes 242 poptosis inhibitor, Kuniz type, 2 1885 up colubes 242 poptosis inhibitor, Kuniz type, 2 1885 up colubes 242 poptosis inhibitor 4 survivi	U27328_s_at	U27328	3338	Lewis blood group included)	3,05	Q.	0.03224
u35286 3349 chromosome segregation 1 (yeast homolog)-like 3.39 up solute carrier family 6 (neurotransmitter transporter, creatine), solute carrier family 6 (neurotransmitter transporter, creatine), solute carrier family 6 (neurotransmitter transporter, creatine), solute carrier family (DNA directed) polypeptide H 3.65 up polassium voltage-gated channel, KQT-like subfamily, member 3.356 up polassium voltage-gated channel, KQT-like subfamily, member 3.357 up colutes 3.356 larninin receptor 1 (67kD, ribosomal protein SA) 3.11 up 5.54 up 1.47025 3362 larninin receptor family, member 1 5.54 up 5.54 up 1.47025 3362 phosphorylases glycogen; brain 2 polypeptide 3.370 discolidin domain receptor family, member 1 5.94 up 6.576 up 1.47025 3382 caudal type homeo box transcription factor 1 5.94 up 6.770 discolidin domain receptor family 1 (neutral amino acid transporter), member 3.385 ATP ase, Na-Mf-k transporting, beta 3 polypeptide 5.75 up 6.09 up 1.453830 3391 Interferon regulatory factor 7 3.94 up 6.09 up 1.453830 3392 ribosomal protein 5.28	U31556_at	U31556	3346	E2F transcription factor 5, p130-binding	4.14	. 2	0.01157
solute carrier family 6 (neurotransmitter transporter, creatine), U37689 3356 polymerase (RNA) II (DNA directed) polypeptide H U40990 3359 1 U42408 3359 polymerase (RNA) II (DNA directed) polypeptide H U43901 3359 1 U446692 3361 ladinin receptor 1 (67kD, ribosomal protein SA) 3.11 up U44602 3367 cystalin B (stefin B) U47025 3368 phosphorylase, glycogen; brain U47025 3368 phosphorylase, glycogen; brain U47025 3369 phosphorylase, glycogen; brain U51095 3370 discoldin domain receptor family, member 1 U51095 3385 ATPase, Na+/K+ transporting, beta 3 polypeptide U51337 3389 5 U53347 3389 5 U53347 3389 5 U62362 3403 Interferon regulatory factor 7 U53830 3396 ribosomal protein S28 U62962 3403 arine finger protein 193 U65177 3409 selenoprotein W, II U73379 3418 ubiquitin carrier protein E2-C U73843 3421 E74-Ilke factor 3 (ets domain transcription factor) U73858 3421 E74-Ilke factor 3 (ets domain transcription factor) U73868 3421 E74-Ilke factor 3 (ets domain transcription factor) U73868 3421 E74-Ilke factor 3 (ets domain transcription factor) U73879 3421 E74-Ilke factor 3 (ets domain transcription factor) U78055 3430 serline protease inhibitor, Kunliz type, 2 U78055 3430 serline protease inhibitor, Kunliz type, 2 U78056 3430 serline protease inhibitor, Kunliz type, 2 U78056 3430 serline protease inhibitor, Kunliz type, 2	U33286_at	U33286	3349	chromosome segregation 1 (yeast homolog)-like	3.39	ı on	0.00939
u35341 3351 member 8 u3589 3356 polymerase (RNA) II (DNA directed) polypeptide H polassium voltage-gated channel, KQT-like subfamily, member u42408 3361 ladinin 1 u42408 3361 ladinin 1 u447025 3362 laminin receptor 1 (67kD, ribosomal protein SA) at u48682 3367 cystafin B (stefin B) u47025 3368 phosphorylase, glyozogan; brain u47025 3388 phosphorylase, glyozogan; brain u5347 3385 ATPase, Na+f/k+ transporting, beta 3 polypeptide solute carrier family 1 (ineutral amino acid transporter), member u53347 3385 ATPase, Na+f/k+ transporting, beta 3 polypeptide solute carrier family 1 (ineutral amino acid transporter), member u53347 3389 interferon regulatory factor 7 u53347 3396 inbosomal protein S28 u62392 3403 clarc finger protein 193 u62392 3404 eukaryotic translation initiation factor 3, subunit 6 (48kD) u62392 3404 eukaryotic translation initiation factor 3, subunit 6 (48kD) u62392 3421 E74-like factor 3 (ets domain transcription factor) u73343 3421 E74-like factor 3 (ets domain transcription factor) u73343 3421 E74-like factor 3 (ets domain transcription factor) u73343 3421 E74-like factor 3 (ets domain transcription factor) at u77625 3429 EST u77805 3430 serine protease Inhibitor, Kunitz type, 2 tat u77805 3430 serine protease Inhibitor, Kunitz type, 2				solute carrier family 6 (neurotransmitter transporter, creatine).		L	
U42408 3356 polymerase (RNA) II (DNA directed) polypeptide H 3.65 up potassium voltage-gated channel, KQT-like subfamily, member 3359 ladinin 1 6.8 up 6.8 u	U36341_ma1_at	U36341	3351	member 8	3.05	Qn.	0.02622
Dudoso 3359 1 U42408 3361 ladinin 1 U42408 3361 ladinin 1 U42408 3361 ladinin 1 E_at U43901 3362 laminin receptor 1 (67kD, ribosomal protein SA) 3.11 up 6.8 up 6.8 up 6.3 and 1 ladinin receptor 1 (67kD, ribosomal protein SA) 3.11 up 6.5 and 1 ladinin receptor 1 (67kD, ribosomal protein SA) 3.11 up 6.5 and 1 ladinin receptor family, member 1 5.94 up 6.5 and 1 ladinin ladinin receptor family, member 1 5.94 up 6.0 and 1 ladinin ladinin receptor family, member 1 5.94 up 6.0 and 1 ladinin l	U37689_at	U37689	3356	polymerase (RNA) II (DNA directed) polypeptide H	3.65	9	0.00044
U40990 3359 1 3.18 up U42408 3361 ladinin 1 e.8 up e.8 e.9 up e.8 e.9				potassium voltage-gated channel, KQT-like subfamily, member		L.	
8-g at U43001 3362 laminin receptor 1 (67kD, ribosomal protein SA) 3.11 up 6.8 up 6.8 up 6.4	U40990_at	U40990	3359		3.18	9	0.00093
s_at U43901 3362 laminin receptor 1 (67kD, ribosomal protein SA) 3.11 up at U46892 3367 cystatin B (stefin B) 5.54 up 5.54 up 6.047025 3368 phosphorylase, glycogen; brain U48705 3360 discoldin domain receptor family, member 1 5.94 up 6.04705 3385 ATPase, Na+ff+ transporting, beta 3 polypeptide 5.75 up 6.09 up 6.053830 3391 interferon regulatory factor 7 3389 5 solute carrier family 1 (neutral amino acid transporter), member 5.75 up 6.09 up 6.23820 3396 inbosomal protein 528 inchosomal protein 528 inchosomal protein 193 interferon regulatory factor 7 6.09 up 6.09 up 6.2392 3404 eukaryotic translation initiation factor 3, subunit 6 (48kD) 4.05 up 6.09 up 6.2392 3404 eukaryotic translation initiation factor 3, subunit 6 (48kD) 4.05 up 6.09 up 6.2392 3404 eukaryotic translation initiation factor 3, subunit 6 (48kD) 4.05 up 6.09 up 6.2392 3404 eukaryotic family 4 (survivin) 4.46 up 6.09 up 6.2392 3424 Treacher Collins-Franceschetti syndrome 1 3.44 up 6.09 at 0.78027 3429 EST 1.885 up 6.1885 up 6.	U42408_at	U42408	3361	ladinin 1	8.9	e o	0.00305
at U46692 3367 cystatin B (stefin B) U47025 3368 phosphorylase, glycogen; brain U47026 3368 phosphorylase, glycogen; brain U47026 3368 phosphorylase, glycogen; brain U51095 3382 caudal type homee box transcription factor 1 U51478 3383 ATPase, Na+/K+ transporting, beta 3 polypeptide Solute carrier family 1 (neutral amino acid transporter), member U53830 3391 interferon regulatory factor 7 U53830 3391 interferon regulatory factor 7 U62962 3396 ribosomal protein S28 U62392 3403 zinc finger protein 193 U62962 3404 eukaryotic translation initiation factor 3, subunit 6 (48kD) U62962 3404 eukaryotic translation initiation factor 3, subunit 6 (48kD) U73379 3418 ubiquitin carrier protein E2-C U73379 3421 E74-like factor 3 (ets domain transcription factor) U73386 3421 Freacher Collins-Franceschetti syndrome 1 U76386 3422 apoptosis inhibitor 4 (survivin) at U76286 3429 EST U78027 3429 EST U78095 3430 serine protease inhibitor, Kunitz type, 2 U78095 3430 serine protease inhibitor, Kunitz type, 2	21 S	U43901	3362	laminin receptor 1 (67kD, ribosomal protein SA)	3.11	2	0.03145
U47025 3368 phosphorylase, glycogen; brain 8.52 up L48705 3370 discoidin domain receptor family, member 1 5.94 up U51095 3382 caudal type homeo box transcription factor 1 4.76 up U51478 3385 ATPase, Na+/K+ transporting, beta 3 polypeptide 5.75 up U53347 3389 5 apolute carrier family 1 (neutral amino acid transporter), member 3.81 up U53850 3391 interferon regulatory factor 7 3.94 up 0 U53850 3394 interferon regulatory factor 7 3.94 up 0 U52862 3404 eukaryotic ranslation initiation factor 3, subunit 6 (48KD) 4.05 up 0 U62392 3404 eukaryotic translation initiation factor 3, subunit 6 (48KD) 4.05 up 0 U62392 3404 eukaryotic translation initiation factor 3, subunit 6 (48KD) 4.05 up U73379 3418 ubiquitin carrier protein E2-C 8.32 up 0 U73843 3422	U46692_rna1_at	U46692	3367	cystatin B (stefin B)	5.54	9	0.00016
s_at U48705 3370 discoidin domain receptor family, member 1 5.94 up C U51095 3382 caudal type homeo box transcription factor 1 4.76 up C U51095 3382 ATPase, Na+/K+ transporting, beta 3 polypeptide 5.75 up C U53347 3389 5 up C 3.81 up C U53830 3391 interferon regulatory factor 7 3.89 up C 3.81 up C U52862 3396 ribosomal protein S28 3.81 up C 3.94 up C U62392 3403 interferon regulatory factor 7 3.81 up C 6.09 up C U62392 3403 eukaryotic translation initiation factor 3, subunit 6 (48KD) 4.05 up C U73379 3418 ubiquilitin carrier protein E2-C B.32 up C U73843 3421 E74-like factor 3 (ets domain transcription factor) 3.44 up C	U47025_s_at	U47025	3368	phosphorylase, glycogen; brain	8.52	- <u>9</u>	0.00134
U51095 3382 caudal type homeo box transcription factor 1 4.76 up U51478 3382 ATPase, Na+/K+ transporting, beta 3 polypeptide 5.75 up U53347 3389 5 up 0 U53830 3391 Interferon regulatory factor 7 3.84 up 0 U53830 3391 Interferon regulatory factor 7 3.94 up 0 U53830 3391 Interferon regulatory factor 7 3.94 up 0 U53830 3391 Interferon regulatory factor 7 3.94 up 0 U52862 3403 Interferon regulatory factor 7 3.94 up 0 U62392 3403 Interferon regulatory factor 3 3.08 up 0 U62392 3404 eukaryotic translation initiation factor 3, subunit 6 (48kD) 4.05 up 0 U67171 3409 selenoprotein W, 1 3.08 up 0 U73379 3421 E74-like factor 3 (ets domain transcription factor) 3.44 up U75285 3424 up 0 0 0	U48705_rna1_s_at	U48705	3370	discoidin domain receptor family, member 1	5.94	. a	0.01323
U51478 3385 ATPase, Na+/K+ transporting, beta 3 polypeptide 5.75 up C U53347 3389 5 up C 3.81 up C U53830 3391 interferon regulatory factor 7 3.84 up C 3.94 up C U58682 3396 ribosomal protein S28 up C 3.94 up C C C Up C	U51095_at	U51095	3382	caudal type homeo box transcription factor 1	4.76	. an	0.02664
solute carrier family 1 (neutral amino acid transporter), member U53830 3391 Interferon regulatory factor 7 U58682 3396 ribosomal protein S28 U62392 3403 zinc finger protein 193 U62392 3404 eukaryotic translation initiation factor 3, subunit 6 (48kD) U62392 3409 selenoprotein W, 1 U73379 3418 ubiquitin carrier protein E2-C U73379 3421 E74-like factor 3 (ets domain transcription factor) U73843 3421 E74-like factor 3 (ets domain transcription factor) U73863 3424 Treacher Collins-Franceschetti syndrome 1 U76366 3424 Treacher Collins-Franceschetti syndrome 1 U76365 3430 serine protease inhibitor, Kunitz type, 2 18,85 up	U51478_at	· U51478	3385	ATPase, Na+/K+ transporting, beta 3 polypeptide	5.75	. g	0.00007
U53347 3389 5 U53830 3391 Interferon regulatory factor 7 3.94 up C U53830 3391 Interferon regulatory factor 7 3.94 up C U5382 3396 ribosomal protein S28 6.09 up C U62392 3403 zinc finger protein 193 3.18 up C U62392 3404 eukaryotic translation initiation factor 3, subunit 6 (48kD) 4.05 up C U67171 3409 selenoprotein W, 1 3.08 up C U73379 3418 ubiquitin carrier protein E2-C 8.32 up C U73379 3421 E74-like factor 3 (ets domain transcription factor) 5.75 up C at U75285 3422 apoptosis inhibitor 4 (survivin) 4.46 up C at U76366 3424 transcription factor 3 (ets domain transcription factor) 3.44 up C at U78027 3420 enhibitor, Kunitz type, 2 18.85 up C 18.85 up C <td< td=""><td></td><td></td><td></td><td>solute carrier family 1 (neutral amino acid transporter), member</td><td></td><td></td><td></td></td<>				solute carrier family 1 (neutral amino acid transporter), member			
U53830 3391 Interferon regulatory factor 7 3.94 up 0 U58682 3396 ribosomal protein S28 6.09 up 0 U62392 3403 zinc finger protein 193 3.18 up 0 U62392 3404 eukaryotic translation initiation factor 3, subunit 6 (48kD) 4.05 up 0 U67171 3409 selenoprotein W, 1 3.08 up 0 U73379 3421 E74-like factor 3 (ets domain transcription factor) 5.75 up 0 1075285 3422 apoptosis inhibitor 4 (survivin) 4.46 up 0 1076366 3424 Treacher Collins-Franceschetti syndrome 1 3.44 up 0 1178027 3429 EST 4.15 up 0 118.85 up 18.85 up	U53347_at	U53347	3389		3.81	Qn	0.00273
U58682 3396 ribosomal protein S28 6.09 up C U62392 3403 zinc finger protein 193 3.18 up C U62392 3404 eukaryotic translation initiation factor 3, subunit 6 (48kD) 4.05 up C U67171 3409 selenoprotein W, 1 3.08 up C U73379 3421 E74-like factor 3 (ets domain transcription factor) 5.75 up C U75285 3422 apoptosis inhibitor 4 (survivin) 4.46 up C U76366 3424 Treacher Collins-Franceschetti syndrome 1 3.44 up C at U78027 3429 EST 4.15 up C U78095 3430 serine protease inhibitor, Kunitz type, 2 18.85 up C	U53830_at	U53830	3391	interferon regulatory factor 7	3.94	9	0.03147
U62392 3403 zinc finger protein 193 3.18 up U62962 3404 eukaryotic translation initiation factor 3, subunit 6 (48kD) 4.05 up U67171 3409 selenoprotein W, 1 3.08 up U73379 3418 ubiquitin carrier protein E2-C 8.32 up U73843 3421 E74-like factor 3 (ets domain transcription factor) 5.75 up at U75285 3422 apoptosis inhibitor 4 (survivin) 4.46 up U76366 3424 Treacher Collins-Franceschetti syndrome 1 3.44 up 6 at U78027 3429 EST 4.15 up 6 U78095 3430 serine protease inhibitor, Kunitz type, 2 18.85 up	U58682_at	U58682	3396	ribosomal protein S28	60.9	+ <u>9</u>	0 00001
U62962 3404 eukaryotic translation initiation factor 3, subunit 6 (48kD) 4.05 up U67171 3409 selenoprotein W, 1 3.08 up U73379 3418 ubiquitin carrier protein E2-C 8.32 up U73843 3421 E74-like factor 3 (ets domain transcription factor) 5.75 up at U75285 3422 apoptosis inhibitor 4 (survivin) 4.46 up U76366 3424 Treacher Collins-Franceschetti syndrome 1 3.44 up at U78027 3429 EST U78095 3430 serine protease inhibitor, Kunitz type, 2	U62392_at	U62392	3403	zinc finger protein 193	3.18	는 음	0.00269
U67171 3409 selenoproteln W, 1 U73379 3418 ubiquitin carrier protein E2-C U73843 3421 E74-like factor 3 (ets domain transcription factor) 5.75 up State of transcription factor 3 (ets domain transcription factor) 4.46 up Capoptosis inhibitor 4 (survivin) 4.46 up U76366 3424 Treacher Collins-Franceschetti syndrome 1 3.44 up Bt U78027 3429 EST U78095 3430 serine protease inhibitor, Kunitz type, 2 18.85 up	U62962_at	U62962	3404	eukaryotic translation initiation factor 3, subunit 6 (48kD)	4.05	9	0.0047
U73379 3418 ubiquitin carrier protein E2-C U73843 3421 E74-like factor 3 (ets domain transcription factor) 5.75 up U75285 3422 apoptosis inhibitor 4 (survivin) U76366 3424 Treacher Collins-Franceschetti syndrome 1 U78027 3429 EST U78095 3430 serine protease inhibitor, Kunitz type, 2 18.85 up	U67171_at	U67171	3409	selenoprotein W, 1	3.08	r S	0.0047
U73843 3421 E74-like factor 3 (ets domain transcription factor) 5.75 up at U75285 3422 apoptosis inhibitor 4 (survivin) U76366 3424 Treacher Collins-Franceschetti syndrome 1 3.44 up at U78027 3429 EST 4.15 up U78095 3430 serine protease inhibitor, Kunitz type, 2 18.85 up	U73379_at	U73379	3418	ubiquitin carrier protein E2-C	832	÷ <u>=</u>	0.00101
at U75285 3422 apoptosis inhibitor 4 (survivin) U76366 3424 Treacher Collins-Franceschetti syndrome 1 U78027 3429 EST U78095 3430 serine protease inhibitor, Kunitz type, 2 18.85 up	U73843_at	U73843	3421	E74-like factor 3 (ets domain transcription factor)	5.75	÷ 9	0.00017
U76366 3424 Treacher Collins-Franceschetti syndrome 1 3.44 up at U78027 3429 EST 4.15 up U78095 3430 serine protease inhibitor, Kunitz type, 2 18.85 up	U75285_rna1_at	U75285	3422	apoptosis inhibitor 4 (survivin)	4.46	h 9	0.02212
at U78027 3429 EST 4.15 up U78095 3430 serine protease inhibitor, Kunitz type, 2 18.85 up	U76366_s_at	U76366	3424	Treacher Collins-Franceschetti syndrome 1	3.44	÷ <u>9</u>	0.00021
U78095 3430 serine protease inhibitor, Kunitz type, 2	U78027_ma3_at	U78027	3429	EST	4.15	3 5	0.00295
	U78095_at	U78095	3430	serine protease inhibitor, Kunitz type, 2	18.85	5 2	C

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	te Direction	Pvalue
U78525_at	U78525	3432	eukaryotic translation initiation factor 3, subunit 9 (eta, 116kD)	4.68	an	0.00132
U78556_at	U78556	3433	cisplatin resistance associated	5.77	. <u>a</u>	0.00241
U79266_at	U79266	3434	protein predicted by clone 23627	3.49	. <u>a</u>	0.00004
U79725_at	U79725	3438	glycoprotein A33 (transmembrane)	8.57	- Q	0.00299
U83246_at	U83246	3443	copine I	3.57	. <u>a</u>	0.01672
U84720_at	U84720	3446	RAE1 (RNA export 1, S.pombe) homolog	3.37	9	0.03586
U85773_at	· U85773	3449	phosphomannomutase 2	3.94	- 9	0.00288
U86409_at	U86409	3450	EST	3.38	1 9	0.00003
U89606_at	U89606	3452	pyridoxal (pyridoxine, vitamin B6) kinase	3.58	}	0.00322
U90549_at	U90549	3456	high-mobility group (nonhistone chromosomal) protein 17-like 3	3.2	gn	0.0401
U90913_at	U90913	3459	Tax interaction protein 1	4.35	1 9	0.00159
U93205_at	U93205	3461	chloride intracellular channel 1	6.14	- 9	0.00058
U93868_at	N93868	3463	polymerase (RNA) III (DNA directed) (32kD)	3.5	on on	0.01235
rc_W02041_at	W02041	3466	EST	4.83	- 9	0.00158
rc_W20391_s_at	W20391	3479	kinesin-like 2	3.98	. <u>a</u>	0.01788
W28362_at	W28362	3488	KIAA0974 protein	3.98	. <u>a</u>	0.00626
rc_W31382_at	W31382	3495	EST	4	· 9	0.00058
rc_W37680_at	W37680	3503	EST	3.55	9	0.01036
rc_W37937_at	W37937		EST	3.07	. <u>e</u>	0.00776
			myeloid/lymphold or mixed-lineage leukemia (trithorax		-	
rc_W38044_s_at	W38044		(Drosophila) homolog); translocated to, 7	7.28	9	0.03105
W39183_s_at	W39183	3508	KIAA0601 protein	3.66	. <u>a</u>	0.00018
rc_W42627_f_at	W42627	3511	EST	3.56	- 9	0.00198
rc_W42957_at	W42957	3516	calmodulin 2 (phosphorylase kinase, delta)	15.22	- 9	0.00007
rc_W44557_at	W44557	3518	chromosome 1 open reading frame 2	4.32	- an	0.00128
rc_W44733_at	W44733	3519	EST	3.02	g S	0.00097
rc_W45487_s_at	W45487	3524	dynamin 2	4.2	- 9	0.00325
rc_W49574_at	W49574	3538	EST	5.97	· 9	0.00045
rc_W49661_s_at	W49661	3539	FK506-binding protein 9 (63 kD)	3.01	· d	0.02259
					•	

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name	Fold Change	Direction	Dyalite
W52858 at	W52858	3545	DKFZP564F0522 pro	4 38	1 -	88000
rc_W60486_at	W60486	3558		92.4	글 등	0.0000
rc_W67251_s_at	W67251	3570		6.13	h 9	0.01463
rc_W70336_at	W70336	3579		3,65	- 9	0.01776
rc_W72276_at	W72276	3583	EST	27.39	음	0.00183
			protein tyrosine phosphatase, receptor type, f polypeptide			
rc_W72861_at	W72861	3586	_	3.01	g	0.00055
rc_W73189_at	W73189	3589	EphB2	3,69	1 9	0.02909
rc_W73914_at	W73914	3595	EST	3.5	9	0.04782
rc_W74233_s_at	W74233	3597	related RAS viral (r-ras) oncogene homolog	6.02	. a	0.01815
W76097_at	W76097	3299	EST	3.83	. <u>a</u>	0.00001
rc_W78057_at	W78057	3600	EST	9.06	. g	0.0034
rc_W80730_at	W80730	3607	EST	6.59	. a	0.00425
rc_W80763_at	W80763	3608	EST	3.83	. <u>a</u>	0.01319
rc_W81375_at	W81375	3613	EST	3.58	. a	0.00322
rc_W81540_at	W81540	3614	serine/threonine kinase 24 (Ste20, yeast homotog)	6.72	d	0.00164
rc_W90146_f_at	W90146	3644	EST	6.23	d	0.01558
rc_W92207_at	W92207	3651	EST	6.77	g.	0.00002
rc_W92449_at	W92449	3652	EST	31.67	g	0.00011
rc_W92608_s_at	W92608	3653	BAI1-associated protein 3	5.12	g.	0.00075
rc_W93726_s_at	W93726	3656	protease inhibitor 5 (maspin)	16.48	g.	0.00014
rc_W93943_at	W93943	3657	EST	4.3	g.	0.00296
W95348_at	W95348	3663	HSPC113 protein	10.89	g	0.01065
rc_W95477_at	W95477	3664	EST	26.51	d	0.00161
X03342_at	X03342	3675	ribosomal protein L32	4.09	g.	0.00008
AFFX-Crex-5_at	X03453	3677	EST	3.03	g.	0.0025
X04347_s_at	X04347	3680	heterogeneous nuclear ribonucleoprotein A1	7.26	d n	0.00018
X05610_at	X05610	3685	collagen, type IV, alpha 2	3.58	d	0.01351
X06617_at	X06617	3687	ribosomal protein S11	4.32	g	0.0002
X07820_at	X07820	3695	matrix metalloproteinase 10 (stromelysin 2)	3.49	d	0.00689

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Sed ID	Known Gene Name	Fold Change	Direction	Dyalita
X12447_at	X12447	3696	aldolase A, fructose-b	10.52		0 00038
X13956_at	X13956	3701	EST	3.2	r en	0.00321
X14850_at	X14850	3706	H2A histone family, member X	4.11	r G	0.0001
X15940_at	X15940	3709	ribosomal protein L31	4.45	. an	0.00004
X17093_at	X17093	3716	EST	4.82	. an	0.00176
X17206_at	X17206	3718	ribosomal protein S2	5.14	dn.	0
X17567_s_at	X17567	3719	small nuclear ribonucleoprotein polypeptides B and B1	3.6	. an	0.00586
X51466_at	X51466	3720	eukaryotic translation elongation factor 2	3.25	. <u>a</u>	0.00019
X51521_at	X51521	3721	villin 2 (ezrin)	3.89	- 9	0.00001
X52851_rna1_at	X52851	3725	EST	3,38	r on	0.0001
X52966_at	X52966	3726	ribosomal protein L35a	3.93	. <u>a</u>	0.00217
X53331_at	X53331	3727	matrix Gla protein	3.66	ā	0.04038
X54667_s_at	X54667	3731	cystatin S, cystatin SN	8.53	e e	0.00059
X55715_at	X55715	3735	ribosomal protein S3	3.72	- a	0.00755
X55954_at	X55954	3736	ribosomal protein L23	3.81	2	0.00025
X56494_at	X56494	3738	pyruvate kinase, muscle	22.97	+ <u>9</u>	0.00001
X56932_at	X56932	3740	ribosomal protein L13a	3.26	음	0
X56997_rna1_at	X56997	3741	ubiquitin A-52 residue ribosomal protein fusion product 1	6. 8.	9	90000
X57348_s_at	X57348	3744	stratifin	12.53	}	0.0003
X62535_at	X62535	3756	diacylglycerol kinase, alpha (80kD)	4.72	- <u>G</u>	0.00315
X62691_at	X62691	3757	ribosomal protein S15a	4.09	- a	0.00005
X63527_at	X63527	3761	ribosomal protein L19	3.17	. <u>a</u>	0.02488
X63629_at	X63629	3762	cadherin 3, P-cadherin (placental)	3.02	. <u>a</u>	0.01654
X64364_at	X64364	3764	basigin	6.45	. <u>a</u>	0.00041
X64707_at	X64707	3765	ribosomal protein L13	4.28	. a	0.00257
X65614_at	X65614	3767	S100 calcium-binding protein P	12.2	. g	0.00065
X66364_at	X66364	3770	cyclin-dependent kinase 5	3.55	. a	0.02824
			proteasome (prosome, macropain) subunit, beta type, 9 (large		•	
X66401_cds1_at	X66401	3771	multifunctional protease 2)	3.68	dn	0.01385
X66899_at	66899X	3772	Ewing sarcoma breakpoint region 1	4.72	d d	0.00011

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Dydlio
				A COLO		Lvaide
X67247_rna1_at	X67247	3774	mitogen-activated protein kinase kinase kinase 3	3 18	<u> </u>	67000
X67325_at	X67325	3775	interferon alpha-inducible protein 27	9 19	3 :	0.00012
X68314_at	X6831/	2770	Alitabliano accondina a constante a consta	9.07	음	0.03245
-	110000	0 0 0	glocal norte peroxidase 2 (gastrointestinal)	14.4	a	0.00222
August IIIal E at	YOSOSS	3/80	zinc finger protein 33a (KOX 31)	4.7	g	0.00062
X68688_rna1_s_at	X68688	3780	zinc finger protein 33a (KOX 31)	3.62	<u> </u>	0.00310
X69150_at	X69150	3782	ribosomal protein S18	7 7	}	0.000
X69391 at	X69391	3783	rihosomal protein I &	ç ç	3	0.0000
ł				3.18	음	0.00003
1 000000			CD4/ anuger (Kn-related antigen, integrin-associated signal			
Xogasa at	X69398	3784	transducer)	3.68	Qn.	0.02332
X69654_at	X69654	3785	ribosomal protein S26	3 11	<u></u>	0.02683
			ATP synthase, H+ transporting, mitochondrial F0 complex	; ;	}	0.02000
X69908 ma1 at	X69908	3786	sublinit c (subjust 0) isoform 3	i		1
			ממחתונו כ (פתחתונו ש), ופסוסווון צ	3.73	육	0.00685
2000			macrophage stimulating 1 receptor (c-met-related tyrosine			
X/0040_at	X70040	3788	kinase)	7	٤	00000
X74929_s_at	X74929	3792	keratin 8	- 1	<u>}</u> :	0.00402
X76180 at	X76180	3705	sodium chancel acmiclisms and delated	5/.4	d	0.00018
V77590 c ct	73700		Sociality indivolution of all alpha	11.68	d	0
A// 360_S_BI	1/288	3/88	N-acetyltransferase, homolog of S. cerevisiae ARD1	3.91	g	0.0221
X/868/_at	X78687	3800	sialidase 1 (lysosomal sialidase)	27		600
X79234_at	X79234	3803	ribosomal profein (11	9 6	S :	0.03
X79882 at	X79882	2805		6.03 1	롸	0.00051
X80408 of	X80408		ining i coloradica-i elated profeiri	6.71	g.	0.0362
X80837 24	00000X	3807	steroidogenic acute regulatory protein related	3.03	d	0.00044
YOOOG C	72007	3808	ribosomal protein L18a	4.13	g	0.0006
A60622_T_at	X80822	3808	ribosomal protein L18a	3.08	d d	0.02481
X80909 at	X80909	3809	nascent-nolyneatide-associated	č		
X83228 24	V02220		indepoint prophermina associated complex alpina polypeptide	3.84	슠	0.00399
X80080 -1	V02220	3810	cadnerin 17, Ll cadherin (liver-intestine)	10.58	ď	0.02147
A69900_at	X88960	3818	EST	9.87	. <u>9</u>	C
2000		!	high-mobility group (nonhistone chromosomal) protein isoform I-		÷	•
A92018_s_at	X92518	3825	ပ	3.12	9	0.00638
X93036_at	X93036	3830	FXYD domain-containing ion transport regulator 3	42.38	} §	0.00000
				4.00	3	0.0016/

Table 6A. Genes up regulated in metastatic tissue versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Cone Name		1	
X95404 at	X95404	3834	Cofilin 1 (non-muscle)	roid Change	- 1	Pvarue
X98482 r at	YORARO	2074		3.18	d	0.00104
X00433 04	730405 700406	- to		5.03	g	0.00002
Xooroo -	X88133	3842	lipocalin 2 (oncogene 24p3)	6.27	dn	0.0453
ruusus_at	Y00503	3849	keratin 19	14.19	. 2	0.00217
Y00705_at	Y00705	3850	serine protease inhibitor, Kazal type 1	0 83	<u> </u>	0.03697
Y10807_s_at	Y10807	3860	HMT1 (hnRNP methyltransferase, S. cerevisiae)-like 2	20.0 A 28	3 5	0.0000
Z23090_at	Z23090	3868	heat shock 27kD protein 1	7.67	}	0.0000
Z24727_at	Z24727	3871	tropomyosin 1 (alpha)		<u>a</u> :	0.0000
I			nuclear factor of kappa light polynentide gene enhancer in B.	4.4	d n	0.00121
Z25749_ma1_at	Z25749	3872	cells inhibitor-like 2	7 7 7		70000
Z26876_at	Z26876	3874	ribosomal protein L38	- c t - c] :	0.00031
Z28407 at	Z28407	3876	ribosomal profein 1.8	.4.4. 6.4.7	<u>a</u>	0.00022
Z30643 at	Z30643	3879	chloride channel Ka	6.53	o S	0.00004
rc Z38150 s at	738150	3883		3.86	合	0.00204
ļ ā	738266	3886	101 101	3.06	d	0.00049
rc 738729 at	738720	2000	. Han	6.58	dn	0.01909
rc 738909 at	738000	2000	101	3.13	ᅀ	0.04514
72007	230070	7600		3.55	d n	0.03195
10_223073_d1	239079	3300	KIAA1058 protein	4.08	d	0.01781
16_239191_BI	738181	3901	EST	8.84	. g	0.00011
rc_239200_at	Z39200	3902	EST	3.29	t <u>9</u>	0.00586
rc_Z39429_at	Z39429	3906	EST	7.84	÷ <u> </u>	0.00000
rc_Z39930_f_at	Z39930	3914	EST	3.07	<u> </u>	0.0000
rc_Z40583_f_at	Z40583	3922	EST	4 24	3 5	0.00002
rc_Z40898_at	Z40898	3925	EST	3.71	}	0.02373
rc_Z40945_at	Z40945	3927	trinucleotide repeat containing 15	7 82	3 5	0.0000
rc_Z41103_at	Z41103	3929	trinucleotide repeat containing 15	10.0	<u>.</u>	0.00007
rc Z41740 s at	241740	3935	EST	5.03	<u>a</u>	0.00444
, 0	741798	3037	בסו בסו	6.76	d	0.00049
) <u>*</u>	769730	200		ဖ	슠	0.00073
774615 of	274645	0847	Junction plakoglobin	3.3	dn	0.0237
774616 s of	774646	5948	collagen, type I, alpha 1	10.47	dn	0.00064
	2,14010	2820	collageri, type i, alpna z	4.83	dn	0.02364

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gane Name	Cold Ober		
rc_AA001603_at	AA001603	6	EST	roid Change	Direction	Pvalue
rc_AA001604_at	AA001604	4	EST	4. c	down	0.00883
AA004231 at	AA004234	. ^	Н	0.00 0.00	uwop ,	0.0215
rc AA004521 at	AA004524	- 0		3.16	down	0.03067
	AA00400E	0 \$	prostate caricer overexpressed gene 1	8.03	down	0.00027
	A 0.05000	=	NAMUSS/ protein	4.63	down	0.00082
10_A000502_dl	AA005202	77	retinol-binding protein 4, interstitial	3.18	down	0.00106
	AA005358	4	EST	5.2	down	0.00318
	AA007629	0	EST	8.01	down	0.00001
rc_AA009719_at	AA009719	20	peroxisomal membrane protein 2 (22kD)	47.12	down	0,00008
	AA010205	23	EST	7.41	down	0
AA010360	AA010360	54	EST	6.55	down	0.00027
	AA010530	52	EST	3.74	down	0.0481
rc_AA010619_at	AA010619	27	EST	8.55	down	0.00057
	AA010750	78	calmodulin 1 (phosphorylase kinase, delta)	10.22	down	0,00959
rc_AAU15/68_at	AA015768	8	EST	15.3	down	80000
rc_AA017146_at	AA017146	36	EST	10.1	down	0.00052
rc_AA017192_at	AA017192	37	EST	3.43	down	0.0000
rc_AA018867_at	AA018867	33	EST	42.87	down	0.0000
rc_AA021623_s_at	AA021623	43	insulin induced gene 1	11 71	down	0.0002
rc_AA025930_at	AA025930	25	EST	2.50	J Gow	0.00084
rc_AA031543_s_at	AA031543	89	translocation protein 1	7.03 000	T COMP	0.00372
AA031548_at	AA031548	69	cell division cycle 42 (GTP-hinding profein 25kD)	2.02 2.65	down down	0.00403
rc_AA032005_at	AA032005	71	EST EST	5.00 5.20	down	0.03029
AA032048_at	AA032048	72	EST	5.0 7.45	i down	0.01202
rc_AA032250_at	AA032250	73	EST	2.50 5.50	down	0000
rc_AA034030_at	AA034030	75	methylmalonyl Coenzyme A mutasa	4.20	liwop Tomil	0.000
rc AA035245 s at	AA035245	29	aldehyde ovidee 1	76.41	LIMOD .	0.00004
rc AA035457 at	AA035457	2 6	ECT	69.82	down	0.00117
	A A D 2 E B 2 B	3 8	- C - C - C - C - C - C - C - C - C - C	10.06	down	0.00085
	A A D 2 6 6 0 0	70	101	9.91	down	0.00541
rc AA037357 f at	A A 0.2.2.2.2.2	S S	- P.O.I.	4.16	down	0.00235
יביייים ביייים בייי	AA03/32/	S	EST	3.53	down	0.02129

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

			Lord Cildinge	Direction	rvalue
AA039335	83	Coadulation factor XII (Hadaman factor)	3	ı	
AA039616	8 8	CORPORATION I ACTOR (TIABELLIAN I ACTOR)	35	down	0.0029
AAN39806	3 2		9.36	down	60000.0
AAAAAA087	- 6	insh (Urosopnila) nomeo box homolog 1	3.53	down	0.00114
1000000V	7 6		4.13	down	0.00123
AA040270	56 6		3.03	down	0.01367
A A O 4 2 5 0 4	y 6	KIAAU669 gene product	3.55	down	0.00308
AA045301.	χ Σ	v-mat musculoaponeurotic fibrosarcoma (avian)	3.81	down	0.01304
AA044622	<u></u>	EST	3.62	down	0.03789
AA044755 AA044845	2 2	ES!	6.7	down	0.01228
AA04404A	200	Autosomal Highly Conserved Protein	5.21	down	6000.0
AA045670 AA046457	2 ;	יייי	5.93	down	0.00017
AA04643/	֡֡֓֞֝֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֟֝֓֓֓֓֓֓֓֡֓֓֓֓֓֓֡֓֓֡֓֡֓֡֡֡֡֓֓֡֡֡֡֡֡֓֡֡֡֓	וטן	3.2	down	0.00513
AA040074	71.1	ו הער	5.17	down	0.02561
AA046747	411		4.82	down	0.00022
AA045640	212	CCAA I /enhancer binding protein (C/EBP), delta	3.79	down	0.03319
AA047157	116	FOI	7.13	down	0.00007
A 4047 107	2:	E0.	3.04	down	0.04306
AA047290	118	EST	3.39	down	0.00024
AA052980	122	EST	4.52	down	0.023
AA055992	136	calumenin	3.51	down	0.00604
AA056170	137	EST	3.82	down	0.0083
AA056247	138	EST	3.48	down	0.03277
AA056482	141	EST	4.82	down	0.00199
AA05/6/8	143	EST	6.88	down	0.00078
AA059489	145	RGC32 protein	3.74	down	0.00734
AA062744	147	EST	3.31	down	0.01909
AA065173	148	EST	4.08	Cwop	0.00377
AA069456	149	KIAA0438 gene product	3.47	CWC)	0.00017
AA069768	151	hevin	4 62	unop domb	0.027.10
AA070090	152	EST	3.24	down down	0.00202
AA070091	153	EST	22	down	4.0000
	AA039335 AA039806 AA03087 AA040270 AA040291 AA044842 AA044842 AA044842 AA04657 AA046874 AA046874 AA046874 AA047151 AA047151 AA047151 AA055992 AA055992 AA056170 AA05647 AA056173 AA069768 AA069768 AA069768 AA069768		89 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	89 coagulation factor XII (Hagernan factor) 90 EST 91 msh (Drosophila) homeo box homolog 1 92 EST 93 EST 94 KIAA0669 gene product 98 v-maf musculoaponeurotic fibrosarcoma (avian) 103 EST 104 EST 111 EST 111 EST 114 EST 115 EST 116 EST 117 EST 118 EST 118 EST 119 EST 111 EST 119 EST	89 coagulation factor XII (Hageman factor) 90 EST 91 msh (Drosophila) homeo box homolog 1 92 EST 93 EST 94 KIAA0669 gene product 93 EST 95 EST 96 Autosomal Highly Conserved Protein 97 EST 98 v-maf musculoaponeurotic fibrosarcoma (avian) 98 TAA0669 gene product 99 EST 90 EST 90 Autosomal Highly Conserved Protein 97 EST 98 v-maf musculoaponeurotic fibrosarcoma (avian) 98 EST 99 EST 90 E

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sed ID	Kanan Garak		•	
rc AA074885 at	AA074885	184	1	Fold Change	Direction	Pvalue
rc_AA074891_at	AA074804	- 4 - 4	niaciopriage receptor with collagenous structure	11.05	down	0.00786
rc AA076238 at	16041000	70.		3.12	down	0.01897
rc AA076249 at	AA076240	202	181	3.23	down	0.00395
rc AAA76236 of	A070549	<u> </u>		3.78	down	0.00029
ופ"ססכח וחשל"מו	AA076326	170	SEC14 (S. cerevisiae)-like 2	10.88	down	0.00616
	٠		solute carrier family 25 (mitochondrial carrier:			0000
rc_AA079758_f_at	AA079758	174	citrate transporter), member 1	7 00	1	
rc_AA083812_at	AA083812	175	DKF7P566F123 protein	50.7	down	0.00359
rc AA084408 at	AAOR4408	170		9.11	down	0.00167
rc aa084668 at	AA084668	2 6		4.05	down	0.00864
rc AA085987 s at	A A O B E O B 1	200	upidniun-like 3	3.19	down	0.0419
rc AA086201 at	/080380/ / V/086304	201	UDP glycosyltransferase 1	40.87	down	0.00004
	AA000201	ရှိ ရှိ	בסו	5.8	down	0.00012
AA090257 at	A400090	8 6	: :	3.23	down	0.02543
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	/CZ06044	08L	superoxide dismutase 2, mitochondrial	11.72	down	0.0000
A A COO 4 24	AA090434	191	diaphanous (Drosophila, homolog) 1	4.61	down	0.01704
AAUSU439_at	AA090439	192	ribosomal protein S6	5 58 5 58	dolen	0.0100
AA092596_at	AA092596	197	bone morphogenetic profein 8	9	TWO P	0.0000
AA092716_at	AA092716	198	HI A-B associated transcript 3	3.40	down	0.02532
AA093923_at	AA093923	200	FOT	13.97	down	0.0000
AA094507 s at	AA094507	200	EST EST	3.82	down	0.03924
AA094999 at	A A DO 4 DO 0	7 6		3.52	down	0.04783
rc AA099225 at	A A COOCA S	\$ 6 6 7	Zinc ringer protein 216	5.12	down	0.0257
	A A DODO 204	9 7	E0	7.33	down	0.00062
75 AAAAAAA 5 24	AA00004	707	myosin, light polypeptide kinase	9.07	down	0.00003
n¦ d	AA039389	012	GDP dissociation inhibitor 2	3.7	down	0.04069
20 AA10133E 24	AA101055	213	leptin receptor	3.14	down	0.0071
rc_A4101633_ct	AA101235	214	EST	8.46	down	0.00822
rc AA112101 5 at	AA101632	217	EST	4.19	down	0.00023
ro 00412200 2 24	10171194	777		8.5	down	0.00004
18 S	AA112209	223	acyl-Coenzyme A dehydrogenase, long chain	3.37	down	0.00084
11000			UDP-N-actey/glucosamine pyrophosphory/ase 1;			
ואלה ואל	AA114949	228	Sperm associated antigen 2	5.12	down	0.01028

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name		- 1	
rc_AA121140_at	AA121140	235	EST	roid Change	- 1	Pvalue
rc_AA122345 f at	AA122345	238	alutamate dehydrogenase 1	3.33 48 E3	UMOD	0.00058
rc AA125831 r at	AA125831	241	myosin light notypoptida binaca	10.33	down	0.00004
rc AA125856 at	AA125856	24.5	Historia, ngin polypepude Kinase	8.18	down	0.00039
rc AA125861 at	AA425864	244	- 60	3.17	down	0.01545
rc AA126059 et	A 4 2 6 0 6 0	243	101	3.69	down	0.01547
rc ΔΔ126722 e et	A 4 26 700	240		3.08	down	0.00706
10 00407444 of	AA120/22	72J	U-6-methylguanine-DNA methyltransferase	8.26	down	0.002
1C_AA1Z/444_8t	AA127444	252	EST	3.56	down	0.0291
16_AA12/514_at	AA127514	253	EST	3.4	down	0.00045
rc_AA133Z15_at	AA133215	277	calcitonin receptor-like receptor activity modifying	4.55	down	0.02092
16_AA133290_81	AA133296	278	EST	4.23	down	0.00041
10_AA133439_81	AA133439	279	EST	4.07	down	0.00022
TO AND THE STATE OF THE STATE O	AA134549	288	EST	3.36	down	0.03438
rc_AA135558_s_at	AA13558	293	peptidase D	4.17	down	0.0068
1c_AA135958_at	AA135958	296	EST	4.02	down	0.00012
rc_AA136079_at	AA136079	297	EST	4.26	down	0.000
rc_AA142849_at	AA142849	306	EST	7 59		70000
AA143019_at	AA143019	309	EST	7. S	down down	0.00604
rc_aa147646_s_at	AA147646	317	DKFZP586A0522 protein	21.82	down down	0.00
	AA148480	318	flavin containing monocycenase 5	10.64	TO WILL	> (
rc_AA148923_at	AA148923	321	decidual profein induced by propesterons	2.5.4	T TOOM	0 12 00 0
rc_AA149253_at	AA149253	323	EST	13.2	down	0.00257
rc_AA150776_at	AA150776	330	EST	21.6	down	0.00863
rc_AA150891_at	AA150891	334	HSH TSH	10.45	down	0.00015
rc_AA151210_at	AA151210	333	TSE TSE	4.22	down	0.01692
	AA151676	227	to the state of th	4.b.	down	0.00008
rc AA156336 et	AA4E6236	3	pepuloyi ai giriire deliminase, type II	4.01	down	0.00911
	00000	न र	nuciear receptor co-repressor 1	3.69	down	0.01276
rc AA156565 at	A A 4 EBEEF	777	4-nitrophenylphosphatase domain and non-			
rc AA157442 of	A A E 3 A A D	† ;	Heuronal Sivap 25-like 1	15.01	down	0.01387
A 467500 24	ZL1/CIAY	345		3.94	down	0.02571
AA137320_at	AA15/520	347	EST	3.18	down	0.00516

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	
			aldo-keto reductase family 7. member A2	Similo Dio	1	Lyaide
rc_AA157799_at	AA157799	348	(aflatoxin aldehyde reductase)	20 00	d d	c
rc_AA164586_s_at	AA164586	329	estrogen receptor 1) u		2000
rc_AA167565_at	AA167565	362	EST	2 2		0.00162
rc_AA171694_at	AA171694	366	cerulopiasmin (ferroxidase)	3 5	I AOD	0.00046
rc_AA172372_at	AA172372	370	EST	21.23	down .	0.00179
rc_AA176233 at	AA176233	376	ו מין	5.48	down	0.00344
rc_AA179004_at	AA179004	277	Fer	11.44	down	0.01856
rc_AA179387_at	AA179387	270	DVE2D424N4000	14.34	down	0.00008
rc AA180356 at	AA180356	0 0	UNTZF434N1Z6 protein	3.7	down	0.01588
rc AA182030 at	A 100000	202	101	3.16	down	0.00917
rc	A 4 60 5 6 8	200		8.32	down	0.00018
	AA188034	288	SIAI induced SIAT inhibitor-2	10.92	down	66000.0
7 2000 C	AA400921	28.5 2.0 2.0	similar to Caenorhabditis elegans protein	4.05	down	0.004
rc	A4190610	382	EST	4.1	down	0.00037
101612	AA191014	386	EST	5.07	down	0.01455
			protein phosphatase 2 (formerly 2A), regulatory			
rc_AA191310_s_at	AA191310	397	subunit A (PR 65), beta isoform	7.28	C YOU	c
rc_AA191488_s_at	AA191488	398	solute carrier family 31 (copper transporters)	2 10	i do	0000
rc_AA191647_at	AA191647	399	ceruloplasmin (ferroxidase)	2 .		0.00013
rc AA193204 at	AA193204	402	Ara/Abl-intersection protein Arabas	4.03	down	0.00029
rc AA193223 at	AA103223	1 6	A B/ADI-II ITEI ACTING PROTEIN ARGBFZ	8.98	down	0.00861
AA193297 at	AA102207	3 5	101	4.2	down	0.02416
rc AA10407E f at	A 4 4 0 40 2 5	\$ 6		4.37	down	0.04676
AA104146 of	AA1940/5	406	nuclear receptor coactivator 4	4.69	down	0.00862
70 194 140 at	AA194146	407	EST	3.53	down	0.00352
	AA194833	411	claudin 1	11.45	down	0.00034
2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	AA19499/	412	EST	16.12	down	0.00103
10_AA183030_81	AA195656	418	KIAA0977 protein	15.29	down	0.00817
2 A A 106267	AA183037	818	FS	6.44	down	0.00016
1C_AA19028/_at	AA196287	420	EST	15.07	down	0 00001
			intercellular adhesion molecule 1 (CD54), human			- 0000
rc_AA19/311_s_at	AA197311	422	rhinovirus receptor	6.07	down	0.00053

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name	10 710	- 1	[
			FERM, RhoGE	roid Cilange	e Direction	Pvalue
AA203222_at	AA203222	424	domain protein 1 (chondrocyte-derived)	4 24	2000	2777
rc_AA205724_at	AA205724	426	EST ()	6.73	G 600	0.00743
rc_AA207123_at	AA207123	430	immunoglobulin superfamily, member 3	, . , .	T COMP	0.00027
rc_AA210850_at	AA210850	431	EST	0.70	i i i	0.00328
rc_AA211388_at	AA211388	433	EST	4.97	DOWIN	0.00735
rc_AA214542_at	AA214542	438	EST	4.00	UMOD -	0.02703
rc_AA215585 s at	AA215585	442	nidiy (nigleoside diabombate linkad metal. xx	4.43 54.0	UMOD.	0.00601
	AA215010	7 7 7	F have autilities of principlinate linked molety X)-	ო	down	0.03027
rc A4218727 at	A A 24 0 2 1 3	2 ;	r-box protein /	6.62	down	0.00921
rc AA210030 at	A 240020	C 44 4	E0.	3.47	down	0.00125
rc AA240204 2.4	AAZ 19039	440		5.76	down	0.00053
rc AA2196673 24	AAZ19304	44/	alpha-2-macroglobulin	21.97	down	0.00011
"I d	AAK 19033	448	EST	4.08	down	0.00607
77 A A 223002 24	AAZZ3335	449	propionyl Coenzyme A carboxylase, beta	5.49	down	0.02761
10	AAZZ390Z	420	EST	9.91	down	0.00003
10 AA22/432 BI	AAZZ/452	455	EST	4.7	down	0.02345
10_7427.460_s_at	AAZ2/480	456	pim-2 oncogene	3.31	down	0.02413
rc_AA227901_at	AA227901	459	SEC24 (S. cerevislae) related gene family,	3.18	down	0.00397
rc_AAZZ8119_at	AA228119	462	pre-B-cell colony-enhancing factor	4.77	down	0.00034
rc_AA232114_s_at	AA232114	463	epoxide hydrolase 2, cytoplasmic	24.34	down	0.0000
rc_AA233152_at	AA233152	467	EST	12.95	down	
rc_AA233347_at	AA233347	470	zinc finger protein 216	9		2000
rc_AA233369_at	AA233369	471	histidine ammonia-lyase	90 0	2000	0.00
rc_AA233763_at	AA233763	472	EST	20.0	Januar P	0.000
rc_AA233837 at	AA233837	474	EST	- i	nom.	0.00004
rc_AA234095_at	AA234005	770	101 101	4.79	down	0.0034
rc A4234527 e at	A A 22 4 E 2 7	0 4		8.08	down	0.00394
rc AA234561 at	AA224521	463	nuclear receptor subtamily 3, group C, member 1	6.19	down	0.00864
ΔΔ234634 f at	A A 22 4 62 4	0 0 0 0 0		3.88	down	0.02058
AA234817 of	AA234034	984	CCAA I /enhancer binding protein (C/EBP), delta	7.48	down	0.03318
٦ ا	AA23461/	490	EST	6.22	down	0.00099
בולטבסבסבים	WK24631	491	ESI	3.42	down	0.00206

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sed ID	Known Gone Name	Eold Chouse		
rc_AA234916_at	AA234916	492	EST	Fold Cilalige		Fvalue
rc AA235233 at	AA235233	493	FST	5. C	down	0.00799
rc_AA235288_at	AA235288	200		6.59	down	0.00755
r AA235310 of	A A 23 E 2 4 O	† ¢	TITLI-associated KnocAP 1	3.7	down	0.00643
ro A A 22 E O 2 4	A A D D T T D T	054	EST	37.86	down	0.00091
ro A A 22 E 6 4 4	AAZ35507	498	golgi autoantigen, golgin subfamily a, 5	3.28	down	0.00249
<u>-</u> ! ,	AA235618	499	EST	3.43	down	0.02127
	AA235765	50	KIAA0214 gene product	3.59	down	0.01148
rc_AA235811_at	AA235811	205	EST	3.64	down	0.01272
rc_AA235873_s_at	AA235873	505	H factor (complement)-like 1,H factor 1	9.98	down	0.01667
	AA236230	208	EST	5.28	down	0.01517
rc_AAZ36365_s_at	AA236365	209	3-phosphoglycerate dehydrogenase	10.23	down	0.00562
	AA236401	510	EST	16.71	down	0.00088
AAK30450	AA236455	512	EST	15.71	down	0.00286
တ'ှ	AA236455	512	EST	11.35	down	0.02859
rc_AAZ36/96_s_at	AA236796	517	follistatin	8.74	down	0.00862
rc_AA236942_at	AA236942	519	EST	3.18	down	
rc_AA236982_at	AA236982	520	sterol carrier protein 2	55.6	C C C C C C C C C C C C C C C C C C C	0 04542
rc_AA242766_at	AA242766	523	EST	3.58	Town of	0.01342
rc_AA243495_at	AA243495	528	lectin, mannose-binding, 1	4 23	T COMP	0.00
rc_AA243582_at	AA243582	529	hemoglobin gamma A	7.45	I MOD	0.001/9
rc AA243595 s at	AA243595	530	EST	61.7	uwop .	U.00Z1
AA247453 at	AA247453	733	TOT	3.11	UMOD.	0.008
rc AA250744 at	AA250744	738	101	3.09	down	0.0015
	A A DE G 7 7 E	2 6	101	3.39	down	0.01137
	C1100744	25	EST	4.52	down	0.01752
rc_AAZ51114_at	AA251114	239	prostate cancer overexpressed gene 1	9.9	down	0.00039
rc_AA25183/_at	AA251837	547	EST	3.87	down	0.00782
			quinolinate phosphoribosyltransferase (nicotinate-			
rc_AA252289_at	AA252289	225	nucleotide pyrophosphorylase (carboxytating))	5.66	down	0.01389
	AA252365	554	EST	3.9	down	0.01796
rc_AA253043_at	AA253043	559	DKFZP58611419 protein	3.89	down	0.00145
AA253129_at	AA253129	260	F-box protein FBL11	6.47	down	0.00001

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Nema			
rc_AA253216 at	AA253216	561	EST	roid Change	- 1	Pvalue
rc_AA253369 s at	AA253369	563	EST	28.18	down.	0.00141
rc AA253455 s at	AA253455	200	- CO	15.59	down	0.00091
rc AA253459 at	AA2E24E0	0 0	- 60 L	3.05	down	0.00533
rc AA255546 at	A A DEFECTA	8 8	LO I	4.51	down	0.00419
ro A A 2 E E C 3 4 C 4	AAZ33340	50C	FS	4	down	0.00301
16_AA253024_at	AAZ55624	571	EST	4.06	down	0.00069
	AA255878	572	KIAA0767 protein	3.96	down	0.00592
rc_AA255903_at	AA255903	573	CD39-like 4	5.67	C C C C C C C C C C C C C C C C C C C	0.00332
rc_AA256171_at	AA256171	575	EST	7.34	2000	0.01667
rc_AA256341_at	AA256341	578	EST	7.37	down down	0.04302
rc_AA256367_s_at	AA256367	579	paraoxonase 3	70.7	down	0.00091
rc_AA256666_at	AA256666	583	EST	7.33	down	0.00192
rc_AA257057_s_at	AA257057	586	EST	50.4	LMOD	0.0018
rc AA258308 at	AA258308	280	FST		uwop .	0.00379
rc_AA258323_at	AA258323	20.00	T S S S S S S S S S S S S S S S S S S S	5.4	down	0.00023
rc_AA258350_at	AA258350	202	בנים	4.31	down	0.00046
rc_AA258353_at	AA258353	202		2.08	down	0.00035
rc AA258567 at	A A DE GE E 2	2 6	- 60	5.28	down	0.00193
rc AA258613 at	AA250307	/80 60	101 101	6.92	down	96000.0
	AAK20013	288	ESI	4.31	down	0.0344
10_AA250613_81	AAZ38813	009	EST	4.63	down	0.02395
16_AAZ33004_81	AAZ59064	602	EST	13.15	down	0.00001
16_AAZ01934_81	AA261954	604	EST	69.2	down	0.00334
10_AAZ0Z033_S_81	AAZ62033	909	EST	4.41	down	0.00054
1C_A4262349_at	AAZ62349	607	EST	3.78	down	0.00043
	AAZ62/66	609	EST	5.66	down	0.03832
	AA2/8112	27.5	EST	3.42	down	0.01444
AA279550 et	AAZ/9533	627	EST	5.01	down	0.04448
	066812044	979	Kruppel-like tactor	4.06	down	0.00957
r AA270802 of	AAZ/30/0	930	deoxyribonuclease I-like 3	23.35	down	0.00001
rc AA270037 at	A A 270027	200	ו הטר זין	3.65	down	0.03366
	VAC18831	934	ĽŠ.	3.38	down	0.02719

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seg ID	Known Gene Name	Eold Chang		
rc_AA280130_at	AA280130	636	EST	roid Criange		Pvalue
			spleen focus forming virus (SEEV) proving	7	- A	41 100.0
rc_AA280413 s at	AA280413	638	integration operation entit	,	•	
IC AA280791 at	V V V O C V V	3 3	inception of the second of the	4.46	down	0.02062
TO AA28440 OF	A4200791	₹ 3	eukaryotic translation initiation factor 5	3.11	down	0.03339
70 A 2045 15 24	AAZ81440	644	EST	6.43	down	0.01246
	AA281545	645	EST	3.64	down	0.0000
rc_AAZ81591_at	AA281591	646	EST	3.23	rwo.p	0.00805
AA281677_at	AA281677	648	DKFZP564M2423 protein	3 05	down down	0.00093
rc_AA281770_at	AA281770	649	seven in absentia (Drosonhila) homolog 1	90.0	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0.0000
rc_AA281796_at	AA281796	650	mannose-P-dolichol utilitzation defect 1	5.30 5.30	T COM	0.00094
			core-binding factor, runt domain, alpha subunit 2.	3	I MOD	0.04108
rc_AA281930_at	AA281930	651	translocated to, 3	2 2 7	9	000000
rc_AA282061_at	AA282061	652	KIAA0962 profein	7.0	1	0.02329
rc_AA282089_at	AA282089	653	EST .	0.80	down	0.01033
rc_AA282179_at	AA282179	922		4.93	down	0.00108
rc ΔΔ282238 et	A A 202020	3 6	. 101	3.09	down	0.01693
r 44282530 at	A A 2005 4 C	000	ו שלים	3.47	down	0.00677
	AAZ62316	000	/-denydrocholesterol reductase	7.67	down	0.0008
16_A44262606_at	AA282886	663	EST	3.57	down	0.00049
	AA282971	665	EST	4.37	down	0.03822
rc_AAZ83758_at	AA283758	670	EST	3.67	down	0.04293
AAZ84558_at	AA284558	674	Nck, Ash and phospholipase C binding protein	3.09	down	0.00027
rc_aaz64/z1_s_at	AA284721	677	EST	3.34	down	0.03296
rc_AAZ84/95_at	AA284795	678	phosphatidylethanolamine N-methyltransferase	10.03	down	0.00019
	AA285053	681	EST	6.95	down	0.00125
rc_AA28/122_at	AA287122	989	EST	3.66	down	0.00161
rc_AA287550_f_at	AA287550	689	DKFZP434C171 protein	3.53	L MOP	0.00101
rc_AA287566_at	AA287566	069	KIAA0187 gene product	20.6		0.00217
rc_AA291323_at	AA291323	669	BCL2-interacting killer (apoptosis-inducing)	9 6	down	0.00013
rc_AA291749_s_at	AA291749	703	estrogen receptor 1	4 78		0.00014
rc_aa292086_s_at	AA292086	705	EST			0.00039
AA292158_s_at	AA292158	902	EST	2, 20	O COMIT	0.00161
1		, 1		R):17	down	0.00031

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gone Name	10 77	•	
rc_AA292328_at	AA292328	707	activation trans	roid Change	- 1	Pvalue
rc AA292711 at	AA292711	711		اد./۱ آو./	down	0.00689
rc AA292773 s at	A A 202773	7,7		m	down	0.01053
rc AA203327 of	A A 2002007	2 5	collagen, type AVIII, alpha 1	7.44	down	0.00158
	AA293327	716	isocitrate dehydrogenase 1 (NADP+), soluble	7.04	down	0.04377
AA208480 24	AAZ93485	718	EST	3.36	down	0.02799
77.290100 at	AA298180	726	EST	3.11	down	0.00747
10 A A 3 1 2 0 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	AAZ89632	28/	ESI	4.23	down	0.00371
0 0 1 2 3 40 S BI	AA312946	731	EST	9.21	down	0.00106
rc 00338512 at	AA314457	733	synaptonemal complex protein 3	4.86	down	0.0013
rc AA342301 at	A4336312 A 4340304	142	10.1 10.1	3.05	down	0.03427
tc	AA342301	40	EST	3.89	down	0.00038
10 A A 2 4 2 4 4 6 5 5 5 5	AA34233/	/4/		3.87	down	0.0069
10 A04440 S BI	AA342446	748	insulin receptor	6.83	down	0.00412
rc_AA34Z//1_8t	AA342771	749	EST	5.33	down	0.00331
rc_AA343142_at	AA343142	751	EST	20.87	down	0.0003
rc_AA344866_s_at	AA344866	752	complement component 8, gamma polypeptide	7.28	down	0.0000
rc_AA347674_at	AA347674	753	EST	10.59	down	0.03216
rc_AA347717_at	AA347717	754	EST	5.25	2000	0.000
rc_AA348284_at	AA348284	755	EST	0.50	O POWER	0.00207
rc AA348466 s at	AA348466	756	requision of G-protein signalling 6	4.04 4.04	uwop .	0.00759
rc AA348485 at	AA348485	75.	VANAGO O O O DIOCENI SIGNICALINO SI	3.2	down	0.00571
	270100	6	NAMA 35 gene product	4.01	down	0.04563
rc AA348022 c of	0000000	1	rarty-acid-Coenzyme A ligase, long-chain 1, fatty-			
70 AA340826 24	AA346922	200	acid-Coenzyme A ligase, long-chain 2	64.27	down	0.00002
ופיספורטע־סו	AA348830	9	EST	3.01	down	0.00911
			KIAA0382 protein; leukemia-associated rho			
rc_AA3/0359_s_at	AA370359	767	guanine nucleotide exchange factor (GEF)	4.82	down	0.01077
AA3/68/5_at	AA376875	770	monoamine oxidase A	3,8	down	0.02746
rc_AA377087_at	AA377087	771	EST	16.75	C)N(C)	20000
rc_AA381125_at	AA381125	772	EST	15.78	The state of	0.00002 0.00002
rc_AA382975_f_at	AA382975	773	EST	6.40	1000	
rc AA393825 at	AA393825	776	FST).c	UMOD	0.00131
1)	2	3	3.62	down	0.0065

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea 1D			- 1	
AA393961 at	AA393961	777	EST Celle Name	Fold Change	- 1	Pvalue
AA397841_at	AA397841	780	F.S.I	3.77	down	0.01029
rc AA397914 at	AA397914	783	ECT.	8.21	down	0
	AA308102	2 6	KIA 6466	3.16	down	0.00336
	A A 308474	100	NAVA429 gene product	6.22	down	0.00396
	AA3060AA	100	growm factor receptor-bound protein 14	7.82	down	0.0000
r 44308257 of	A A 200057) (calcium/calmodulin-dependent protein kinase	3.78	down	0.00019
70 A 208280 24	AA396237	5	/-dehydrocholesterol reductase	4.43	down	0.04169
	AA398280	792	EST	12.43	down	0.00134
	AA398386	793	EST	5.71	down	0.00007
	AA398422	794	EST	3.94	down	0.00388
10_A4398423_81	AA398423	795	EST	8.26	down	0.00063
10 A A 308902 24	AA398445	98/	EST	4.28	down	0.01764
10_AA390992_81	AA398892	800	similar to yeast BET3 (S. cerevisiae)	7.43	down	0.00038
10_A440030_at	AA400030	806	EST	3.98	down	0.00088
rc_AA400246_at	AA400246	810	mitogen-activated protein kinase-activated	3.09	down	0.00000
rc_A4400251_at	AA400251	811	EST	4.07	down	0.00010
rc_AA400258_at	AA400258	812	EST	11 89	Target Care	0.0002
rc_AA400259_at	AA400259	813	EST	3.65	i do	0.00476
rc_AA400471_at	AA400471	816	EST) r	I ACM	0.00470
	AA400780	818	FRAT	5.45	down	0.0056
rc_AA400831_at	AA400834	2 5	181	3.5	down	0.00107
rc AA400834 f at	AAA00824	<u> </u>	F01	3.49	down	0.00105
rc AA400864 at	AAA00864	020	- 21	4.73	down	0.01523
rc AA400915 at	AAA0004E	- 20	101 Hori	7.51	down	0.02237
rc AA400934 at	VA400034	023	Hor	9.84	down	0.00351
rc AA400979 at	AA400934	924	E01	4.98	down	0.02013
rc AA404151 at	AAAAAA	070	calcitonin receptor-like receptor activity modifying	6.65	down	0.01051
rc AA401343 at	AA401151	/20	lysozyme (renal amyloidosis)	3.01	down	0.0051
rc AA401376 24	A 4 0 4 0 4 0	070	101	3.11	down	0.01929
rc 44401562 s at	A401576	828		3.97	down	0.00797
	A4401362	200	EST	50.45	down	0.00301
18 - CO35th 27	AA402000	834	EST	4.19	down	0.00094

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sed ID	Known Gone Name			-
AA402095 s at	AA402095	835	EST	roid Change	Direction	Fvaiue
rc_AA402224_at	AA402224	836	arowth arrest and DNA-damage industria	3.12	down	0.01412
rc_AA402656_at	AA402656	841	EST	14.41	uwop	0.00012
rc AA402799 at	AA02700	5 6	ו מ	12.05	down	0.00001
	AAAA253	4 6	[50]	11.81	down	0.00031
rc AA404352 et	AA404232	8 4 6 5 6	lectin, mannose-binding, 1	16.15	down	0.00001
	AA404502	200	101	7	down	0.00059
2004547721	A4404500	852	EST	4.16	down	0.01375
10_A4403619_8t	AA405819	865	KIAA0668 protein	8.59	down	0.02034
10_A4403832_at	AA405832	998	EST	12.24	down	0.00441
1c_/440390/_at	AA405907	867	EST	3.12	down	0
16_88400125_s_at	AA406125	868	EST	4.95	down	0.01027
	AA406126	869	EST	8.43	down	0.00569
1c_A4406231_s_at	AA406231	873	KiAA0381 protein	4.46	down	0.04049
AA406435_at	AA406435	877	EST	3.24	down	0.00941
rc_AA410181_at	AA410181	881	EST	ന	down	0.00268
rc_AA410255_at	AA410255	882	EST	7.56	down	0.00203
rc_AA410507_at	AA410507	884	EST	2 73	T ACT	0.00043
rc_AA410523_at	AA410523	886	EST	6.75	down	0.01703
rc_AA411764_at	AA411764	891	similar to APOBEC1	5. A	down down	0.03506
rc_AA412034_at	AA412034	894	EST	00 %	down	0.01481
rc_AA412063_at	AA412063	895	EST	90.0 90.0	down	0.02309
rc_AA412184_at	AA412184	868	EST	0.50	GOWII	0.00001
rc_AA412481_s_at	AA412481	902	EST	3.00	down	0.00012
rc_AA416723_at	AA416723	906	EST	0.0	i mon	0.00014
rc AA416740 at	AA416740	000	FST	3.5/	uwop	0.01042
rc 4446873 at	0446070	5 8	- H	3.08	down	0.01592
	A44 100/3	<u> </u>	ESI soblingomyelin phosphodiodosoco 4	7.82	down	0.00005
rc_AA416890_s_at	AA416890	606	sprimganyani prospriodiesterase 1, acid lysosomal (acid sphingomyelinase)	w w	9	. 00
70 AA446006 at		;	5-methyltetrahydrofolate-homocysteine) 5		0.00
1C_AA410930_at	AA416936	910	methyltransferase reductase	4.98	down	0.00632
rc_AA41/046_at	AA417046	915	fatty-acid-Coenzyme A ligase, very long-chain 1	44	down	0

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name		- 1	
rc_AA417078_at	AA417078	916	EST	roid Cilange	- 1	Pvalue
rc AA417373 at	AA417373	017	101 101	7.4	down	0.00414
rc AA417375 at	AA44737E	- 6	181	4.8	down	0.01342
0.000 TV	0/6/1490	0 6	121	4.21	down	0.00231
A44 10030_81	AA418098	920	CAMP responsive element binding protein-like 2	3.18	down	0.03824
			cytochrome P450, subfamily I (aromatic			
rc_AA418907_s_at	AA418907	922	compound-inducible), polypeptide 1	4.05	down	0.04276
AA419507_at	AA419507	924	EST	5.58	D'AVD	0.01210
rc_AA419608_at	AA419608	925	EST	9,00	down	0.0000
rc_AA419622_at	AA419622	926	EST	9.7		0.0000
rc AA421049 at	AA421049	027	and the state of t	4.02	down	0.00386
rc AA421052 at	AAA240E2	770	activating transcription factor 5	44.41	down	0.00179
TC AAA21244 & ct	2017#W	878	pranched chain alpha-ketoacid dehydrogenase	3.52	down	0.00869
	A4421244	932	SH3-domain binding protein 5 (BTK-associated)	4.32	down	0.007
AA434303 - 4	A4421361	933	insulin-like growth factor 2 (somatomedin A)	9.98	down	0.00007
**************************************	AA424307	944	EST	5.73	down	0.0074
rc_AA4246/2_s_at	AA424672	946	dermatopontin	4.69	down	0.00843
rc_AA424798_at	AA424798	947	EST	17.45	CWO P	0.00352
rc_AA424813_at	AA424813	948	EST	5.77	doub doub	0.00332
rc_AA425294_at	AA425294	952	EST	10.5	down	0.0000
rc AA425309 at	AA425309	953	niiclear factor I/B	0.01	uwop .	0.00083
rc AA425782 at	AA425792	200		6.4	down	0.00466
	A 4 4 2 5 0 2 C A 4 A 4 A 5 C	200	KIAAU8/4 protein	5.52	down	0.03433
	A4423030	/CR		4.55	down	0.00035
AA426150_81	AA426156	626	EST	3.67	down	0.00153
AAACOOA	AA426168	096	KIAA0805 protein	3.73	down	0.01477
	AA426304	962	EST	6.61	down	0.01092
	AA426330	963	N-acylsphingosine amidohydrolase (acid	4.24	down	0.00668
rc_A4426468_at	AA426468	996	EST	3.38	down	0.0099
	AA426609	898	EST	6.28	down	0.01233
	AA42/178	978	EST	3.57	down	0.00368
	AA427783	979	EST	4.37	down	0000
rc_AA42/819_at	AA427819	980	midline 2	3.44	down	0.00063
AA428006_at	AA428006	984	DKFZP564B167 protein	3.71	down	0.02325

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name	Pold Change		
rc_AA428150_at	AA428150	985	EST	Fold Change	- 1	Pvaiue
rc_AA428325_at	AA428325	886	EST	92.0	down	0.00167
rc AA428567 at	AA428567	080	EST	0.30	uwop .	0.00002
rc AA428607 at	AA428607		in the second se	3.99	down	0.00788
rc_AA428863_at	AA428863	990	nbosoniai protein so pseudogene 1	4.21	down	0.04305
rc AA428900 at	AA428900	600	- 53 - 181	3.5	down	0.01726
rc AA429038 at	AA429038	992	- 23	7.01	down	0.00037
rc 004204 2t	A 4 20 4 20	200		3.29	down	0.00927
ro 0000000 at	AA429478	266	ESI	3.41	down	0.02599
1C_A442904_at	AA429904	1005	EST	7.26	down	0.00524
A4430011_at	AA430011	1006	EST	8.35	down	0.00729
AA430026	AA430026	1007	EST	3.31	down	0.00786
rc_AA430028_at	AA430028	1008	EST	9.14	down	0.00246
	AA430044	1010	EST	7.78	down	0.00124
rc_AA430047_at	AA430047	101	EST	3.44	down	0.0016
rc_AA430108_at	AA430108	1013	EST	3.8	down	0.04484
rc_AA430666_at	AA430666	1016	EST	5.12	down	0.00377
rc_AA431337_at	AA431337	1020	EST	6.26	down	0.00053
rc_AA431462_at	AA431462	1022	EST	4.45	down	0.00956
rc_AA431480_s_at	AA431480	1023	EST	4.3	down	0.0000
rc_AA431773_at	AA431773	1026	EST	7.61	down	0.00063
rc_AA432168_at	AA432168	1031	S-adenosylhomocysteine hydrolase-like 1	4.71	down	0.0000
rc_AA433946_at	AA433946	1033	EST	43.74	down	0.000
rc_AA435591_at	AA435591	1038	kinesin family member 3B	3.5	down	0.0000
rc_AA435753_at	AA435753	1045	EST	4.71	down	0.000
			solute carrier family 25 (mitochondrial carrier:	-		
rc_AA435777_f_at	AA435777	1047	citrate transporter), member 1	7.48	down	0.00613
rc_AA435824_at	AA435824	1048	EST	3 03	down	0.0000
rc_AA435985_at	AA435985	1049	EST	27.7	i down	0.02704
rc AA436489 at	AA436489	1053	EST	7.7	down	0
rc_AA436560_at	AA436560	40EE	20 C	45.7	down	0.001
rc AA436600 et	0000000VVV	2 5		11.41	down	0.00756
	08000	200	- Cu	4.58	down	0.00948

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sed ID	Known Gond Name		- 1	
rc AA436880 at	AA43680	1056	Eer	Fold Change	Direction	Pvalue
AA436926 at	AA426036		100	3.22	down	0.00699
rc AA43703E e of	4 4 4 3 3 3 5 7	SCO!	E01	5.5	down	0.00984
70 AAA27065 0 04	A443/235	1060	EST	7.15	down	0.01455
2 00421203 S SI	AA43/265	1061	EST	4.39	down	0.00826
	AA437295	1062	ribosomal protein L7a	4.35	down	0.00347
rc_AA441791_at	AA441791	1065	EST	3.58	down	0.00357
	AA442334	1069	EST	7.15	down	0.00018
AA442342_at	AA442342	1070	EST	5.62	Lwop	0.00018
rc 00443272_at	AA443272	1074	EST	7.68	down	0.00869
75 AAAA3756 of	AA443658	1079	transmembrane 7 superfamily member 2	90.6	down	0.00048
rc AA443822 at	A4443755	1080	ובער	5.05	down	0.00341
rc AA443034 of	AA443822	1082		5.46	down	0.02538
77 AA43036 2 21	AA443834	1083	GTP-binding protein Rho7	3.09	down	0.00214
20 00443999 S. C.	AA443836	1084	EST	22.96	down	0.00627
15 A446940	AA443893	1086	EST	3.21	down	0.02948
1C A4440342 at	AA446342	1088	seven in absentia (Drosophila) homolog 1	4.84	down	0.00015
rc_AA44658/_at	AA446587	1091	EST	ις: α	The second	0.00010
rc_AA446651_at	AA446651	1093	EST	5 5	1000	0.00012
rc_AA446666_at	AA446666	1094	EST	5. c	down	0.01902
1				4.03	down	0.02369
rc AA447549 at	A A A A 7 E A O	7077	OLF-IN-acieyigiucosamine pyrophosphorylase 1;			
70 AAA7647 of	040/44/V	5	Sperm associated antigen 2	6.37	down	0.02815
20 00447017_at	AA44/61/	1103	EST	3.26	down	0.04687
10_7444/140_BI	AA447740	1106	EST	3.22	down	0.02518
_'	AA447971	1110	EST	8.08	down	0.00035
ic_AA44/9// s_at	AA447977	111	EST	3.84	down	0.00045
rc_AA448002_at	AA448002	1113	putative type II membrane protein	10.05	down	
rc_AA448282_at	AA448282	1115	EST	3 87	9000	1 0
	•		FXYD domain-containing ion transport regulator 1	9	i Acco	0.00217
rc_AA448300_at	AA448300	1116	(phospholemman)	20 02	9	70000
rc_AA449267_at	AA449267	1120	EST	25.43	down	0.00001
rc AA449297 at	AA449297	1101	Fet	10.44	down	0.00926
	10701	171		3.78	down	0.00039

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sed ID	Known Gone Neme			
rc_AA449306_at	AA449306	1122	EST	rold Change	Direction	Pvalue
rc_AA449327_at	AA449327	1123			down	0.0006
rc AA440448 24	A A 40 449	3 6		4.77	down	0.01248
20 AAE0444 24	74449440	0711	EST	3.97	down	0.00103
10_704301 [4_8]	AA450114	1131	EST	4.96	down	0.01238
10_VV4501Z/_at	AA450127	1132		7.98	down	0.00078
16_AA450Z81_at	AA450281	1134		5.55	down	0.00004
	AA451836	1137	EST	4.9	down	0.01412
rc_AA451911_at	AA451911	1139	EST	3.44	down	0.00221
rc_AA452158_at	AA452158	1141	ras homolog gene family, member B	28.96	down	0.00064
AA452454_at	AA452454	1144	EST	4.45	down	0.00179
rc_AA452549_at	AA452549	1146	platelet-derived growth factor receptor, alpha	හ.	down	0.04155
AA452559_S	AA452559	1147	EST	4,35	down	0.00804
rc_aa452598_s_at	AA452598	1148	genethonin 1	5.49	down .	0.00163
rc_AA452855_at	AA452855	1150	lectin, mannose-binding, 1	9.88	down	0.00428
rc_AA452860_at	AA452860	1151	EST	3,99	down	0.00831
	AA452915	1152	EST	3.13	down	0.00561
rc_AA453770_s_at	AA453770	1157	EST	909	C C C	0.00534
AA453917_at	AA453917	1159	EST	, et	מאסט	0.00324
rc_AA453988_at	AA453988	1160	methionine adenosyltransferase I. alpha	5,00	down down	0.01090
rc AA454086 f at	AA454086	1161	UDP-directed debydrocepase	94.43 1.00	down	0.00381
rc AA454159 at	AA454150	4462	Col. Bigges deligated ase	4.29	down	0.00981
	07454400	1102	- 60 L	10.81	down	0.00132
	0 2 4 5 4 7 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	3 3	101	3.11	down	0.03
20 00454104 Ot	A4404177	1104	E.S	10.3	down	0.0008
٦ (AA404184	1100	ES.	3.96	down	0.04605
ַה יְמּ	AA404733	1169	ESI	5.61	down	0.01182
20 004E5967 04	AA455097	11/2	EST	6.03	down	0.00419
AAA5AA3	AA455367	9/11	DKFZP586F1018 protein	3.73	down	0.00202
20 AAAE88E 04	AA455403	//11	EST	15.46	down	0.01547
	AA455865	1180	phosphatidylinositol glycan, class B	5.41	down	0.00004
70 AAAE082 24	AA455896	1181	glypican 1	3.46	down	0.00887
10 TOM 2000 AI	A4400902	1182	ES	3.1	down	0.03905

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name	0 7	- 1	
rc AA455987 at	AA455987	1183	FOT	roio change	9 Direction	Pvalue
)		3	hithmoholoto (mamma)	5.36	down	0.00029
rc AA455988 at	AAAECOOO	,	Jimyropetaine (gamma), Z-oxoglutarate			
rc AA456055 at	A A 450000	100	dloxygenase (gamma-butyrobetaine hydroxylase)	15.54	down	0.00001
	A4430033	1185	EST	5.16	down	0.00158
10_A450141_81	AA456147	1188	general transcription factor IIIA	4.23	down	0.00088
IC_AA430Z89_BI	AA456289	1189	EST	15.31	TAIL OF	00000
rc_AA456311_s_at	AA456311	1190	EST	0.07 10.08		4,000
rc_AA456326_at	AA456326	1191	EST	5.5	E A	0.001
rc_AA456589_at	AA456589	1194	EST	3.35	down	0.00489
AA456687 at	AA45687	1,01	191	4.23	down	0.00102
	A A 457277	200	101 101	3.08	down	0.01189
	74437377	1021		3.1	down	0.00549
	AA438632	1202	EST	8.26	down	0.00001
10_74430923_8t	AA458923	1207	EST	3.36	down	0.00421
1c_AA456946_at	AA458946	1209	EST	15.88	9	0.000
rc_AA459256_at	AA459256	1212	lectin, mannose-binding. 1	3.00	down	0.0004
rc_AA459293_at	AA459293	1213	EST	5.6	dowii	0.00094
rc_AA459389_at	AA459389	1216	tymosylaratein sulfatrandens	3.2	down	0.0001
rc_AA459420_at	AA459420	1212	grosylprotein sunot an sierase z FST	3.72	down	0.02252
rc AA459668 at	AA459668	1240		7.25	down	0.0214
rc aa459690 s at	AA450600	22.5	5-nydroxyisobutyryl-Coenzyme A hydrolase	7.62	down	0.00225
	06060400	1771		9.18	down	0.00732
400040			solute carrier family 22 (extraneuronal			
16_A4400012_at	AA460012	1224	monoamine transporter), member 3	4.27	down	0.04975
AA460U4/_at	AA460047	1226	EST	3.33	קטועט	0.010.0
AA460128_at	AA460128	1227	similar to S. pombe dim1+	3.28		0.040
rc_AA460449_at	AA460449	1228	EST	0.10		0.01239
rc_AA460661 at	AA460661	1229	FSE	17.7	down	0.00011
rc AA460916 at	AA460946	1000		7.02	down	0.00053
rc AA461057 at	AA64057	25.5		3.69	down	0.04841
rc AA461303 at	AA64202	4 5	iluciear localization signal deleted in	5.22	down	0.00051
	A4401303	1238	UNFZP386D1519 protein	4.77	down	0.0438
rc AA461458 at	AA461444	1239	EQ.	11.56	down	0.00167
	A4401400	1741	ESI	3.37	down	0.02427

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name	Fold Object		
rc_AA463194_s_at	AA463194	1244	KIAA1037 protein	rold Change	- 1	Fvailue
rc AA463195 at	AA463195	1245	EST FOR	4.92	down	0.01866
AA463311 at	AAA62244	77.40		3.41	down	0.00413
m 44463720 at	A 4 602700	1240	E0.	3.71	down	0.04902
20 00 00 00 00 00 00 00 00 00 00 00 00 0	A4403729	0071	ESI	4.07	down	0.00676
12 A 4630 46 21	AA463876	1252	EST	3.31	down	0.00109
A A 4644 00 0	AA463946	1254	pigment epithelium-derived factor	3.38	down	0.0018
70 AAAAAAA	AA464188	1256	EST	4.82	down	0.03208
rc AA465240 at	AA464603	1260	EST	3.26	down	0.0007
10_04403240_al	AA465240	1270	EST	4.03	down	0.0046
10 AA478324 6 04	AA470153	12/5	solute carrier family 21 (organic anion	13.26	down	0.00315
AA476346	AA416324	1281	EST.	55.22	down	0.00132
rc AA476352 at	AA476352	1202	E01	3.12	down	0.01067
rc AA477119 at	AA477440	1004	F31	3.41	down	0.02233
AA477919 at	AA477119	1289	וסו	3.13	down	0.0338
AA477078 c of	0407474	1283	EX.	4.69	down	0.00141
rc 00478416 of	A44/19/8	1294	short-chain dehydrogenase/reductase 1	8.53	down	0.01651
	A44/6410	0051	ES	4.04	down	0.00078
0 770122 21	AA478441	1302	cathepsin F	5.07	down	0.00752
	AA479132	1309	EST	3.12	down	0.00876
rc_AA4/9148_at	AA479148	1311	EST	38.05	down	
1C_AA4/9488_at	AA479488	1313	S-adenosylhomocysteine hydrolase-like 1	4	down	0.0269
	AA479498	1314	EST	5.78	down	0.01489
10_A4479682_8t	AA479885	1318	KIAA0843 protein	15.57	down	0.00024
	AA479968	1321	arylsulfatase A	9.01	down	0.00224
	AA480975	1322	EST	8.95	down	0.00259
rc AA484433 c ot	A4480991	1323	EST	8.59	down	0.00156
r AA481526 of	AA461432	1328	Tibronectin 1	7.76	down	0.0061
AA484670 24	A4401020	1329	E0.	3.73	qown	0.00002
rc 44482594 at	A44616/U	1330	retinal short-chain dehydrogenase/reductase	6.2	down	0.0078
	AA402394	133/	101	5.42	down	0.00387
	24403003	<u>\$</u>	E31	5.46	down	0.00044

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	on Confession
rc_AA485326_at	AA485326	1342	ATP-binding a	308	1 -	0.00415
rc_AA485413_at	AA485413	1344	EST S S S S S S S S S S S S S S S S S S	454	down	0.00413
			aldehyde dehydrogenase 5 family, member A1	·	}	
rc_AA486410_at	AA486410	1348	(succinate-semialdehyde dehydrogenase)	8.08	down	0.00485
AA486511_at	AA486511	1349	EST	22.21	down	0.00113
rc_AA486567_at	AA486567	1350	EST	Ŋ	down	0.00002
rc_AA487161_at	AA487161	1353	ubiquilin 2	3.13	down	0.00023
rc_AA487503_at	AA487503	1356	EST	8.85	down	0.00012
rc_AA487606_at	AA487606	1358	EST	3.05	down	0.00291
	AA488843	1362	cornichon-like	8.58	down	0.02131
rc_AA489061_at	AA489061	1367	EST	3.49	down	0.00223
rc_AA489629_at	AA489629	1369	EST	8.08	down	0.00109
rc_AA489636_at	AA489636	1370	EST	10.7	down	C
rc_AA489798_at	AA489798	1373	hypothetical protein, estradiol-induced	8.75	down	0.00544
rc_AA490159_at	AA490159	1374	glucose-6-phosphatase, transport (glucose-6-	5.44	down	0
rc_AA490214_at	AA490214	1376	EST	3.12	down	0.02382
rc_AA490620_at	AA490620	1378	EST	4.77	down	0,00201
rc_AA490670_at	AA490670	1379	EST	96.6	down	0.00454
			UDP-N-acetylglucosamine-2-epimerase/N-			
AA490775_at	AA490775	1380	acetylmannosamine kinase	5.34	down	0.00118
rc_AA490882_s_at	AA490882	1381	EST	3.29	down	0.00319
rc_AA490890_at	AA490890	1382	EST	3.02	down	2,0000.0
rc_AA491000_at	AA491000	1385	EST	4.23	down	0.02305
rc_AA491001_i_at	AA491001	1386	EST	8.52	down	0.01118
rc_AA491001_f_at	AA491001	1386	EST	3.73	down	0.01957
AA495758_s_at	AA495758	1391	EST	3.94	down	0.00772
	AA495820	1393	EST	3.98	down	0.00218
rc_AA496053_at	AA496053	1396	EST	3.28	down	0.00095
AA496423_at	AA496423	1399	WW domain binding protein 2	3.52	down	0.01314
rc_AA496914_at	AA496914	1401	v-maf musculoaponeurotic fibrosarcoma (avian)	3.48	down	0.00361
rc_AA497052_at	AA497052	1408	DKFZP727G051 protein	7.28	down	0.01745

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gobe Name		- 1	
rc AA504492 at		1414	tuhulin alaha	roid Change	- 1	Pvalue
1 (1		1 5	raballit, alpita, upiquitous	4.21	down	0.00752
	AA303186	1419		3.41	down	0.0343
1C_AA3Z1Z9U_at	•	1421	EST	4.53	down	0.0148
rc_AA521292_at	•	1422	EST	8.58	uwop	0 00064
rc_AA521306_at	AA521306	1423	EST	4.27	down	0.00567
			UDP-N-acet/Iglucosamine-2-epimerase/N-	į		20000
rc_AA598417_at	AA598417	1426	acetylmannosamine kinase	8 50	2000	0.04630
rc_AA598419_s_at	AA598419	1427	translational inhibitor protein n14 5	9000	TAO T	0.01030
rc_AA598675_at		1433	EST	23.0 3.25	down	0.00036
rc_AA598679_at	AA598679	1434	EST	2.50	C C C C C C C C C C C C C C C C C C C	0.03934
rc_AA598746 at		1437	EST	 	down	0.00467
rc_AA598926_at	•	1441	TO L	0 1	uwop .	0.02667
rc A4599211 at	AA599214	1445	chort choic dobudes and the first of	3.7	down	0.00432
1 6		7 1	short-chain denydrogenase/reductase 1	7.85	down	0.00911
10 ACC 175 11	•	1447	murine leukemia viral (bmi-1) oncogene homolog	3.9	down	0.0068
IC_AA3894/Z_at		1451	succinate-CoA ligase, GDP-forming, beta subunit	5.07	down	0.00447
rc_AA599526_at	AA599526	1453	cartilage associated protein	3.02	down	0.00043
rc_AA599814_at		1456	EST	12.37	down	0 0000
rc_AA599937_s_at	•	1458	insulin-like growth factor-binding protein 4	26.92	down	0.00094
rc_AA599954_at	•	1459	cell cycle progression 8 protein	3.15	down	0.00024
rc_AA608546_at	AA608546 1	1463	EST	12.52	down	0.0003
rc_AA608671_at	•	1466	EST	3.14	2000	0.0000
rc_AA608729_at		1468	EST	. e	TWO P	0.04343
rc_AA608751_i_at	_	1469	EST	5.35 7.78	T Apple	0.0
rc_AA608802_at	AA608802 1	1470	EST	8.00 8.00 8.00		0.01404
rc_AA608807_s_at	ν	1471	Inhibin, beta B (activin AB beta polypeptide)	4.05	down	0.00203
rc_AA608837_at	AA608837 1	1472	EST	6.2	down	0.0000
rc_AA609011_at	•	1476	EST	3.94	down	0.0000
rc_AA609164_at	•	1480	cytochrome b-561	88	down	0.000
rc_AA609316_at	•	1481	EGF-like-domain, multiple 5	7.97	down	0.02230
rc_AA609519_at	_	1482	EST	8.13	down	0.0000
rc_AA609537_s_at	AA609537 1	1483	hepatic leukemia factor	8.76	down	0.00018

· : ·

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

rc_AA609572_at rc_AA609574_at rc_AA609773_at rc_AA609774_at rc_AA609934_at rc_AA620343_at rc_AA620343_at rc_AA62036_at rc_AA62043_at rc_AA62043_at rc_AA62043_at rc_AA62043_at rc_AA62043_at rc_AA62043_at rc_AA62043_at	AA609572 AA609574 AA609576 AA609773 AA609934 AA609996	1484	LOI	2000	9000	1
	AA609574 AA609576 AA609773 AA609934 AA609996	1485	- 3	3.02		0.01534
a a a a a a a a a a a a a a a a a a a	AA609576 AA609773 AA609774 AA609934 AA609996)	EST	5.03	down	C
	AA609773 AA609774 AA609934 AA609996	1486	EST	23.1	down	0.00266
स स के व्यवस्था के स	AA609774 AA609934 AA609996	1489	EST	60.9	down	0.01103
# # # # # # # # # # # # # # # # # # #	AA609934 AA609996	1490	EST	4.02	down	0.00424
* * * * * * * * * * * * * * * * * * *	AA609996	1493	EST	6.84	down	0.00048
# # # # # # # # #	,,,,,,,	1495	EST	3.93	down	0.00988
** ** ** **	AA620343	1500	EST	5.04	down	0.00407
at at at	AA620556	1505	EST	32.4	down	0.00353
ळ ,ळ ,ळ	AA620667	1506	protein tyrosine phosphatase type IVA, member 1	5.92	down	0.00206
ਛ ਼ ਛ	AA620830	1509	DKFZP5641122 protein	3.42	down	0.02421
	AA621131	1513	EST	35.37	down	0
	AA621192	1515	EST	5.39	down	0.0016
'at	AA621209	1516	similar to Caenorhabditis elegans protein	6.34	down	0.00144
ja,	AA621235	1517	EST	3.44	down	0.0021
rc_AA621274_i_at	AA621274	1519	EST	7.43	down	0.00065
rc_AA621430_at	AA621430	1525	doublecortex; lissencephaly, X-linked	3.09	down	0.00024
rc_AA621796_at	AA621796	1531	kinesin family member 3B	4.44	down	0.00032
			PDZ domain containing guanine nucleotide			
	AB002311	1535	exchange factor(GEF)1; RA(Ras/Rap1A-	4.21	down	0.00476
	AB002328	1536	calcineurin binding protein 1	5.55	down	0.00016
'at	AF000573	1543	homogentisate 1,2-dioxygenase (homogentisate	13.76	down	0.00002
AF005039_at	AF005039	1548	secretory carrier membrane protein 3	3.42	down	0.04953
			solute carrier family 4, sodium bicarbonate			
AF007216_at	AF007216	1550	cotransporter, member 4	5.79	down	0.00005
C01257_at	C01257	1554	EST	5.35	down	0.00608
C01286_s_at	C01286	1555	integral membrane protein 2B	4.11	down	0.00292
C01409_s_at	C01409	1556	EST	4.41	down	0.01725
C01686_at	C01686	1557	EST	3.01	down	0.00048
C02099_s_at	C02099	1560	CGI-131 protein	5.85	down	0.02377
C02460_at	C02460	1562	EST	3.64	down	0.02705

1

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pyalue
rc_C14963_s_at	C14963	1572	nicotinamide nucleotide transhydrogenase	3.9	1 -	0.0044
C15871_at	C15871	1575	EST	3.26	down	0.00046
C16420_s_at	C16420	1576	EST	5.95	down	0.00119
rc_C20653_at	C20653	1578	EST	10.59	down	0.00001
rc_C20810_at	C20810	1579	EST	5.17	down	0.00614
rc_C20911_at	C20911	1580	antithrombin III	6.56	down	0.00175
rc_C20974_at	C20974	1581	Vanin 1	99.9	down	0.00272
rc_C21130_at	C21130	1583	EST	8.79	down	0.00008
rc_C21238_at	C21238	1584	EST	4.54	down	0.02074
		•	cytochrome P450, subfamily IIIA (niphedipine			
	D00003	1586	oxidase), polypeptide 3	22.05	down	0.00059
			cytochrome P450, subfamily IIIA (niphedipine			
D00003_at	D00003	1586	oxidase), polypeptide 3	9.46	down	0.00001
D00097_s_at	D00097	1588	amyloid P component, serum	16.72	down	0.00098
			cytochrome P450, subfamily IIIA (niphedipine			
			oxidase), polypeptide 3, cytochrome P450,			
			subfamily IIIA (niphedipine oxidase), polypeptide			
D00408_s_at	D00408	1589	5, cytochrome P450, subfamily IIIA, polypeptide 7	11.1	down	0
D00632_at	D00632	1591	glutathione peroxidase 3 (plasma)	6.55	down	0.00121
D00723_at	D00723	1592	glycine cleavage system protein H (aminomethy)	4.18	down	0.00543
D10040_at	D10040	1593	fatty-acid-Coenzyme A ligase, long-chain 2	20.51	down	0
			acetyl-Coenzyme A acetyltransferase 1			
D10511_at	D10511	1594	(acetoacetyl Coenzyme A thiolase)	10.68	down	0.0002
rc_D11756_f_at	D11756	1596	EST	5.49	down	0.01272
rc_D11802_at	D11802	1597	angiotensinogen	5,65	down	600000
rc_D11835_at	D11835	1598	low density lipoprotein receptor (familial	21.76	down	0.00307
rc_D11881_at	D11881	1599	KIAA0962 protein	4.37	down	0.01627
:			phosphodiesterase l/nucleotide pyrophosphatase			
D12485_at	D12485	1600	1 (homologous to mouse Ly-41 antigen)	4.57	down	0.00008

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change Direction	Olrection	Pyshio
			ı			
D12620_s_at	D12620	1601	2,cytochrome r 430, sublamily IVr, polypeptide 3 (leukotriene B4 omega hydroxylase)	35.09	down	0.00045
			cytochrome P450, subfamily IVF, polypeptide			2000
			2, cytochrome P450, subfamily IVF, polypeptide 3			
D12620_s_at	D12620	1601	(leukotriene B4 omega hydroxylase)	13.45	down	C
D13243_s_at	D13243	1602	pyruvate kinase, liver and RBC	20.22	down	· C
D13643_at	D13643	1609	KIAA0018 gene product	10.84	owo down	0 00058
D13705_s_at	D13705	1610	cytochrome P450, subfamily IVA, polypeptide 11	3.7	down	0.0003
D13814_s_at	D13814	1611	angiotensin receptor 1, angiotensin receptor 1B	3.12	down	0.0000
D14012_s_at	D14012	1612	HGF activator	12.75	down	0.0035
D14664_at	D14664	1616	KIAA0022 gene product	8.98	down	0.00011
D14695_at	D14695	1618	KIAA0025 gene product; MMS-inducible gene	6.48	down	0
1			acetyl-Coenzyme A acyltransferase 2			•
D16294_at	D16294	1619	(mitochondrial 3-oxoacyl-Coenzyme A thiolase)	4.81	down	0.03921
D16350_at	D16350	1620	SA (rat hypertension-associated) homolog	3.83	down	0.00117
			hydroxyacyl-Coenzyme A dehydrogenase/3-			
			ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme			
D16481_at	D16481	1621	A hydratase (trifunctional protein), beta subunit	3.18	down	0.00695
D16626_at	D16626	1622	histidine ammonia-lyase	22.66	down	C
D16626_at	D16626	1622	histidine ammonia-lyase	9.25	down	0.00025
rc_D20350_át	D20350	1624	EST	13.97	down	0.00057
D31117_at	D31117	1640	ribosome binding protein 1 (dog 180kD homolog)	5.3	down	0.02749
D31225_at	D31225	1641	EST	3.17	down	0.01073
D31289_at	D31289	1642	EST	4.16	down	0.02166
D31381_at	D31381	1644	dynein, axonemal, light polypeptide 4	4.97	down	0.01806
D31628_s_at	D31628	1646	4-hydroxyphenylpyruvate dioxygenase	50.48	down	0.00002
D31716_at	D31716	1647	basic transcription element binding protein 1	5.35	down	0.00086
D31815_at	D31815	1648	regucalcin (senescence marker protein-30)	10.55	down	0.00037
D31887_at	D31887	1649	KIAA0062 protein	4.26	down	0.00101
D37931_at	D37931	1650	ribonuclease, RNase A family, 4	5.81	down	0.00836

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Eold Change		9.10
			inter-alpha (old	old Citating	חופכווסוו	Lvalue
D38535_at	D38535	1654	Kallikrein-sensitive alycoprotein)	13.2	down	0.01465
rc_D45529_at	D45529	1662	EST	3.82	down	0.01.03
rc_D45556_at	D45556	1663	EST	4 83	T COP	0.00
rc_D45714_at	D45714	1664	EST	5.64	L Copy	0.0104
D49357_at	D49357	1665	methionine adenosyltransferase I, alpha	11.28	down	0.00334
D49387_at	D49387	1666	NADP dependent leukotriene b4 12-	8.17	down	0.0000
D49742_at	D49742	1668	hyaluronan-binding protein 2	18.13	uw op	0.00012
rc_D51199_at	D51199	1677	EST	5,05	down	0.0012
rc_D51279_s_at	D51279	1679	ovarian granulosa cell protein (13kD)	5.88	uwop	0.01271
rc_D5209/_s_at	D52097	1682	prostatic binding protein	8.1	down	0.00141
D5/823_at	D57823	1690	Sec23 (S. cerevisiae) homolog A	4.43	down	0
D36231_s_at	D58231	1692	ubiquitin-like 3	3.07	down	0.0002
rc_D59344_s_at	D59344	1695	EST	3.34	down	0.01337
rc_Dogo54_t_at	D59554	1698	EST	6.7	down	0
rc_D59714_s_at	D59714	1700	mitogen inducible 2	17.62	down	0.00014
rc_D60670_at	De0670	1702	EST	3.73	down	0.00382
rc_D60769_s_at	D60769	1703	KIAA0096 protein	4.31	down	0.00142
rc_D60856_f_at	D60856	1705	UDP-glucose dehydrogenase	6.45	down	0.01222
D61991_at	D61991	1706	EST	4.84	down	0.00005
D62103_s_at	D62103	1707	EST	4.11	down	0.0263
rc_D62518_at	D62518	1708	EST	17.49	down	0.00017
D63160_at	D63160	1709	ficolin (collagen/fibrinogen domain-containing	4.01	down	0.00391
D/8011_at	D78011	1717	dihydropyrimidinase	21.37	down	0.00003
	D79276	1722	succinate-CoA ligase, GDP-forming, beta subunit	6.8	down	0.00047
D/9687_at	D79687	1723	KIAA1053 protein	5.06	down	0.00047
rc_D80050_at	D80050	1726	EST	4.64	down	0.01001
rc_D80217_t_at	D80217	1727	H91620p protein	3.61	down	0.01973
rc_D80218_t_at	D80218	1728	brain acid-soluble protein 1	3.83	down	0.0137
rc_D80312_r_at	D80312	1730	EST	3.74	down	0.01909
rc_ບຮບ4ບຮ_at	D80408	1731	EST	3.36	down	0.00102

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sed ID	Known Gene Name		1	
rc_D80905_at	D80905	1735	EST	rold Criange	- 1	rvalue
D82061 at	D82061	1741	Kes dene molise himan hamalan af	9.09 9.09	uwop .	0.000
D82422_at	CC7C8C	4745	for gene, mouse, number normong of	6.1	down	0.00104
D85481 at	D05422	047	terroportin 1; fron regulated gene 1	6.01	down	0.02351
D86062 5 5	185181	1/50	sterol-C5-desaturase (fungal ERG3, delta-5-	9.56	down	0.00005
D02075	D86062	1752	ES1 (zebrafish) protein, human homolog of	3.63	down	0.0001
D87079_81	08/0/5	1760	solute carrier family 23 (nucleobase transporters),	4.15	down	0.00067
D67450_at	D8/436	1761	KIAA0249 gene product	5.49	down	0.00333
D8/449_Bt	D87449	1762	KIAA0260 protein	4.58	down	0.00026
D87466_at	D87466	1763	KIAA0276 protein	4.83	down	0.0007
D90042_at	D90042	1767	N-acetyltransferase 2 (arylamine N-	7.06	down	0
DSUZBZ_at	D90282	1769	carbamoyl-phosphate synthetase 1, mitochondrial	27.29	down	0.00002
rozozo al	F02028	1774	EST	23.48	down	0.00465
1C_r02034_81	F02094	1775	ecotropic viral integration site 5	3.41	down	0.00495
1C_F02245_at	F02245	1776	monoamine oxidase A	3.9	down	0.02943
10_F02343_81	F02345	1779	EST	3.9	down	0.0033
เราเจรากาสเ	F03200	1783	EST	3.75	down	0.01805
	1		matrix metalloproteinase 2 (gelatinase A, 72kD			
rc_F03969_at	F03969	1785	gelatinase, 72kD type IV collagenase)	7.87	down	0.00014
rc_F04335_at	F04335	1787	EST	3.16	down	0.0058
rc_r04611_at	F04611	1792	EST	23.96	down	0.00018
rc_F04944_s_at	F04944	1795	acyl-Coenzyme A oxidase	4.01	down	0.00242
	F08817	1796	EST	8.29	down	0.0077
rc_F08941_at	F08941	1798	EST	3.48	down	0.00428
rc_rugusa at	F09058	1799	EST	3.6	down	0.00595
rc_F09350_at	F09350	1801	EST	4.79	down	0.00088
rc_F09353_at	F09353	1802	solute carrier family 5 (inositol transporters),	3,3	down	0.02841
			core-binding factor, runt domain, alpha subunit 2;	!		
rc_F095/8_at	F09578	1804	translocated to, 3	4.66	down	0.04463
rc_F09979_at	F09979	1809	EST	4.36	down	0.02555
rc_F10182_s_at	F10182	1812	hepsin (transmembrane protease, serine 1)	58.92	down	0.0020
rc_F10276_s_at	F10276	1814	dual specificity phosphatase 6	8.13	down	0.0001

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea 1D	Known Gone Name	10 7	-	
rc F10466 at	F10466	1820	FCT	rold Change		Pvalue
rc F10640 at	E40640	1070		5.32	down	0.02494
rc E10874 # 24	1004	1701		3.58	down	0.00152
70 510075 05	F108/4	1823	EST	4.19	down	0.00025
10_F 100/3_8(F108/5	1824	EST	5.09	down	0.00004
1c_F13/0z_at	F13702	1826	EST	6.01	down	0.00064
rc_F13/82_s_at	F13782	1827	LIM binding domain 2	4.17	down	0.00109
			TEK tyrosine kinase, endothelial (venous			0000
rc_H02848_s_at	H02848	1831	malformations, multiple cutaneous and mucosal)	3 47	down	0000
rc_H02855_at	H02855	1832	EST	5.96	down down	0.0009
rc_H03348_at	H03348	1833	claudin 1	5.77	down	0.000
rc_H03945_at	H03945	1835	EST	4 94		0.0001
rc_H04142_f_at	H04142	1836	EST	10.6		0.02003
rc_H04242 at	H04242	1837	RABSB member RAS oncoons family	9.07	uwon .	0.01906
H04854 at	H04854	1842	inforbally a monator account of the second	3.27	down	0.04826
rc H05072 at	H05072	40.4	interreducir of receptor accessory protein	6.58	down	0.00007
rc H05974 s at	10001	2 0	101	3.12	down	0.01248
20 HOEORE 24	100374	1820		6.28	down	0.00549
TOOOG TO	C86C0H	1851	hypothetical protein	6.43	down	0.04887
IC_HUBUBS_S_at	H06063	1852	chondroitin sulfate proteoglycan 3 (neurocan)	3.15	down	0.00589
1C_H00144_at	H06144	1853	EST	3.1	down	0.00745
וכ חוס וססיי	H06166	1854	EST	3.31	down	0.03778
rc_H06935_s_at	H06935	1855	electron-transferring-flavoprotein dehydrogenase	6.82	down	0.00175
rc_H08054_at	H08054	1857	EST	4.2	LWO C	0000
rc_H08102_at	H08102	1858	breast cell glutaminase	77.77	down	0.0000
rc_H09167_at	H09167	1860	KIAA0195 gene product	3 34	doug doug	0.00032
rc_H09353_at	H09353	1866	EST	5 6	TIMOD TO	0.00313
H09364 s at	H09364	1867	s in the second operation of the second of t	23.00	down	0.00094
rc H09594 at	H09594	1868	succinate denyanogenase complex, subunit A,	5.74	down	0.03125
rc H09959 s at	HOODED	1000		3.12	down	0.00231
H10482 at	103303	1007		3.25	down	0.00225
10 11040E at	70407	0/9		3.19	down	0.01611
1 000 - 1 - 2 - 1 - 2 - 1 - 2 - 1 - 2 - 2 - 2	1.00011	18/1	EST	4.54	down	0.00276

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Dyelis
			methylenetetrahydrofolate dehydrogenase	C		
			(NADP+ dependent), methenyltetrahydrofolate			
rc_H10//9_s_at	H10779	1872	cyclohydrolase, formyltetrahydrofolate synthetase	9.73	down	0.00035
rc_H11274_at	H11274	1874	EST	4.13	down	0.01478
			glycine dehydrogenase (decarboxylating; glycine			
rc_H11739_s_at	H11739	1876	decarboxylase, glycine cleavage system protein	10.33	down	0.00023
rc_H11746_at	H11746	1877	EST	3.92	down	0.00012
rc_H12257_at	H12257	1879	EST	3.19	down	0.0069
rc_H12593_at	H12593	1880	zinc-finger protein 265	10.72	down	0.0056
rc_H13696_at	H13696	1882	EST	3.48	down	0.01796
rc_H14372_s_at	H14372	1883	ATP-binding cassette, sub-family A (ABC1),	5.16	down	0.00012
rc_H16/68_at	H16768	1887	EST	3.72	down	0.00688
rc_H18950_at	H18950	1892	EST	3.85	down	0.00162
rc_H18997_at	H18997	1893	F-box protein 21	3.87	пмор	0.00611
rc_H19504_f_at	H19504	1895	EST	3.13	down	0.04948
rc_H20543_at	H20543	1897	DKFZP586B1621 protein	31.03	down	0.00074
rc_H25124_at	H25124	1903	EST	3.65	down	0.00004
rc_H25551_at	H25551	1904	EST	3.54	down	0.00366
rc_H25836_at	H25836	1905	tumor necrosis factor (ligand) superfamily,	3.3	down	0.03125
rc_H26417_at	H26417	1906	EST	3.22	down	0.03672
rc_H26763_at	H26763	1907	EST	3.39	down	0.04188
rc_H27330_at	H27330	1909	EST	3.2	down	0.00067
rc_H27442_s_at	H27442	1910	erythrocyte membrane protein band 7.2	6.81	down	0.00083
rc_H29568_at	H29568	1914	EST	11.45	down	0.00058
rc_H30270_at	H30270	1915	EST	17.09	down	0.00001
rc_H38246_s_at	H38246	1917	EST	9.25	down	0.00157
rc_H39119_at	H39119	1919	EST	3.06	down	0.03349
rc_H40149_at	H40149	1921	KIAA0937 protein	4.59	down	0.00112
rc_H40424_s_at	H40424	1922	butyrate response factor 1 (EGF-response factor	3.56	down	0.04066
rc_H40534_at	H40534	1923	EST	3.18	down	0.01381
rc_H41084_at	H41084	1924	EST	6.31	down	0.0227

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name	Fold Change	Direction	Discourse Ordered
rc_H41280_at	H41280	1925	EST	2 68	- 1	OOMEE
rc_H42053_s_at	H42053	1927	EST	3.49	1 A A A	0.00455
rc_H46001_at	H46001	1931	EST	5.03	dwob	0.01553
H46990_at	H46990	1933	cytochrome P450, subfamily IIE (ethanol-	3.2	down	0.00095
rc_H47391_at	H47391	1935	EST	3.1	down	0.03807
rc_H47838_at	H47838	1936	carboxypeptidase B2 (plasma)	16.74	down	0.00002
rc_H49415_at	H49415	1938	EST	3.72	down	0.0005
H51340_at	H51340	1941	EST	3.73	down	0.02643
rc_H54285_s_at	H54285	1947	EST	5.14	down	0.00426
rc_H55759_at	H25759	1949	EST	11.52	down	0.00034
			4-nitrophenylphosphatase domain and non-			
rc_H56584_at	H56584	1951	neuronal SNAP25-like 1	9.5	down	0
rc_H57060_s_at	H27060	1954	EST	30.98	down	0.01687
rc_H57166_at	H57166	1955	EST	92.09	down	0.00007
rc_H57816_at	H57816	1957	EST	4.41	down	0.00206
			protein phosphatase 2 (formerly 2A), regulatory			
rc_H57850_at	H57850	1958	subunit A (PR 65), beta isoform	3 02	down	0.00123
rc_H58673_at	H58673	1959	EST	14.85	down	0.00150
rc_h58692_s_at	H58692	1960	formyltetrahydrofolate dehydrogenase	81.41	down	0
rc_H59136_at	H59136	1962	EST	8.64	down	0.00013
rc_H59141_at	H59141	1963	EST	3.12	uwop	0.00293
rc_H60595_s_at	H60595	1966	progesterone binding protein	15.8	down	0.01078
H61295_s_at	H61295	1968	CD4 antigen (p55)	10.71	down	0.00925
rc_H62838_at	H62838	1971	EST	3.09	down	0.03201
	H63251	1972	KIAA0606 protein; SCN Circadian Oscillatory	3.27	down	0.02455
rc_H65650_at	H65650	1976	EST	3.88	down	0.0083
H66367_at	H66367	1977	EST	6.68	down	0.0001
rc_H66840_at	H66840	1978	EST	3.67	down	0.0143
rc_H67094_at	H67094	1979	EST	3.24	down	0,00075
H67840_at	H67840	1980	EST	3.1	down	0.00528
rc_H68097_at	H68097	1982	EST	3.83	down	0.00797

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name	Fold Change	20100	
H68953_at	H68953	1985	transferrin	SA CITALING	DII BCIIOII	rvaiue 0 00422
rc_H69138_at	H69138	1986	v-Ki-ras2 Kirsten rat sarcoma 2 viral oncodene	6.78 8.78		0.00132
rc_H69565_at	H69565	1987	EST	4.11	down down	0.000
rc_H70554_at	H70554	1989	EST	10.99	down	0.0002
rc_H71169_at	H71169	1992	putative protein similar to nessy (Drosophila)	4	down	60200.0
			glucan (1,4-alpha-), branching enzyme 1			
rc_H71861_s_at	H71861	1993	(glycogen branching enzyme, Andersen disease,	5.97	down	0.00007
rc_H73535_s_at	H73535	1996	EST	6.89	down	0.00202
rc_H74317_s_at	H74317	1997	apolipoprotein A-II	45.09	down	0.01982
rc_H77597_f_at	H77597	2000	metallothionein 1H	16.03	down	0.00675
	H78628	2003	EST	4.98	down	0.00729
rc_H/9820_at	H79820	2004	EST	3.25	down	0.01466
	H80901	2005	ficolin (collagen/fibrinogen domain-containing) 3	50.61	down	0.00262
rc_H810/0_t_at	H81070	2006	RNA helicase-related protein	25.74	down	0.00126
rc_H82966_s_at	H82966	2011	apolipoprotein B (including Ag(x) antigen)	3.42	down	0.00769
rc_H83109_t_at	H83109	2012	EST	16.55	down	0.00001
rc_H83442_s_at	H83442	2013	catechol-O-methyltransferase	3.99	down	0.00594
rc_H83451_at	H83451	2014	EST	3.35	down	0.00498
rc_H8/144_at	H87144	2016	EST	3.41	down	0.00387
rc_H8//65_at	H87765	2017	KIAA0626 gene product	3.86	down	0.00131
H88033 s_at	H88033	2019	KIAA0733 protein	4.42	down	0.02032
rc_H88359_s_at	H88359	2020	nuclear factor (enythroid-derived 2)-like 2	5.16	down	0.01253
	H88675	2022	EST	5.63	down	0.00554
rc_H89514_s_at	H89514	2023	protein kinase, cAMP-dependent, catalytic, alpha	3.44	down	0.00435
	H89893	2025	EST	3.17	down	0.00658
rc_H89980_at	H89980	2026	protein phosphatase 1, regulatory (inhibitor)	31.13	down	0.00006
rc_neu417_s_at	H90417	2028	EST	4.17	down	0.015
တ	H91325	2029	aldolase B, fructose-bisphosphate	45.85	down	0.00505
rc_H91456_s_at	H91456	2030	nuclear receptor subfamily 1, group H, member 4	4.9	down	0.00255
rc_H91680_s_at	H91680	2032	prosping yease, glycogen, livel (ners disease, glycogen storage disease type VI)	4.15	down	0.00746

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
			glutamate-cysteine ligase (gamma-			
rc_H93053ຼs_at	H93053	2034	glutamylcysteine synthetase), catalytic (72.8kD)	5.06	down	0.01029
H93246_s_at	H93246	2035	EST	15.3	down	0.00233
rc_H93381_at	H93381	2036	EST	24.23	down	0
rc_H93562_at	H93562	2038	proline synthetase co-transcribed (bacterial	3.17	down	0.00113
			3-hydroxy-3-methylglutaryl-Coenzyme A synthase			
rc_H94247_s_at	H94247	2041	2 (mitochondrial)	9.49	down	0.02373
rc_H94475_s_at	H94475	2043	alpha-2-plasmin inhibitor	40.92	down	0.00271
rc_H94648_at	H94648	2044	EST	4.77	down	0.00266
rc_H94666_at	H94666	2045	alpha-1-B glycoprotein	47.03	down	0.01158
rc_H95358_at	H95358	2049	EST	3.17	down	0.00182
rc_H95569_i_at	H95569	2051	DKFZP586A0522 protein	28.48	down	0.00139
rc_H95978_at	H95978	2052	EST	8.55	down	0.00046
rc_H96614_at	H96614	2054	EST	4.02	down	0,01565
rc_H97868_at	H97868	2064	EST	3.86	down	0.00362
rc_H97986_at	H97986	2065	EST	3.86	down	0.01534
rc_H98071_at	H98071	2066	EST	4.66	down	0.03722
rc_H98083_at	H98083	2067	EST	5.09	down	0.00025
rc_H98771_i_at	H98771	2069	BCL2/adenovirus E1B 19kD-interacting protein 3	ω	down	0.0018
rc_H98822_at	H98822	2070	EST	3.31	down	0.00174
rc_H98910_s_at	H98910	2071	EST	4.38	down	0.00548
rc_H98977_at	H98977	2073	EST	3.57	down	0.00298
rc_H99393_s_at	H99393	2076	endothelin receptor type B	3.43	down	0.00093
rc_H99727_at	H99727	2080	adipose differentiation-related protein; adipophilin	5.83	down	0.04346
rc_H99935_s_at	H99935	2085	interleukin 6 signal transducer (gp130, oncostatin	3.59	down	0.00366

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change Direction	Direction	Pvalue
				0		
			·			
J02843_at	J02843	2088	cytochrome P450, subfamily IIE (ethanol-	22.58	down	0.00935
J02888_at	J02888	2089	NAD(P)H menadione oxidoreductase 2 dioxin-	3.15	2000	0.0000
J02943 at	J02943	2090	corticostaroid hinding globulin	5 5	1 MOD	0.02303
J03242 S at	103242	2002	location and footons (account to the contract of the contract	0.90	uwop	0.00087
103507 of	103501	7000	Ilisuilli-like growin factor 2 (somatomedin A)	4.01	down	0.00042
303307 at	/0320r	2082	complement component 7	3.77	down	0.00184
JU3/64_at	103764	2097	plasminogen activator inhibitor, type I	5.6	down	0.02196
			protein phosphatase 2 (formerly 2A), catalytic			
J03805_s_at	103805	2098	subunit, beta isoform	3.87	down	0.0116
J03810_at	J03810	2099	solute carrier family 2 (facilitated glucose	21.99	down	0.0000
J03910_ma1_at	J03910	2101	EST	12.42		0.00004
	•		methylenetetrahydrofolate dehydrogenase	! i		
	•		(NADP+ dependent), methenyltetrahydrofolate			
J04031_at	J04031	2103	cyclohydrolase, formyltetrahydrofolate synthetase	3.4	uwop	0.00786
J04056_at	J04056	2104	carbonyl reductase 1	5.19	down	0.0000
J04080_at	J04080	2105	complement component 1. s subcomponent	7 48	90,00	0000
J04093 s at	.104093	2108	LIDB altwoodfragaeforms 4	2.40	nom:	0.0239
i t)	-	Obl Bigooginanoidiada I	18.92	down	0

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change Direction		Pvalue
J04093_s_at	J04093	2106	UDP glycosyltr	18.92		0
			cytochrome P450, subfamily IIIA (niphedipine			
J04449_at	J04449	2110	oxidase), polypeptide 3	5.25	down	0.01583
J04615_at	J04615	2112	SNRPN upstream reading frame	3.14	down	0.02928
			syndecan 2 (heparan sulfate proteoglycan 1, cell			
J04621_at	J04621	2113	surface-associated, fibroglycan)	3.38	down	0.00275
			cytochrome P450, subfamily IIIA (niphedipine			
J04813_s_at	J04813	2114	oxidase), polypeptide 5	9.67	down	0.0107
J05037_at	105037	2116	serine dehydratase	16.24	down	0.00015
J05158_at	J05158	2117	carboxypeptidase N, polypeptide 2, 83kD	8.52	down	0
J05428_at	J05428	2120	UDP glycosyltransferase 2 family, polypeptide B7	16.14	down	0.00563
K02100_at	K02100	2123	ornithine carbamoyltransferase	10.24	down	0.0000
K02215_at	K02215	2124	angiotensinogen	16.51	down	0.0000
			coagulation factor IX (plasma thromboplastic			
K02402_at	K02402	2125	component, Christmas disease, hemophilia B)	28.81	down	0.00001
K02766_at	K02766	2126	complement component 9	21.24	down	0
			cytochrome P450, subfamily IIA (phenobarbital-			
K03192_f_at	K03192	2127	inducible), polypeptide 6	69.92	down	0
			cytochrome P450, subfamily IIA (phenobarbital-			
K03192_f_at	K03192	2127	Inducible), polypeptide 6	50.16	down	C
L00190_s_at	L00190	2130	antithrombin III	42.41	down	0.00012
L00352_at	L00352	2131	low density lipoprotein receptor (familial	4.19	down	0.00352
L00972_at	L00972	2133	cystathionine-beta-synthase	7.19	down	0.00008
L04751_at	L04751	2138	cytochrome P450, subfamily IVA, polypeptide 11	36.79	down	0.00004
L05144_at	L05144	2139	phosphoenolpyruvate carboxykinase 1 (soluble)	4.76	down	0.02289
L05779_at	L05779	2140	epoxide hydrolase 2, cytoplasmic	5.35	down	0.00006
			3-hydroxymethyl-3-methylglutaryl-Coenzyme A			
L07033_at	L07033	2144	lyase (hydroxymethylglutaricaciduria)	3.49	down	0
			enoyl-Coenzyme A, hydratase/3-hydroxyacyl			
L07077_at	L07077	2145	Coenzyme A dehydrogenase	4.82	down	0.00403
L07765_at	L07765	2147	carboxylesterase 1 (monocyte/macrophage	20.53	down	0.00025

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affv ID	Genhank	Cl neg				
	Compania	2002	- 1	Fold Change Direction	Direction	Pvalue
1 33020 1			glucan (1,4-alpha-), branching enzyme 1			
LU/956_at	707956	2148	(glycogen branching enzyme, Andersen disease,	5.6	down	0.00029
100000			ratty-acid-Coenzyme A ligase, long-chain 1, fatty-			
LUSZZS Sat	L09229	2150	acid-Coenzyme A ligase, long-chain 2	18.34	down	0.00016
L09708_at	L09708	2152	complement component 2	3.92	down	0.00693
L09717_at	L09717	2153	lysosomal-associated membrane protein 2	4.06	uwop	0.00034
L11005_at	L11005	2154	aldehyde oxidase 1	16.3	down	0.00065
L11244_s_at	L11244	2155	complement component 4-binding protein, beta	43.33	down	
L11244_s_at	L11244	2155	complement component 4-binding protein, beta	12.03	uwo b	0 000
L11708_at	L11708	2158	hydroxysteroid (17-beta) dehydrogenase 2	5.99	down	0.01516
L11931_at	L11931	2159	serine hydroxymethyltransferase 1 (soluble)	7.27	down	0.00041
L12760_s_at	L12760	2162	phosphoenolpyruvate carboxykinase 1 (soluble)	12.75	uwop	0.00035
L13278_at	L13278	2163	crystallin, zeta (quinone reductase)	5.83	down	0.0000
L15702_at	L15702	2165	B-factor, properdin	3.7	down	0.04693
			cytochrome P450, subfamily IIC (mephenytoin 4-	į		
L16883_s_at	L16883	2166	hydroxylase), polypeptide 9	84 71	מאמף	0.00327
L17128_at	L17128	2167	gamma-glutamyl carboxylase	4 02	T CO	0.00327
			phosphodiesterase 4A, cAMP-specific (dunce	1		0.0000
L20965_at	L20965	2175	(Drosophila)-homolog phosphodiesterase F2)	3.02	dy.	0.04477
			solute carrier family 10 (sodium/bile acid			
L21893_at	L21893	2176	cotransporter family), member 1	13.18	מאַטעָּט	0.00155
L22548_at	L22548	2178	collagen, type XVIII, alpha 1	3.87	down down	0000
L25878_s_at	L25878	2183	epoxide hydrolase 1. microsomal (xenoblotic)	10.0 Na 90	down down	0.0233
L25880_s_at	L25880	2184	epoxide hydrolase 1, microsomal (xenoblotic)	78 7	down	0000
L27050 at	L27050	2186	apolipoprotein F	10.5	down	0.00013
L29008 at	1 29008	2189	sorbitol debydrodepase	0.20	I MONIT	0.00026
1 29433 at	1 20422	250		3.51	down	0.00825
1 22440 -1	1.204.53	1817	coagulation ractor X	7.74	down	0.00244
L32/40_at	L32140	2192	atamin	17.31	down	0.00003
L32179_at	L32179	2193	arylacetamide deacetylase (esterase)	23.83	down	0
			bile acid Coenzyme A: amino acid N-)
L34081_at	L34081	2199	acyltransferase (glycine N-choloyltransferase)	11.96	down	0.00008

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name	Fold Change	Diroction	or love
				PRINCIPLE I		Lvaide
L35546_at	L35546 2	2203	glutamylcysteine synthetase), regulatory (30.8kD)	14.18	down	0.00018
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			glutamate-cysteine ligase (gamma-			
L35546_at		2203	glutamylcysteine synthetase), regulatory (30.8kD)	5.56	down	0.0005
L36033_at	L36033 2	2204	stromal cell-derived factor 1	5.1	down	0.00603
L38490_s_at	L38490 2	2207	ADP-ribosylation factor 4-like	3.13	down	0.01306
			5,10-methenyltetrahydrofolate synthetase (5-)		
L38928_at	L38928 2	2209	formyltetrahydrofolate cyclo-ligase)	10.97	down	0.0267
			5,10-methenyltetrahydrofolate synthetase (5-			1040.0
L38928_at	L38928 2	2209	formyltetrahydrofolate cyclo-ligase)	5.17	down	0.00726
L40401_at	L40401 2	2211	putative protein	6.97	down	0.00079
L40401_at	L40401 2	2211	putative protein	4.26	down	0.00194
L41067_at	L41067 2	2213	nuclear factor of activated T-cells, cytoplasmic 3	4.96	down	0.00473
L47726_at	L47726 2	2219	phenylalanine hydroxylase	25.63	down	0.00019
L48516_at	L48516 2	2220	paraoxonase 3	22.21	down	0 0000
L49169_at	L49169 2	2221	FBJ murine osteosarcoma viral oncogene	3.4	down	0.01193
L76465_at		2224	hydroxyprostaglandin dehydrogenase 15-(NAD)	3.56	down	0.00688
L76571_at		2226	nuclear receptor subfamily 0, group B, member 2	4.44	down	0.00312
L76687_at	L76687 2	2227	growth factor receptor-bound protein 14	5.16	down	0.00199
L76927_ma1_at	L76927 2	2228	galactokinase 1	3.66	down	0.00999
			solute carrier family 25 (mitochondrial carrier;			
L77567_s_at	L77567 2	2229	citrate transporter), member 1	3.14	down	0.04095
M10058_at	M10058 2	2230	asialoglycoprotein receptor 1	23.96	down	·
M10612_at		2232	apolipoprotein C-II	17.13	down	0.00746
M10942_at		2233	metallothionein 1E (functional)	6.19	down	0.00428
M10943_at		2234	metallothionein 1F (functional)	3.88	down	0
M11025_s_at		2235	asialogiycoprotein receptor 2	17.56	down	0.00003
M11313_s_at	111313	2236	alpha-2-macrogíobulin	10.05	down	0.00014
M11321_at	11321	2237	group-specific component (vitamin D binding	16.52	down	0.01416
		2238	kininogen	18.38	down	0.00006
M11437_cds2_at	M11437 2	2238	kininogen	16.19	down	0.02277

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	SealD	Known Gene Name	Fold Change	Diroction	21,000
M11567_rna1_at	M11567	2239	angiogenin. rib	22.25	DII GCIIOII	Lyaine
M12174 at	M12174	2242	the beautiful the fact of the	32.23	down	0.0001
	#/17/W	7477	ras nomorog gene ramily, member B	5.44	down	0.0088
			alcohol dehydrogenase 1 (class I), alpha			
			polypeptide, alcohol dehydrogenase 2 (class 1),			
M12272_s_at	M12272	2243	beta polypeptide, alcohol dehydrogenase 3 (class	32.42	down	0.0034
M12529_at	M12529	2244	apolipoprotein E	300	1	0.000
M12625 at	M12625	2245	locithin cholonian on dennation	0.00	LWOD .	0.03776
M12712 c of	240240	25.40	icolumi i o di diesteroli acyltransferase	4.55	down	0.01584
18 S 71 /7 INI	ZL/ZLM	2246	protein C (inactivator of coagulation factors Va	7.37	down	0.01866
			alcohol dehydrogenase 1 (class I), alpha			
1			polypeptide, alcohol dehydrogenase 2 (class I).			
M12963_s_at	M12963	2248	beta polypeptide, alcohol dehydrogenase 3 (class	48.95	down	0.00104
M13143_at	M13143	2249	kallikrein B plasma, (Fletcher factor) 1	10.39	down	0.00019
M13149_at	M13149	2250	histidine-rich glycoprotein	18.65		0.000.0
M13232_s_at	M13232	2251	coagulation factor VII (serum prothrombin	0 0		0.02974
M13690_s_at	M13690	2252	complement component 1 inhibitor (andipedama	6.03	T CONTRACT	0.00014
M13699 at	M13699	2253	Certifolisemin (ferrovidees)) i	L MOD	0.00045
M13829 s at	M12820	225	celulopiaaliiii (leiloxidase)	15.85	down	0.00012
MATADED	6707 M	4C77	v-rai murine sarcoma 3611 viral oncogene	6.52	down	0
IM 14036_81	M14058	2256	complement component 1, r subcomponent	99.9	down	0.00229
M14091_at	M14091	2257	thyroxin-binding globulin	10.66	down	0.00024
M14218_at	M14218	2259	argininosuccinate iyase	608	down down	0.00078
M14338_at.	M14338	2260	protein S (alpha)	12.33	down	0.00
,			phosphorylase, glycogen; liver (Hers disease.			•
M14636_at	M14636	2262	glycogen storage disease type VI)	3.45	C/A/C/C	0.00423
M15465_s_at	M15465	2266	pyruvate kinase, liver and RRC		4000	0.000
M15517 cds5 at	M15517	2267	FST	- 1	I MOD	0.0009
	MARGE	2000		22.76	down	0.03365
M16447 Ct	0000 IVI	2202	aldolase B, fructose-bisphosphate	99.96	down	0
	M16447	2270	quinoid dihydropteridine reductase	6.57	down	0.00015
IVI 104/4 S. BI	M16474	2271	butyrylcholinesterase	5.82	down	0.00113
M16594_at	M16594	2272	glutathione S-transferase A2	73.21	down	· c
M16750_s_at	M16750	2273	pim-1 oncogene	3.08	down	0.01811
M16961_at	M16961	2274	alpha-2-HS-glycoprotein	21.45	TWO P	0.01275
			•	?		

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name	Fold Charge	- 1	
M16967 at	M16967	2275	Coadillation fa			Pvalue
M16973_at	M16973	2276	complement component 8 heta polymentido	3.36	Dawn	0.00047
M16974 s at	M16974	2277	Complement compensate 8. of the column is	67.75	down	0.00001
M17262 at	M47263	0000	complement component a, alpha polypeptide	49.47	down	0.00046
M47262 ct	202/11/1	0/77	coagulation factor II (thrombin)	44.3	down	0.00345
W17202 at	797/LM	27/8	coagulation factor II (thrombin)	14.24	down	0.00028
M17466_at	M17466	2279	coagulation factor XII (Hageman factor)	9.76	down	0.00285
			dystrophin (muscular dystrophy, Duchenne and			
			Becker types), includes DXS142, DXS164,			
M18533_at	M18533	2284	DXS206, DXS230, DXS239, DXS268, DXS269,	3,45	down	0.00313
M19828_s_at	M19828	2287	apolipoprotein B (including Ag(x) antigen)	29.37	down	0.00137
MZUZ18_at	M20218	2288	coagulation factor XI (plasma thromboplastin	6.4	down	0.00004
M20786_at	M20786	2290	alpha-2-plasmin inhibitor	16.95	down	0.00709
MZ0867_s_at	M20867	2291	glutamate dehydrogenase 1	17.73	down	0.00002
MZ090Z_at	M20902	2292	apolipoprotein C-I	3.14	down	0.0389
M21642_at	M21642	2294	antithrombin III	15.82	down	0.01027
M21642_s_at	M21642	2294	antithrombin III	15.23	down	0.0008
M22976_at	M22976	2297	cytochrome b-5	7 30	2000	0.02000
M23161_at	M23161	2298	EST	20.6	down	0.02431
M23234 s at	M23234	2299	ATP-binding cassette sub-family B (MOD/TAB)	1 6	I MOD	0.00733
			androgen receptor (dihydrotestosterone receptor:	0.00	UMOD	>
			testicular feminization; spinal and bulbar			
M23263_at	M23263	2300	muscular atrophy; Kennedy disease)	4.6	down	0.00005
			androgen receptor (dihydrotestosterone receptor;			
17 000001			resucular reminization; spinal and bulbar			
Wiz3z03_at	MZ3Z63	2300	muscular atrophy; Kennedy disease)	3.35	down	0.02551
M24283 at	M24283	2202	riversellate addesion molecula i (CD54), numan			
M25079 s at	M25070	2200	timiovinas receptor	3.19	down	0.04985
MA25280 24	M2500	2007	ileliogiobili, peta	9.15	down	0.01399
Macago de de	082CZINI	2306	selectin L (lymphocyte adhesion molecule 1)	3.39	down	0.004
WZOSSS S SI	MZ6393	2309	acyl-Coenzyme A dehydrogenase, C-2 to C-3	16.27	down	0.00007
M2/492_at	M27492	2312	interleukin 1 receptor, type I	4.62	down	0.0082

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
M29194_at	M29194	2315	lipase, hepatic	12.18	down	0.00012
M29873_s_at	M29873	2318	cytochrome P450, subfamily IIB (phenobarbital-	56.71	down	0.0054
M29874_s_at	M29874	2319	cytochrome P450, subfamily IIB (phenobarbital-	18.44	down	0.00081
M29971_at	M29971	2320	O-6-methylguanine-DNA methyltransferase	3.97	down	0.00424
M30185_at	M30185	2321	cholesteryl ester transfer protein, plasma	3.83	down	0.0013
M30185_at	M30185	2321	cholesteryl ester transfer protein, plasma	3.39	down	0.00089
M30257_s_at	M30257	2322	vascular cell adhesion molecule 1	3.11	down	0.00064
M30269_at	M30269	2323	nidogen (enactin)	3.4	down	0.00026
M31169_s_at	M31169	2325	propionyl Coenzyme A carboxylase, beta	4.65	down	0.00467
M31627_at	M31627	2330	X-box binding protein 1	6.97	down	0.00052
			cytochrome P450, subfamily I (aromatic			
M31667_f_at	M31667	2331	compound-inducible), polypeptide 2	4.38	down	0.00078
M31994_at	M31994	2332	aldehyde dehydrogenase 1, soluble	11.24	down	0.01192
			cytochrome P450, subfamily IIA (phenobarbital-			
M33317_f_at	M33317	2338	Inducible), polypeptide 7	32.63	down	0
			cytochrome P450, subfamily IIA (phenobarbital-			
M33318_r_at	M33318	2339	inducible), polypeptide 6	3.21	down	0.01621
M34276_at	M34276	2341	plasminogen	24.73	down	0.00031
M35410_s_at	M35410	2344	insulin-like growth factor binding protein 2 (36kD)	6.45	down	0.04517
MIP1-B_at	M35590	2345	small inducible cytokine A4	5.96	down	0.00604
MIP1-B_at	M35590	2345	small inducible cytokine A4	4.74	down	0.01225
MIP1-B_at	M35590	2345	small inducible cytokine A4	4.62	down	0.01268
M35878_at	M35878	2346	insulin-like growth factor binding protein 3	4.3	down	0.0027
			glutamic-oxaloacetic transaminase 1, soluble			
M37400_at	M37400	2348	(aspartate aminotransferase 1)	8.7	down	0.0004
M55150_at	M55150	2352	fumarylacetoacetate	3.93	down	0.00213
			potassium voltage-gated channel, shaker-related			
M55513_s_at	M55513	2354	subfamily, member 5	4.81	down	0.02141
M55671_at	M55671	2355	protein Z, vitamin K-dependent plasma	4.74	down	0.00078
M57731_s_at	M57731	2359	GRO2 oncogene	13.87	down	0.0123
M58286_s_at	M58286	2360	tumor necrosis factor receptor superfamily,	8.15	down	0.00037

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sed ID	Known Gene Name	Fold Change	Direction	01100
M58569_s_at	M58569	2361	EST	16 15	1 -	000174
M58600_rna1_at	. W28600	2362	heparin cofactor II	39.79	down	0.00034
			tissue factor pathway inhibitor (lipoprotein-			
M59499_at	M59499	2363	associated coagulation inhibitor)	5,92	down	0.0005
M59815_at	M59815	2364	complement component 4A	8.02	down	0.00049
			sphingomyelin phosphodiesterase 1, acid			
M59916_at	M59916	2365	lysosomal (acid sphingomyelinase)	3.36	down	0.0038
M60974_s_at	M60974	2368	growth arrest and DNA-damage-inducible, alpha	3.48	down	00000
			cytochrome P450, subfamily IIC (mephenytoin 4-	}		
M61853_at	M61853	2369	hydroxylase), polypeptide 18	7.82	down	0.00024
M61854_s_at	M61854	2370	cytochrome P450, subfamily IIC (mephenytoin 4-	3.3	down	0.04185
1			cytochrome P450, subfamily IIC (mephenytoin 4-			
M61855_at	M61855	2371	hydroxylase), polypeptide 9	38.82	down	0.00023
M62403_s_at	M62403	2373	insulin-like growth factor-binding protein 4	4.12	down	0.00226
M62486_at	M62486	2374	complement component 4-binding protein, alpha	22.08	down	0.00272
			glutathione S-transferase M1, glutathione S-			
M63509_s_at	M63509	2376	transferase M2 (muscle),glutathione S-	7.06	down	0.03887
M63967_at	M63967	2378	aldehyde dehydrogenase 5	4.04	down	0.00058
M64554_rna1_at	M64554	2380	coagulation factor XIII, B polypeptide	5.87	down	0.00011
			glycine dehydrogenase (decarboxylating; glycine			
M64590_at	M64590	2381	decarboxylase, glycine cleavage system protein	6.41	down	0.00002
M65131_rna1_at	M65131	2384	methylmalonyl Coenzyme A mutase	7.44	down	0.00004
M65134_s_at	M65134	2385	complement component 5	12.01	down	0.00012
M65292_s_at	M65292	2386	H factor (complement)-like 1,H factor 1	7.56	down	0.01152
M68516_rna1_at	M68516	2387	protein C inhibitor (plasminogen activator inhibitor	20.54	down	0
M68840_at	M68840	2388	monoamine oxidase A	3.96	down	0.01396
M68895_ma1_at	M68895	2390	alcohol dehydrogenase 6 (class V)	4.25	down	0.00354
M69177_at	M69177	2392	monoamine oxidase B	11.64	down	0.00001
M72885_rna1_s_at	M72885	2393	putative lymphocyte G0/G1 switch gene	6.5	down	0.03461
M/4587_ma1_s_at	M74587	2394	insulin-like growth factor binding protein 1	11.42	down	0.00274
M/5106_at	M75106	2397	carboxypeptidase B2 (plasma)	40.63	down	0

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

A6615						
Ally ID	Genbank	Sed ID	Known Gene Name	Fold Change	Direction	Pvalue
M76665_at	M76665	2398	hydroxysteroid (11-beta) dehydrogenase 1	19 22	1 -	70000
M80482 at	M80482	2403	naired hasic amino acid cleaning system 4	79.07	1	0.0000
M04407 0 04	707707	2 6	pariod basic attitud acid cicavilly system 4	4.20	down	0.00041
INIO 1 102 S BIL	M81182	2404	ATP-binding cassette, sub-family D (ALD),	3.45	down	0.00499
M81349_at	M81349	2405	serum amyloid A4, constitutive	76.15	down	0.00015
M83216_s_at	M83216	2407	caldesmon 1	4.27	down	0.00037
M83652_s_at	M83652	2408	properdin P factor, complement	į c	CWOD CWOD	00000
M83772_at	M83772	2409	flavin containing monooxygenase 3	19.54	down down	20000
M86826 at	M86826	2413	insulin-like growth factor binding protein acid	75.6	T ACOM	77
	1486972	2 7 7	alominates alominidated billianing protein, acid	0.70	UMOD	0.01157
18 - COOM	100001/3	7414	plasminogen, plasminogen-like	17.54	down	0
			SWINNE Felated, matrix associated, actin			
M88163_at	M88163	2416	dependent regulator of chromatin, subfamily a,	3.37	down	0.00098
M91432_at	M91432	2420	acyl-Coenzyme A dehydrogenase, C-4 to C-12	6.74	down	0.00008
M92843_s_at	M92843	2421	zinc finger protein homologous to Zfp-36 in	3.02	do.kn	0.000
M93143_at	M93143	2423	plasminogen-like	10.05	1	0.000
M93405 at	MOSANE	7070	Section 1 to 1	00.01	- A	0.00030
	100400	+7+7	memyimaionate-semiaidenyde denydrogenase	23.06	down	0
M94065 s at	M94065	2425	dihydroorotate dehydrogenase	11.78	down	0.00034
M94065_at	M94065	2425	dihydroorotate dehydrogenase	6.47	down	0.00013
M95585_s_at	M95585	2430	hepatic leukemia factor	4.2	down	0.00212
M95767_at	M95767	2432	chitobiase, di-N-acetvi-	70 7	90,00	0.000
			dlutathione S-transferase M1 olutathione S.	r P		0.00004
MO6233 6 24	MACADOS	0070				
1400040 A	1,000,0	2455	iransferase MZ (muscle), glutathione S-	4.23	down	0.04227
Webs43 at	M96843	2435	EST	8.42	down	0.02394
M96843_at	M96843	2435	EST	4.08	down	0.02912
M99439_at	M99439	2438	transducin-like enhancer of split 4, homolog of	5.14	down	0.00001
rc_N20113_s_at	N20113	2439	EST	5.24	down	0.01346
rc_N21079_at	N21079	2441	nucleolar cysteine-rich protein	4.1	down	0.00028
rc_N21550_at	N21550	2444	EST	308	down	90000
rc N21646 at	N21646	2446	EST	2 0		0.0000
rc N22404 at	POPCCIN	0117		3./9	down	0.00079
20 N22424 24	NZZ404	7450	E01	3.99	down	0.01152
	N22434	2451	EST	4.37	down	0.01725
rc_N22854_s_at	N22854	2452	CASP2 and RIPK1 domain containing adaptor	3.34	down	0.0084

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name			
rc_N22938_s at	· N22938	2453	serum amyloid	roid Change	Direction	Pvalue
rc N23665 s at	N23665	2455	hydroxystoroid (47-bots) debi-descens	80.00 0.40	LIMOD .	0.00128
rc N23730 e ot	NIOS 750	7 10		9. 4.	down	0.00055
2 N33764 24	1827.30	7430	V-10s FBJ murine osteosarcoma viral oncogene	4.38	down	0.04395
NOSSI BI	NZ3/61	2457	DKFZP586G011 protein	5.41	down	0.00448
N23817_at	N23817	2458	EST	3.76	down	0.00288
rc_N24879_at	N24879	2460	EST	9.44	down	0.00008
rc_N25082_s_at	N25082	2463	amplified in osteosarcoma	5.19	down	0.0000
rc_N25193_at	N25193	2464	EST	3.13	LWOD LWOD	0.00035
	•		protein kinase, cAMP-dependent, regulatory, type) ;		0.0
rc_N25969_s_at	N25969	2466	I, alpha (tissue specific extinguisher 1)	4.32	down	0.00304
rc_N26184_at	N26184	2467	MYLE protein	4.82	down	0.00056
rc_N2/524_at	N27524	2472	EST	3.13	down	0.00216
rc_N27563_at	N27563	2473	EST	ි ල	down	0.00021
N27670_at	N27670	2474	progesterone membrane binding protein	6.15	down	0.00321
rc_N27834_at	N27834	2475	alpha2,3-sialyltransferase	5,31	down	0.00039
rc_N29319_at	N29319	2476	EST	4.58	down	0.00011
rc_N29353_at	N29353	2477	kynurenine 3-monooxygenase (kynurenine 3-	4.78	down	0.00019
rc_N30856_at	N30856	2485	solute carrier family 19 (thiamine transporter),	3.71	down	0.00393
rc_N31598_at	N31598	2488	EST	3.	down	00000
rc_N31741_at	N31741	2489	serine hydroxymethyltransferase 1 (soluble)	14.76	2000	0.00203
rc_N31952_at	N31952	2490	EST	2.42	u dona	0.0000
rc_N32071_at	N32071	2491	EST	0.0 7.0	down	0.01461
rc_N33009_s_at	N33009	2492	apolipoprotein E	5.5	Cowin	0.0000
rc_N34441_at	N34441	2496	EST	200.04 4 0.7	down	0.0093
rc_N34804_at	N34804	2497	DKFZP434.1214 protein	5 6	down	0.00100
rc N36001 at	N36001	2504	EST.	o.00	UMOD	0.00028
rc N36250 at	NISEDEO	100		6.16	down	0.00222
rc N20400_at	N30463	2002	cellular repressor of E1A-stimulated genes	4.06	down	0.00776
20103 BI	100001	6007	metallotnionein 1L	4.3	down	0.03917
10.38201_81 20.0140480 _4	N39201	. 2510	protease inhibitor 4 (kallistatin)	24.91	down	0.00253
NA0200 St	N40188	2513	EST	3.72	down	0.01771
18-02c0-NI	N40320	2514	EST	7.56	down	0.01584

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sed ID	Known Gone Neme		- 1	
rc_N45232_at	N45232	2517	EST	Fold Change	- 1	Pvalue
rc N45307 s at	N45307	251B		3.61	down	0.01308
rc N45908 at	NAFOOD	20.00		4.55	down	90000'0
rc N47760 at	006641	7520	E0-	3.14	down	0.00337
10 N479409_81	N47469	2522	EST	3.34	down	0.00329
10_N4794Z_81	N47942	2523	progesterone membrane binding protein	4.51	down	0.00168
10 N40100 81	N48180	2526	EST	3.36	down	0.00543
10 146515 at	N48315	2527	adaptor-related protein complex 2, mu 1 subunit	5.3	down	0.0149
1C_1V4860Z_8t	N48602	2529	EST	3.17	down	0.02913
IC_14466/4_at	N48674	2530	EST	4.06	down	0.00028
10_146/8/_at	N48787	2531	protease inhibitor 1 (anti-elastase), alpha-1-	4.4	down	0.00292
1C_1449090_at	N49090	2533	EST	18	down	0.00501
10 NA0113 24	N49104	2534	nuclear receptor interacting protein 1	3.83	down	0.00144
20 N40344 24	N49113	2535	EST	3.4	down	0.00162
10_1492.14_81	N49214	2536	EST	4.74	down	0.00064
IC_IN49595_BI	N49595	2538	EST	10.39	down	0.0000
rc_N49902_at	N49902	2540	EST	3.55	down	0.00022
rc_N51117_at	N51117	2544	EST	0.00	90,00	0.00433
rc_N51737_at	N51737	2547	mitogen-activated protein kinase kinase kinase	3.30	down down	0.00001
rc_N51773_at	N51773	2549	EST	40.02	1000	0.00370
rc N52271 at	N52271	2552	I IM protein (cimiler to not angle in the con-	16.32	down	0.0007
rc N52322 at	NESSON	2002	Link protein (Similar to rat protein Kinase C.	8.06	down	0.00011
rc N52845 at	NEDOAE	2002	101	3.27	down	0.00933
10_01201201 10_N52085_24	N52645	4007		5.53	down	0.00088
rc N53034 6 04	N52903	7222	nidogen (enactin)	4.21	down	0.01385
ro NE33E3 et	15055V	2556	UDP glycosyltransferase 2 family, polypeptide B4	97.58	down	0.00022
14.0000Z	7055CN	2558	EST	3.22	down	0.00416
			cytochrome P450, subfamily IIJ (arachidonic acid			
rc_N53549_s_at	N53549	2559	epoxygenase) polypeptide 2	4.68	down	0.00018
rc_N53757_at	N53757	2560	EST	3 97	2000	0.000.0
rc_N54053_at	N54053	2561	secreted phosphoprotein 2, 24kh	500	III.	0.00233
rc_N54311_at	N54311	2564	EST	60.59	down	0.00087
rc N54399 at	N54399	2566	EST	4.07	UMOD	0.00183
		2007	- 63	3.34	down	0.00048

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sed ID	Known Gene Name	Eold Change		
rc_N54417_s_at	N54417	2567	fibrinoden. A a	OO OO	Direction	Lyalue
rc_N54429_at	N54429	2568	EST	57.81	down	0.0000
rc_N54511_s_at	N54511	2569	KIAA0265 protein	3.45	down	0.03362
rc_N54604_at	N54604	2570	EST	3.72	down	0.00362
			cytidine monophosphate-N-acetylneuraminic acid	l		
rc_N54792_at	N54792	2571	hydroxylase (CMP-N-acetylneuraminate	3.23	down	0.00099
rc_N54950_s_at	N54950	2573	ketohexokinase (fructokinase)	17.17	down	0.00078
N57464_at	N57464	2576	CCAAT/enhancer binding protein (C/EBP), delta	14.69	down	0.00018
rc_N57934_s_at	N57934	2577	formiminotransferase cyclodeaminase	13.81	down	0.00171
rc_N58326_at	N58326	2579	EST	14.97	down	0.00647
rc_N59089_at	N29089	2581	EST	4.74	down	0.00055
rc_N59231_s_at	N59231	2582	pyruvate carboxylase	3.45	down	0.02066
rc_N59283_at	N59283	2583	EST	4.65	down	0.02343
rc_N59474_at	N59474	2584	EST	6.93	down	0.00337
rc_N59532_s_at	N59532	2585	aminomethyltransferase (glycine cleavage	6.73	down	0.00005
rc_N59543_at	N59543	2587	PDZ domain containing 1	9.6	down	0.00052
rc_N59550_at	N59550	2588	EST	25.56	down	0.00024
rc_N62443_at	N62443	2590	EST	3.72	down	0.01717
rc_N62523_at	N62523	2592	hepatic leukemia factor	5.02	down	0.00087
rc_N62652_s_at	N62652	2593	EST	5.23	down	0.03006
rc_N63391_at	N63391	2600	EST	7.39	down	0.00565
rc_N63688_at	N63688	2603	EST	3.13	down	0.002
rc_N63698_at	N63698	2604	EST	7.92	down	0.00001
rc_N63845_at	N63845	2605	phytanoyl-CoA hydroxylase (Refsum disease)	25.92	down	0.00084
rc_N64017_at	N64017	2606	EST	5.27	down	0.00022
			enoyl-Coenzyme A, hydratase/3-hydroxyacyl			
rc_N64036_s_at	N64036	2607	Coenzyme A dehydrogenase	66.6	down	0.00125
rc_N64436_at	N64436	2609	EST	3.51	down	0.00441
rc_N64535_at	N64535	2610	EST	6.19	down	0.00106
rc_N65959_at	N65959	2612	EST	5.43	down	0.00044
rc_N66066_at	99099N	2613	EST	28.35	down	0,00055

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Neme			
rc N66130 at		2614	Drodesterone	roid Change	- 1	rvalue
rc_N66422_at	N66422	2616		5.80	UMOD	0.0106
rc_N66763_at	N66763	2640	F04	4. - ;	umop	0.00237
NGC967	1007 03	2018	- 22	3.79	down	0.03015
וב ומספסו שו	/cgoon	2620	EST	15.03	down	0.00005
0000014			prion protein (p27-30) (Creutzfeld-Jakob disease,			
rc_No/009_s_at	N67009	2622	Gerstmann-Strausler-Scheinker syndrome, fatal	3.55	down	0.00956
rc_N6/096_at	960Z9N	2623	EST	3.23	down	0.00446
rc_N67105_at	N67105	2624	EST	5.01	down	0.00178
rc_N67378_at	N67378	2626	KIAA1053 protein	7.14	down	0
rc_N67876_s_at	N67876	2628	insulin-like growth factor 1 (somatomedin C)	8.89	down	0.00042
rc_N6/893_at	N67893	2629	EST	10.48	down	0.00341
rc_N68596_s_at	N68596	2636	betaine-homocysteine methyltransferase	40.99	down	0
rc_N68/30_at	N68730	2637	EST	3.88	down	0.00091
rc_N68974_at	N68974	2640	EST	16.44	down	0.00087
rc_N68993_at	N68993	2641	EST	3.06	down	0.00867
rc_N69136_at	N69136	2645	EST	18.53	- Corporation	0.00368
rc_N69216_at	N69216	2646	EST	3.4	down	0.00303
rc_N69299_at	N69299	2649	EST	3.63	down	0.03778
rc_N70005_at	N70005	2653	EST	3.42	u v v v	0.000
rc_N70057_s_at	N70057	2654	DNA segment on chromosome 6 (unique) 49	5.24	down	0.0178
rc_N70305_at	N70305	2655	EST	4 41	down	0.000
rc_N70358_s_at	N70358	2657	growth hormone receptor	34.25	e do do	0.000
rc_N70861_at	N70861	2661	EST	6.55	down	0 00001
:			solute carrier family 10 (sodium/bile acid	}	: :	
rc_N70966_s_at	N70966	2663	cotransporter family), member 1	34.06	down	0.0006
rc_N71542_at	N71542	2665	kidney- and liver-specific gene	21.05	down	
rc_n71935_s_at	N71935	2667	multiple PDZ domain protein	16.28	down	o c
rc_N72259_at	N72259	2670	cornichon-like	4.65	down	0.0054
rc_N72695_s_at	N72695	2671	EST	97.0	down	00000
rc_N73461_f_at	N73461	2673	EST	4.25	o de la constante de la consta	0.00008
rc_N73468_s_at	N73468	2674	protein S (alpha)	4 4	T T T T T T T T T T T T T T T T T T T	0.00102
				t F	T AGO	0.0000

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pyalite
rc_N73543_at	N73543	2675	EST	17		0 00003
rc_N73561_at	N73561	2676	EST	12.96	down	0.00011
rc_N73883_at	N73883	2682	EST	9.35	down	0
rc_N73988_at	N73988	2683	EST	10.27	down	0.00083
rc_N74025_at	N74025	2685	deiodinase, iodothyronine, type I	22.79	down	0
rc_N74422_at	N74422	2686	EST	30.32	down	0
rc_N74558_at	N74558	2687	EST	3.19	down	0.00247
rc_N75072_at	N75072	2689	EST	3.73	down	0.00379
N75203_s_at	N75203	2691	EST	6.15	down	0.00181
N75870_s_at	N75870	2693	dual specificity phosphatase 1	13.41	down	0.00251
rc_N76012_r_at	N76012	2694	EST	36.71	down	0.00598
N77326_at	N77326	2696	EST	7.51	down	0.00542
N77606_at	N77606	2697	EST	4.22	down	0.00119
!			macrophage stimulating 1 (hepatocyte growth			
rc_N78850_s_at	N78850	2699	factor-like), macrophage stimulating, pseudogene	13.69	down	0.00421
rc_N78902_at	N78902	2700	leptin receptor	6.79	down	0.0041
rc_N79435_at	N79435	2701	chromosome 15 open reading frame 3	3.12	down	0.00861
rc_N79778_at	N79778	2702	extracellular matrix protein 2, female organ and	5.15	down	0.00286
rc_N80129_I_at	N80129	2703	metallothionein 1L	66.48	down	0.00415
rc_N80129_f_at	N80129	2703	metallothionein 1L	13.6	down	0.00196
rc_N81025_at	N81025	2705	EST	8.61	down	0.00015
rc_N81036_at	N81036	2706	EST	6.89	down	0.00276
N89302_s_at	N89302	2708	HLA-B associated transcript-3	23.44	down	0.00192
rc_N89738_at	N89738	2710	EST	10.06	down	0.00052
rc_N90584_at	N90584	2714	EST	3.08	down	0.02602
N90820_at	N90820	2715	DKFZP566B1346 protein	4.86	down	0.03008
N91087_at	N91087	2717	EST	6.91	down	0.00109
rc_N91273_r_at	N91273	2718	EST	4.07	down	0.02965
rc_N91882_at	N91882	2720	alpha2,3-sialyltransferase	14.52	down	0.00024
rc_N93155_f_at	N93155	2729	calmodulin 1 (phosphorylase kinase, delta)	4.39	down	0.0002
rc_N93155_i_at	N93155	2729	calmodulin 1 (phosphorylase kinase, delta)	3.46	down	0.00031

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gone Name			
rc_N93191_at	N93191	2730	FST	roid Criange		Pvalue
rc_N93246_f_at	N93246	2731	EST	3.20	down	0.00232
rc N93764 at	N93764	2727	FIGH	5.05	UMOD	0.00049
NO4146 at	MOAAA	1017		2.92	down	0.0109
10 756 POIN 02	100404V	8612	E0.	8.05	down	0
10 NO400 21	N94367	2740	EST	8.79	down	0.01003
ro NOEAGE of	N94930	2741	multiple PDZ domain protein	10.06	down	0.00226
ic_Neo489_at	N95495	2742	EST	5.61	down	0.00308
Alooga at	N95585	2743	EST	3.1	down	0.0083
N9934Z_at	N99542	2747	orosomucoid 1	8.41	down	0.00001
ic_lysseop_at	99866N	2748	EST	3.13	down	0.04148
ic_Ruuzso_at	K00296	2750	EST	3.98	down	0.04632
rc_K00843_s_at	R00843	2751	fragile histidine triad gene	3.68	down	0.03578
C_RUIDZ3_s_at	R01023	2752	glucokinase (hexokinase 4) regulatory protein	50.71	down	0.00321
	K01081	2753	EST	3.3	down	0.00839
200000			glucose-6-phosphatase, catalytic (glycogen			
rc_KUZ365_t_at	R02365	2755	storage disease type I, von Gierke disease)	17.17	down	0.00124
rc_R023/1_at	R02371	2756	EST	3.75	down	0.0000
rc_R025/2_at	R02572	2757	fibronectin 1	7.1	down	0.00059
rc_K02/52_at	R02752	2758	EST	3.05	down	0.00362
rc_K05309_t_at	R05309	2759	EST	3.72	down	0.0008
rc_KU5490_at	R05490	2761	SEC24 (S. cerevisiae) related gene family,	3.03	down	0.00317
rc_KU5518_at	R05518	2762	EST	4.15	down	0.0125
rc_K06002_s_at	R06002	2763	EST	10.15	down	0.00003
rc_RU6Z/1_s_at	R06271	2766	EST	6.14	down	0.00063
IC_RUD/Z6_S_at	K06726	2770	protease inhibitor 1 (anti-elastase), alpha-1-	12.26	down	0.03905
10 K00/46 at	K06746	2771	EST	15.77	down	6000000
10_KU07.04_8_81	K06/64	2772	apolipoprotein B (including Ag(x) antigen)	4.91	down	0.00167
C KOOS// T at	K06977	2775	glucokinase (hexokinase 4) regulatory protein	6.1	down	0.00049
rc_KU/b3/_at	K07637	2778	EST	3.04	down	0.00118
rc_K08548_at	R08548	2779	EST	9.94	down	0.00326
rc_K08564_at	R08564	2780	plasminogen-like	60.18	down	0.00091

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_R08615_s_at	R08615	2781	homogentisate 1,2-dioxygenase (homogentisate	21.85	down	0.00026
rc_R08850_at	R08850	2782	EST	12.55	down	0.0000
rc_R09053_at	R09053	2783	EST	5.9	uwop	0.0002
rc_R10138_at	R10138	2784	EST	4	down	0.00032
rc_R10287_at	R10287	2785	EST	11.2	down	0.0003
rc_R10378_s_at	R10378	2786	fibrinogen-like 1	8.13	down	0.00189
rc_R10662_f_at	R10662	2787	mutL (E. coli) homolog 1 (colon cancer,	3.2	down	0.0005
rc_R10684_at	R10684	2788	EST	5.51	down	0.00741
rc_R12472_at	R12472	2789	EST	55.18	down	0.00011
rc_R12579_at	R12579	2790	EST	3.5	down	0.00137
rc_R15825_r_at	R15825	2792	KIAA0946 protein; Huntingtin interacting protein	5.33	down	0.00391
rc_R16098_at	R16098	2793	EST	63.41	down	0.00038
rc_R17762_at	R17762	2795	EST	3.37	down	0.01822
rc_R21232_at	R21232	2798	EST	3.56	down	0.00246
rc_R22196_at	R22196	2799	EST	3.75	down	0.02867
rc_R22905_at	R22905	2801	EST	4.64	down	0.0043
rc_R26904_f_at	R26904	2805	EST	3.51	down	0.00058
R31641_at	R31641	2814	EST	9.6	uwop	0.00011
rc_R31917_s_at	R31917	2815	EST	3.91	down	0.00071
rc_R32036_s_at	R32036	2816	interleukin 1 receptor-like 1	4.02	down	0.00051
rc_R32440_at	R32440	2817	EST	7.41	down	0.00159
rc_R32490_s_at	R32490	2818	EST	8.95	down	0.00215
rc_R33146_at	R33146	2819	EST	7	down	0.00043
rc_R34133_at	R34133	2821	EST	4.13	down	0.00008
rc_R34362_at	R34362	2822	KIAA0327 gene product	5.4	down	0.04615
rc_R36228_at	R36228	2824	EST	4.39	down	0.00033
rc_R36989_s_at	R36989	2826	hypothetical protein, estradiol-induced	13.7	down	0.00056
rc_R37128_s_at	R37128	2827	complement component 4A	39.51	down	0.00364
rc_R38185_at	R38185	2829	EST	6.32	down	0.00063
rc_R38709_s_at	R38709	2833	superoxide dismutase 2, mitochondrial	8.23	down	0.01578
rc_K39234_r_at	R39234	2835	EST	3.24	down	0.0412

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	011010
rc_R40395_s_at	R40395	2841	lecithin-choles	37 33	_ I `	r value
rc_R40492_at	R40492	2842	EST	S &	u de la constante de la consta	0.00032
rc_R40556_s_at	R40556	2843	EST	3 57	down down	0.00223
rc_R40899_f_at	R40899	2844	divoline receptor, heta	5 6	down	0.00184
rc_R40946_f_at	R40946	2845	crystallin, zeta (outnone reductase)		down down	0.0009
rc_R42241_at	R42241	2846	EST	3.97	Con	0.00130
rc_R43166_i_at	R43166	2847	EST	3.37	Two P	0.00123
rc_R43174_s_at	R43174	2848	paraoxonase 1	74.04	down	0.0038
rc_R43365_at	R43365	2850	EST	5.37	down	0.0000
rc_R43799_at	R43799	2851	EST	16.35	down	0.00208
rc_R43910_at	R43910	2852	EST	5.71	uwop	C
rc_R44025_at	R44025	2854	EST	4.4	down	0.01325
· 1	R44761	2858	aryl hydrocarbon receptor nuclear translocator	3.12	down	0.02663
	R45656	2865	EST	10.21	down	0.00179
rc_K48307_at	R48307	2870	EST	7.18	down	0.00007
rc_R48540_s_at	R48540	2873	EST	6.05	down	0.00086
rc_R48732_s_at	R48732	2876	EST	5.12	cwop	0.00837
rc_R49035_at	R49035	2877	EST	8.02	uwop	0.0091
rc_R49459_s_at	R49459	2882	transferrin receptor 2	85.61	down	0.000
rc_R49602_at	R49602	2885	EST	36.5	down	0.0001
R50008_s_at	R50008	2887	7-dehydrocholesterol reductase	6.67	down	0.00409
rc_R51256_at	R51256	2889	EST	3.04	down	0.00286
rc_R51309_at	R51309	2890	KIAA1077 protein	3.54	down	0.04112
rc_R51831_at	R51831	2891	EST	5.03	down	0.00761
K52800	R52800	2895	EST	3.96	down	0.00749
rc_K52822_1_at	R52822	2896	EST	12.79	down	0.00001
rc_K52949_at	R52949	2897	EST	3.46	down	0.00395
rc_K54416_at	R54416	2901	EST	3.14	down	0.00236
rc_R56094_at	R56094	2905	EST	4.87	down	0.00214
rc_R56602_at	R56602	2907	lg superfamily protein	3.06	down	0.02464
rc_K59ZZ1_at	R59221	2912	progesterone binding protein	7.54	down	0.00159

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affv (D	Genbank	Cl nes	Known Gane Name			
rc R59325 at	R59325	2914	EST COLONIES	roid Change		Pvalue
rc_R59722_at	R59722	2916	EST	10.74	u down	0.00117
rc_R61740_f_at	R61740	2923	EST	4 02	i wood	0.00010
rc_R62173_f_at	R62173	2924	UDP-glucose dehydrogenase	5.76	down	0.0006
rc_R62519_f_at	R62519	2926	EST	10.83	down	0.00243
R63545_at	R63545	2927	EST	5.4	down	0.00202
rc_R64131_at	R64131	2930	EST	20.58	down	0.01028
rc_R64144_s_at	R64144	2932	cAMP responsive element binding protein-like 2	4.58	down	0,00495
R64199_at	R64199	2933	SEC22, vesicle trafficking protein (S. cerevisiae)-	9.19	down	0.00387
rc_R65593_s_at	R65593	2935	kynurenine 3-monooxygenase (kynurenine 3-	21.27	down	0.00007
R67751_at	R67751	2939	EST	3.12	down	0.00319
rc_R67970_s_at	R67970	2940	gamma-glutamyl carboxylase	9.45	down	0.00212
rc_R69031_at	R69031	2941	EST	3.19	down	0.00798
R69417_at	R69417	2942	EST	7.79	down	0.03795
rc_R70790_at	R70790	2948	EST	4.07	down	0.02354
rc_R71491_at	R71491	2954	EST	3.55	down	0.01903
rc_R73485_at	R73485	2958	EST	7.77	down	6000'0
rc_R73816_at	R73816	2961	EST	11.53	down	0.00259
R77628_at	R77628	2966	Insulin induced gene 1	29.23	down	0.00122
R80048_at	R80048	2972	EST	12.28	down	0.00128
R80573_at	R80573	2973	EST	3.08	down	0.02126
rc_R82074_f_at	R82074	2974	syndecan 1	99.9	down	0.01336
R82229_at	R82229	2975	phosphatidylserine decarboxylase	3.08	down	0.03455
rc_R82837_at	R82837	2976	KIAA0970 protein	ວ	down	0.00181
R87373_s_at	R87373	2978	EST	4.09	down	0.02253
rc_R89811_s_at	R89811	2980	HGF activator	62.51	down	0.00148
rc_R91503_s_at	R91503	2982	ATP-binding cassette, sub-family C (CFTR/MRP),	9.64	down	0.00584
rc_R92458_f_at	R92458	2986	hemoglobin, gamma G	3.31	down	0.00763
rc_R92475_s_at	R92475	2987	flavin containing monooxygenase 3	26.13	down	0
rc_R92737_at	R92737	2988	EST	4.53	down	0.04447
rc_R92768_at	R92768	2989	EST	13.2	down	0.00001

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sed ID	Known Gene Name	Fold Change	Direction	Pysline
rc_R93714 at	R93714	2992	fetuin B	10.42		0 00043
R93776_s_at	R93776	2993	EST	39.32		0.00043
rc_R93908_at	R93908	2994	EST	5.8	down	0.02699
R94662_at	R94662	2995	heme-binding protein	4.41	down	0.02301
rc_R94674_s_at	R94674	2996	EST	10.76	down	0.00008
R96417_at	R96417	2998	EST	3.0	down	0.00019
rc_R96822_at	R96822	3000	EST	8.25	down	0.00008
rc_R97302_at	R97302	3003	EST	3.73	down	0.01887
			cytochrome P450, subfamily VIIIB (sterol 12-	•		
rc_R97419_at	R97419	3004	alpha-hydroxylase), polypeptide 1	65.07	down	0.0039
rc_R97711_at	R97711	3005	EST	3.37	down	0.00838
rc_R97798_at	R97798	3007	EST	3.79	down	0.00015
K98073_at	R98073	3000	EST	46.87	down	0
rc_R98074_at	R98074	3010	EST	9.21	down	0.00048
rc_R98413_at	R98413	3012	EST	9.71	down	0.00007
rc_R98624_at	R98624	3013	EST	21.32	down	0
rc_R98774_at	R98774	3014	EST	3.93	down	0.00001
rc_R99591_at	R99591	3016	CD5 antigen-like (scavenger receptor cysteine	9.52	down	0.00006
rc_R99909_at	R99909	3017	EST	4.27	down	0.00045
S48983_at	S48983	3018	serum amyloid A4, constitutive	23.04	down	0.00022
S52028_s_at	S52028	3019	cystathionase (cystathionine gamma-lyase)	3.21	down	0.00476
S62539_s_at	S62539	3022	insulin receptor substrate 1	3.7	down	0.01307
S67325_at	S67325	3024	propionyl Coenzyme A carboxylase, beta	4.19	down	0.00151
			aldo-keto reductase family 1, member C4			
			(chlordecone reductase; 3-alpha hydroxysteroid			
S68287_at	S68287	3025	dehydrogenase, type 1; dihydrodiol	24.11	down	0
S68805_at	S68805	3026	glycine amidinotransferase (L-arginine:glycine	18.19	down	0.00083
S69232_at	S69232	3027	electron-fransferring-flavoprotein dehydrogenase	4.9	down	0.00017
S70004_at	S70004	3029	glycogen synthase 2 (liver)	9.36	down	0.00001
S72370_at	S72370	3030	pyruvate carboxylase	5.31	down	0.00075
S72370_at	S72370	3030	pyruvate carboxylase	4.54	down	0.0001

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name	Fold Change	Diroction	Gillord
S74728 at	S74728	3033	antiquitin 1	501		COOOB
S77356_at	S77356	3034	EST	5.83	down	0.0000
S77410_at	S77410	3035	angiotensin receptor 1	10.4	down	27.00.0
S90469_at	S90469	3040	P450 (cytochrome) oxidoreductase	4.32	down	0.0182
S95936_at	S95936	3041	transferrin	19.76	down	0.02009
rc_T03441_f_at	T03441	3044	cytochrome b-561	5.74	down	0.02781
rc_T03651_s_at	T03651	3047	tubulin, beta polypeptide	6.47	down	0.00843
T08879_at	T08879	3049	cathepsin F	5.29	down	0.0008
rc_T10108_s_at	T10108	3050	EST	3.85	down	0.01155
rc_t10264_s_at	T10264	3051	EST	3.84	down	0.00874
rc_110322_at	T10322	3053	dihydropyrimidinase-like 2	4.23	down	0.01527
rc_110822_at	T10822	3022	EST	3.16	down	0.00635
rc_T15482_f_at	T15482	3060	EST	5.04	down	0.00233
rc_T15674_f_at	T15674	3061	EST	4.12	down	0.02111
rc_T16175_s_at	T16175	3064	protein tyrosine phosphatase, non-receptor type	3.07	down	0.01007
	T16269	3067	EST	3.36	down	0.00282
rc_T16478_at	T16478	3070	EST	4	down	0.01041
rc_T16484_s_at	T16484	3071	EST	7.69	down	0.00805
rc_T17411_s_at	T17411	3078	transthyretin (prealbumin, amyloidosis type I)	13.49	down	0.00203
rc_T23430_at	T23430	3080	EST	3.12	down	0.00949
rc_T23680_at	T23680	3084	calcium channel, voltage-dependent, gamma	3.29	down	0.0003
rc_T23882_s_at	T23882	3085	kininogen	42.85	down	0.00641
rc_T23986_s_at	T23986	3086	hydroxyacyl glutathione hydrolase; glyoxalase 2	7.26	down	0.0062
rc_T24055_s_at	T24055	3087	ribosomal protein L26	3.9	down	0.00046
rc_T24106_at	T24106	3089	EST	12.13	down	0.01687
rc_T25506_at	T25506	3090	EST	4.51	down	0.00529
T30341_s_at	T30341	3101	EST	3.04	down	0.04567
rc_T33011_at	T33011	3104	EST	3.57	down	0.02486
139897_s_at	T39897	3114	androgen induced protein	10	down	0.00466
rc_T40936_at	T40936	3118	EST	46.92	down	0.00056
rc_I 40995_t_at	T40995	3119	alcohol dehydrogenase 3 (class I), gamma	13.25	down	0.01531

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Dvalue
rc_T41047_s_at	T41047	3120	EST	4.74	1 -	0.00015
rc_T41232_at	T41232	3122	EST	3.57	down	0.00846
rc_T46901_at	T46901	3123	EST	77.28	down	0.000
rc_T47778_s_at	T47778	3127	fibrinogen, A alpha polypeptide	30	C C C C C C C C C C C C C C C C C C C	0.0000
rc_T48039_s_at	T48039	3129	protein C (inactivator of coaquiation factors Va	84.39	C ACC	0.0143
rc_T48075_f_at	T48075	3130	hemoglobin, alpha 1	32.56	down	0.00172
rc_T48278_at	T48278	3132	EST	15.04	down	0.04754
rc_T48980_s_at	T48980	3134	calmodulin 1 (phosphorylase kinase, delta)	4.2	Lwop	0.0046
rc_T49061_at	T49061	3135	EST	3.06	down	0.00768
rc_T51150_at	T51150	3137	EST	10.52	down	0.00377
			solute carrier family 22 (extraneuronal			
rc_T51617_at	T51617	3138	monoamine transporter), member 3	17.67	down	0.00018
rc_T51930_at	T51930	3139	EST	66.6	down	0.00066
rc_T52564_at	T52564	3141	EST	3,28	down	0.01506
rc_T52813_s_at	T52813	3142	putative lymphocyte G0/G1 switch gene	16.71	down	0.03897
rc_T54160_s_at	T54160	3145	EST	3.24	down	0,00168
rc_T55547_at	T55547	3148	EST	3.28	down	0.00047
56264_:	T56264	3149	apolipoprotein C-II	53.04	down	0.00938
rc_156279_s_at	T56279	3150	H factor (complement)-like 3	28.39	down	0.00016
rc_156281_f_at	T56281	3151	RNA helicase-related protein	32.34	down	0.00002
15/140 s_at	T57140	3152	paraoxonase 3	28.8	down	0
rc_158032_s_at	T58032	3153	3-hydroxyanthranilate 3,4-dioxygenase	8.86	down	0.00023
rc_158/56_at	T58756	3156	EST	13.39	down	0.00013
rc_158775_at	T58775	3157	small inducible cytokine subfamily A (Cys-Cys),	21.18	down	0.0000
rc_159148_s_at	T59148	3158	carbamoyl-phosphate synthetase 1, mitochondrial	88.89	down	0
rc_T60407_at	T60407	3161	EST	9.9	down	0.00167
rc_T61256_s_at	T61256	3162	ketohexokinase (fructokinase)	13.59	down	0.00425
			vitronectin (serum spreading factor, somatomedin			
rc_161373_s_at	T61373	3163	B, complement S-protein)	44.9	down	0.03172
rc_161389_t_at	T61389	3164	haptoglobin	18.95	down	0.04873
rc_161649_f_at	T61649	3165	superoxide dismutase 2, mitochondrial	26.09	down	0.00734

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	SealD	Known Gene Name	Fold Change		
rc T61801 s at	T61801	3167	hemonexin	roid Cilatige		Fvalue
rc T63364 at	T63364	3170	ficulty collade of the poden domain contains 3	7.07	Dwop	29510.0
rc T63490 at	T63490	3474	EST	0.72	LIMON	0.00383
ro T64675 o ot	1001	- 6		16.54	down	o
16-10-10-10-10-10-10-10-10-10-10-10-10-10-	1645/5	3//2	F.S.	10.46	down	0.00014
rc_16488/_r_at	164887	3173	protein phosphatase 5, catalytic subunit	5.66	down	0.00349
rc_lbb9/2_at	165972	3177	EST	3.21	down	0.04847
rc_T66189_s_at	T66189	3178	glutaryl-Coenzyme A dehydrogenase	8.61	down	0.00003
			succinate dehydrogenase complex, subunit D,			
T67231_at	T67231	3181	integral membrane protein	7.04	down	0.03554
	T67705	3183	asialoglycoprofein receptor 2	31.6	down	0.00705
rc_167931_at	T67931	3184	fibrinogen, B beta polypeptide	49.55	down	0
T68083_at	T68083	3185	short-chain dehydrogenase/reductase 1	4.03	down	0.01593
rc_T68426_s_at	T68426	3186	CD81 antigen (target of antiproliferative antibody	3.11	down	0.01634
T68510_at	T68510	3187	EST	3.87	down	0.00617
rc_168711_at	T68711	3188	EST	37.65	down	0.00036
rc_T68855_at	T68855	3189	EST	34.04	down	0
rc_T68873_f_at	T68873	3190	metallothionein 1L	28.72	down	0.02953
rc_T68878_f_at	T68878	3191	carboxylesterase 1 (monocyte/macrophage	60.35	down	0.00409
rc_T69009_s_at	T69009	3192	quinoid dihydropteridine reductase	6.54	down	0.00145
rc_169020_s_at	T69020	3193	EST	5.39	down	0.00383
rc_T69029_f_at	T69029	3194	haptoglobin	33.18	down	0.02825
rc_169164_at	T69164	3195	EST	4.38	down	0.00548
rc_T69284_s_at	T69284	3196	mannose-binding lectin (protein C) 2, soluble	36.53	down	0
T69384_at	T69384	3198	perlod (Drosophila) homolog 1	5.88	down	0.01219
rc_T69728_at	T69728	3199	heat shock 90kD protein 1, beta	3.98	down	0.00786
rc_T 70087_at	T70087	3200	EST	4.7	down	0.00173
rc_I /1012_s_at	T71012	3201	fibrinogen, B beta polypeptide	43.61	down	0.00743
rc_1/1021_at	171021	3202	EST	6.74	down	0.0017
rc_1/13/3_at	171373	3203	EST	83.08	down	0.00069
rc_1/1//6_at	171776	3204	EST	10.3	down	0.00897
rc_1/19/8_at	171978	3205	EST	4.39	down	0.0017

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_T72171_s_at	T72171	3206	thyroxin-bindin	10.41	, -	0.00163
rc_T72268_s_at	T72268	3207	B-factor, properdin	7.43	down	0.01197
rc_T72502_at	T72502	3208	EST	8.87	down	600000
rc_T72629_i_at	T72629	3209	EST	3.24	down	0.00556
rc_T72906_at	T72906	3210	EST	7.56	down	0.00062
rc_T73420_at	T73420	3211	short-chain dehydrogenase/reductase 1	4.58	down	0.00656
rc_T73433_s_at	T73433	3212	angiotensinogen	48.3	down	0.00049
rc_T73442_at	T73442	3213	EST	94.41	down	0
			alanine-glyoxylate aminotransferase (oxalosis I;			
rc_T73739_s_at	T73739	3214	hyperoxaluria I; glycolicaciduria; serine-pyruvate	16.18	down	0.00277
rc_T74542_s_at	T74542	3215	UDP glycosyltransferase 2 family, polypeptide	32.36	down	0.00004
rc_T74608_at	T74608	3216	hydroxyacid oxidase (glycolate oxidase) 1	14.03	down	0
rc_T74884_r_at	T74884	3217	EST	3.76	down	0.02547
rc_T77729_f_at	T77729	3218	pyruvate carboxylase	7.29	down	0.00022
rc_T78433_s_at	T78433	3220	glycogen synthase 2 (liver)	8.62	down	0.00072
rc_T78889_s_at	T78889	3221	fibronectin 1	19.87	down	0.00912
rc_T79758_at	T79758	3224	EST	3.94	down	0.00581
rc_T79842_at	T79842	3225	EST	3.16	down	0.03159
rc_T79863_at	T79863	3226	EST	5.62	down	0.00074
rc_T81315_at	T81315	3227	EST	4.28	down	0.00187
rc_T82254_at	T82254	3229	EST	3.82	down	0.00091
rc_T82259_at	T82259	3230	EST	3.12	down	0.01122
rc_T82323_at	T82323	3231	immunoglobulin superfamily, member 4	10.14	down	0
rc_T83356_s_at	T83356	3232	apolipoprotein H (beta-2-glycoprotein I)	64.34	down	0.00802
T83397_at	T83397	3233	phytanoyi-CoA hydroxylase (Refsum disease)	63.6	down	0
T85532_f_at	T85532	3236	EST	4.33	down	0.00591
rc_T86464_at	T86464	3237	EST	3.17	down	0.00498
rc_T86482_at	T86482	3238	transferrin	11.15	down	0.00006
rc_T86978_s_at	T86978	3239	glutamate dehydrogenase 1	9.44	down	900000
rc_T87174_at	T87174	3240	EST	21.71	down	0.00681
rc_T90037_at	T90037	3246	EST	3.99	down	0.0016

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

	190492 190520	3778	FST	3.88		0 00 454
~	90520	247	-		מאס	1000
~	,	3249	EST	8.67	down	0.00072
~	190531	3250	EST	3.6	down	0.00301
	190841	3251	EST	5.74	down	0.01876
	T91161	3253	EST	3.48	down	0.00002
	F91348	3254	EST	3.57	down	0.00011
	92950	3256	EST	3.01	down	0.00497
	194862	3258	EST	3.07	down	0.01417
	195064	3260	EST	5.75	down	0.00604
s_at	95515	3261	KIAA0249 gene product	6.77	down	0.0001
. at	95813	3262	KiAA1051 protein	38.38	down	0.00008
,at	196969	3264	EST	3.42	down	0.00053
'at	197234	3265	EST	4.34	down	0.00263
	98199	3267	EST	4.86	down	0.00431
at J	98676	3269	EST	46.94	down	0.0001
_at	199636	3271	complement component 3	29.6	down	0.00051
U00115_at U	100115	3272	B-cell CLL/lymphoma 6 (zinc finger protein 51)	5.18	down	0.00045
			glucose-6-phosphatase, catalytic (glycogen			
U01120_at U	01120	3274	storage disease type I, von Gierke disease)	13.41	down	0.00147
			solute carrier family 1 (glial high affinity glutamate			
ر	101824	3276	transporter), member 2	3.2	down	0.00021
س	102020	3277	pre-B-cell colony-enhancing factor	3.37	down	0.01112
_	J02388	3278	cytochrome P450, subfamily IVF, polypeptide 2	9.38	down	0.00001
.	103056	3280	hyaluronoglucosaminidase 1	6.64	down	0
U03105_at U	03105	3281	proline-rich protein with nuclear targeting signal	4.69	down	0.00017
			aldo-keto reductase family 1, member C1			
			(dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-			
at C	J05861	3285	hydroxysteroid dehydrogenase)	23.22	down	0.00002
s_at	106641	3287	UDP glycosyltransferase 2 family, polypeptide	24.32	down	0.00001
	J06863	3288	follistatin-like 1	3.09	down	0.00091
U08006_s_at	90080	3290	complement component 8, alpha polypeptide	16	down	0.00111

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pyalite
U08198_rna1_at	U08198	3292	complement component 8, gamma polypeptide	19.71	1	0
U08854_s_at	U08854	3293	UDP glycosyltransferase 2 family, polypeptide	7.38	down	0.00005
U11313_at	U11313	3297	sterol carrier protein 2	5.44	down	0.00187
U12778_at	U12778	3301	acyl-Coenzyme A dehydrogenase,	5.68	down	0.00116
			sulfotransferase family 2A,			
U13061_rna1_at	U13061	3302	dehydroepiandrosterone (DHEA) -preferring,	11.32	down	0.00048
U16660_at	U16660	3313	enoyl Coenzyme A hydratase 1, peroxisomal	3.96	down	0.00002
U19495_s_at	U19495	3319	stromal cell-derived factor 1	4.59	down	0.00011
U19523_at	U19523	3320	GTP cyclohydrolase 1 (dopa-responsive	5.25	down	0.00029
U20530_at	U20530	3322	secreted phosphoprotein 2, 24kD	16.93	down	0
U20938_at	U20938	3324	dihydropyrimidine dehydrogenase	3.92	down	0.00053
U21931_at	U21931	3326	fructose-bisphosphatase 1	3.4	down	0.00709
			cytochrome P450, subfamily IIA (phenobarbital-			
U22029_f_at	U22029	3327	inducible), polypeptide 7	71.98	down	0
U22961_s_at	U22961	3330	albumin	22.22	down	0.01531
			aldehyde dehydrogenase 4 (glutamate gamma-			
U24266_at	U24266	3331	semialdehyde dehydrogenase; pyrroline-5-	14.54	down	0
U25182_at	U25182	3333	thioredoxin peroxidase (antioxidant enzyme)	3.13	down	0.02543
U26173_s_at	U26173	3335	nuclear factor, interleukin 3 regulated	6.4	down	0.00001
U27460_at	U27460	3339	UDP-glucose pyrophosphorylase 2	11.46	down	0.00088
			solute carrier family 6 (neurotransmitter			
U27699_at	U27699	3340	transporter, betaine/GABA), member 12	3.65	down	0,00381
U28833_at	U28833	3341	Down syndrome candidate region 1	3.3	down	0.00306
U29953_rna1_at	U29953	3342	pigment epithelium-derived factor	15.33	down	0.00212
U31449_at	U31449	3345	transmembrane 4 superfamily member 4	11.53	down	0.00187
U32576_rna1_at	U32576	3347	apolipoprotein C-IV	18.59	down	0.00005
U32576_rna1_at	U32576	3347	apolipoprotein C-IV	5.81	down	0.04343
U32989_at	N32989	3348	tryptophan 2,3-dioxygenase	10.07	down	0.02825
			aldehyde dehydrogenase 9 (gamma-			
U34252_at	U34252	3350	aminobutyraldehyde dehydrogenase, E3	4.31	down	0.00613
U36922_at	U36922	3352	EST	3.06	down	0.01388

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name	Fold Change	Olyportlon	Girloy
			macrophage stimulating 1 (hepatocyte growth	offinio nio		200
U37055_ma1_s_at	U37055	3353	factor-like), macrophage stimulating, pseudogene	18.28	down	0
U44111_at	U44111	3363	histamine N-methyltransferase	3.5	down	0.00942
U46499_at	U46499	3365	microsomal glutathione S-transferase 1	4.27	down	0.00244
U46689_at	U46689	3366	aldehyde dehydrogenase 10 (fatty aldehyde	3,5	down	0.01292
U48296_at	U48296	3369	protein tyrosine phosphatase type IVA, member 1	4.25	down	0.02037
U48707_at	U48707	3371	protein phosphatase 1, regulatory (inhibitor)	14.22	down	C
U48959_at	U48959	3372	myosin, light polypeptide kinase	3.61	down	0.00084
U49082_at	U49082	3373	transporter protein	9.17	down	0.00088
U49248_at	U49248	3374	ATP-binding cassette, sub-family C (CFTR/MRP),	7.06	down	0.00067
U49352_at	U49352	3375	2,4-dienoyl CoA reductase 1, mitochondrial	5.41	down	0.02371
U49785_at	U49785	3376	D-dopachrome tautomerase	3.84	down	0.00044
U50196_at	U50196	3377	adenosine kinase	3.82	down	0.01425
U50527_s_at	U50527	3378	EST	3.93	down	0.00123
U50929_at	U50929	3380	betaine-homocysteine methyltransferase	36.91	down	C
U51010_s_at	U51010	3381	nicotinamide N-methyltransferase	27.79	down	0.00366
U51333_s_at	U51333	3383	hexokinase 3 (white cell)	4.88	down	0.00055
U51903_at	U51903	3387	IQ motif containing GTPase activating protein 2	3.23	down	0.00242
· U53003_at	U53003	3388	ES1 (zebrafish) protein, human homolog of	4.84	down	0.00077
U56814_at	U56814	3393	deoxyribonuclease I-like 3	29.43	down	0.00003
U56814_at	U56814	3393	deoxyribonuclease I-like 3	11.36	down	0.00001
U57721_at	U57721	3395	kynureninase (L-kynurenine hydrolase)	4.34	down	0.0197
U60205_at	U60205	3401	sterol-C4-methyl oxidase-like	5.16	down	0.00061
U62389_at	U62389	3402	isocitrate dehydrogenase 1 (NADP+), soluble	3.15	down	0.03949
U66674_at	U66674	3408	ATP-binding cassette, sub-family C (CFTR/MRP),	6.13	down	0.00127
U67963_at	N67963	3410	lysophospholipase-like	3.19	down	0.00029
U68233_at	U68233	3412	nuclear receptor subfamily 1, group H, member 4	6.76	down	0.00022
	U68494	3413	EST	4.82	down	0.00881
U69141_at	U69141	3414	glutaryl-Coenzyme A dehydrogenase	3.06	down	0.00053
U70732_ma1_at	U70732	3415	glutamic-pyruvate transaminase (alanine	27.63	down	0
U70732_ma1_at	U70732	3415	glutamic-pyruvate transaminase (alanine	5.64	down	0.00146

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
U73514_at	U73514	3419	hydroxyacyl-Coenzyme A dehydrogenase, type II	3.79		0.01392
U73682_at	U73682	3420	meningioma expressed antigen 6 (colled-coll	3.08	down	0.01249
U76376_at	076376	3425	harakiri, BCL2-interacting protein (contains only	11.77	down	0.00002
U77396_at	077396	3426	LPS-induced TNF-alpha factor	4.47	down	0.00108
U77594_at	U77594	3428	retinoic acid receptor responder (tazarotene	11.95	down	0,00527
U78190_rna1_at	U78190	3431	GTP cyclohydrolase I feedback regulatory protein	3.94	down	0.034
U79294_at	U79294	3435	Phosphatidic acid phosphatase type 2b	3.13	down	0.00129
U79303_at	U79303	3436	protein predicted by clone 23882	4.45	down	0
U79716_at	U79716	3437	reelin	3.51	down	0.00053
			solute carrier family 9 (sodium/hydrogen			
U82108_s_at	U82108	3441	exchanger), isoform 3 regulatory factor 2	3.19	down	0.01545
U82468_at	U82468	3442	tubby like protein 1	3.34	down	0.0097
U84569_at	U84569	3445	chromosome 21 open reading frame 2	3.46	down	0.01844
U86529_at	U86529	3451	glutathione S-transferase zeta 1	3.41	down	0.0118
U90544_at	U90544	3454	solute carrier family 17 (sodium phosphate),	6.42	down	0.00023
U90545_at	U90545	3455	solute carrier family 17 (sodium phosphate),	4.14	down	0.00005
U95090_at	N95090	3464	nephrosis 1, congenital, Finnish type (nephrin)	14.01	down	0.00018
U95090_at	N95090	3464	nephrosis 1, congenital, Finnish type (nephrin)	7.44	down	0.00004
W03796_at	W03796	3468	EST	8.3	down	0.0032
W07723_at	W07723	3471	EST	3.51	down	0.00026
rc_W15528_at	W15528	3475	EST	3.56	down	0.00424
W20094_at	W20094	3477	DKFZP586A0522 protein	38.09	down	0.00188
W20276_f_at	W20276	3478	EST	3.82	down	0.00033
rc_W20467_f_at	W20467	3480	EST	7.76	down	0.00008
W26769_at	W26769	3483	CGI-86 protein	8.14	down	0.00204
W26996_at	W26996	3484	EST	6.42	down	0.00005
W27023_at	W27023	3485	neuroendocrine-specific protein C like (foocen)	6.79	down	0.00805
W28798_at	W28798	3492	phosphodiesterase 6A, cGMP-specific, rod, alpha	7.01	down	0.00017
W28824_at	W28824	3493	EST	15.8	down	0.0000
W28944_at	W28944	3494	EST	37.07	down	0.00205
rc_W31478_s_at	W31478	3496	EST	3.36	down	0.01511

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_W33167_at	W33167	3499	EST	8.01	down	0.00028
W35309_at	W35309	3500	EST	3.11	down	0.029
W36290_s_at	W36290	3501	Kreisler (mouse) maf-related leucine zipper	3.94	down	0.02718
rc_W37382_at	W37382	3502	EST	4.37	down	0.00677
rc_W38407_at	W38407	3506	EST	4.17	down	0.00392
rc_W42483_at	W42483	3510	EST	3.04	down	0.02518
rc_W42789_at	W42789	3515	EST	9.38	down	0.00059
rc_W42996_at	W42996	3517	EST	6.18	down	0.00587
rc_W44745_at	W44745	3520	EST	9.02	down	0.00276
rc_W45051_at	W45051	3521	EST	4.68	down	0.00433
W45259_at	W45259	3522	EST	3.78	down	0.00069
rc_W45560_at	W45560	3525	EST	5.06	down	0.00996
rc_W46391_at	W46391	3527	alpha integrin binding protein 63	4.03	down	0.01363
rc_W46404_at	W46404	3528	EST	3.73	down	0.00116
rc_W47175_at	W47175	3534	3-prime-phosphoadenosine 5-prime-	5.54	down	0.00914
rc_W51951_s_at	W51951	3542	dCMP deaminase	3.14	down	0.01691
			CD36 antigen (collagen type I receptor,			
W52581_at	W52581	3543	thrombospondin receptor)-like 2 (lysosomal	3.08	down	0.00091
W52821_at	W52821	3544	leucine aminopeptidase	4.02	down	0.03787
W55903_at	W55903	3546	adipose differentiation-related protein; adipophilin	9.12	down	0.00459
rc_W57821_at	W57821	3548	EST	5.03	down	0.00277
W58540_at	W58540	3553	KIAA1131 protein	4.28	down	0.0184
rc_W58756_at	W58756	3554	EST	12.17	down	0.00087
rc_W60002_s_at	W60002	3555	plastin 3 (T isoform)	4.88	down	0.01694
rc_W60186_at	W60186	3557	EST	3.24	down	0.00228
rc_W61000_at	W61000	3560	EST	3.15	down	0.03143
rc_W61319_at	W61319	3561	EST	3.02	down	0.00031
W61377_at	W61377	3562	EST	9.33	down	0.0012
rc_W61378_s_at	W61378	3563	EST	8.31	down	0
rc_W63728_at	W63728	3565	EST	5.03	down	0.00311
rc_W63785_at	W63785	3567	EST	3.91	down	0.04089

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name F	Fold Change	Direction	Pvalue
rc_W67147_at	W67147	3568	deleted in liver cancer 1	9.74	down	0.00002
rc_W67199_at	W67199	3569	EST	3.09	down	0.01528
rc_W67564_s_at	W67564	3571	nuclear receptor subfamily 0, group B, member 2	30.34	down	0
rc_W68721_f_at	W68721	3572	cleft lip and palate associated transmembrane	6.34	down	0.01504
rc_W69675_at	W69675	3575	EST	4.42	down	0.00019
rc_W70115_s at	W70115	3576	histidine ammonia-lyase	11.65	down	0.0003
rc_W70313_at	W70313	3578	EST	က	down	0.00643
rc_W72044_at	W72044	3580	insulin induced gene 1	24.58	down	0.00001
rc_W72079_at	W72079	3581	EST	6.36	down	0.00641
rc_W72972_at	W72972	3587	EST	5.61	down	0.00939
rc_W73194_at	W73194	3590	dermatopontin	3.45	down	0.02211
rc_W73601_at	W73601	3592	EST	32.25	down	0
rc_W73818_at	W.73818	3593	EST	4.32	down	0.00385
rc_W73889 s_at	W73889	3594	tetranectin (plasminogen-binding protein)	7.45	down	0.00091
W74158_at	W74158	3596	EST	4.81	down	0.00233
W79046_at	W79046	3602	peroxisomal D3,D2-enoyl-CoA isomerase	27.9	down	0.00023
rc_W79422_s_at	W79422	3604	fumarylacetoacetate	14.94	down	0.00059
rc_W80609_at	W80609	3606	EST	4.68	down	0.01729
W81053_at	W81053	3610	EST	4.91	down	0.00164
rc_W81079_at	W81079	3611	EST	3.31	down	0.0167
!			protein kinase, interferon-inducible double			
W81268_at	W81268	3612	stranded RNA dependent	4.2	down	0.00007
rc_W85765_at	W85765	3618	EST	3.83	down	0.00379
rc_W85847_at	W85847	3619	EST	7.28	down	0.00024
rc_W85886_at	W85886	3621	EST	3.46	down	0.00814
rc_W85888_at	W85888	3622	EST	3.99	down	0.00697
rc_W86075_at	W86075	3624	EST	13.83	down	0.00057
rc_W86375_s_at	W86375	3626	EST	19.29	down	0.0061
rc_W86431_s_at	W86431	3627	protein C inhibitor (plasminogen activator inhibitor	14.94	down	0.00152
rc_W86600_at	W86600	3628	EST	32.14	down	0
rc_W86756_at	W86756	3630	retinoid X receptor, alpha	3.77	down	0.02472

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
			solute carrier family 25 (mitochondrial carrier;			
rc_W86850_f_at	W86850	3631	citrate transporter), member 1	4.9	down	0.03105
rc_W87454_at	W87454	3632	homogentisate 1,2-dioxygenase (homogentisate	7.93	down	0.00149
rc_W87480_at	W87480	3633	STAT induced STAT inhibitor-2	3.24	down	0.01063
rc_W87532_at	W87532	3634	putative glycine-N-acyltransferase	12.34	down	0.00014
rc_W87606_s_at	W87606	3635	protein Z, vitamin K-dependent plasma	9.23	down	0.00085
rc_W87781_at	W87781	3636	EST	6.1	down	0.00045
rc_W87824_at	W87824	3637	EST	3.67	down	0.01559
rc_W88568_at	W88568	3638	glycogenin 2	4.16	down	0.00111
rc_W88946_at	W88946	3639	putative glycine-N-acyltransferase	58.26	down	0
rc_W88985_at	W88985	3640	KIAA0903 protein	3.94	down	0.00295
rc_W89178_at	W89178	3641	transferrin receptor 2	10.85	down	0.00116
rc_W90128_s_at	W90128	3643	X-box binding protein 1	10.04	down	0.00018
rc_W90455_s_at	W90455	3646	alpha-2-macroglobulin	10.35	down	0.00063
rc_W90560_at	W90560	3647	EST	3.35	down	0.00388
rc_W90583_r_at	W90583	3648	EST	4.35	down	0.00318
rc_W90766_at	W90766	3649	EST	7.58	down	0.00057
rc_W92148_s_at	W92148	3650	kininogen	51.09	down	0.00376
rc_W92713_at	W92713	3654	EST	16.55	down	0.00097
rc_W92771_s_at	W92771	3655	glycine cleavage system protein H (aminomethyl	4.36	down	0.0064
rc_W94427_at	W94427	3659	EST	3.86	down	0.02649
rc_W94942_i_at	W94942	3661	dual specificity phosphatase 10	7.23	down	0.00137
rc_W95041_at	W95041	3662	EST	12.79	down	0.00001
W95795_at	W95795	3665	EST	7.8	down	0.00359
X00129_at	X00129	3667	retinol-binding protein 4, interstitial	18.57	down	0.02378
AFFX-HSAC07/X00351_M_st	X00351	3668	actin, beta	4.76	down	0.0003
X01038_ma1_s_at	X01038	3669	apolipoprotein A-I, apolipoprotein C-III	19.97	down	0.0275
X01388_at	X01388	3670	apolipoprotein C-III	10.9	down	0.01246
X02160_at	X02160	3671	insulin receptor	5.29	down	0.0001
X02160_at	X02160	3671	insulin receptor	3.27	down	0.0007
X02176_s_at	X02176	3672	complement component 9	9.61	down	0.00004

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change Direction	Direction	Pvalue
X02750_at	X02750	3673	protein C (inactivator of coagulation factors Va	7.04	down	0.00079
			vitronectin (serum spreading factor, somatomedin			
X03168_at	X03168	3674	B, complement S-protein)	25.88	down	0.00911
X03350_at	X03350	3676	alcohol dehydrogenase 2 (class I), beta	19.32	down	0.00001
X04085_rna1_at	X04085	3678	catalase	11.27	down	0.0002
			gap junction protein, beta 1, 32kD (connexin 32,			
X04325_at	X04325	3679	Charcot-Marie-Tooth neuropathy, X-linked)	10.17	down	0.00061
X04729_s_at	X04729	3682	plasminogen activator inhibitor, type I	3.15	down	0.01337
l j			guanine nucleotide binding protein (G protein),			
X04828_at	X04828	3683	alpha inhibiting activity polypeptide 2	5.22	down	0.01278
X05409_at	X05409	3684	aldehyde dehydrogenase 2, mitochondrial	3.99	down	0.01029
X06562_at	X06562	3686	growth hormone receptor	10.87	down	0.00001
X07173_at	X07173	3690	inter-alpha (globulin) inhibitor, H2 polypeptide	30.3	down	0.00016
			cytochrome P450, subfamily IID (debrisoquine,			
X07618_s_at	X07618	3691	sparteine, etc., -metabolising), polypeptide 7a	35.79	down	0.00065
			cytochrome P450, subfamily IID (debrisoquine,			
X07618_s_at	X07618	3691	sparteine, etc., -metabolising), polypeptide 7a	13.58	down	0
			cytochrome P450, subfamily IID (debrisoquine,			
X07619_s_at	X07619	3692	sparteine, etc., -metabolising), polypeptide 7a	4.96	down	0.00004
X07732_at	X07732	3693	hepsin (transmembrane protease, serine 1)	28.21	down	0
X07767_at	X07767	3694	protein kinase, cAMP-dependent, catalytic, alpha	5.94	down	0.00028
X12662_rna1_at	X12662	3697	arginase, liver	20.59	down	0
X13227_at	X13227	3698	D-amino-acid oxidase	4.81	down	0.0002
X13334_at	X13334	3699	CD14 antigen	12.77	down	0.00887
			cytochrome P450, subfamily IIA (phenobarbital-			
X13930_f_at	X13930	3700	inducible), polypeptide 6	38.52	down	0
X14690_s_at	X14690	3703	pre-alpha (globulin) inhibitor, H3 polypeptide	16.07	down	0.00438
X14787_at	X14787	3704	thrombospondin 1	3.69	down	0.01115
			acetyl-Coenzyme A acyltransferase 1			
X14813_at	X14813	3705	(peroxisomal 3-oxoacyl-Coenzyme A thiolase)	11.61	down	0.0002
X15422_at	X15422	3708	mannose-binding lectin (protein C) 2, soluble	8.29	down	0.00015

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

שון אווא	Constant	OBC ID	NOWN Gene Name	Fold Change	Direction	Fvalue
X16260_s_at	X16260	3710	Inter-alpha (globulin) inhibitor, H1 polypeptide	44.65	down	0.00933
X16260 s at	X16260	3710	inter-alpha (globulin) inhibitor, H1 polypeptide	26.39	down	0.0004
X16349_s_at	X16349	3712	sex hormone-binding globulin	9.34	. uwop	0.00007
X17025_at	X17025	3715	isopentenyl-diphosphate delta isomerase	3.13	down	0.0043
			paired basic amino acid cleaving enzyme (furin,			
X17094_at	X17094	3717	membrane associated receptor protein)	8.5	down	0
X52150 rna1 s at	X52150	3722	arylsulfatase A	3.51	down	0.00113
X52520 at	X52520	3723	tyrosine aminotransferase	13.51	down	0.00002
X52541_at	X52541	3724	early growth response 1	3.77	down	0.00894
l			alanine-glyoxylate aminotransferase (oxalosis I;			
X53414 at	X53414	3728	hyperoxaluria I; glycolicaciduria; serine-pyruvate	13.87	down	0.00003
X53595 s at	X53595	3729	apolipoprotein H (beta-2-glycoprotein I)	27.28	down	0.0066
X54380 at	X54380	3730	pregnancy-zone protein	8.44	down	0.00059
X55283 rna1 s at	X55283	3734	asialoglycoprotein receptor 2	84.99	down	0.00084
X56411_rna1_at	X56411	3737	alcohol dehydrogenase 4 (class II), pi polypeptide	25.14	down	0.00144
X56692_at	X56692	3739	C-reactive protein, pentraxin-related	15.15	down	0.01884
X57025_at	X57025	3742	insulin-like growth factor 1 (somatomedin C)	4.72	down	0.00087
X58022_at	X58022	3747	corticotropin releasing hormone-binding protein	4.09	down	0.00076
X58528_s_at	X58528	3748	ATP-binding cassette, sub-family D (ALD),	4.91	down	0.00728
X59766_at	X59766	3749	alpha-2-glycoprotein 1, zinc	12.96	down	0.00043
			cytochrome P450, subfamily XXVIIA (steroid 27-			
X59812_at	X59812	3750	hydroxylase, cerebrotendinous xanthomatosis),	4.65	down	0.036
X59834_at	X59834	3751	glutamate-ammonia ligase (glutamine synthase)	4.29	down	0.00255
X60673_s_at	X60673	3752	adenylate kinase 3	8.3	down	0.00016
X61123_at	X61123	3753	B-cell translocation gene 1, anti-proliferative	3.2	down	0.00796
X62822_at	X62822	3758	sialyltransferase 1 (beta-galactoside alpha-2,6-	4.89	down	0.00274
X63359_at	X63359	3759	UDP glycosyltransferase 2 family, polypeptide	13.66	down	0.00051
X64877 at	X64877	3766	H factor (complement)-like 3	14.6	down	0
X64877 s at	X64877	3766	H factor (complement)-like 3	12.33	down	0
X65727 cds2 s at	X65727	3768	glutathione S-transferase A2, glutathione S-	73.64	down	0
Y65062 s at	VEEDES	2760	cytochrome DASO eribfamily IIC (menhanytoin 4-	E 47	40,00	7 7000

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

t X67235 3773 hematopoletically expressed homeobox X67491 3776 glutamate dehydrogenase 1 X68277 3777 dual specificity phosphatase 1 X68679 3779 complement factor H related 3,complement factor 3 3789 endoglin (Osler-Rendu-Weber syndrome 1) X72177 3790 complement component 6 X75252 3783 prostatic binding protein X76105 3794 death-associated protein X76105 3794 death-associated protein X76105 3799 dutar-doxin (thiotransferase) X76717 3790 metallothionein 1L X77548 3798 nuclear receptor coactivator 4 X78992 3802 butyrate response factor 2 (EGF-response factor prion protein (p27-30) (Creutzfeld-Jakob disease, prior protein (p27-30) (Greutzfeld-Jakob disease, prior prior protein p14-5 protein p14-5 prior protein p14-5 prior passente, sub-femily C (CFTR/MRP), x95876 sign grand-coulpied receptor 9 X95715 sign prior protein p14-5 prior p14-20-20-20-20-20-20-20-20-20-20-20-20-20-	Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
X67491 3776 Glutamate dehydrogenase 1	X67235 s at	X67235	3773	hematopoletically expressed homeobox	3.17	down	0.0045
X68277 3777 dual specificity phosphatase 1 X68679 3779 complement factor H related 3,complement factor X68733 3781 alpha-1-antichymotrypsin X72012 3789 endoglin (Osler-Rendu-Weber syndrome 1) X72177 3790 complement component 6 X72552 3793 prostatic binding protein X7648 3796 dutaredoxin (thioltransferase) X76717 3797 metallothioneln 1L X77548 3797 metallothioneln 1L X77648 3797 motallothioneln 1L X77648 3797 motallothioneln 1L X77648 3797 motaline acetyltransferase X783706 3801 carnitine acetyltransferase X783716 3801 carnitine acetyltransferase X83618 3811 Gerstmann-Strausler-Scheinker syndrome, fatal 3-hydroxy-3-methylglutaryl-Coenzyme A synthase X836401 3813 2 (mitochondrial) X8516 3814 EST X90579 3819 EST X90579 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 X9148 3821 microsomal triglycaride transfer protein (large X92720 3826 phosphoenolpyruvate carboxykinase 2 X9274 3827 defensin, beta 1 X95384 3831 translational inhibitor protein p14.5 X95384 3833 translational inhibitor protein p14.5 X95387 3836 G protein-coupled receptor 9	X67491 f at	X67491	3776	glutamate dehydrogenase 1	7.45	down	0.00019
X68679 3779 complement factor H related 3,complement factor 3781 alpha-1-antichymotrypsin X72012 3789 andoglin (Osler-Rendu-Weber syndrome 1) X7217 3790 complement component 6 X75252 3793 prostatic binding protein X76105 3794 death-associated protein X76105 3794 death-associated protein X76717 3797 metallothionein 1L X77548 3798 nuclear receptor coactivator 4 X78706 3801 carnitine acetyltransferase X78706 3811 Gertmann-Strausler-Scheinker syndrome, fatal 3-hydroxy-3-methylglutaryl-Coenzyme A synthase X83618 3813 2 (mitochondrial) and X8744 3817 EST x80999 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 X9148 3821 microsomal triglyceride transfer protein (large X9274 3827 defensin, beta 1 X95394 3831 translational inhibitor protein p14.5 X95715 3838 G protein-coupled receptor 9	X68277 at	X68277	3777	dual specificity phosphatase 1	6.68	down	0.0036
X72012 3789 alpha-1-antichymotrypsin		X68679	3779	complement factor H related 3, complement factor	38.22	down	0.00036
X72012 3789 endoglin (Osler-Rendu-Weber syndrome 1)	X68733 rna1 at	X68733	3781	alpha-1-antichymotrypsin	7.87	down	0.03266
x72177 3790 complement component 6 X75252 3793 prostatic binding protein X76105 3794 death-associated protein X7648 3796 glutaredoxin (thioltransferase) X76717 3797 metallothioneln 1L X77548 3798 nuclear receptor coactivator 4 X77892 3801 carnitine acetyltransferase X7892 3802 carnitine acetyltransferase X83416 3814 carnitine acetyltransferase X83618 3813 2 (mitochondrial) S_at X86401 3815 glycine amidinotransferase (L-arginine:glycine X87344 3817 EST X90579 3826 hydroxyacyl glutathione hydrolase; glyoxalase 2 X9148 3821 microsomal triglyceride transfer protein (large X9274 3827 defensin, beta 1 X95384 3831 aranslational inhibitor protein p14.5 X95716 3835 ATP-binding cassette, sub-family C (CFTR/MRP), X95876 3836 G protein-coupled receptor 9	X72012 at	X72012	3789	endoglin (Osler-Rendu-Weber syndrome 1)	4.2	down	0.005
X75252 3793 prostatic binding protein X7648 3794 death-associated protein X7648 3796 glutaredoxin (thioltransferase) X77548 3797 metallothioneln 1L X77548 3798 nuclear receptor coactivator 4 X77548 3799 nuclear receptor coactivator 4 X77548 3799 nuclear receptor coactivator 4 X77549 3801 carnitine acetyltransferase X78992 3802 butyrate response factor 2 (EGF-response factor prion prion prion protein (p27-30) (Creutzfeld-Jakob disease) X83416 3813 Gerstmann-Strausler-Scheinker syndrome, fatal 3-hydroxy-3-methylglutaryl-Coenzyme A synthase X83516 3813 2 (mitochondrial) X85401 3814 erythrocyte membrane protein band 7.2 A86401 3815 glycine amidinotransferase (L-arginine:glycine X87344 381 EST A80579 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 X91448 3821 microsomal triglyceride transfer protein (large X92720 3826 phosphoenolpyruvate carboxykinase 2 <td>- 1</td> <td>X72177</td> <td>3790</td> <td>complement component 6</td> <td>12.94</td> <td>down</td> <td>0.00011</td>	- 1	X72177	3790	complement component 6	12.94	down	0.00011
X76405 3794 death-associated protein X76648 3796 glutaredoxin (thioltransferase) X77574 3797 metallothionein 1L X77548 3798 nuclear receptor coactivator 4 X77806 3801 carnitine acetyltransferase X7892 3802 butyrate response factor 2 (EGF-response factor prion protein (p27-30) (Creutzfeld-Jakob disease, prion prion protein part and prion protein protein part and prion protein part and prion protein part and prion part and protein part and part and protein part and protein part and protein part and protein part and p	X75252 at	X75252	3793	prostatic binding protein	3.78	down	0.00231
X76648 3796 glutaredoxin (thioltransferase) X76717 3797 metallothionein 1L X77548 3798 nuclear receptor coactivator 4 X78706 3801 carnitine acetyltransferase X78992 3802 butyrate response factor 2 (EGF-response factor prion protein (p27-30) (Creutzfeld-Jakob disease, seat X83416 3813 2 (mitochondrial) X85116 3814 erythrocyte membrane protein band 7.2 X86401 3815 glycine amidinotransferase (L-arginine:glycine x87344 3817 EST X90579 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 X91148 3821 microsomal triglyceride transfer protein (large X92720 3826 phosphoenolpyruvate carboxykinase 2 X9274 3827 defensin, beta 1 X95190 3832 acyl-Coenzyme A oxidase 2, branched chain x95190 3833 translational inhibitor protein p14.5 X95715 3835 ATP-binding cassette, sub-family C (CFTR/MRP), x95876 3836 G protein-coupled receptor 9	X76105 at	X76105	3794	death-associated protein	3.02	down	0.00944
X76717 3797 metallothioneln 1L X77548 3798 nuclear receptor coactivator 4 X77806 3801 carnitine acetyltransferase X78992 3802 butyrate response factor 2 (EGF-response factor prion protein (p27-30) (Creutzfeld-Jakob disease, 3814 Gerstmann-Strausler-Scheinker syndrome, fatal 3-hydroxy-3-methylglutaryl-Coenzyme A synthase X8516 3813 2 (mitochondrial) x86401 3813 2 (mitochondrial) x87344 3817 EST X90579 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 X91148 3821 microsomal trighycaride transfer protein (large X92720 3826 phosphoenolpyruvate carboxykinase 2 X9274 3827 defensin, beta 1 X94563 3831 EST X95384 3831 EST X95384 3833 translational inhibitor protein p14.5 X95715 3835 ATP-binding cassette, sub-family C (CFTR/MRP), X95876 3836 G protein-coupled receptor 9	X76648 at	X76648	3796	glutaredoxin (thioltransferase)	4	down	0.00211
X77548 3798 nuclear receptor coactivator 4 X78706 3801 carnitine acetyltransferase X78992 3802 butyrate response factor 2 (EGF-response factor prion protein (p27-30) (Creutzfeld-Jakob disease, prion protein (p27-30) (Creutzfeld-Jakob disease, 3814 Gerstmann-Strausler-Scheinker syndrome, fatal 3-hydroxy-3-methylglutaryl-Coenzyme A synthase X85401 x83416 3813 2 (mitochondrial) x85401 3814 erythrocyte membrane protein band 7.2 x85401 3815 glycine amidinotransferase (L-arginine:glycine and protein band 7.2 x85401 3815 EST x80599 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 x81148 3821 microsomal triglyceride transfer protein (large x8274 x82720 3826 phosphoenolpyruvate carboxykinase 2 x82744 3827 defensin, beta 1 x94563 383 text x95384 3833 translational inhibitor protein p14.5 x95715 3835 ATP-binding cassette, sub-family C (CFTR/MRP), x95876 G protein-coupled receptor 9	X76717 at	X76717	3797	metallothionein 1L	8.09	down	0.00025
X78706 3801 carnitine acety/transferase X78992 3802 butyrate response factor 2 (EGF-response factor prion protein (p27-30) (Creutzfeld-Jakob disease, prion protein (p27-30) (Creutzfeld-Jakob disease, 2814 3814 Gerstmann-Strausler-Scheinker syndrome, fatal 3-hydroxy-3-methylglutaryl-Coenzyme A synthase X85116 3814 erythrocyte membrane protein band 7.2 at X86401 3815 glycine amidinotransferase (L-arginine:glycine X87344 3817 EST X90579 3819 EST X90999 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 X92744 3827 defensin, beta 1 X92744 3827 defensin, beta 1 X95190 3832 acyl-Coenzyme A oxidase 2, branched chain X95384 3833 translational inhibitor protein p14.5 X95715 3835 ATP-binding cassette, sub-family C (CFTR/MRP), X95876 3836 G protein-coupled receptor 9	X77548_at	X77548	3798	nuclear receptor coactivator 4	3.76	down	0.00758
X78992 3802 butyrate response factor 2 (EGF-response factor prion protein (p27-30) (Creutzfeld-Jakob disease, X83416 3811 Gerstmann-Strausler-Scheinker syndrome, fatal 3-hydroxy-3-methylglutaryl-Coenzyme A synthase X83618 3813 2 (mitochondrial) X85116 3814 erythrocyte membrane protein band 7.2 x86401 3815 glycine amidinotransferase (L-arginine:glycine x87344 3817 EST X90999 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 x91148 3821 microsomal triglyceride transfer protein (large X92720 3826 phosphoenolpyruvate carboxykinase 2 x9274 3827 defensin, beta 1 x95790 3832 acyl-Coenzyme A oxidase 2, branched chain X95384 3833 translational inhibitor protein p14.5 x95715 3835 ATP-binding cassette, sub-family C (CFTR/MRP), X95876 3836 G protein-coupled receptor 9	X78706 at	X78706	3801	carnitine acetyltransferase	4.65	down	0.00442
x83416 3811 Gerstmann-Strausler-Scheinker syndrome, fatal 3-hydroxy-3-methylglutaryl-Coenzyme A synthase x85518 3813 2 (mitochondrial) x855116 3814 erythrocyte membrane protein band 7.2 x85516 3814 erythrocyte membrane protein band 7.2 at x855401 3815 glycine amidinotransferase (L-arginine:glycine x87344 3817 EST x90579 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 x91148 3821 microsomal triglyceride transfer protein (large x92720 3826 phosphoenolpyruvate carboxykinase 2 x9274 3827 defensin, beta 1 x94563 3831 EST x95590 3832 acyl-Coenzyme A oxidase 2, branched chain x95596 3835 ATP-binding cassette, sub-family C (CFTR/MRP), x95876 3836 G protein-coupled receptor 9	X78992_at	X78992	3802	butyrate response factor 2 (EGF-response factor	4.69	down	0.01995
x83416 3811 Gerstmann-Strausler-Scheinker syndrome, fatal 3-hydroxy-3-methylglutaryl-Coenzyme A synthase x83618 3813 2 (mitochondrial) x85516 3814 erythrocyte membrane protein band 7.2 x86401 3815 glycine amidinotransferase (L-arginine:glycine at x80579 3819 EST x90599 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 x91148 3821 microsomal triglyceride transfer protein (large x92720 3826 phosphoenolpyruvate carboxykinase 2 x9274 3827 defensin, beta 1 x94563 3831 EST x95190 3832 acyl-Coenzyme A oxidase 2, branched chain x95384 3833 translational inhibitor protein p14.5 x95715 3835 G protein-coupled receptor 9	l			prion protein (p27-30) (Creutzfeld-Jakob disease,			
3-hydroxy-3-methylglutaryl-Coenzyme A synthase X83618 3813 2 (mitochondrial) x85116 3814 erythrocyte membrane protein band 7.2 X86401 3815 glycine amidinotransferase (L-arginine:glycine x87344 3817 EST X90999 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 X91148 3821 microsomal triglyceride transfer protein (large x92720 3826 phosphoenolpyruvate carboxykinase 2 X9274 3827 defensin, beta 1 X94563 3831 EST X95190 3832 acyl-Coenzyme A oxidase 2, branched chain x95190 3833 translational inhibitor protein p14.5 X95384 3835 ATP-binding cassette, sub-family C (CFTR/MRP), x95876 3836 G protein-coupled receptor 9	X83416_s_at	X83416	3811	Gerstmann-Strausler-Scheinker syndrome, fatal	3.28	down	0.00221
x83618 3813 2 (mitochondrial) s_at x85116 3814 erythrocyte membrane protein band 7.2 st x86401 3815 glycine amidinotransferase (L-arginine:glycine r x87344 3817 EST x90579 3819 EST x90999 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 t x9148 3821 t x92720 3826 t x92744 3827 defensin, beta 1 x94563 t x94563 3831 t x95190 3832 t x95384 3833 t x95715 3835 t x95715 3836 g protein-coupled receptor 9				3-hydroxy-3-methylglutaryl-Coenzyme A synthase			
x85116 3814 erythrocyte membrane protein band 7.2 x86401 3815 glycine amidinotransferase (L-arginine:glycine x87344 3817 EST x90579 3819 EST x90699 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 x91148 3821 microsomal triglyceride transfer protein (large x92720 3826 phosphoenolpyruvate carboxykinase 2 t x92744 3827 defensin, beta 1 x94563 3831 EST x955190 3832 acyl-Coenzyme A oxidase 2, branched chain x95515 3835 ATP-binding cassette, sub-family C (CFTR/MRP), x95876 3836 G protein-coupled receptor 9	X83618 at	X83618	3813	2 (mitochondrial)	6.27	down	0.02099
X86401 3815 glycine amidinotransferase (L-arginine:glycine x87344 3817 EST x90579 3819 EST x90599 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 x9148 3821 microsomal triglyceride transfer protein (large x92744 3826 phosphoenolpyruvate carboxykinase 2 x92744 3827 defensin, beta 1 x94563 3831 EST x95190 3832 acyl-Coenzyme A oxidase 2, branched chain x95384 3833 translational inhibitor protein p14.5 x95715 3835 ATP-binding cassette, sub-family C (CFTR/MRP), x95876 3836 G protein-coupled receptor 9	X85116 rna1 s at	X85116	3814	erythrocyte membrane protein band 7.2	6.37	down	0.00356
X87344 3817 EST X90579 3819 EST X90579 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 X90999 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 X9148 3821 microsomal triglyceride transfer protein (large X92720 3826 phosphoenolpyruvate carboxykinase 2 X9274 3827 defensin, beta 1 X94563 3831 EST X95190 3832 acyl-Coenzyme A oxldase 2, branched chain X95384 3833 translational inhibitor protein p14.5 X95715 3836 G protein-coupled receptor 9	X86401 s at	X86401	3815	glycine amidinotransferase (L-arginine:glycine	22.7	down	0
x90579 3819 EST X90999 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 X9148 3821 microsomal triglyceride transfer protein (large X92720 3826 phosphoenolpyruvate carboxykinase 2 X9274 3827 defensin, beta 1 X94563 3831 EST X95190 3832 acyl-Coenzyme A oxldase 2, branched chain X95384 3833 translational inhibitor protein p14.5 X95715 3836 G protein-coupled receptor 9	-	X87344	3817	EST	3.04	down	0.02779
X90999 3820 hydroxyacyl glutathione hydrolase; glyoxalase 2 X91148 3821 microsomal triglyceride transfer protein (large at X92720 3826 phosphoenolpyruvate carboxykinase 2 X9274 3827 defensin, beta 1 X94563 3831 EST X95190 3832 acyl-Coenzyme A oxidase 2, branched chain at X95384 3833 translational inhibitor protein p14.5 X95715 3835 ATP-binding cassette, sub-family C (CFTR/MRP), at X95876 3836 G protein-coupled receptor 9	X90579 s at	X90579	3819	EST	29.82	down	0.00273
X92720 3826 phosphoenolpyruvate carboxykinase 2 X92720 3826 phosphoenolpyruvate carboxykinase 2 X92744 3827 defensin, beta 1 X94563 3831 EST X95190 3832 acyl-Coenzyme A oxidase 2, branched chain X95384 3833 translational inhibitor protein p14.5 X95715 3835 ATP-binding cassette, sub-family C (CFTR/MRP), at X95876 3836 G protein-coupled receptor 9	X90999 at	66606X	3820	hydroxyacyl glutathione hydrolase; glyoxalase 2	5.27	down	0.00047
at X92720 3826 phosphoenolpyruvate carboxykinase 2 at X92744 3827 defensin, beta 1 _r_at X94563 3831 EST at X95190 3832 acyl-Coenzyme A oxidase 2, branched chain at X95384 3833 translational inhibitor protein p14.5 at X95715 3835 ATP-binding cassette, sub-family C (CFTR/MRP), at X95876 3836 G protein-coupled receptor 9	X91148_at	X91148	3821	microsomal triglyceride transfer protein (large	5.91	down	0.00045
x92744 3827 defensin, beta 1 r at x94563 3831 EST at x95190 3832 acyl-Coenzyme A oxidase 2, branched chain at x95384 3833 translational inhibitor protein p14.5 at x95715 3835 ATP-binding cassette, sub-family C (CFTR/MRP), at x95876 3836 G protein-coupled receptor 9	X92720 at	X92720	3826	phosphoenolpyruvate carboxykinase 2	9.7	down	0.00001
Lr_at X94563 3831 EST acyl-Coenzyme A oxidase 2, branched chain 3832 acyl-Coenzyme A oxidase 2, branched chain at X95384 3833 translational inhibitor protein p14.5 at X95715 3835 ATP-binding cassette, sub-family C (CFTR/MRP), at X95876 3836 G protein-coupled receptor 9	X92744 at	X92744	3827	defensin, beta 1	4.96	down	0.01804
x95190 3832 acyl-Coenzyme A oxidase 2, branched chain x95384 3833 translational inhibitor protein p14.5 at x95715 3835 ATP-binding cassette, sub-family C (CFTR/MRP), x95876 3836 G protein-coupled receptor 9	X94563 xpt2 r at	X94563	3831	EST	3.52	down	0.00928
X95384 3833 translational inhibitor protein p14.5 X95715 3835 ATP-binding cassette, sub-family C (CFTR/MRP), X95876 3836 G protein-coupled receptor 9	X95190 at	X95190	3832	acyl-Coenzyme A oxidase 2, branched chain	12.81	down	0
at X95715 3835 ATP-binding cassette, sub-family C (CFTR/MRP), at X95876 3836 G protein-coupled receptor 9	X95384 at	X95384	3833	translational inhibitor protein p14.5	17.69	down	0.00048
at X95876 3836 G protein-coupled receptor 9	X95715 at	X95715	3835	ATP-binding cassette, sub-family C (CFTR/MRP),	6.78	down	0.00045
	X95876_at	X95876	3836	G protein-coupled receptor 9	3.12	down	0.001

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
X96752_at	X96752	3837	L-3-hydroxyacyl-Coenzyme A dehydrogenase,	4.94	down	0.00359
X97324_at	X97324	3839	adipose differentiation-related protein; adipophilin	5.97	down	0.04638
X98337_s_at	X98337	3840	complement factor H related 3, complement factor	13.5	down	0.00001
Y00097_s_at	Y00097	3844	annexin A6	3.4	down	0.00233
Y00317_at	Y00317	3845	UDP glycosyltransferase 2 family, polypeptide B4	18.34	down	0.00001
Y00317_at	Y00317	3845	UDP glycosyltransferase 2 family, polypeptide B4	8.97	down	0.00025
Y00318_at	Y00318	3846	I factor (complement)	10	down	0.00019
Y00339_s_at	Y00339	3847	carbonic anhydrase II	6.89	down	0
Y00451_s_at	Y00451	3848	aminolevulinate, delta-, synthase 1	10.52	down	0.00107
Y08374_rna1_at	Y08374	3853	chitinase 3-like 1 (cartilage glycoprotein-39)	3.5	down	0.04208
Y08409 at	Y08409	3854	thyrold hormone responsive SPOT14 (rat)	5.84	down	0.00455
Y09616_at	Y09616	3857	carboxylesterase 2 (intestine, liver)	18.78	down	0.00026
Y10032 at	Y10032	3858	serum/glucocorticoid regulated kinase	4.24	down	0.00148
Y10659_at	Y10659	3859	interleukin 13 receptor, alpha 1	4.22	down	0.00061
Y10659_at	Y10659	3859	interleukin 13 receptor, alpha 1	3.17	down	0.00095
Y12711_at	Y12711	3861	progesterone binding protein	14.83	down	0.00285
Z11559_at	Z11559	3862	iron-responsive element binding protein 1	4.3	down	0.00066
Z11737_at	Z11737	3863	flavin containing monooxygenase 4	3.84	down	0.00043
Z11737 at	Z11737	3863	flavin containing monooxygenase 4	3.67	down	0.00632
Z11793_at	Z11793	3864	selenoprotein P, plasma, 1	9.94	down	0.00021
			branched chain keto acid dehydrogenase E1,			
Z14093_at	Z14093	3865	alpha polypeptide (maple syrup urine disease)	3.24	down	0.00301
Z20777_at	Z20777	3866	EST	29.59	down	0.00044
Z24459_rna1_at	Z24459	3869	mature T-cell proliferation 1	5.29	down	0.00001
Z24725_at	Z24725	3870	mitogen inducible 2	7.9	down	0
Z26491_s_at	Z26491	3873	catechol-O-methyltransferase	3.08	down	0.00877
			aldo-keto reductase family 1, member D1 (delta 4.			
Z28339_at	Z28339	3875	3-ketosteroid-5-beta-reductase)	24.66	down	0
Z29481_at	Z29481	3877	3-hydroxyanthranilate 3,4-dioxygenase	6.39	down	0.00029
Z29481_at	Z29481	3877	3-hydroxyanthranllate 3,4-dioxygenase	3.64	down	96000.0
Z30425_at	Z30425	3878	nuclear receptor subfamily 1, group I, member 3	26.64	down	0

Table 6B. Down regulated in metastatic cancers versus normal sample set 2.

Affy ID	Genbank	Sea ID	Known Gene Name	Fold Change	Direction	Division
Z30425_at	Z30425	3878	nuclear recept	7.88		0 0000
Z31357_at	Z31357	3880	cystelne dioxygenase, type I	11.2	down	0.0001
Z31690_s_at	Z31690	3881	lipase A, lysosomal acid, cholesterol esterase	3.83	down	0.00103
rc_Z38161_at	Z38161	3884	EST	4.38	down	0.0011
rc_Z38192_s_at	Z38192	3885	EST	3.35	down	0.00184
rc_Z38435_at	Z38435	3890	ribosomal protein L21	3.12	down	0.03617
rc_Z38777_f_at	Z38777	3895	nuclear receptor binding factor-2	3.28	down	0.022
rc_Z39059_at	Z39059	3899	EST	5.19	down	0.0014
rc_Z39406_at	Z39406	3905	nuclear receptor co-repressor 1	4.18	down	0.00439
rc_Z39431_at	Z39431	3907	KIAA1086 protein	3.68	down	0.0013
rc_Z39476_at	Z39476	3908	EST	5.9	down	0.00687
rc_z39622_s_at	Z3962Z	3910	EST	4.4	down	0.00001
rc_Z39818_at	Z39818	3912	EST	3.26	down	0.00089
rc_Z39833_at	Z39833	3913	GTP-binding protein	16.89	down	0.00034
rc_Z39976_at	Z39976	3915	EST	5.76	down	0.00012
rc_Z39978_at	Z39978	3916	EST	3.56	down	0.04051
rc_Z40192_at	240192	3918	EST	3.89	down	0.00223
rc_Z40259_s_at	Z40259	3919	EST	8.18	down	0.00002
rc_Z40305_at	Z40305	3920	EST	6.45	down	0.00001
rc_Z40715_at	240715	3923	delta-6 fatty acid desaturase	18.68	down	0.0007
rc_Z40902_at	Z40902	3926	SEC14 (S. cerevisiae)-like 2	12.87	down	0.00001
rc_Z41042_at	Z41042	3928	EST	3.63	down	0.00943
Z47553_at	Z47553	3939	flavin containing monooxygenase 5	6.17	down	0.00011
Z48199_at	Z48199	3942	syndecan 1	4.43	down	0.00408
Z48475_at	Z48475	3943	glucokinase (hexokinase 4) regulatory protein	13.84	down	0
Z49269_at	Z49269	3945	small inducible cytokine subfamily A (Cys-Cys),	18.46	down	0.00001
Z49878_at	Z49878	3946	guanidinoacetate N-methyltransferase	13.96	down	0.00021
Z69923_at	Z69923	3948	HGF activator	11.37	down	0.00053
Z80345_rna1_s_at	Z80345	3951	acyl-Coenzyme A dehydrogenase, C-2 to C-3	5.93	down	0.0024
	Z84718	3952	EST	3.26	down	0.02252
Z84721_cds2_at	284721	3953	hemoglobin, zeta	8.77	down	0.01446

Table 7A. Up reglated in hepatocellular carcinoma versus normal sample set 2.

															•				
		on Pvalue	_			0.01801 0.02387	0.00968 0.03807	0.00997	0.00023	0.01313	0.01569	0.00087	0.0349 0 00503	0.02055	0.03035 0.02774	0.01108	0.00567 0.0347E	0.01058	0.03495 0.00508
	- 1	의	down	down	down	uwob down	down	down	down	down	down	down	down	down	_	down			_
	Fold	5.51	5.56	5.71 25.52	5.28	7.97	5.33	3.84 3.05	4.77	3.06 6.63	3.07 3.24	10.88 3.85	4.65	3.31 4.74	3.03	6.59	4.18 4.36	3.75 4.03	3.45 3.19
	Seq 10 14 14	19	_ ,	40 core months	79 aldehyde oxidase 1 80 FST	-		114 EST 141 EST		~		171 EST Consideralike 2		190 superoxide dismutase 2, mitochondrial	206 EST Protein S6			306 EST 317 DKFZP586A0522 prodol-	
Gonhari						AA039335 AA039616	AA046457 AA046747	AA056482	AA057678 AA069696	AA070191	AA076326 AA076386	AA084668	AA085987 AA090257	AA090439	10				
Affy ID	rc_AA005358_at rc_AA007395_s_at	rc_AA010205_at	rc_AA010619_at	rc_AA035245 s_at	ه اثار	rc_AA039616_at	rc_AA046747_at	rc_AA057678_at	rc_AA069696_at	rc_AA074885_at	rc_AA076326_at rc_AA076383_at	rc_aa084668_at rc_AA085987_st	AA090257_at	AA090439_at rc_AA099225_at	rc_AA100026_at	rc_AA122345 f at	rc_AA129390_at	rc_aa147646_s_at	

Table 7A. Up reglated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_AA150776_at	AA150776	330	EST	6.17	down	0.00004
rc_AA151676_at	AA151676	337	peptidyl arginine deiminase, type II	3.85	down	0.00875
			aldo-keto reductase family 7, member A2 (aflatoxin			
rc_AA157799_at	AA157799	348	aldehyde reductase)	3.08	down	0.00207
rc_AA164586_s_at	AA164586	359	estrogen receptor 1	3.56	down	0.01231
rc_AA167565_at	AA167565	362	EST	3.81	down	0.04057
rc_AA172372_at	AA172372	370	EST	5.12	down	0.00032
rc_AA182030_at	AA182030	387	EST	3.51	down	0.0403
AA188921_at	AA188921	393	similar to Caenorhabditis elegans protein C42C1.9	3.38	down	0.00862
rc_AA194997_s_at	AA194997	412	EST	4.8	down	0.00153
rc_AA196287_at	AA196287	420	EST	4.86	down	0.01656
rc_AA210850_at	AA210850	431	EST	3.12	down	0.00288
rc_AA223902_at	AA223902	450	EST	4.22	down	0.01315
rc_AA232114_s_at	AA232114	463	epoxide hydrolase 2, cytoplasmic	6.18	down	0.00231
rc_AA233152_at	AA233152	467	EST	5.8	down	0.00272
rc_AA233837_at	AA233837	474	EST	3.46	down	0.01365
rc_AA235310_at	AA235310	496	EST	7.08	down	0.04056
rc_AA236401_at	AA236401	510	EST	5.31	down	0.01787
rc_AA236455_r_at	AA236455	512	EST	6.73	down	0.02418
	AA236455	512	EST	5.1	down	0.00307
rc_AA253216_at	AA253216	56.1	EST	4.14	down	0.0014
rc_AA253369_s_at	AA253369	563	EST	5.64	down	0.00478
rc_AA256367_s_at	AA256367	579	paraoxonase 3	8.37	down	0.02326
rc_AA258350_at	AA258350	592	EST	4.1	down	0.02962
rc_AA279676_s_at	AA279676	630	deoxyribonuclease I-like 3	10.52	down	0.00181
rc_AA282061_at	AA282061	652	KIAA0962 protein	3.46	down	0.00698
rc_AA282886_at	AA282886	663	EST	3.29	down	0.00025
rc_AA284795_at	AA284795	678	phosphatidylethanolamine N-methyltransferase	2.7	down	0.00004
rc_AA285053_at	AA285053	681	EST	2	down	0.00718
rc_AA287122_at	AA287122	989	EST	5.21	down	0.00523
rc_AA287566_at	AA287566	069	KIAA0187 gene product	6.99	down	0.00023

Table 7A. Up reglated in hepatocellular carcinoma versus normal sample set 2.

rc_AA291749_s_at rc_AA297532_f_at rc_AA343142_at		<u> </u>	Known Gene Name		Direction	Pvalue
rc_AA297532_f_at rc_AA343142_at	AA291749	703	estrogen receptor 1	5.06	down	0.00044
rc AA343142 at	AA297532	725	EST	5.01	down	0.00745
	AA343142	751	EST	5.79	down	0.02747
	-		fatty-acid-Coenzyme A ligase, long-chain 1,fatty-acid-			
rc_AA348922_s_at	AA348922	758	Coenzyme A Ilgase, long-chain 2	11.4	down	0.00848
AA376875_at	AA376875	770	monoamine oxidase A	3.45	down	0.00105
rc_AA377087_at	AA377087	771	EST	4.61	down	0.01616
AA397841_at	AA397841	780	EST	3.29	down	0.00825
rc_AA398892_at	AA398892	800	similar to yeast BET3 (S. cerevisiae)	4.33	down	0.01326
AA400177_at	AA400177	808	EST	3.21	down	0.03901
rc_AA401376_at	AA401376	829	EST	3.39	down	0.01403
rc_AA401562_s_at	AA401562	830	EST	7.97	down	0.00527
rc_AA402224_at	AA402224	836	growth arrest and DNA-damage-inducible, gamma	3.66	down	0.0033
rc_AA404487_at	AA404487	851	EST	3.01	down	0.0059
rc_AA417046_at	AA417046	915	fatty-acid-Coenzyme A ligase, very long-chain 1	8.49	down	0.02476
			small inducible cytokine subfamily B (Cys-X-Cys),			
rc_AA426640_at	AA426640	696	member 14 (BRAK)	4.8	down	0.00539
rc_AA428325_at	AA428325	988	EST	4.09	down	0.02486
rc_AA433946_at	AA433946	1033	EST	10.24	down	0.00663
rc_AA435746_f_at	AA435746	1043	GTPase activating protein-like	4.21	down	0.03192
rc_AA435985_at	AA435985	1049	EST	3.86	down	0.01713
AA442334_at	AA442334	1069	EST	3.02	down	0.01936
rc_AA446864_at	AA446864	1095	EST	11.57	down	0.0001
rc_AA448002_at	AA448002	1113	putative type II membrane protein	14.14	down	0
			FXYD domain-containing ion transport regulator 1			
rc_AA448300_at	AA448300	1116	(phospholemman)	9.27	down	0.00108
rc_AA450114_at	AA450114	1131	EST	3.29	down	0.01171
rc_AA450127_at	AA450127	1132	growth arrest and DNA-damage-inducible, beta	3.37	down	0.00647
rc_AA453988_at	AA453988	1160	methionine adenosyltransferase I, alpha	7.78	down	0.02695
rc_AA454733_s_at	AA454733	1169	EST	5.73	down	0.00748
rc_AA455367_at	AA455367	1176	DKFZP586F1018 protein	3.47	down	0.00138

Table 7A. Up reglated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
			butyrobetaine (gamma), 2-oxoglutarate dioxygenase			
rc_AA455988_at	AA455988	1184	(gamma-butyrobetaine hydroxylase)	12.51	down	0
rc_AA458652_at	AA458652	1202	EST	5.03	down	0.00065
l			solute carrier family 22 (extraneuronal monoamine			
rc AA460012 at	AA460012	1224	transporter), member 3	3.73	down	0.0313
rc_AA460449_at	AA460449	1228	EST	3.53	down	0.01247
rc_AA460661_at	AA460661	1229	EST	5.46	down	0.00151
rc_AA461444_at	AA461444	1239	EST	3.19	down	0.02844
rc AA465233 s at	AA465233	1269	succinate-CoA ligase, GDP-forming, beta subunit	3.19	down	0.00036
rc_AA477119_at	AA477119	1289	EST	4.62	down	0.00072
AA477919 at	AA477919	1293	EST	3.9	down	0.00265
rc AA478298 s at	AA478298	1297	adipose specific 2	5.29	down	0.00943
rc AA480991 s at	AA480991	1323	EST	4.83	down	0.03498
AA486511_at	AA486511	1349	EST	3.9	down	0.01409
rc_AA490620_at	AA490620	1378	EST	6.25	down	0.03613
rc_AA599472_at	AA599472	1451	succinate-CoA ligase, GDP-forming, beta subunit	3.31	down	0.02619
rc_AA599814_at	AA599814	1456	EST	4.09	down	0.00235
rc_AA599937_s_at	AA599937	1458	insulin-like growth factor-binding protein 4	6.31	down	0.0477
rc AA608802 at	AA608802	1470	EST	3.44	down	0.01709
rc_AA608837_at	AA608837	1472	EST	5.15	down	0.00005
rc_AA609519_at	AA609519	1482	EST	5.23	down	0.00068
rc AA609537 s at	AA609537	1483	hepatic leukemia factor	4.88	down	0.00118
rc AA621131 at	AA621131	1513	EST	4.57	down	0.03867
rc_AA621209_at	AA621209	1516	similar to Caenorhabditis elegans protein C42C1.9	4.01	down	0.00563
C02386 s at	C02386	1561	hypothetical protein	3.66	down	0.00673
C02460 at	C02460	1562	EST	3.92	down	0.03073
rc C20653 at	C20653	1578	EST	4.32	down	. 0.00718
rc C20810 at	C20810	1579	EST	3.57	down	0.02116
rc_C21130_at	C21130	1583	EST	3.24	down	0.03355
l I			cytochrome P450, subfamily IIIA (niphedipine oxidase),	,	-	
D00003_at	D00003	1586	polypeptide 3	9.46	down	0.00001

Table 7A. Up reglated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
			cytochrome P450, subfamily IIIA (niphedipine oxidase),			
D00003_s_at	D00003	1586	polypeptide 3	6.8	down	0.01328
			cytochrome P450, subfamily IIIA (niphedipine oxidase),			
			polypeptide 3, cytochrome P450, subfamily IIIA			
			(niphedipine oxidase), polypeptide 5, cytochrome P450,			
D00408 s at	D00408	1589	subfamily IIIA, polypeptide 7	3.58	down	0.02048
D10040 at	D10040	1593	fatty-acid-Coenzyme A ligase, long-chain 2	4.15	down	0.02947
rc_D11756_f at	D11756	1596	EST	4.08	down	0.02972
i i			cytochrome P450, subfamily IVF, polypeptide			
			2, cytochrome P450, subfamily IVF, polypeptide 3			
D12620_s_at	D12620	1601	(leukotriene B4 omega hydroxylase)	6.03	down	0.03947
] 			cytochrome P450, subfamily IVF, polypeptide			
			2, cytochrome P450, subfamily IVF, polypeptide 3			-
D12620 s at	D12620	1601	(leukotriene B4 omega hydroxylase)	4.7	down	0.04091
D13243 s at	D13243	1602	pyruvate kinase, liver and RBC	5.58	down	0.04029
D13705_s_at	D13705	1610	cytochrome P450, subfamily IVA, polypeptide 11	3.3	down	0.0051
D14012 s at	D14012	1612	HGF activator	7.27	down	0.00145
D31628 s at	D31628	1646	4-hydroxyphenylpyruvate dloxygenase	13.18	down	0.02064
rc D45529 at	D45529	1662	EST	3.01	down	0.03105
D49357_at	D49357	1665	methionine adenosyltransferase I, alpha	4.85	down	0.04435
rc_D62518_at	D62518	1708	EST	5.96	down	0.00027
ļ			ficolin (collagen/fibrinogen domain-containing lectin) 2			
D63160_at	D63160	1709	(hucolin)	3.72	down	0.00312
D78011_at	D78011	1717	dihydropyrimidinase	5.54	down	0.0312
D78725 at	D78725	1720	KIAA0914 gene product	3.19	down	0.01083
D79276_at	D79276	1722	succinate-CoA ligase, GDP-forming, beta subunit	4.34	down	0.00836
D90042_at	D90042	1767	N-acetyltransferase 2 (arylamine N-acetyltransferase)	3.79	down	0.00697
rc_F02028_at	F02028	1774	EST	3.15	down	0.00902
rc F02245 at	F02245	1776	monoamine oxidase A	3.51	down	0.01692
1			matrix metalloproteinase 2 (gelatinase A, 72kD			
rc_F03969_at	F03969	1785	gelatinase, 72kD type IV collagenase)	3.36	down	0.01685

Table 7A. Up reglated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_H02855_at	H02855	1832	EST	4.29	down	0.0138
rc_H05704_s_at	H05704	1848	EST	3.07	down	0.00363
rc_H06935_s_at	H06935	1855	electron-transferring-flavoprotein dehydrogenase	4.04	down	0.01498
rc_H08102.at	H08102	1858	breast cell glutaminase	12.85	down	0.0424
rc_H09317_at	H09317	1864	EST	3.2	down	0.00914
			methylenetetrahydrofolate dehydrogenase (NADP+			
			dependent), methenyltetrahydrofolate cyclohydrolase,			
rc H10779 s at	H10779	1872	formyltetrahydrofolate synthetase	3.09	down	0.0496
rc H20543 at	H20543	1897	DKFZP586B1621 protein	13.06	down	0.00218
rc_H27330_at	H27330	1909	EST	3.37	down	0.01318
rc H29568 at	H29568	1914	EST	5	down	0.00426
rc_H55759_at	H55759	1949	EST	4.36	down	0.0398
rc_H57060_s_at	H57060	1954	EST	7.57	down	0.00875
rc_H57816_at	H57816	1957	EST	3.09	down	0.01327
rc_H58673_at	H58673	1959	EST	15.49	down	0.00002
rc_h58692_s_at	H58692	1960	formyitetrahydrofolate dehydrogenase	20.18	down	0.00485
rc_H59136_at	H59136	1962	EST	6.63	down	0.00033
rc_H62212_at	H62212	1969	telomeric repeat binding factor 2	3.23	down	0.00513
H66367_at	H66367	1977	EST	3.84	down	0.00133
rc_H66840_at	H66840	1978	EST	3.34	down	0.01884
rc_H77597_f_at	H77597	2000	metallothionein 1H	9.01	down	0.00022
			ficolin (collagen/fibrinogen domain-containing) 3 (Hakata			
rc_H80901_s_at	H80901	2005	antigen)	18.59	down	0
rc_H81070_f_at		2006	RNA helicase-related protein	39.64	down	0.00002
rc_H87765_at	H87765	2017	KIAA0626 gene product	3.94	down	0.00123
H93246 s at	H93246	2035	EST	4.14	down	0.00058
rc_H93381_at	H93381	2036	EST	8.62	down	0.01271
rc_H99727_at	H99727	2080	adipose differentiation-related protein; adipophilin	3.91	down	0.00325
HG1428-HT1428 s at HG1428-HT1428	HG1428-HT1428		hemoglobin, beta	8.98	down	0.02071
HG2379-HT3996 s at HG2379-HT3996	HG2379-HT3996		serine hydroxymethyltransferase 1 (soluble)	3.81	down	0.01837
HG2730-HT2827_s_at HG2730-HT28	HG2730-HT2827		fibrinogen, A alpha polypeptide	3.84	down	0.00795

Table 7A. Up reglated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
HG2730-HT2828 s at HG2730-HT2828			fibrinogen, A alpha polypeptide	3.62		0.01013
HG2841-HT2968_s_at HG2841-HT2968	HG2841-HT2968		albumin	4.62	down	0.00552
HG4533-HT4938_at	HG4533-HT4938		protease inhibitor 4 (kallistatin)	3.35	down	0.01605
J02843_at	J02843	2088	cytochrome P450, subfamily IIE (ethanol-inducible)	6.18	down	0.01308
			solute carrier family 2 (facilitated glucose transporter),			
J03810_at	J03810	2099	member 2	3.6	down	0.02376
J03910 rna1 at	J03910	2101	EST	18.13	down	0.00119
J04093 s at	J04093	2106	UDP glycosyltransferase 1	3.28	down	0.02286
1			cytochrome P450, subfamily IIIA (niphedipine oxidase),			
J04449_at	J04449	2110	polypeptide 3	5.07	down	0.01733
J05158 at	J05158	2117	carboxypeptidase N, polypeptide 2, 83kD	3.37	down	0.01156
J05428_at	J05428	2120	UDP glycosyltransferase 2 family, polypeptide B7	4.86	down	0.03414
l			coagulation factor IX (plasma thromboplastic component,			
K02402_at	K02402	2125	Christmas disease, hemophilia B)	6.64	down	0.04082
K02766 at	K02766	2126	complement component 9	5.03	down	0.0433
Ī			cytochrome P450, subfamily IIA (phenobarbital-inducible),			
K03192_f_at	K03192	2127	polypeptide 6	14.19	down	0.0307
Į Į			cytochrome P450, subfamily IIA (phenobarbital-inducible),			
K03192_f_at	K03192	2127	polypeptide 6	8.02	down	0.03483
			low density lipoprotein receptor (familial			
L00352_at	L00352	2131	hypercholesterolemia)	3.3	down	0.03487
			cytochrome P450, subfamily I (aromatic compound-			
L00389_f_at	L00389	2132	inducible), polypeptide 2	3.87	down	0.00844
L04751 at	L04751	2138	cytochrome P450, subfamily IVA, polypeptide 11	8.13	down	0.02065
L05144_at	L05144	2139	phosphoenolpyruvate carboxykinase 1 (soluble)	4	down	0.021
l			fatty-acid-Coenzyme A ligase, long-chain 1, fatty-acid-			
L09229_s_at	L09229	2150	Coenzyme A ligase, long-chain 2	4.5	down	0.01347
L11931_at	L11931	2159	serine hydroxymethyltransferase 1 (soluble)	3.74	down	0.0056
L12760_s_at	L12760	2162	phosphoenolpyruvate carboxykinase 1 (soluble) cytochrome P450, subfamily IIC (mephenytoin 4-	90.9	down	0.01005
L16883_s_at	L16883	2166	hydroxylase), polypeptide 9	5.85	down	0.04368

Table 7A. Up reglated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
			solute carrier family 10 (sodium/bile acid cotransporter			
L21893_at	L21893	2176	family), member 1	5.23	down	0.03367
L27050 at	127050	2186	apolipoprotein F	4.18	down	0.04901
L32140_at	L32140	2192	afamin	5.39	down	0.02767
M10942_at	M10942	2233	metallothionein 1E (functional)	4.05	down	0.01412
M10943 at	M10943	2234	metallothionein 1F (functional)	6.23	down	0.00007
M13143_at	M13143	2249	kallikrein B plasma, (Fletcher factor) 1	3.04	down	0.008
M14777 s at	M14777	2263	glutathione S-transferase A2, glutathione S-transferase A3	13.23	down	0.03224
M16594 at	M16594	2272	glutathione S-transferase A2	5.42	down	0.03813
M16750 s at	M16750	2273	pim-1 oncogene	3.07	down	0.02391
M16974_s_at	M16974	2277	complement component 8, alpha polypeptide	10.85	down	0.02313
M25079_s_at	M25079	2305	hemoglobin, beta	4.31	down	0.01567
M26393_s_at	M26393	2309	acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain	4.3	down	0.02294
M29873_s_at	M29873	2318	cytochrome P450, subfamily IIB (phenobarbital-inducible)	17.92	down	0.01469
M29874 s at	M29874	2319	cytochrome P450, subfamily IIB (phenobarbital-inducible)	8.13	down	0.01064
M30185 at	M30185	2321	cholesteryl ester transfer protein, plasma	3.82	down	0.00131
M30185_at	M30185	2321	cholesteryl ester transfer protein, plasma	3.31	down	0.00109
			cytochrome P450, subfamily I (aromatic compound-			
M31667_f_at	M31667	2331	inducible), polypeptide 2	4.47	down	0.01116
			cytochrome P450, subfamily IIA (phenobarbital-inducible),			
M33317_f_at	M33317	2338	polypeptide 7	11.47	down	0.02611
M34276_at	M34276	2341	plasminogen	3.08	down	0.02754
M57731_s_at	M57731	2359	GRO2 oncogene	3.16	down	0.02204
l I			cytochrome P450, subfamily IIC (mephenytoin 4-			
M61854_s_at	M61854	2370	hydroxylase)	3.45	down	0.02949
M63967_at	M63967	2378	aldehyde dehydrogenase 5	3.88	down	0.00274
M68840_at	M68840	2388	monoamine oxidase A	3.1	down	0.01953

Table 7A. Up reglated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
M68895_rna1_at	M68895	2390	alcohol dehydrogenase 6 (class V)	3.21	down	0.02095
M72885_rna1_s_at	M72885	2393	putative lymphocyte G0/G1 switch gene	3.34	down	0.02943
M76665_at	M76665	2398	hydroxysteroid (11-beta) dehydrogenase 1	90.9	down	0.01317
M81349_at	M81349	2405	serum amyloid A4, constitutive	10.97	down	0.01946
M83652_s_at	M83652	2408	properdin P factor, complement	ဖ	down	0.00002
M83772_at	M83772	2409	flavin containing monooxygenase 3	5.14	down	0.02023
			insulin-like growth factor binding protein, acid labile			
M86826_at	M86826	2413	subunit	3.75	down	0.01157
M93405_at	M93405	2424	methylmalonate-semialdehyde dehydrogenase	3.09	down	0.03285
M94065_s_at	M94065	2425	dihydroorotate dehydrogenase	7.87	down	0.0011
M94065_at	M94065	2425	dihydroorotate dehydrogenase	3.61	down	0.00229
M95585 s at	M95585	2430	hepatic leukemia factor	3.36	down	0.00492
i			transducin-like enhancer of split 4, homolog of Drosophila			
M99439_at	M99439	2438	E(sp1)	4.82	down	0.00121
rc_N22404_at	N22404	2450	EST	3.44	down	0.02267
rc_N22938_s_at	N22938	2453	serum amyloid A4, constitutive	4.91	down	0.01918
rc_N29353_at	N29353	2477	kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)	3.44	down	0.01212
rc_N29764_at	N29764	2482	EST	4.48	down	0.013
rc_N31741_at	N31741	2489	serine hydroxymethyltransferase 1 (soluble)	5.66	down	0.00212
rc_N34804_at	N34804	2497	DKFZP434J214 protein	3.97	down	0.0175
rc_N39163_at	N39163	2509	metallothionein 1L	4.3	down	0.03917
rc_N39201_at	N39201	2510	protease inhibitor 4 (kallistatin)	4.79	down	0.02015
rc_N49902_at	N49902	2540	EST	3.02	down	0.00951
rc_N51117_at	N51117	2544	EST	8.17	down	0.00105
rc_N51773_at	N51773	2549	EST	6.92	down	0.01839
			LIM protein (similar to rat protein kinase C-binding			
rc_N52271_at	N52271	2552	enigma)	3.67	down	0.01102
rc_N52322_at	N52322	2553	EST	4.58	uwop .	0.02077
rc_N54053_at	N54053	2561	secreted phosphoprotein 2, 24kD	12.87	down	0.01821
rc_N54417_s_at	N54417	2567	fibrinogen, A alpha polypeptide	6.47	down	0.00733

Table 7A. Up reglated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank Seq ID	ID Known Gene Name	Fold Change	Direction	Pvalue
rc_N54429_at	N54429 2568	88 EST	6.85	down	0.03334
rc_N54950_s_at		73 ketohexokinase (fructokinase)	6.47	down	0.0223
N57464_at	N57464 2576	76 CCAAT/enhancer binding protein (C/EBP), delta	4.87	down	0.00111
rc_N57934_s_at		77 formiminotransferase cyclodeaminase	3.28	down	0.01555
rc_N58009_at		78 formiminotransferase cyclodeaminase	8.52	down	0.01808
rc_N59550_at	N59550 2588		4.78	down	0.02924
rc_N63391_at	N63391 2600	00 EST	3.87	down	0.02935
rc_N63845_at	N63845 2605	35 phytanoyl-CoA hydroxylase (Refsum disease)	6.82	down	0.00369
		enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A			
rc_N64036_s_at			6.12	down	0.00476
rc_N65959_at			3.38	down	0.00785
rc_N66066_at	N66066 2613	13 EST	4.33	down	0.0184
rc_N67105_at		24 EST	4.69	down	0.00194
rc_N68596_s_at			10.46	down	0.01971
rc_N70358_s_at	N70358 2657	57 growth hormone receptor	8.47	down	0.00816
		solute carrier family 10 (sodium/bile acid cotransporter			
rc_N70966_s_at	N70966 2663	33 family), member 1	10.8	down	0.02894
rc_N73543_at	N73543 2675		4.64	down	0.03981
rc_N74025_at	N74025 2685	35 deiodinase, lodothyronine, type I	8.18	down	0.01363
N77326_at		36 EST	4.08	down	0.00768
rc_N80129_i_at		33 metallothionein 1L	26.87	down	0.00999
rc_N80129_f_at	N80129 2703		11.48	down	0.00167
rc_N90584_at			3.36	down	0.01561
N91087_at		17 EST	3.66	down	0.00725
N99542_at	N99542 2747	-	3.53	down	0.00607
rc_R01023_s_at			4.56	down	0.04036
rc_R08564_at			8.77	down	0.01284
rc_R09053_at			3.45	down	0.03074
rc_R12472_at			12.09	down	0.02379
rc_R22905_at			4.31	down	0.01744
rc_R40395_s_at	R40395 2841	11 lecithin-cholesterol acyltransferase	12.85	down	0.01334

Table 7A. Up reglated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank Seq ID	ID Known Gene Name	Fold Change	Direction	Pvalue
rc_R40492_at	R40492 2842	2 EST	6.4	down	0.00527
rc_R40899_f_at	R40899 2844		4.84	down	0.02369
rc_R43799_at	R43799 2851		3.93	down	0.005
rc_R49602_at	R49602 2885	5 EST · ·	16.17	down	0.00279
rc_R59722_at	R59722 2916	6 EST	6.24	down	0.02361
rc_R65593_s_at	R65593 2935	5 kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)	9:9 (9:	down	0.01982
rc_R66002_at	R66002 2936		4.33	down	0.00789
R69417_at	R69417 2942		6.43	down	0.00778
rc_R73816_at	R73816 2961	1 EST	7.05	down	0.01287
R77628_at			5.51	down	0.0404
R79750_at			4.89	down	0.00695
R80048_at	R80048 2972	_	3.61	down	0.01209
rc_R89811_s_at	R89811 2980	0 HGF activator	13.29	down	0.00148
rc_R92475_s_at		7 flavin containing monooxygenase 3	6.46	down	0.02269
rc_R93714_at	R93714 2992	2 fetuin B	4.65	down	0.03704
R93776_s_at	R93776 2993		5.55	down	0.00084
rc_R94674_s_at	R94674 2996	6 EST	4.58	down	0.0047
		cytochrome P450, subfamily VIIIB (sterol 12-alpha-			
rc_R97419_at	R97419 3004	4 hydroxylase), polypeptide 1	19.3	down	0.00807
R98073_at	R98073 3009		8.37	down	0.01436
rc_R99591_at	R99591 30	3016 CD5 antigen-like (scavenger receptor cysteine rich family) aldo-keto reductase family 1, member C4 (chlordecone reductase: 3-albha hydroxysteroid dehydrogenase tyne l	lly) 7.41	down	0.00043
S68287_at	S68287 3	3025 dihydrodiol dehydrogenase 4)	5.04	down	0.02895
S70004_at	S70004 3	3029 glycogen synthase 2 (liver)	5.13	down	0.00183
S77356_at	S77356 3	3034 EST	3.55	down	0.03874
rc_t10264_s_at	T10264 3051	11 EST	3.26	down	0.01718
rc_T16484_s_at	T16484 3071		4.78	down	0.0000
rc_T40936_at	T40936 3	3118 EST	4.62	down	0.02844

Table 7A. Up reglated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_T40995_f_at	T40995	3119	alcohol dehydrogenase 3 (class I), gamma polypeptide	3.42	down	0.00957
rc_T41047_s_at	T41047	3120	EST	3.08	down	0.00553
rc_T41232_at	T41232	3122	EST	3.14	down	0.02012
rc_T47778_s_at	T47778	3127	fibrinogen, A alpha polypeptide	3.33	down	0.00637
rc_T48075_f_at	T48075	3130	hemoglobin, alpha 1	35.75	down	0.00471
rc_T48278_at	T48278	3132	EST	24.1	down	0.00595
rc_T51150_at	T51150	3137	EST	8.65	down	0.00553
			solute carrier family 22 (extraneuronal monoamine			
rc_T51617_at	T51617	3138	transporter), member 3	6.16	down	0.04198
rc_T52813_s_at	T52813	3142	putative lymphocyte G0/G1 switch gene	5.4	down	0.02021
rc_T56281_f_at	T56281	3151	RNA helicase-related protein	14.64	down	0.00027
T57140_s_at	T57140	3152	paraoxonase 3	8.47	down	0.01048
rc_T58756_at	T58756	3156	EST	16.61	down	0
rc_T61256_s_at	T61256	3162	ketohexokinase (fructokinase)	3.56	down	0.04957
rc_T61649_f_at	T61649	3165	superoxide dismutase 2, mitochondrial	4.08	down	0.0389
			ficolin (collagen/fibrinogen domain-containing) 3 (Hakata			
rc_T63364_at	T63364	3170	antigen)	6.27	down	0.00455
rc_T64575_s_at	T64575	3172	EST	3.16	down	0.01855
rc_T67931_at	T67931	3184	fibrinogen, B beta polypeptide	17.25	down	0.00128
T68510_at	T68510	3187	EST	3.19	down	0.01504
rc_T68711_at	T68711	3188	EST	35.98	down	0.0003
rc_T68873_f_at	T68873	3190	metallothionein 1L	13.68	down	0.00593
			carboxylesterase 1 (monocyte/macrophage serine			
rc_T68878_f_at	T68878	3191	esterase 1)	4.18	down	0.02474
rc_T69305_at	T69305	3197	EST	15.87	down	0.02258
rc_T72502_at	T72502	3208	EST	4.74	down	0.00404
rc_T72906_at	T72906	3210	EST	4.91	down	0.00512
rc_T74542_s_at	T74542	3215	UDP glycosyltransferase 2 family, polypeptide B10	7.19	down	0.011
rc_T74608_at	T74608	3216	_	6.1	down	0.00249
rc_T78433_s_at	T78433	3220	glycogen synthase 2 (liver)	5.74	down	0.00949
T83397_at	T83397	3233	phytanoyl-CoA hydroxylase (Refsum disease)	8.03	down	0.02173

Table 7A. Up reglated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_T87174_at	T87174	3240	EST	3.46	down	0.00026
T95813_f_at	T95813	3262	KIAA1051 protein	20.36	down	0.01361
rc_T98199_i_at	T98199	3267	EST	4.05	down	0.00753
rc_T98676_at	T98676	3269	EST	11.15	down	0.0323
U02388_at	U02388	3278	cytochrome P450, subfamily IVF, polypeptide 2	4.4	down	0.00761
U06641_s_at	U06641	3287	UDP glycosyltransferase 2 family, polypeptide B15	6.37	down	0.01594
U08006_s_at	900800	3290	complement component 8, alpha polypeptide	3.96	down	0.04272
U08021_at	U08021	3291	nicotinamide N-methyltransferase	3.63	down	0.03726
U20530_at	U20530	3322	secreted phosphoprotein 2, 24kD	5.31	down	0.01119
U21931_at	U21931	3326	fructose-bisphosphatase 1	3.17	down	0.0143
			cytochrome P450, subfamily IIA (phenobarbital-inducible),			
U22029_f_at	U22029	3327	polypeptide 7	11.85	down	0.03538
			solute carrier family 6 (neurotransmitter transporter,			
U27699_at	U27699	3340	betaine/GABA), member 12	3.65	down	0.00381
U50196_at	U50196	3377	adenosine kinase	3.03	down	0.00975
U50929_at	U50929	3380	betaine-homocysteine methyltransferase	8.04	down	0.0188
U51010_s_at	U51010	3381	nicotinamide N-methyltransferase	4.69	down	0.03099
U56814_at	U56814	3393	deoxyribonuclease I-like 3	17.69	down	0.00007
U56814_at	U56814	3393	deoxyribonuclease I-like 3	5.75	down	0.00152
U65932_at	U65932	3405	extracellular matrix protein 1	3.18	down	0.00575
U95090_at	U95090	3464	nephrosis 1, congenital, Finnish type (nephrin)	4.63	down	0.01595
W07723_at	W07723	3471	EST	3.51	down	0.00026
W26996_at	W26996	3484	EST	4.46	down	0.00734
W28414_at	W28414	3490	EST	4.06	down	0.00083
W28798_at	W28798	3492	phosphodiesterase 6A, cGMP-specific, rod, alpha	3.33	down	0.00222
W28944_at	W28944	3494		6.9	down	0.01014
rc_W44745_at	W44745	3520		3.87	down	0.01051
rc_W45560_at	W45560	3525	EST	3.48	down	0.0179
W55903_at	W55903	3546		5.64	down	0.00014
rc_W63728_at	W63728	3565	EST	3.86	down	0.00288
rc_W67147_at	W67147	3568	deleted in liver cancer 1	4.37	down	0.00069

Table 7A. Up reglated in hepatocellular carcinoma versus normal sample set 2:

Affy ID	Genbank	Sed ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_W72044_at	W72044	3580	insulin induced gene 1	3.1	down	0.03445
1			oxidative 3 alpha hydroxysterold dehydrogenase; retinol			
rc_W72382_at	W72382	3584	dehydrogenase	9.89	down	0.03091
rc_W73601_at	W73601	3592	EST	3.45	down	0.01382
	W73818	3593	EST .	3.47	down	0.00927
rc_W81552_at	W81552	3615	EST	12.97	down	0.00244
rc_W86075_at	W86075	3624	EST	6.04	down	0.01486
rc_W86600_at	W86600	3628	EST	3.67	down	0.04208
rc_W87532_at	W87532	3634	putative glycine-N-acyltransferase	5.5	down	0.00739
rc_W87781_at	W87781	3636	EST	4.02	down	0.00284
rc_W88946_at	W88946	3639	putative glycine-N-acyltransferase	25.28	down	0.00221
rc_W95041_at	W95041	3662	EST	4.22	down	0.01005
X02176_s_at	X02176	3672	complement component 9	3.84	down	0.01793
X06562_at	X06562	3686	growth hormone receptor	4.8	down	0.00507
X06985_at	X06985	3689	heme oxygenase (decycling) 1	3.34	down	0.00045
X13227_at	X13227	3698	D-amino-acid oxidase	3.22	down	0.01753
			cytochrome P450, subfamily IIA (phenobarbital-inducible),			
X13930_f_at	X13930	3700	polypeptide 6	8.1	down	0.0219
			acetyl-Coenzyme A acyltransferase 1 (peroxisomal 3-			
X14813_at	X14813	3705	oxoacyf-Coenzyme A thiolase)	3.53	down	0.00059
X16260_s_at	X16260	3710	inter-alpha (globulin) inhibitor, H1 polypeptide	3.76	down	0.00291
X16349_s_at	X16349	3712	sex hormone-binding globulin	6.61	down	0.00008
X54380_at	X54380	3730	pregnancy-zone protein	7.71	down	0.00069
X56411_rna1_at	X56411	3737	alcohol dehydrogenase 4 (class II), pi polypeptide	9.87	down	0.01416
X58022_at	X58022	3747	corticotropin releasing hormone-binding protein	4.09	down	0.00076
X63359_at	X63359	3759	UDP glycosyltransferase 2 family, polypeptide B10	4.26	down	0.01725
X64177_f_at	X64177	3763	metallothionein 1H	3.26	down	0.03928
X67491_f_at	X67491	3776	glutamate dehydrogenase 1	4.06	down	0.00273
X72177_rna1_at	X72177	3790	complement component 6	4.25	down	0.01598
X76717_at	X76717	3797	metallothionein 1L	5.64	down	0.00215
X90579 s at	X90579	3819	EST	4.26	down	0.04759

Table 7A. Up reglated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change Direction Pvalue	Direction	Pvalue
X95190_at	X95190	3832	acyl-Coenzyme A oxidase 2, branched chain	6.22	down	0.00162
X97324 at	X97324	3839	adipose differentiation-related protein; adipophilin	3.72	down	0.00202
Y00317 at	Y00317	3845	UDP glycosyltransferase 2 family, polypeptide B4	4.63	down	0.02986
Z20777 at	Z20777	3866	EST	15.73	down	0.00147
I			aldo-keto reductase family 1, member D1 (delta 4-3-			
Z28339_at	Z28339	3875	ketosteroid-5-beta-reductase)	8.03	down	0.00853
ı			lipase A, Iysosomal acid, cholesterol esterase (Wolman			
Z31690 s at	Z31690	3881	disease)	3.29	down	0.00161
rc Z40259 s at	Z40259	3919	EST	4.47	down	0.00093
rc Z40305 at	Z40305	3920	EST	4.09	down	0.00096
rc_Z40902_at	Z40902	3926	SEC14 (S. cerevisiae)-like 2	4.97	down	0.04627
rc_Z41042_at	Z41042	3928	EST	3.37	down	0.00703
Z48475 at	248475	3943	glucokinase (hexokinase 4) regulatory protein	4.6	down	0.01693
I			small inducible cytokine subfamily A (Cys-Cys), member			
Z49269 at	Z49269	3945	14	7.24	down	0.01047
Z69923_at	Z69923	3948	HGF activator	3.95	down	0.00012
Z80345 rna1 s at	Z80345	3951	acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain	3.21	down	0.04734
Z84721_cds2_at	Z84721	3953	hemoglobin, zeta	7.39	down	0.01921

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_AA001504 f at	AA001504	2	EST	4.44	dn	0.03077
rc_AA005262_at	AA005262	5	EST	3.09	요	0.0064
			KIAA1080 protein; Golgi-associated, gamma-adaptin ear			
rc AA007507 at	AA007507	18	containing, ARF-binding protein 2	5.23	dn	0.00159
rc AA010065 s at	AA010065	22	CDC28 protein kinase 2	3.71	dn	0.00432
rc_AA011209_s_at	AA011209	30	melanoma-associated antigen recognised by T	6.45	읔	0.00088
rc AA011679 at	AA011679	32	EST	3.08	dn	0.03649
rc_AA018346_at	AA018346	38	EST	3.69	dn	0.04582
rc_AA021549_at	AA021549	42	EST	3.17	g	0.00158
rc_AA022623_at	AA022623	44	EST	3.27	d	0.01556
rc_AA024658_at	AA024658	47	ribosomal protein S19	7.55	9	0.00592
rc_AA024776_at	AA024776	48	EST	3.44	d	0.00334
rc AA025166 s at	AA025166	20	fusion, derived from t(12,16) malignant liposarcoma	3.17	dn	60000'0
rc_AA026356_at	AA026356	24	EST	5.04	dn	0.02483
rc_AA027833_i_at	AA027833	26	EST	5.02	9	0.01123
rc_AA029288_at	AA029288	65	EST	3.36	dn	0.04908
rc_AA031814_at	AA031814	2	KIAA0958 protein	3.07	ď	0.00681
rc_AA037058 s_at	AA037058	88	laminin, gamma 1 (formerly LAMB2)	4.11	dn	0.02264
rc AA037433 at	AA037433	98	EST	4.9	đ	0.0194
rc_AA037766_at	AA037766	87	EST	3.63	g	0.0328
rc_AA040465_at	AA040465	92	EST	3.63	đ	0.01806
AA043111 s at	AA043111	97	EST	6.36	dn	0.0005
rc_AA043959_at	AA043959	101	tropomyosin 4	4.37	dn	0.01641
rc_AA045365_at	AA045365	106	EST	3.17	dn	0.0149
rc AA046103 at	AA046103	109	EST	3.75	đ	0.02893
rc AA046410 s at	AA046410	110	EST	3.18	ᅀ	0.00797
rc_AA046745_at	AA046745	113	Wolf-Hirschhorn syndrome candidate 1	3.33	dn	0.00648
rc_AA047379_s_at	AA047379	119	karyopherin (importin) beta 1	3.15	ф	0.01572
rc_AA047704_at	AA047704	120	EST	3.2	dn	0.0029
rc_AA052941_at	AA052941	121	EST	3.36	ф	0.00088
rc_AA053662_f_at	AA053662	129	EST	3.3	đ	0.00558

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affv ID	Genbank	Sea 1D	Known Gene Name	Fold Change	Direction	Pvalue
rc AA053680 at	AA053680	130	high-mobility grou	4.07	음	0.03144
rc_AA055892_at	AA055892	134	EST	3.02	ď	0.04984
rc_AA055896_at	AA055896	135	collagen, type V, alpha 1	10.87	dn	0.00907
rc_AA070206_at	AA070206	155	EST	3.15	dn	0.03914
rc_AA070485_at	AA070485	156	interleukin 13 receptor, alpha 1	3.19	<u>а</u>	0.03465
rc_AA070827_at	AA070827	157	EST	4.37	ф	0.02617
AA071387 at	AA071387	158	jumping translocation breakpoint	3.31	dn	0.0001
rc AA074162 s at	AA074162	159	superkiller viralicidic activity 2 (S. cerevisiae homolog)-	3.23	dn	0.00642
rc AA076138 at	AA076138	167	H2A histone family, member Y	3.75	d	0.01442
rc_AA086071_at	AA086071	184	chromosome-associated polypeptide C	3.77	ф	0.01993
l I			kangai 1 (suppression of tumorigenicity 6, prostate;			
			CD82 antigen (R2 leukocyte antigen, antigen detected			
rc AA086232 f at	AA086232	186	by monoclonal and antibody IA4))	4.52	d	0.00452
rc_AA086412_at	AA086412	187	DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 16	3.13	g	0.00327
AA089997 at	AA089997	189	EST	4.9	g	0.0241
AA091752_at	AA091752	193	purine-rich element binding protein B	3.25	đ	0.01419
AA092129 f_at	AA092129	194	EST	2.67	ģ	0.00011
AA092290 f at	AA092290	195	EST	3.25	롸	0.01616
AA094752_at	AA094752	203	hypothetical 43.2 Kd protein	3.44	dn	0.04445
rc AA099404 s at	AA099404	208	EST	20.22	ф	0
rc_AA101272_at	AA101272	215	EST	3.83	ф	0.0386
rc AA102489 at	AA102489	219	EST	5.28	ф	0.02122
rc_AA102837_f_at	AA102837	221	EST	4.13	ф	0.0067
rc AA112679 at	AA112679	224	EST	4.19	ф	0.00572
rc AA115562 at	AA115562	229	EST	3.35	dn	0.00283
rc AA115735 s at	AA115735	230	EST	4.8	dn	0.02671
rc AA116036 at	AA116036	233	chromosome 20 open reading frame 1	3.41	ф	0.00089
rc_AA122386_at	AA122386	239	collagen, type V, alpha 2	3.44	đ	0.02566
rc AA125808 at	AA125808	240	EST	3.04	슠	0.02112
rc_AA127444_at	AA127444	252	EST	3.87	合	0.01751
rc_AA127741_at	AA127741	256	EST	4.49	ф	0.0463

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_AA128407_at	AA128407	259	EST	3.33	đn	0.02298
rc_AA129757_at	AA129757	264	EST	3.75	dn	0.0166
rc_AA131220_at	AA131220	267	EST	3.18	g	0.00974
rc_AA132032_s_at	AA132032	271	trinucleotide repeat containing 1	3.84	d	0.01136
rc_AA132514_at	AA132514	272	EST	3.2	d	0.00876
rc_AA133527_at	AA133527	281	EST	5.23	d	0.00037
rc_AA133666_s_at	AA133666	283	cysteine-rich protein 2	5.35	g.	0.00433
rc_AA134052_s_at	AA134052	285	Rab geranylgeranyltransferase, alpha subunit	5.47	g	0.00982
rc_AA135153_at	AA135153	291	EST	5.58	d.	0.00327
rc_AA135871_at	AA135871	294	EST	3.56	d	0.01718
rc_AA136269_at	AA136269	298	EST	7.5	d	0.00014
rc_AA136474_at	AA136474	301	Meis (mouse) homolog 2	3.15	g	0.02837
rc_AA136547_at	AA136547	302	EST	4.19	dn	0.00098
rc_AA136864_at	AA136864	304	zinc finger protein homologous to Zfp-36 in mouse	3.31	g.	0.00346
rc_AA142857_at	AA142857	307	EST	9.48	g	0.00376
rc_AA142858_at	AA142858	308	EST	4.07	đ	0.0022
rc_AA146849_s_at	AA146849	313	target of myb1 (chicken) homolog	4.72	슠	0.00326
rc_AA148885_at	AA148885	320	minichromosome maintenance deficient (S. cerevisiae) 4		đ	0.00112
rc_AA148977_at	AA148977	322	EST	9.3	d	0.00002
rc_AA149889_at	AA149889	326	neighbor of A-kinase anchoring protein 95	8.55	롸	0.00224
rc_AA151435_at	AA151435	336	EST	4.52	g	0.01134
			ATP synthase, H+ transporting, mitochondrial F0		·	
rc_AA156187_at	AA156187	339	complex, subunit b, isoform 1	9.38	음	0.02007
rc_AA156460_at	AA156460	343	EST	4.39	g	0.01223
rc_AA159025_at	AA159025	353	EST	6.58	d	0.01946
rc_AA160775_s_at	AA160775	355	BCL2-antagonist of cell death	3.8	용	0.01145
			3-prime-phosphoadenosine 5-prime-phosphosulfate			
rc_AA165526_at	AA165526	360	synthase 1	3.68	d	0.00021
rc_AA167708_at	AA167708	363	EST	3.19	d n	0.01871
rc_AA171760_at	AA171760	367	EST	4.39	dn	0.04582
rc_AA173430_at	AA173430	371	EST	3.74	롸	0.01159

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affv ID	Genbank	Sea ID	Known Gene Name	Fold Change	Direction	Pvalue
AA173505 at	ည	372	EST	က	ф	0.01738
AA173597_at	AA173597	373	EST	3.37	d	0.03622
rc_AA173755_at	AA173755	374	EST	6.73	dn	0.00666
rc_AA179787_at	AA179787	380	polyglutamine binding protein 1	4.71	음	0.00725
rc AA179845 at	AA179845	381	EST	3.55	ф	0.02484
rc AA181580 s at	AA181580	383	karyopherin (importin) beta 1	3.01	đ	0.0125
rc_AA181705 f_at	AA181705	385	EST	5.9	g	0.00023
rc_AA182001_r_at	AA182001	386	EST	3.78	đ	0.04446
AA187579 at	AA187579	390	MCT-1 protein	3.4	d	0.02455
rc AA188378 i at	AA188378	392	EST	4.88	dn	0.01653
rc AA194730 at	AA194730	410	EST	4.57	d	0.00801
rc_AA194998_at	AA194998	413	purinergic receptor (family A group 5)	3.06	dn	0.04752
rc_AA195067_i_at	AA195067	414	GTPase activating protein-like	3.24	dn	0.00606
rc_AA204927_at	AA204927	425	tropomyosin 1 (alpha)	6.11	ď	0.0014
rc_AA207103_at	AA207103	429	EST	3.36	ф	0.00131
rc_AA211483_at	AA211483	435	EST	4.11	ф	0.0365
AA215299 s at	AA215299	439	U6 snRNA-associated Sm-like protein LSm7	4.81	ф	0.00119
rc_AA215379_at	AA215379	440	EST	4.44	ф	0.01675
rc_AA218663_at	AA218663	444	acid-inducible phosphoprotein	4.34	dn	0.00161
rc_AA226932_at	AA226932	453	DKFZP564F0923 protein	5.25	đ	0.00612
rc_AA227145_at	AA227145	454	EST	3.4	슠	0.03422
rc_AA227541_at	AA227541	457	NS1-binding protein	3.6	dn	0.02801
AA232837_at	AA232837	465	EST	8.85	슠	0.0048
rc_AA233897_at	AA233897	476	EST	3.8	g	0.02145
rc_AA234096_at	AA234096	479	EST	5.75	đ	0.01169
rc_AA235289_at	AA235289	495	RAP2A, member of RAS oncogene family	4.31	đ	0.00135
AA235448_s_at	AA235448	497	EST	29.6	g	0.00077
rc_AA235853_at	AA235853	503	CGI-96 protein	3.16	g.	0.00744
rc_AA235868_at	AA235868	504	nuclear transcription factor Y, beta	3.49	읔	0.01897
			3-prime-phosphoadenosine 5-prime-phosphosulfate			
rc_AA236150_at	AA236150	207	synthase 1	3.46	읈	0.0008

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
AA236412_at	AA236412	511	EST	3.1	dn	0.04463
rc_AA236532_s_at	AA236532	513	EST	3.04	d d	0.03747
rc_AA236672_at	AA236672	515	EST	4.37	g	0.00385
rc_AA236904_at	AA236904	518	EST	3.07	음	0.01503
rc_AA242757_at	AA242757	522	EST	3.27	ď	0.00286
rc_AA243133_at	AA243133	525	serine/threonine kinase 15	7.03	g	0.00005
rc_AA243173_at	AA243173	526	EST	3.49	음	0.0401
AA249819_s_at	AA249819	535	EST	5.22	ဌ	0.00049
rc_AA251230_at	AA251230	540	EST	3.25	음	0.01417
rc_AA251299_s_at	AA251299	54	KIAA0014 gene product	4.74	g	0.0252
rc_AA251428_at	AA251428	545	DKFZP586I2223 protein	3.15	g	0.01223
rc_AA251766_at	AA251766	543	EST	3.06	dn	0.0098
rc_AA251769_at	AA251769	544	EST	4.45	dn	0.01431
rc_AA251792_at	AA251792	546	fatty-acid-Coenzyme A ligase, long-chain 4	7.44	롸	0.00285
rc_AA251909_at	AA251909	549	EST	3.59	dn	0.01129
rc_AA252060_at	AA252060	220	EST	4.88	dn	0.00169
rc_AA252355_at	AA252355	553	EST	3.02	dn	0.00715
rc_AA252524_at	AA252524	222	EST	3.17	dn	0.00686
			chaperonin containing TCP1, subunit 6A (zeta 1), homeo			
rc_AA252627_s_at	AA252627	556	box B5	4.28	đ	0.00363
۳i	AA253011	558	KIAA0713 protein	3.15	đ	0.00035
rc_AA255486_at	AA255486	268	EST	3.72	g	0.00154
rc_AA256131_at	AA256131	574	glycophosphatidylinositol anchor attachment 1	3.16	ф	0.00011
rc_AA256268_at	AA256268	276	EST	3.13	dn	0.03874
rc_AA256524_at	AA256524	280	AD022 protein	3.06	dn	0.00626
rc_AA256606_at	AA256606	581	EST	3.92	đ	0.03087
rc_AA256688_s_at	AA256688	584	EST	4.23	g	0.03094
rc_AA258131_at	AA258131	287	putative GTP-binding protein similar to RAY/RAB1C	6.23	g	0.00931
rc_AA258182_at	AA258182	589	EST	3.55	dn	0.01198
rc_AA258387_at	AA258387	594	EST	3.15	d	0.02028
rc_AA258421_at	AA258421	269	hypothetical protein	6.5	d	0.00559

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy 1D	Genbank	Sed ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_AA258614_s_at	AA258614	599	EST	3.94	s	0.0048
rc_AA262477_at	AA262477	809	ribonuclease HI, large subunit	4.57	음	0.00724
rc_AA262957_at	AA262957	612	EST	3.76	g.	0.00157
			ATP synthase, H+ transporting, mitochondrial F0			
AA263032_s_at	AA263032	614	complex, subunit b, isoform 1	6.73	g	0.04478
rc_AA278768_f_at	AA278768	617	EST	3.77	g	0.03239
rc_AA278817_at	AA278817	618	EST	3.5	d	0.01159
rc_AA279418_at	AA279418	979	EST	3.23	9	0.02054
rc_AA280734_i_at	AA280734	639	KIAA0618 gene product	6.83	음	0.001
rc_AA280840_at	AA280840	641	casein kinase 1, gamma 2	4.51	9	0.0186
rc_AA281599_at	AA281599	647	EST	4.87	d	0.00248
rc_AA282247_at	AA282247	657	EST .	5.88	d	0.01112
rc_AA282343_at	AA282343	658	purine-rich element binding protein B	5.78	dn	0.00128
rc_AA282571_at	AA282571	662	FSHD region gene 1	3.16	dn	0.01355
rc_AA283182_at	AA283182	999	EST	6.78	dn	0.01784
rc_AA283832_at	AA283832	672	EST	4.77	읔	0.00156
rc_AA284565_f_at	AA284565	675	EST	3.27	읔	0.0362
rc_AA284720_at	AA284720	9/9	EST	3.03	슠	0.00252
rc_AA284945_at	AA284945	680	EST	6.25	음	0.0002
rc_AA285132_at	AA285132	682	apoptotic protease activating factor	3.1	g	0.00844
rc_AA286911_at	AA286911	684	EST	3.36	9	0.00037
rc_AA291137_at	AA291137	694	EST	3.67	đ	0.03243
rc_AA291139_at	AA291139	695	EST	6.22	ď	0.03491
rc_AA291168_at	AA291168	969	EST	4.93	음	0.01633
rc_AA291644_at	AA291644	701	EST	3.28	롸	0.00033
rc_AA291659_at	AA291659	702	EST	4.15	dn	0.00019
AA291786_s_at	AA291786	704	FE65-LIKE 2	4.15	dn	0.00362
rc_AA292765_at	AA292765	712	ZW10 interactor	7.24	함	0.00498
rc_AA292788_s_at	AA292788	714	EST	3.65	음	0.01765
rc_AA293420_s_at	AA293420	717	EST	4.05	롸	0.01189
rc_AA293589_s_at	AA293589	719	zinc finger protein	3.02	읈	0.01809

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
AA293868_s_at	AA293868	721	EST	3.04	음	0.0054
AA296994_s_at	AA296994	724	seven transmembrane domain protein	3.16	9	0.0076
AA313213_at	AA313213	732	flotillin 1	3.59	g.	0.00878
AA320369_s_at	AA320369	735	chromosome 19 open reading frame 3	3.88	<u> </u>	0.00452
rc_AA321833_at	AA321833	736	EST	3.16	<u> </u>	0.00523
rc_AA335191_f_at	AA335191	741	creatine kinase, brain	6.47	g	0.01462
rc_AA338760_at	AA338760	744	EST	3.96	g	0.01307
rc_AA365708_s_at	AA365708	764	microfibrillar-associated protein 1	3.01	<u>s</u>	0.02372
AA365742_s_at	AA365742	765	tetraspan NET-6 protein	4.12	음	0.00255
rc_AA370163_at	AA370163	992	EST	3.41	을	0.00134
AA384184 s_at	AA384184	774	DKFZP586B0519 protein	3.42	음	0.01222
AA393139_at	AA393139	775	geminin	7.44	음	0.00888
rc_AA394258_s_at	AA394258	779	RD RNA-binding protein	7.27	d n	0.00054
rc_AA398141_at	AA398141	788	EST	3.3	a	0.00211
rc_AA398205_at	AA398205	789	EST	4.22	g	0.00059
rc_AA398563_at	AA398563	797	EST	3,14	음	0.01895
rc_AA398908_at	AA398908	801	EST .	20.72	g.	0.00114
rc_AA398926_f_at	AA398926	805	EST	8.25	음	0.00066
rc_AA399251_at	AA399251	804	EST	4.3	g	0.01578
rc_AA399264_at	AA399264	802	EST	3.51	9	0.00327
rc_AA400184_at	AA400184	809	KIAA0907 protein	4.11	dn	0.01123
AA400643_s_at	AA400643	817	GAS2-related on chromosome 22	4.04	9	0.03751
rc_AA400896_at	AA400896	822	EST	3.54	g	0.00889
rc_AA401965_at	AA401965	833	tumor suppressor deleted in oral cancer-related 1	7.58	9	0.00089
rc_AA402272_at	AA402272	837	EST	3.73	9	0.02336
rc_AA402968_at	AA402968	844	EST	3.68	<u> 9</u>	0.00123
			O-linked N-acetylglucosamine (GlcNAc) transferase			
			(UDP-N-acetylglucosamine:polypeptide-N-			
rc_AA404560_at	AA404560	853	acetylglucosaminyl transferase)	3.73	9	0.0143
rc_AA405098_at	AA405098	855	EST	60.9	9	0.01224
rc_AA405505_at	AA405505	860	RNA helicase family	4.05	9	0.00747

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_AA405544_f_at	AA405544	861	EST	3.09	읔	0.04146
rc_AA405791_at	AA405791	864	EST	11.79	읔	0.00587
rc_AA406216_at	AA406216	871	EST	3.4	롸	0.00529
rc_AA406384_at	AA406384	875	KIAA0670 protein/acinus	3.23	음	0.00486
rc_AA410469_at	AA410469	883	EST	5.45	9	0.00068
rc_AA410962_s_at	AA410962	887	peroxisome proliferative activated receptor, delta	4.91	음	0.0044
rc_AA412301_at	AA412301	899	EST	3.42	음	0.0129
rc_AA412720_at	AA412720	902	EST	3.06	음	0.02153
rc_AA416970_at	AA416970	912	Mad4 homolog	5.3	음	0.00418
rc_AA416973_at	AA416973	913	EST	4.29	음	0.00155
rc_AA417030_at	AA417030	914	EST	7.35	ŝ	0.00555
rc_AA417884_at	AA417884	919	cyclin-dependent kinase inhibitor 2C (p18, inhibits	3.42	용	0.02997
AA421213_at	AA421213	931	Lsm3 protein	3.34	g	0.00198
rc_AA421562_at	AA421562	934	anterior gradient 2 (Xenepus laevis) homolog	5.02	9	0.02818
rc_AA421951_at	AA421951	936	EST	69.9	8	0.00013
rc_AA423827_f_at	AA423827	941	chromosome 22 open reading frame 3	4.39	읔	0.00345
rc_AA423841_f_at	AA423841	942	EST	3.71	요	0.01481
rc_AA424029_at	AA424029	943	EST	4.54	g	0.02721
rc_AA424487_at	AA424487	945	EST	4.68	슠	0.0013
rc_AA424881_at	AA424881	949	EST	3.39	음	0.03546
			eukaryotic translation initiation factor 2B, subunit 2 (beta	-		
rc_AA425544_s_at	AA425544	955	39KD)	3.05	읔	0.0346
rc_AA425852_s_at.	AA425852	928	EST	3.98	9	0.02796
rc_AA425852_i_at	AA425852	928	EST	3.82	음	0.0395
rc_AA426291_at	AA426291	961	EST	3.03	읔	0.00365
rc_AA426374_f_at	AA426374	964	tubulin, alpha 2	3.25	읔	0.04346
rc_AA426447_at	AA426447	965	EST	3.01	육	0.02414
rc_AA426521_at	AA426521	296	Sjogren's syndrome nuclear autoantigen 1	3.33	읔	0.01163
rc_AA427734_at	AA427734	977	cholinergic receptor, nicotinic, epsilon polypeptide	3.08	ဌ	0.04796
AA428172_f_at	AA428172	986	Notch (Drosophila) homolog 3	9.63	슠	0.00195

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank S	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
			cofactor required for Sp1 transcriptional activation,			
rc_AA428204_at	AA428204	987	subunit 6 (77kD)	3.08	9	0.00313
rc_AA429470_at	AA429470	966	EST	3.2	dn	0.0153
rc_AA429472_at	AA429472	266	DKFZP434P106 protein	8.78	음	0.00063
AA429539_f_at	AA429539	666	EST	4.3	음	0.01035
rc_AA429572_at		1000	ribosomal protein S6	3.31	g	0.02144
AA429825_at	AA429825	1003	DKFZP566B023 protein	3.11	đ	0.01857
rc_AA430032_at		1009	pltuitary tumor-transforming 1	10.67	d	0.00052
rc_AA430048_at	AA430048	1012	KIAA0160 protein	4.32	9	0.00279
rc_AA430154_at	AA430154	1014	EST	3.09	9	0.04401
rc_AA430474_at		1015	EST	4.69	d	0.00007
rc_AA430675_at	AA430675	1019	Fanconi anemia, complementation group G	3.16	đ	0.01007
rc_AA431571_at	AA431571	1024	EST	4.62	9	0.0174
rc_AA431719_at	AA431719	1025	EST	3.19	ď	0.00294
rc_AA433947_at	AA433947	1034	EST	3.09	ď	0.00253
rc_AA434418_at	AA434418	1036	KIAA1115 protein	6.75	dn	0.0032
rc_AA435662_f_at	AA435662	1039	EST	3.27	g	0.0433
rc_AA435665_at	AA435665	1040	EST	3.94	롸	0.00274
rc_AA435681_s_at	AA435681	1041	EST	3.07	롸	0.01166
rc_AA435748_at	AA435748	1044	EST	5.01	dn	0.01812
rc_aa435769_s_at	AA435769	1046	EST	3.06	dn	0.00615
AA442054_s_at	AA442054	1067	phospholipase C, gamma 1 (formerly subtype 148)	4.94	dn	0.04102
rc_AA442155_at	AA442155	1068	transforming acidic colled-coil containing protein 3	3.35	dn	0.00344
AA442400_at	AA42400	1071	hepatitis B virus x-interacting protein (9.6kD)	3.02	ф	0.04037
rc_AA442763_at	AA442763	1072	cyclin B2	3.49	dn	0.04176
rc_AA443271_at	AA443271	1073	KIAA0546 protein	3.44	dn	0.00324
rc_AA443316_s_at	AA443316	1075	v-Ha-ras Harvey rat sarcoma viral oncogene homolog	3.4	dn	0.00133
rc_AA443602_at	AA443602	1078	EST	5.71	d dn	0.00736
rc_AA443802_at	AA443802	1081	EST	4.07	đ	0.01546
rc_AA446242_at	AA446242	1087	EST	6.3	dn	0.00169
rc_AA446570_at	AA446570	1089	EST	3.12	d	0.02228

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_AA446581_at	AA446581	1090	DKFZP564P0462 protein	4.04	g	0.00479
rc_AA446970_at	AA446970	1098	EST	3.09	- <u>e</u>	0.01627
rc_AA447574_at	AA447574	1102	EST	4.12	음	0.00779
rc_AA448252_at	AA448252	1114	EST	က	S	0.00256
rc_aa449073_s_at	AA449073	1117	EST	5.61	g	0.01214
rc_aa449431_s_at	AA449431	1124	translation initiation factor IF2	3.76	음	0.00571
rc_AA449828_at	AA449828	1130	EST	3.35	. an	0.01609
rc_AA450247_at	AA450247	1133	EST	3.13	- <u>e</u>	0.00531
			hepatocellular carcinoma associated protein; breast		•	
rc_AA451680_at	AA451680	1136	cancer associated gene 1	3.85	9	0.0018
rc_AA451877_at	AA451877	1138	EST	4.6	g	0.04045
AA451992_at	AA451992	1140	HSPC039 protein	3.33	ď	0.01696
rc_AA452167_at	AA452167	1142	EST	3.29	g	0.03337
AA452724_at	AA452724	1149	programmed cell death 5	7.7	dn	0.00085
rc_AA453628_at	AA453628	1154	EST	3.17	d n	0.00849
rc_AA453656_at	AA453656	1155	EST	3.02	g	0.00958
rc_AA453783_s_at	AA453783	1158	EST	4.07	g.	0.00786
rc_AA454597_s_at	AA454597	1166	EST	4.23	음	0.00917
rc_AA454830_at	AA454830	1170	DKFZP586M2123 protein	6.48	g	0.00555
AA454908_s_at	AA454908	1171	KIAA0144 gene product	6.39	음	0.01835
rc_AA455239_at	AA455239	1174	chromosome-associated polypeptide C	5.78	dn	0.00003
rc_AA456415_at	AA456415	1192	KIAA0537 gene product	3.32	dn	0.00155
rc_AA456583_s_at	AA456583	1193	PL6 protein	3.37	9	0.00139
rc_AA456646_at	AA456646	1196	EST	3.34	유	0.0309
rc_AA456852_at	AA456852	1199	suppressor of white apricot homolog 2	3.66	음	0.00614
rc_AA458878_s_at	AA458878	1204	EST	5.49	dn	0.00977
rc_AA458890_at	AA458890	1206	EST	3.27	<u>a</u>	0.00079
rc_AA459254_at	AA459254	1211	EST	6.22	d	0.00001
AA459542_s_at	AA459542	1218	regulatory factor X-associated ankyrin-containing protein	3.4	g	0.00841
rc_AA460665_at	AA460665	1230	EST	4.01	슠	0.01866
rc_aa460909_s_at	AA460909	1232	EST	5.02	롸	0.01354

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_AA461063_at	AA461063	1235	EST	4.3	g	0.00074
AA461282_s_at	AA461282	1237	dihydropyrimidinase-like 2	3.42	<u>g</u>	0.02014
rc_AA461476_at	AA461476	1243	EST	3.72	g	0.00744
rc_AA463254_s_at	AA463254	1247	histone deacetylase 3	4.01	g	0.01856
rc_AA463934_at	AA463934	1253	splicing factor 3b, subunit 4, 49kD	3.15	g	0.00952
AA464043_s_at	AA464043	1255	EST	3.99	g	0.00056
rc_AA464251_at	AA464251	1257	EST	3.45	<u>a</u>	0.02229
rc_AA464414_i_at	AA464414	1258	EST	4.08	9	0.02299
rc_AA464423_at	AA464423	1259	EST	3.06	g	0.01416
rc_aa464722_s_at	AA464722	1263	DKFZP566C243 protein	3.51	g	0.00101
rc_AA464963_at	AA464963	1265	EST	4.77	음	0.00086
AA465000_s_at	AA465000	1266	EST	3.86	9	0.00431
rc_AA465093_at	AA465093	1267	TIA1 cytotoxic granule-associated RNA-binding protein	3.3	g.	0.01314
rc_AA465218_at	AA465218	1268	DKFZP586M1523 protein	3.17	9	0.00357
rc_AA465342_at	AA465342	1271	EST	3.21	g.	0.01378
rc_AA470156_at	AA470156	1276	EST	4.99	g	0.0206
AA471384_at	AA471384	1278	divalent cation tolerant protein CUTA	3.44	9	0.01161
rc_AA476473_at	AA476473	1285	EST	ო	9	0.01324
rc_AA476754_s_at	AA476754	1287	EST	3.18	d	0.01696
rc_AA476944_at	AA476944	1288	EST	3.29	g	0.00189
rc_AA477316_at	AA477316	1290	calumenin	3.05	đ	0.00608
rc_AA477549_s_at	AA477549	1291	T-cell, immune regulator 1	4.84	d	0.04096
rc_AA478017_at	AA478017	1295	zyxin	4.25	d	0.01223
rc_AA478300_at	AA478300	1298	CD39-like 2	3.75	g	0.00152
rc_AA478415_at	AA478415	1299	EST	3.14	S	0.0483
rc_AA478422_at	AA478422	1301	unc-51 (C. elegans)-like kinase 1	3.83	g	0.00116
rc_AA478615_s_at	AA478615	1305	H1 histone family, member X	3.09	g	0.0499
			disabled (Drosophila) homolog 2 (mitogen-responsive			
rc_AA478971_s_at	AA478971	1306	phosphoprotein)	3.25	g	0.02698
rc_AA479096_at	AA479096	1308	EST	3.32	g	0.00118
rc_AA479139_s_at	AA479139	1310	acid phosphatase 1, soluble	3.42	S	0.01853

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_AA479881_at	AA479881	1317	EST	3.34	9	0.03289
rc_AA481060_at	AA481060	1326	EST	3.08	dn	0.00029
rc_AA481420_at	AA481420	1327	EST	3.08	<u> </u>	0.0206
rc_AA482104_s_at	AA482104	1332	non-metastatic cells 3, protein expressed in	4.78	<u>a</u>	0.00135
rc_AA482224_f_at	AA482224	1334	putative type II membrane protein	4.47	. a	0.0001
AA482319_f_at	AA482319	1335	putative type II membrane protein	4.9	g	0.00028
AA482319_I_at	AA482319	1335		3.13	g S	0.00071
rc_AA485060_at	AA485060	1339	EST	3.83	g.	0.03172
rc_AA485084_s_at	AA485084	1340	EST	3.31	g	0.01232
rc_AA485431_s_at	AA485431	1345	EST	3.81	g	0.00441
rc_AA485697_at	AA485697	1346	EST	3.53	음	0.03566
rc_AA487218_at	AA487218	1355	EST	4.43	d	0.03198
rc_AA487856_at	AA487856	1359	KIAA0676 protein	3.59	g	0.01408
rc_AA488074_at	AA488074	1360	cell division cycle 42 (GTP-binding protein, 25kD)	3.74	đ	0.01887
rc_AA488432_at	AA488432	1361	phosphoserine phosphatase	4.2	g	0.00128
rc_AA488872_s_at	AA488872	1363	EST	3.35	g	0.03191
rc_AA488892_at	AA48892	1364	EST	4.14	d	0.04766
rc_AA489091_at	AA489091	1368	EST	3.58	đ	0.0002
rc_AA489707_at	AA489707	1371	EST	3.5	d d	0.03208
rc_AA489712_at	AA489712	1372	EST	4.69	<u>a</u>	0.00587
rc_AA490212_at	AA490212	1375	H2A histone family, member Y	3.52	. <u>a</u>	0.02202
			solute carrier family 2 (facilitated glucose transporter),		•	
AA491188_at	AA491188	1387	member 3	5.04	dn	0.02291
rc_AA491295_at	AA491295	1390	calcium/calmodulin-dependent protein kinase kinase 2,	3.71	g.	0.0103
AA495857_at	AA495857	1394	EST	3.21	<u> </u>	0.02243
rc_AA496715_f_at	AA496715	1400	spectrin SH3 domain binding protein 1	3.44	g	0.00069
			v-erb-b2 avian erythroblastic leukemia viral oncogene		•	
rc_AA496981_at	AA496981	1404	homolog 3	5.82	đ	0.00521
rc_AA497018_at	AA497018	1406		4.81	ౚ	0.00352
AA504413_at	AA504413	1413	EST	3.31	9	0.00036
rc_AA504512_s_at	AA504512	1415	KIAA0943 protein	5.72	롸	0.00384

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
			solute carrier family 2 (facilitated glucose transporter),			
rc_AA505133_at		1417	member 3	12.21	g	0.00169
rc_AA505141_at	AA505141	1418	EST	3.08	S	0.02327
rc_AA521149_at	AA521149	1420	EST	3.33	g	0.00211
rc_AA598405_at	AA598405	1424	membrane interacting protein of RGS16	3.87	9	0.00649
rc_AA598447_at	AA598447	1428	exportin, tRNA (nuclear export receptor for tRNAs)	3.5	g.	0.01201
rc_AA598589_at	AA598589	1431	EST	3.24	g.	0.00432
			SWI/SNF related, matrix associated, actin dependent		•	
rc_AA598648_s_at	AA598648	1432	regulator of chromatin, subfamily a, member 4	3.46	g	0.00293
rc_AA598712_at	AA598712	1436	EST	3.45	g.	0.00005
rc_AA598749_at	AA598749	1438	ESŢ	3.01	g	0.03714
			heterogeneous nuclear ribonucleoprotein U (scaffold			
rc_AA598829_s_at	AA598829	1439	attachment factor A)	3.04	<u>g</u>	0.00967
rc_AA598831_f_at	AA598831	1440	EST	3.41	g	0.00452
rc_AA599469_at	AA599469	1450	EST	3.07	g	0.04154
rc_AA599808_at	AA599808	1455	EST	3.09	g	0.00726
rc_AA599850_at	AA599850	1457	EST	3.55	g	0.03215
rc_AA600153_at	AA600153	1460	DEK oncogene (DNA binding)	3.71	슠	0.02967
rc_AA608668_at	AA608668	1465	erythrocyte membrane protein band 4.1-like 2	3.33	dn	0.02014
rc_AA608897_at	AA608897	1473	EST	5.05	g	0.01782
rc_AA609008_at	AA609008	1475	EST	4.04	dn	0.00002
rc_AA609080_at	AA609080	1478	EST	3.71	g	0.0306
rc_AA610073_at	AA610073	1497	EST	3.25	đ	0.00859
rc_AA610089_at	AA610089	1498	U4/U6-associated RNA splicing factor	4.07	đ	0.00361
rc_AA610116_i_at	AA610116	1499	tetraspan NET-6 protein	16.35	đ	0.00249
rc_AA620461_at	AA620461	1501	EST	3.45	g	0.01146
rc_AA620553_s_at	AA620553	1504	flap structure-specific endonuclease 1	7.56	dn	0.00101
rc_AA620761_at	AA620761	1507	EST	3.3	g	0.00285
rc_AA620779_at	AA620779	1508	golgin-67	3.35	đ	0.00297
rc_AA620881_at	AA620881	1510	trinucleotide repeat containing 3	9.49	dn	0.00062
rc_AA621146_at	AA621146	1514	MUF1 protein	3.15	ф	0.02116

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Sed ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_AA621242_s_at	AA621242	1518	hypothetical protein, peptidylprolyl isomerase B	4.59	dn	0.00081
rc_AA621367_at	AA621367	1523	EST	3.1	g	0.00066
rc_AA621409_at	AA621409	1524	putative type II membrane protein	3.5	a.	0.00462
rc_AA621530_at	AA621530	1526	EST	3.26	<u> </u>	0.00298
rc_AA621535_at	AA621535	1527	FE65-LIKE 2	3.37	g.	0.0167
rc_AA621752_at	AA621752	1529	26S proteasome-associated pad1 homolog	3.13	<u>a</u>	0.01571
AB002373_at	AB002373	1538	KIAA0375 gene product	4.41	<u>a</u>	0.00795
AF003521_at	AF003521	1545	jagged 2	3.58	9	0.00299
AF004022_at	AF004022	1546	serine/threonine kinase 12	3.29	<u>a</u>	0.00841
C00358_at	C00358	1552	nucleolar protein 3 (apoptosis repressor with CARD	3.45	g	0.00985
C01721_at	C01721	1558	phospholipase C, beta 3, neighbor pseudogene	5.89	ď	0.0383
C01766_s_at	C01766	1559	EST	8.18	đ	0.00505
rc_C14051_f_at	C14051	1565		4.79	9	0.00548
rc_C14098_f_at	C14098	1566	EST	4.62	롸	0.01654
rc_C14756_f_at	C14756	1570	MLN51 protein	3.75	g.	0.0226
rc_C14835_f_at	C14835	1571	EST	3.35	g.	0.0316
D00596_at	D00596	1590	thymidylate synthetase	5.58	요	0.0098
D13370_at	D13370	1603	APEX nuclease (multifunctional DNA repair enzyme)	3.07	g	0.00857
			general transcription factor IIIC, polypeptide 2 (beta			
D13636_at	D13636	1606		3.12	9	0.00022
D13640_at	D13640	1608		3.55	요	0.00347
D14657_at	D14657	1615		3.84	g	0.02048
rc_D20899_at	D20899	1626		3.13	G	0.02128
			minichromosome maintenance deficient (S. cerevisiae) 2		i	
D21063_at	D21063	1628	(mitotin)	3.25	9	0.03558
D26129_at	D26129	1635		6.9	g	0.00008
. D28589_at	D28589	1637	EST	3.38	g S	0.01144
D30946_at	D30946	1638		3.43	음	0.01458
D31094_at	D31094	1639	G8 protein	9.37	9	0.0048
D31294_at	D31294	1643		3.3	g	0.004
D31417_at	D31417	1645	secreted protein of unknown function	3.69	롸	0.0004

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank Seg ID	ID Known Gene Name	Fold Change	Direction	Pvalue
D38073_at	D38073 1651	minichromosome	4.1	gn	0.01195
D38305_at	D38305 1652	-	3,22	음	0.0215
D42040_s_at	D42040 1657	77 female sterile homeotic-related gene 1 (mouse homolog)	4.02	<u> </u>	0.00389
rc_D51072_s_at	D51072 1674		3.34	a n	0.0254
rc_D51276_f_at	•	'8 leukemia-associated phosphoprotein p18 (stathmin)	9.42	<u>8</u>	0.00015
D55716_at	•	_	5.48	<u>a</u>	0.00003
rc_D57317_at	•	18 activated RNA polymerase II transcription cofactor 4	3.17	9	0.00464
rc_D59355_s_at	•	16 cytoskeleton-associated protein 1	6.05	- 9	0.0015
rc_D59553_f_at	_	-	5.95	Э	0.00169
rc_D59570_f_at	•		4.34	g S	0.00487
rc_D60811_s_at	•		4.34	9	0.00217
D63478_at	D63478 1711	_	3.89	g.	0.00253
D63486_at	•	2 KIAA0152 gene product	3.56	g	0.00063
rc_D80420_at		12 ubiquinol-cytochrome c reductase hinge protein	3.86	9	0.00412
rc_D80710_f_at		i4 integral type I protein	3.17	đ	0.04549
rc_D80917_f_at	-	_	3.09	롸	0.00168
rc_D80946_f_at		-	3.07	đ	0.00986
D81608_at		O polymerase (RNA) II (DNA directed) polypeptide K	3.52	음	0.00437
D82226_s_at		_	4.35	9	0.00184
D82277_s_at		3 LDL induced EC protein	3.33	g	0.00355
D82558_at	D82558 1746	6 novel centrosomal protein RanBPM	4.67	d n	0.00458
		trinucleotide repeat containing 11 (THR-associated			
D83783_at			4.16	9	0.00055
D84557_at		_	3.97	9	0.0017
D86957_at		_	3.08	9	0.02949
D86977_at		_	3.03	d D	0.00053
rc_F01538_s_at	•		4.88	g.	0.00292
rc_F01568_at			4.13	d	0.00084
rc_F01831_at		3 EST	5.95	9	0.00532
rc_F02254_s_at	•-		5.1	용	0.00329
rc_F02807_at	F02807 1781	11 KIAA0838 protein	5.67	음	0.02064

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_F02863_at	F02863	1782	EST	3.05	3	0.03504
rc_F04320_s_at	F04320	1786	replication factor C (activator 1) 4 (37kD)	6.29	음	0.00042
rc_F04444_at	F04444	1788	EST	4.13	g	0.00944
rc_F04479_at	F04479	1789	KIAA1067 protein	3.23	g	0.04522
rc_F08876_at	F08876	1797	EST	9.06	- 음	0
			procollagen-proline, 2-oxoglutarate 4-dioxygenase			
rc_F09788_at	F09788	1808	(proline 4-hydroxylase), alpha polypeptide II	3.67	9	0.01682
rc_F10199_f_at	F10199	1813	EST	3.93	<u> </u>	0.03209
rc_F10290_at	F10290	1815	EST	3.39	<u>a</u>	0.02392
rc_F10453_at	F10453	1819	EST	3.64	음	0.01878
rc_F10741_at	F10741	1822	KIAA0622 protein	3.01	<u> </u>	0.03079
rc_F13809_f_at	F13809	1828	tropomyosin 1 (alpha)	4.4	9	0.01221
rc_H00540_at	H00540	1829	EST	3.74	g.	0.00234
rc_H05084_at	H05084	1844	EST	5.85	9	0.0059
rc_H07873_at	H07873	1856	EST	3.53	g	0.0391
rc_H08863_at	H08863	1859	hypothetical protein	7.18	음	0.02102
rc_H09241_s_at	H09241	1861	EST	3.05	9	0.01487
rc_H09271_f_at	H09271	1862	EST	4.78	음	0.00072
rc_H10933_at	H10933	1873	EST	6.18	롸	0.00003
rc_H11320_s_at	H11320	1875	SUMO-1 activating enzyme subunit 2	3.06	음	0.00167
rc_H16251_s_at	H16251	1886	EST	3.3	9	0.03286
rc_H27188_f_at	H27188	1908	collagen-binding protein 2 (colligen 2)	5.84	음	0.01826
rc_H27897_s_at	H27897	1911	hypothetical protein	3.01	음	0.00174
rc_H28333_f_at	H28333	1912	melanoma adhesion molecule	4.94	음	0.00166
rc_H41529_at	H41529	1926	EST	5.06	9	0.03309
H46486_s_at	H46486	1932	nesca protein	4.57	9	0.00749
rc_H47357_f_at	H47357	1934	EST	3.65	9	0.03799
rc_H48459_s_at	H48459	1937	KIAA0186 gene product	3.1	롸	0.02325
rc_H52937_at	H52937	1944	roundabout (axon guidance receptor, Drosophila)	4.02	음	0.00163
rc_H56345_r_at	H56345	1950	EST	3.73	롸	0.00853
rc_H57709_s_at	H57709	1956	ribosomal protein L31	4.41	롸	0.00091

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_H59617_at	H59617	1964	EST	5.81		0.0115
rc_H62474_f_at	H62474	1970	EST	3.39	. a	0.04173
rc_H64493_f_at	H64493	1973	immunoglobulin heavy constant gamma 3 (G3m marker)	4.74	<u> </u>	0.00751
			phospholipase A2, group VII (platelet-activating factor		•	
rc_H65030_s_at	H65030	1974	acetylhydrolase, plasma)	3.26	9	0.02278
rc_H65042_at	H65042	1975	EST	3.44	<u> </u>	0.0006
H67964_at	H67964	1981	EST	3.06	· <u>9</u>	0.02707
rc_H68794_at	H68794	1984	EST	3.67	. <u>a</u>	0.00327
rc_H70739_f_at	H70739	1991	EST	4.34	. <u>G</u>	0.00106
rc_H73484_s_at	H73484	1995	ferritin, heavy polypeptide 1	3.18	ď	0.00432
rc_H78211_at	H78211	2001	EST	7.5	<u> </u>	0.02674
rc_H86072_f_at	H86072	2015	EST	4.49	. <u>G</u>	0.01301
rc_H88674_s_at	H88674	2021	collagen, type I, alpha 2	4.15	g.	0.02664
rc_H89987_s_at	H89987	2027	ATP-binding cassette, sub-family C (CFTR/MRP),	3.13	g	0.01194
rc_H91632_at	H91632	2031	EST	3.5	g	0.03688
rc_H94471_at	H94471	2042	occludin	6.26	g	0.00379
rc_H96850_at	H96850	2055	dolichyl-diphosphooligosaccharide-protein	3.03	g	0.00679
rc_H97012_at	H97012	2058	EST	3.51	<u> </u>	0.03505
rc_H97013_at	H97013	2059	ephrin-A4	6.8	9	0.00023
rc_H97677_s_at	H97677	2062	EST	4.34	g	0.00753
rc_H99261_s_at	H99261	2074	EST	3.33	g	0.00319
rc_H99364_at	H99364	2075	chloride channel 7	3.03	g	0.01727
rc_H99473_s_at	H99473	2077	regulator of nonsense transcripts 1	6.51	d n	0.00025
rc_H99489_s_at	H99489	2078	quiescin Q6	3.4	d	0.02682
rc_H99587_s_at	H99587	2079	EST	4.44	d	0.00532
rc_H99774_at	H99774	2081	EST	3.51	g	0.0000
rc_H99877_at		2083	exportin, tRNA (nuclear export receptor for tRNAs)	3.75	g	0.00302
rc_H99879_at	H99879	2084	EST	10.81	d'n	0.001

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
J00231_f_at	J00231	2087	immunoglobulin heavy constant gamma 3 (G3m marker)	6.23	g	0.00177
J03040_at	J03040	2091	secreted protein, acidic, cysteine-rich (osteonectin)	3.77	g	0.00594
J03464_s_at	J03464	2094	collagen, type I, alpha 2	10.37	. <u>a</u>	0.00979
			keratin 10 (epidermolytic hyperkeratosis; keratosis		-	
J04029_s_at	J04029	2102	palmaris et plantaris)	3.02	g	0.00032
J05614_at	J05614	2122	EST	3.73	. o	0.03419
L03411_s_at	L03411	2134	RD RNA-binding protein	4.06	9	0.00467
L04270_at	·L04270	2135	lymphotoxin beta receptor (TNFR superfamily, member	3.5	. <u>a</u>	0.01547
L06797_s_at	L06797	2143	chemokine (C-X-C motif), receptor 4 (fusin)	3.23	. g	0.04782
L11669_at	L11669	2157	tetracycline transporter-like protein	3.4	. <u>a</u>	0.02062
			high-mobility group (nonhistone chromosomal) protein		•	
L17131_ma1_at	L17131	2168	isoforms I and Y	4.45	a	0.03141
			TATA box binding protein (TBP)-associated factor, RNA		•	
L25444_at	L25444	2181	polymerase II, E, 70/85kD	3.78	an	0.00011
			cyclin-dependent kinase inhibitor 3 (CDK2-associated		•	
L25876_at	L25876	2182	dual specificity phosphatase)	4.43	g	0.00082
L28821_at	L28821	2188	mannosidase, alpha, class 2A, member 2	4.63	. <u>a</u>	0.00876
L29218_s_at	L29218	2190	CDC-like kinase 2	6.51	. <u>a</u>	0.00019
L29218_at	L29218	2190	CDC-like kinase 2	3.82	. <u>a</u>	0.00035
L33930_s_at	L33930	2198	CD24 antigen (small cell lung carcinoma cluster 4	4.35	. <u>a</u>	0.03968
			transcription elongation factor B (SIII), polypeptide 1		•	
L34587_at	L34587	2200	(15kD, elongin C)	3.12	a	0.00946
L47125_s_at	L47125	2218	glypican 3	10.69	. <u>a</u>	0.04129
L76191_at	L76191	2222	interleukin-1 receptor-associated kinase 1	3.85	. <u>a</u>	0.00152
			excision repair cross-complementing rodent repair		•	
L76568_xpt3_f_at	L76568	2225	deficiency, complementation group 4	3.4	g	0.0172
M12125_at	M12125	2241	tropomyosin 2 (beta)	7.13	g	0.0004
M14483_ma1_s_at	M14483	2261	prothymosin, alpha (gene sequence 28)	3.36	g	0.00033
M19267_s_at	M19267	2286	tropomyosin 1 (alpha)	4.3	g	0.00893

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank Se	Sed ID	Known Gene Name	Fold Change	Direction	Pvalue
M21259_at	M21259 2	2293 s	small nuclear ribonucleoprotein polypeptide E	3.68	1	0.00415
M26576_cds2_at			EST	3.48	. <u>a</u>	0.00062
AFFX-M27830_5_at	_	2314 E	EST	4.6	d n	0.04719
AFFX-M27830_M_at		2314 E	EST	3.54	. <u>a</u>	0.00777
AFFX-M27830_5_at			EST	3.3	g	0.02453
M31303_rna1_at			leukemia-associated phosphoprotein p18 (stathmin)	5.86	음	0.00071
M32977_s_at	M32977 2	2336 v	vascular endothelial growth factor	3.93	ď	0.04917
		•	v-erb-b2 avian erythroblastic leukemia viral oncogene			
M34309_at	M34309 2	2342 1	homolog 3	3.49	g	0.00191
M35252_at		-	transmembrane 4 superfamily member 3	4.65	ď	0.04128
M37583_at		_	H2A histone family, member Z	4.25	g	0.00135
M55210_at	M55210 2		laminin, gamma 1 (formerly LAMB2)	3.47	g	0.02551
M55998_s_at		_	collagen, type I, alpha 1	3.54	ď	0.01449
M57710_at			lectin, galactoside-binding, soluble, 3 (galectin 3)	6.76	d	0.00103
M57730_at			ephrin-A1	3.39	dn	0.00199
M60784_s_at			small nuclear ribonucleoprotein polypeptide A	4.74	g	0.00001
M61916_at		_	aminin, beta 1	3.18	요	0.01171
M63573_at			peptidylprolyl Isomerase B (cyclophilin B)	3.59	đ	0.00916
M68864_at	M68864 2		ORF	3.95	d	0.00144
M86667_at	M86667 2	2411 r	nucleosome assembly protein 1-like 1	3.08	g	0.00473
		w	stress-induced-phosphoprotein 1 (Hsp70/Hsp90-			
M86752_at		2412 c	organizing protein)	5.15	đ	0.02881
M87339_at	M87339 2	2415 r	replication factor C (activator 1) 4 (37kD)	4.59	g.	0.00116
_M91083_at	M91083 2	2419 c	chromosome 11 open reading frame 13	3.19	Д	0.00243
		_	membrane component, chromosomal 4, surface marker			
M93036_at	M93036 2	_	(35kD glycoprotein)	3.07	g	0.04199
M94250_at	M94250 2	2426 r	midkine (neurite growth-promoting factor 2)	9.86	g	0.02104
M94345_at			capping protein (actin filament), gelsolin-like	3.59	g	0.04508
M97856_at	M97856 2	2436 r	nuclear autoantigenic sperm protein (histone-binding)	3.21	9	0.00444
rc_N21407_at	N21407 2	2443 E	EST	3.47	g	0.01037
rc_N21648_s_at	N21648 2	2447 N	MpV17 transgene, murine homolog, glomerulosclerosis	3.73	롸	0.00071

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank Se	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_N26904_at	N26904 2	2469	EST	15.38	9	0.00077
rc_N29484_at	N29484 2	2478	EST	3.08	· S	0.04834
rc_N29742_at	N29742 2	2481	EST	3.74	đ	0.00104
rc_N31597_s_at	N31597 2	2487	DKFZP564G2022 protein	3.17	9	0.03017
rc_N33920_at	N33920 2	2493	diubiquitin	50.29	g	0
rc_N34825_s_at	N34825 2	2498	DKFZP434P106 protein	3.27	<u> </u>	0.01334
rc_N35913_at	N35913 2	2503	EST	3.48	g	0.0016
N36432_at	N36432 2	2507	erythrocyte membrane protein band 4.1-like 2	7.95	. <u>a</u>	0.00067
rc_N39237_at	N39237 2	2511	EST	3.45	9	0.02481
N42272_s_at	N42272 2	2515	EST	3.03	. <u>q</u>	0.0017
			eukaryotic translation initiation factor 3, subunit 3		•	
rc_N47956_at	N47956 2	2524	(gamma, 40kD)	3.76	9	0.00968
rc_N48790_at		2532	EST	3.32	g	0.00654
rc_N51590_s_at	N51590 2	2546	EST	3.01	g	0.04345
rc_N51771_at	N51771 2	2548	KIAA0652 gene product	3.5	g	0.00028
			ADP-ribosyltransferase (NAD+; poly (ADP-ribose)			
rc_N51855_at	N51855 2	2550	polymerase)-like 3	3.39	g	0.00115
rc_N52168_at		2551	EST	3.66	g.	0.00127
rc_N53067_at	_	2557	DKFZP547E1010 protein	3.1	g	0.00101
rc_N54067_at	N54067 2	2562	mitogen-activated protein kinase kinase kinase kinase 4	4.82	g	0.00229
rc_N54841_at		2572	EST	5.87	요	0.02752
rc_N56935_s_at		2575	EST	4.04	g	0.00797
rc_N59536_at		2586	EST	11.68	dn	0.00484
rc_N62126_at		2589	EST	6.42	g	0.00109
rc_N64374_at	N64374 2	2608	KIAA0537 gene product	3.25	đ	0.01652
rc_N67815_f_at		2627	EST	3.84	đ	0.00439
rc_N68018_at	_	2631	TBP-associated factor 172	3.84	d	0.00277
rc_N68241_at	N68241 2	2634	EST	4.32	d	0.00532
rc_N69084_i_at	N69084 2	2643	EST	3.11	g	0.0094
rc_N69252_f_at	••	2647	ferritin, light polypeptide	3.69	음	0.04116
rc_N69263_at	N69263 2	2648	EST	5.26	g	0.0276

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_N69390_at	N69390	2650	EST	3.99	dп	0.00016
rc_N69879_s_at	N69879	2651	drebrin 1	3.15	. g	0.01659
rc_N70481_at	N70481	2658	EST	4.13	g G	0.0099
rc_N70678_s_at	N70678	2660	TAR (HIV) RNA-binding protein 1	3.78	. <u>a</u>	0.02858
			solute carrier family 11 (proton-coupled divalent metal		•	
rc_N72116_s_at	N72116	2668	ion transporters), member 2	5.57	đ	0.00709
rc_N73705_at	N73705	2677	EST	3.75	<u> </u>	0.01762
rc_N73762_f_at	N73762	2678	EST	3.67	<u> </u>	0.00796
rc_N73808_f_at	N73808	2679	EST	6.44	<u> </u>	0.00352
rc_N73865_at	N73865	2681	EST	4.43	<u>a</u>	0.00177
rc_N75541_at	N75541	2692	EST	4.43	<u> </u>	0.01059
rc_N80703_at	N80703	2704	EST	5.65	. <u>s</u>	0.0001
rc_N90238_l_at	N90238	2712	EST	3.13	. .	0.02492
rc_N91773_at	N91773	2719	lysyl oxidase	4.31	9	0.00302
rc_N92948_s_at	N92948	2726	nuclear phosphoprotein similar to S. cerevisiae PWP1	4.09	9	0.0019
rc_N93299_f_at	N93299	2732	nuclear receptor co-repressor 1	6.99	G	0.0371
rc_N93316_at	N93316	2733	EST	3.16	음	0.01262
rc_N93798_at	N93798	2738	protein tyrosine phosphatase type IVA, member 3	4.91	음	0.00245
rc_N98464_s_at	N98464	2744	EST	3.68	g	0.03007
rc_N98758_f_at	N98758	2745	EST	3.54	9	0.02609
rc_N99944_s_at	N99944	2749		3.46	<u>a</u>	0.00104
rc_R05316_s_at	R05316	2760		4.2	g	0.00011
rc_R06251_f_at	R06251	2764	tumor protein D52-like 2	4.88	ď	0.03097
rc_R06254_f_at	R06254	2765	tumor protein D52-like 2	3.53	9	0.04865
rc_R06400_at	R06400	2768	EST	3.03	9	0.03266
rc_R06986_f_at	R06986	2776	peptidylprolyl isomerase B (cyclophilin B)	7.03	g S	0.00628
rc_R07172_i_at	R07172	2777	EST	5.54	g	0.01322
rc_R15740_at	R15740	2791	carbohydrate (keratan sulfate Gal-6) sulfotransferase 1	3.36	g	0.00268
rc_R16144_at	R16144	2794	EST	3.24	ဌ	0.0087
rc_R20817_s_at	R20817	2797	ubiquitin-conjugating enzyme E2A (RAD6 homolog)	3.03	g	0.01091
rc_R22565_at	R22565	2800	EST	3.52	롸	0.04352

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank Seq ID	D Known Gene Name	Fold Change	Direction	Pvalue
rc_R26744_at	R26744 2804	midline 1 (Opitz/B	3.8	음	0.00266
		myristoylated alanine-rich protein kinase C substrate	٠		
rc_R27016_s_at	R27016 2806	; (MARCKS, 80K-L)	3.53	g	0.03056
rc_R27296_f_at	R27296 2807	EST	3.41	g.	0.00309
		UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase,		•	
rc_R28636_at	R28636 2809		3.06	9	0.03678
rc_R31607_at	R31607 2813		3.41	g	0.00163
rc_R33498_s_at	R33498 2820	EST EST	3.5	음	0.03336
rc_R39191_s_at	R39191 2834	KIAA1020 protein	5.18	<u>g</u>	0.03185
R39390_at	R39390 2837	EST	4.18	롸	0.0004
rc_R39610_s_at	R39610 2838	s calpain, large polypeptide L2	3.13	롸	0.01863
rc_R43952_at	R43952 2853	homeo box B5	3.39	d	0.04829
rc_R44617_f_at	R44617 2857	WyoD family inhibitor	6.54	g	0.02505
rc_R44793_at	R44793 2859	EST EST	5.4	dn	0.00329
rc_R44839_at	R44839 2861	i-beta-1,3-N-acetylglucosaminyltransferase	S	đ	0.01812
rc_R45569_at	R45569 2864	DKFZP547E1010 protein	3.96	dn	0.00259
rc_R45994_f_at	R45994 2867	EST	6.48	d	0.00358
rc_R46079_f_at	R46079 2868	EST	3.03	đ	0.00755
rc_R46337_s_at	R46337 2869	secretory carrier membrane protein 3	3.01	d	0.00374
rc_R48447_at	R48447 2871	EST	4.76	음	0.00533
rc_R48473_f_at	R48473 2872	_	3.46	g	0.01196
rc_R48594_s_at	R48594 2875	_	6.15	đ	0.03831
rc_R49395_s_at	R49395 2881	EST	3.31	음	0.00867
rc_R49476_at	R49476 2883		4.93	읔	0.00763
rc_R49482_at	R49482 2884	L EST	3.27	음	0.0161
rc_R49708_s_at	R49708 2886		4.56	슠	0.03767
rc_R51908_s_at	R51908 2892		3.16	đ	0.0083
rc_R52161_at	R52161 2893	_	3.41	g	0.00053
rc_R52649_at	R52649 2894	t EST	4.69	đ	0.00135
rc_R53109_f_at	R53109 2899		3.31	đ	0.02406
rc_R54614_s_at	R54614 2902	2 EST	3.22	đ	0.00334

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_R56095_s_at	R56095	2906	EST	3.67	g	0.0158
ഗ	R60512	2918	KIAA0191 protein	3.08	đ	0.00856
rc_R61374_at	R61374	2921	EST	4.33	d	0.01489
rc_R61557_at	R61557	2922	KIAA0100 gene product	3.9	g	0.00292
rc_R62456_at	R62456	2925	EST	3.44	9	0.00285
rc_R66469_f_at	R66469	2937	pleckstrin and Sec7 domain protein	3.52	9	0.0272
rc_R70005_at	R70005	2944	EST	4.98	음	0.00007
rc_R70253_at	R70253	2945	EST	3.38	9	0.03125
rc_R70532_at	R70532	2947	EST	3.44	g	0.02186
rc_R70801_s_at	R70801	2950	EST	90.9	9	0.00291
rc_R71395_at	R71395	2952	EST	4.12	g	0.03719
rc_R72886 s_at	R72886	2956	KIAA0422 protein	5.5	d	0.00091
rc_R73569_s_at	R73569	2960	EST	3.54	d n	0.01962
			O-linked N-acetylglucosamine (GlcNAc) transferase			
			(UDP-N-acetylglucosamine:polypeptide-N-			
rc_R76782_s_at	R76782	2963	acetylglucosaminyl transferase)	3.73	ď	0.00094
rc_R77451_i_at	R77451	2964	EST	3.67	<u>a</u>	0.00078
rc_R79246_f_at	R79246	2969	melanoma adhesion molecule	90.9	ď	0.00057
rc_R91753_at	R91753	2983	EST	3.45	đ	0.02391
rc_R91819_at	R91819	2984	EST	12.81	dn	0.00037
rc_R92449_s_at	R92449	2985	KIAA0323 protein	4.34	dn	0.00104
rc_R96527_s_at	R96527	2999	KIAA0253 protein	4.62	d	0.00702
rc_R96924_s_at	R96924	3001	EST	7.04	g	0.00012
S67070_at	S67070	3023	heat shock 27kD protein 2	3.12	g	0.01688
S78187_at	S78187	3036	cell division cycle 25B	4.83	d	0.00547
rc_T03438_s_at	T03438	3043	EST	3.79	đ	0.02042
rc_T03580_f_at	T03580	3046	pyruvate kinase, muscle	2.57	g	0.01344
rc_T03749_at	T03749	3048		4.23	ታ	0.00776
rc_T10316_s_at	T10316	3052		3.2	9	0.04794
rc_T10698_s_at	T10698	3054		3.86	d	0.00195
rc_T15852_f_at	T15852	3062	EST	5.21	슠	0.00642

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
rc_T16206_s_at	T16206	3065	EST	4.29	9	0.00868
rc_T16226_at	T16226	3066	EST	7.23	S	0.00119
rc_T16550_at	T16550	3072	vacuolar protein sorting 45B (yeast homolog)	5.88	9	0.00004
rc_T16652_s_at	T16652	3073	BCS1 (yeast homolog)-like	3.63	g	0.00434
rc_T16983_s_at	T16983	3074	cleavage and polyadenylation specific factor 4, 30kD	4.23	<u>a</u>	0.0106
rc_T17066_s_at	T17066	3075	SET domain, bifurcated, 1	5.14	9	0.00073
rc_T17339_f_at	T17339	3076	EST	3.29	9	0.00669
rc_T17353_s_at	T17353	3077	EST	3.52	đ	0.02085
rc_T23426_s_at	T23426	3079	EST	3.51	d	0.00674
rc_T23465_at	T23465	3081	EST	3.64	9	0.00265
rc_T23516_f_at	T23516	3083	3-phosphoglycerate dehydrogenase	3.39	9	0.00551
rc_T24068_s_at	T24068	3088	EST	8.65	ဌ	0.00118
rc_T26471_at	T26471	3094	EST	3.76	g	0.0165
			X-ray repair complementing defective repair in Chinese			
rc_T26646_f_at	T26646	3097	hamster cells 1	3.49	d	0.02482
rc_T30214_at	T30214	3099	EST	4.46	g	0.03654
rc_T33489_s_at	T33489	3105	EST	4.6	ď	0.00285
rc_T33508_s_at	T33508	3106	phosphatidylinositol-4-phosphate 5-kinase, type II, beta	4.96	d	0.00064
rc_T33619_s_at	T33619	3107	EST	3.36	g	0.01283
rc_T33625_at	T33625	3108	EST	3.36	9	0.04096
rc_T33859_at	T33859	3109	KIAA0365 gene product	3.9	g	0.0019
			potassium voltage-gated channel, shaker-related			
T34377_at	T34377	3111	subfamily, beta member 2	4.55	d	0.00041
rc_T40439_s_at	T40439	3115	smalf nuclear ribonucleoprotein polypeptide B"	3.06	9	0.02842
rc_T41078_at	T41078	3121	bromodomain adjacent to zinc finger domain, 2B	3.08	S	0.03426
rc_T47032_s_at	T47032	3124	partner of RAC1 (arfaptin 2)	60.9	9	0.00019
.rc_T47325_s_at	T47325	3125	EST	5.6	S	0.02923
			ceroid-lipofusclnosis, neuronal 3, juvenile (Batten,			
rc_T47969_s_at	T47969	3128	Spielmeyer-Vogt disease)	3.19	읈	0.02283
rc_T51972_at	T51972	3140	EST	3.44	dn	0.00406

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change	Direction	Pvalue
			cytochrome P450, subfamily XIA (cholesterol side chain			
rc_T53590_s_at	T53590	3144	cleavage)	5.09	dn	0.00002
rc_T55196_at	T55196	3147	EST	4.24	g	0.00046
rc_T58607_at	T58607	3155	EST	6.83	g	0.03711
rc_T59668_s_at	T59668	3160	lysyl oxidase	3.5	ŝ	0.00083
rc_T62521_at	T62521	3168	EST	4.1	g	0.00392
rc_T62918_at	T62918	3169	EST	5.25	g	0.00687
rc_T65957_f_at	T65957	3176	ribosomal protein S3A	3.94	<u> </u>	0.04187
rc_T66935_at	T66935	3179	EST	3.01	g	0.00123
rc_T67053_f_at	T67053	3180	EST	ß	g.	0.01846
rc_T77733_s_at	T77733	3219	tubulin, gamma 1	4	<u>a</u>	0.00526
rc_T78922_s_at	T78922	3222	stem cell growth factor; lymphocyte secreted C-type	3.89	d n	0.00604
rc_T79477_s_at	T79477	3223	death-associated protein 6	4.4	<u>a</u>	0.00074
rc_T81393_s_at	T81393	3228	HMT1 (hnRNP methyltransferase, S. cerevisiae)-like 1	3.32	ď	0.0023
rc_T88814_at	T88814	3242	EST	4.87	dn	0.00001
rc_T89703_at	T89703	3244	EST	5.27	9	0.00019
rc_T90190_s_at	T90190	3247	H1 histone family, member 2	4.88	đ	0.00555
rc_T94452_at	T94452	3257	EST	3.23	9	0.02245
rc_T95057_f_at	T95057	3259	EST	6.46	dn	0.00613
rc_T97679_at	T97679	3266	EST	3.32	đ	0.01566
rc_T99312_at	T99312	3270	EST	3.22	d	0.00084
U18018_at	U18018	3317	ets variant gene 4 (E1A enhancer-binding protein, E1AF)	3.9	9	0.0403
U18321_at	U18321	3318	death associated protein 3	3.14	d	0.00833
			proteasome (prosome, macropain) 26S subunit, non-			
U24704_at	U24704	3332	ATPase, 4	3.45	g	0.00037
			cyclin-dependent kinase inhibitor 2A (melanoma, p16,		•	
U26727_at	U26727	3337	Inhibits CDK4)	3.53	d	0.02913
U30825_at	U30825	3343	splicing factor, arginine/serine-rich 9	3.07	요	0.01928
U45285_at	U45285	3364	T-cell, immune regulator 1	5.75	음	900000
U47025_s_at	U47025	3368	phosphorylase, glycogen; brain	4.47	롸	0.00037

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank Seg ID	D Known Gene Name	Fold Change	Direction	Pvalue
		slah binding protein 1; FBP interacting repressor;			
		pyrimidine tract binding splicing factor; Ro			
U51586_at	U51586 3386	i ribonucleoprotein-binding protein 1	3.65	g	0.00403
		gamma-glutamyi hydrolase (conjugase,			
U55206_at	U55206 3392	: folylpolygammaglutamyl hydrolase)	3.34	g	0.00315
U59321_at	U59321 3398	DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 17	3.12	<u> </u>	0.02469
U62392_at	U62392 3403	zinc finger protein 193	3.56	g	0.0407
U66661_at	U66661 3406	gamma-aminobutyric acid (GABA) A receptor, epsilon	3.55	<u>a</u>	0.0045
U68142_at	U68142 3411		3.02	. <u>G</u>	0.0296
		SHC (Src homology 2 domain-containing) transforming		•	
U73377_at	U73377 3417		4.64	g	0.00081
U73379_at	U73379 3418	ubiquitin carrier protein E2-C	3.32	. <u>a</u>	0.00808
U75285_rna1_at	U75285 3422	apoptosis inhibitor 4 (survivin)	5.32	<u> </u>	0.01127
U85625_at	U85625 3448	i ribonuclease 6 precursor	4	<u>a</u>	0.01664
U90426_at	U90426 3453	_	3.24	. G	0.00035
U90551_at	U90551 3457		3.54	<u> </u>	0.01523
U90904_at	U90904 3458		3.02	g	0.00381
U91930_at			3.68	g	6000000
rc_W02041_at	W02041 3466		5.34	g.	0.00027
rc_W02695_at	W02695 3467	EST	3.1	g	0.04745
rc_W04507_s_at	W04507 3469		3.02	g	0.04091
rc_W04550_at	W04550 3470	EST	4.01	g	0.00349
rc_W15495_at	W15495 3474	chromosome 21 open reading frame 5	3.09	g.	0.00491
W26716_at		_	5.47	g	0.00146
W28362_at	W28362 3488	MIAA0974 protein	4.38	d _n	0.00322
W28366_at	W28366 3489	EST EST	3.21	dn	0.01007
rc_W31906_at	W31906 3497		6.62	d _n	0.00926
rc_W42627_f_at			4.37	d	0.00021
rc_W42674_at	W42674 3512		3.07	dn	0.0261
rc_W42778_at	W42778 3513	S EST	3.27	ď	0.02411
rc_W42788_at	W42788 3514	deoxynucleotidyltransferase, terminal	3.24	롸	0.02261

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank Se	Seq ID Known Gene Name	Fold Change	te Direction	Pvalue
rc_W42957_at	W42957 3	3516 calmodulin 2 (phosphorylase kinase, delta)	5.79		0.03669
rc_W44557_at	W44557 3	3518 chromosome 1 open reading frame 2	4.1	g S	0.00433
rc_W45320_f_at	W45320 3	3523 KRAB-associated protein 1	10.05	<u>a</u>	0.00002
rc_W46286_s_at	W46286 3	3526 EST	3.68	g	0.00311
rc_W46634_at		_	5.03	9	0.02152
rc_W46810_s_at		3531 HMT1 (hnRNP methyltransferase, S. cerevisiae)-like 2		음	0.03434
rc_W46846_at			5.11	9	0.00025
rc_W46947_at		_	3.42	d n	0.04665
rc_W47206_at		_	3.23	9	0.01931
W49743_at	W49743 3	3540 EST	3.11	dn'	0.01121
rc_W49791_at		3541 plasminogen activator, tissue	3.58	g	0.02438
rc_W56642_at	W56642 38	3547 EST	3.15	d _n	0.00654
rc_W57931_at	W57931 3	3549 EST	3.01	음	0.02661
rc_W58081_at	W58081 3	3550 neuroendocrine-specific protein C like (foocen)	3.05	g	0.03767
W58247_s_at	W58247 3	3551 kinesin family member 4	3.08	g	0.00048
		DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide, Y		•	
rc_W60097_at	W60097	_	4.82	dn	0.04903
rc_W60486_at		_	4.27	g	0.0046
rc_W63608_at		_	3.33	g	0.02443
W69302_at		3573 EST	4.37	g	0.00165
rc_W69468_at		_	3.25	g	0.00055
rc_W70336_at		_	4.46	g.	0.00023
rc_W72187_at		_	3.09	g	0.00134
rc_W72276_at		_	3.56	9	0.0476
rc_W73038_at		3588 EST	4.83	g	0.00902
rc_W74536_s_at		3598 advanced glycosylation end product-specific receptor	r 3.07	g	0.00251
rc_W78057_at		_	5.53	g	0.01231
rc_W79421_at		_	3.57	d	0.00895
rc_W79773_at	W79773 3	3605 EST	4.89	9	0.00034
rc_W80730_at		_	3.35	g	0.01526
rc_W80763_at	W80763 3	3608 EST	4.98	ᅀ	0.01026

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank Se	Seq ID Known Gene Name	6	Fold Change	Direction	Pvalue
		KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein	reticulum protein			
rc_W80852_at	•	_	•	6.37	음	0.00005
rc_W81654_at	_		3	90.9	đ	0.00127
rc_W84447_at				3.34	9	0.00986
rc_W85875_at				4.91	g	0.01198
rc_W86214_at	W86214 36	3625 EST		4.3	<u> </u>	0.00194
rc_W86748_at	W86748 36	3629 EST		5.09	9	0.01882
rc_W90146_f_at	W90146 36	3644 EST		3.58	g.	0.00322
rc_W92608_s_at	W92608 36	3653 BAI1-associated protein 3		4.84	g	0.00599
rc_W94281_s_at	W94281 36	3658 integral membrane protein 2C		3.51	g	0.01689
rc_W94885_at	W94885 36	3660 EST		6.53	g	0
rc_W95841_at	W95841 36	3666 EST		ო	g	0.00466
X04347_s_at	X04347 36	3680 heterogeneous nuclear ribonucleoprotein A1	ein A1	3.34	g	0.00123
X05610_at	X05610 36	3685 collagen, type IV, alpha 2		6.04	d	0.00062
		collagen, type III, atpha 1 (Ehlers-Danios syndrome type	los syndrome type			
X06700_s_at	X06700	3688 IV, autosomal dominant)		3.58	dn	0.02964
		keratin 10 (epidermolytic hyperkeratosis; keratosis	is; keratosis			
X14487_rna1_s_at	X14487 3	3702 palmaris et plantaris)		3.19	dn	0.01268
	X14850 3	3706 H2A histone family, member X		3.13	<u>g</u>	0.01523
X17567_s_at			eptides B and B1	3.96	d _n	0.00317
X53331_at		3727 matrix Gla protein		3.95	d n	0.0151
X54667_s_at	X54667 37	_		3.51	dn	0.00187
X54941_at		_		3.99	dn	0.0016
X54942_at		3733 CDC28 protein kinase 2		3.8	ф	0.0035
X56494_at		3738 pyruvate kinase, muscle		3.65	g	0.04795
X57129_at		3743 H1 histone family, member 2		4.63	g	0.00663
X57809_s_at		3746 immunoglobulin lambda locus		3.64	g	0.02655
X62153_s_at		3754 minichromosome maintenance deficient (S. cerevisiae) 3	int (S. cerevisiae) 3		g	0.00704
X62534_s_at	X62534 3.	3755 high-mobility group (nonhistone chromosomal) protein 2	nosomal) protein 2	3.39	9	0.0186
X64364_at				3.57	g	0.00902
X66899_at	X66899 3	3772 Ewing sarcoma breakpoint region 1		3.41	ф	0.03777

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change Direction	Direction	Pvalue
			transmembrane protein (63kD), endoplasmic			
X69910_at	X69910	3787	reticulum/Golgi intermediate compartment	3.35	an	0.00898
X74801_at	X74801	3791	chaperonin containing TCP1, subunit 3 (gamma)	3.86	- G	0.00453
X79536_at	X79536	3804	heterogeneous nuclear ribonucleoprotein A1	3.06	g	0.00449
X83425_at	X83425	3812	Lutheran blood group (Auberger b antigen included)	3.66	. an	0.02661
X87212_at	X87212	3816	cathepsin C	3.45	9	0.02486
			DNA segment on chromosome X (unique) 9879		•	
X92896_at	X92896	3829	expressed sequence	3.1	9	0.0405
X99920_at	X99920	3843	S100 calcium-binding protein A13	4.66	9	0.00113
Y00705_at	Y00705	3850	serine protease inhibitor, Kazal type 1	28.88	- <u>9</u>	0.00003
Y00764_at	Y00764	3851	ublquinol-cytochrome c reductase hinge protein	3.04	9	0.01294
Y08302_at	Y08302	3852	dual specificity phosphatase 9	3.48	. <u>9</u>	0.00787
Y08999_at	Y08999	3855	actin related protein 2/3 complex, subunit 1A (41 kD)	3.13	9	0.02376
			eukaryotic translation elongation factor 1 delta (guanine		-	
Z21507_at	Z21507	3867	nucleotide exchange protein)	3.57	g	0.01898
Z23090_at	ZZ3090	3868	heat shock 27kD protein 1	3.69	- <u>a</u>	0.00628
Z24727_at	Z24727	3871	tropomyosin 1 (alpha)	3.64	9	0.00388
Z37987_s_at	Z37987	3882	glypican 3	10.66	on on	0.02304
rc_Z38299_at	Z38299	3887	EST	3.71	dn.	0.0036
rc_Z38431_at	Z38431	3889	EST	3.09	Э	0.0083
rc_Z38444_at	Z38444	3891	KIAA0923 protein	3.38	Э	0.02918
rc_Z38462_at	Z38462	3892	KIAA0938 protein	4.69	<u> </u>	0.0142
rc_Z38904_at	Z38904	3896	EST	3.02	g	0.00814
rc_Z39191_at	Z39191	3901	EST	3.47	a	0.00756
rc_Z39200_at	Z39200	3902	EST	4.07	<u>a</u>	0.00075
rc_Z39379_at	Z39379	3903	EST	3.77	. a	0.00513
rc_239429_at	Z39429	3906	EST	3.58	đ	0.00416
rc_239682_s_at	Z39682	3911	KIAA0954 protein	96.9	đ	0.01966
	240006	3917	EST	3.54	g	0.00156
	Z40883	3924	EST	3.26	đ	0.01863
rc_241349_at	241349	3931	EST	3.45	롸	0.01503

Table 7B. Down regulated in hepatocellular carcinoma versus normal sample set 2.

Affy ID	Genbank	Seq ID	Known Gene Name	Fold Change Direction Pvalue	Direction	Pvalue
			succinate dehydrogenase complex, subunit A.			
rc_Z41747_at	Z41747	3936	flavoprotein (Fp)	3.04	an	0.01336
Z47727_at	Z47727	3940	polymerase (RNA) II (DNA directed) polypeptide K	3.28	9	0.00317
Z74615_at	Z74615	3949	collagen, type I, alpha 1	5.47	9	0.00283
Z74616_s_at	Z74616	3950	collagen, type I, alpha 2	5.95	S	0.02212

Table 8A. Genes and ESTs expressed only in hepatocellular carcinoma versus normal sample set 2.

				fold		pcc	hcc	pcc			
				change		sample	sample	sample	normal	normal	normal
				in hcc		set 2:	set 2:	set 2:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	set 2	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
			DEK oncogene (DNA								
AA093497_s_at	AA093497	199	binding)	W/N#	#N/A	180.58	107.64	165.71	52.11	48.84	26.51
AA248283 at	AA248283	534	EST	#N/V	#N/A	67.18	45.86		21.63		11 71
AA291456 s at	AA291456	200	EST	W/N#	#N/A	828.34	830.24		67121	4.	629 13
I I			GAS2-related on	: :					<u>!</u>		
AA400643 s at	AA400643	817	chromosome 22	4.04	0.03751	118.72	123.18	137.15	-43.6	-33.96	60,39
AA421079 at	AA421079	930	EST	#N/A	W/W#	37.17	34.26				15.28
I			Notch (Drosophila) homolog								
.AA428172_f_at	AA428172	986		9.63	0.00195	335.57	374.9	231.52	-9.64	-15.61	56.16
AA464043_s_at	AA464043	1255	EST	3.99	0.00056	116.97	115.99		14.27	10.06	25.86
H19562_at	H19562	1896	PTD010 protein	#N/A	W/V#	522.13	432.65	•	393.61	326.53	182.71
L08044_s_at	L08044	2149	trefoll factor 3 (intestinal)	#N/A	#N/A	214.6	108.17	238.79	107.82		184.16
L29218_s_at	L29218	2190	CDC-like kinase 2	6.51	0.00019	219.64	237.35		6.53	-10.03	59.8
L37747_s_at	L37747	2206	lamin B1	#N/A	#N/A	43.42	28.65	37.33	5.97	5.1	7.57
N34257_at	N34257	2495	EST	#N/A	#N/A	20.76	21.48		-1.84	-2.74	8.53
R50692_at	R50692	2888	KIAA0476 gene product	#N/A	#N/A	197.89	187.87	-	Ť	_	63.03
R60368_at	R60368	2917	EST	#N/A	#N/A	29.68	28.93	31.9	·		41.68
R66475_at	R66475	2938	EST	#N/A	#N/A	45.68	32.34	34.37	7.64		6.3
			potassium voltage-gated channel, shaker-related								
T34377_at	T34377	3111	subfamily, beta member 2 DEAD/H (Asp-Glu-Ala- Asp/His) box polypeptide 11 (S.cerevisiee CHI 1-like	4.55	0.00041	113.59	120.58	51.65	6.87	11.17	25.69
U75968_s_at	U75968	3423	helicase)	#N/#	V W W W	187.33	200.16			_	77.77
W28696_i_at	W28696	3491	NixAvovo gene product	¥N#	V V N W W	14.7	20.64	20.23	45.59	40.39	19.89
										•	

Table 8A. Genes and ESTs expressed only in hepatocellular carcinoma versus normal sample set 2.

				fold		hcc	pcc	pcc			
				change		sample	sample	sample	normal	normal	normal
				in hcc		set 2:	set 2:	set 2:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	set 2	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
			H1 histone family, member								
X57129_at	X57129	3743	2	4.63	0.00663	137.13	137.75	87.31	8.38	5.39	28.3
rc_AA024658_at	AA024658	47	ribosomal protein S19	7.55	0.00592	278.11	120.83	373.3	7.62	5.03	10.68
rc_AA029288_at	AA029288	92	EST	3.36	0.04908	134.53	56.15	209.69	4.09	3.35	8.39
rc_AA037828_at	AA037828	88	KIAA0614 protein	#N/A	#N/A	53.61	46.86	41.68	13.32	10.65	11.96
rc_AA040465_at	AA040465	95	EST	3.63	0.01806	229.8	210.67	180.94	47.15	45.53	5.48
rc_AA053660_at	AA053660	128	EST	#N/A	#N/A	543.66	223.47	685.44	95.24	79.97	42.99
			cAMP responsive element								
rc_AA136332_at	AA136332	299	binding protein 3 (luman)	W/A#	#N/¥	49.04	33.07	31.07	-18.27	-20.23	13.05
rc_AA149530_at	AA149530	324	interferon regulatory factor 3	#N/A	#N/A	32.94	23.12	34.23	4.21	5.38	8.53
rc_AA149586_at	AA149586	325	EST	#N/A	#N/¥	24.99	26.6	34.37	5.26	9.11	23.41
rc_AA206023_at	AA206023	427	EST	#N/A	#N/A	154.13	170.36	85.33	108.57	111.76	58.39
			N-ethylmaleimide-sensitive								
rc_aa234530_s_at	AA234530	484	factor	#N/A	#N/A	143.67	135.48	82.59	51.33	42.9	35.02
rc_AA251909_at	AA251909	549	EST	3.59	0.01129	92.19	79.34	72.73	8.88	11.22	8.27
rc_AA262030_at	AA262030	605	EST	#N/A	¥N\#	119.75	89.66	103.84	31.51	32.91	14.46
			ribonuclease HI, large								
rc_AA262477_at	AA262477	809	subunit	4.57	0.00724	242.42	199.5	182.26	44.51	36.87	22.37
rc_AA283759_at	AA283759	671	EST	¥N\#	#N/A	91.82	76.73	42.28	46.87	.45.86	21.54
rc_AA291644_at	AA291644	701	EST	3.28	0.00033	114.73	117.29	44.59	32.77	30.24	21.1
rc_AA338760_at	AA338760	744	EST	3.96	0.01307	129.77	130.26	87.27	14.91	21.91	26.96
rc_AA398205_at	AA398205	789	EST	4.22	0.00059	125.4	107.84	63.85	15.01	7.37	26.26
			tumor suppressor deleted in								
rc_AA401965_at	AA401965	833	oral cancer-related 1	7.58	0.00089	932.74	924.02	593.69	120.58	93.29	109.41
rc_AA402272_at	AA402272	837	EST	3.73	0.02336	348.91	340	230.15	99.7	92.28	80.27
rc_AA404597_at	AA404597	854	EST	#N/A	#N/A	609.98	525.02	371.31	379.26	336.33	167.43
rc_AA417030_at	AA417030	914	EST	7.35	0.00555	200.3	168.21	135.63	6.42	7.5	7.77

Table 8A. Genes and ESTs expressed only in hepatocellular carcinoma versus normal sample set 2.

				fold		pcc	pcc	pcc			
				change		sample	sample	sample	normal	normal	normal
				in hcc		set 2:	set 2:	set 2:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	set 2	p value	Mean	Medlan	Std Dev	Mean	-	Std Dev
rc_AA423820_at	AA423820	940	EST	#N/A	#N/A	111.38	111.23	120.84	41.9	I~	44.58
rc_AA425852_i_at	AA425852	928	EST	3.82	0.0395	131.52	95.35	166.76	7.02	5.22	4.75
			pituitary tumor-transforming								
rc_AA430032_at	AA430032	1009	_	10.67	0.00052	377.69	320.44	294.49	26.8	15.31	35.24
rc_AA430673_at	AA430673	1017	EST	#N/A	#N/A	45.74	34.15	44.8	-1.21	3.63	15.26
rc_AA443321_at	AA443321	1076	EST	#N/A	#N/A	33.93	32.89	11.76	10.79	9.65	7.26
			fumor suppressing								
rc_AA443941_at	AA443941	1085	subtransferable candidate 1	#N/A	#N/A	97.74	103.38	47.48	31.09	34.9	16.61
rc_AA447223_at	AA447223	1100	EST	#N/A	#N/A	31.66	18.91	31.1	4.45	3.74	6.5
			translation initiation factor								
rc_aa449431_s_at	AA449431	1124	IF2	3.76	0.00571	94.41	95.64	54.08	17.4	16.96	5.38
rc_AA454597_s_at	AA454597	1166	EST	4.23	0.00917	342.59	311.81	207.71	9.99	57.29	23.41
rc_AA458882_at	AA458882	1205	EST	#N/A	#N/A	93.56	52.28	98.72	24.97	22.52	17.66
rc_AA458934_at	AA458934	1208	EST	#N/A	#N/A	33.6	28.19	29.02	7.1	7.91	4.22
rc_AA465342_at	AA465342	1271	EST	3.21	0.01378	131.07	109.99	95.4	30.07	33.06	23.97
rc_AA477561_at	AA477561	1292	EST	#N/A	#N/A	146.3	127.03	97.99	63.83	76.56	37.87
			calcium/calmodulin-								
		!	dependent protein kinase								
rc_AA491295_at	AA491295	1390	kinase 2, beta	3.71	0.0103	180.61	173.47	118.85	46.95	31.51	65.56
			RAD51 (S. cerevisiae)								
			nomolog (E coll KecA								
rc_AA608545_at	AA608545	1462	homolog) flan structura-specific	W/A#	#N/A	70.5	57.51	53.36	7.76	8.92	6.17
rc AA620553 s at	AA620553	1504	endonicleses 1	7 58	0.000	76.090	222 62	201 66	11 11	A 05	20 53
A 6004 20	A 004000	5 6	Olivoridos de la companya de la comp	9.	0.00.0	202.01	232.03	201.00	14.44	4.00	50.55
rc_AA621325_at	AA621325	1522	HINK-1 suifotransferase	#N/A	#N/A	74.57	70.64	46.61	27.23	25.89	16.03
rc_AA621/80_at	AA621780	1530	CGI-96 protein	#N/A	¥N\¥	81.72	92.23	49.69	12.06	11.27	19.2
rc_F02807_at	F02807	1781	KIAA0838 protein	2.67	0.02064	260.02	219.01	229.96	20.93	16.66	22.24

Table 8A. Genes and ESTs expressed only in hepatocellular carcinoma versus normal sample set 2.

٠				fold		hcc	hcc	pcc			
				change		sample	sample	sample	normal	normai	normal
				in hcc		set 2:	set 2:	set 2:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	set 2	p value	Mean	_	Std Dev	Mean	Median	Std Dev
rc_F04444_at	F04444	1788	EST	4.13	0.00944	371.21	360.5	186.45	119.68	121.27	109.82
rc_F04524_s_at	F04524	1790	stomatin-like protein 1	#N/A	#N/A	117.77	135.65	68.29	46.56	44.53	33.75
rc_F08876_at	F08876	1797	EST	9.06	0	209.64	201.85	53.21	-22.5	-20.17	37.21
rc_F10161_at	F10161	1811	EST	#N/A	#N/A	50.78	46.73	32.42	15.4	14.78	11.87
rc_F10453_at	F10453	1819	EST	3.64	0.01878	135.07	138.53	85.7	27.28	14.2	54.04
rc_H04649_at	H04649	1838	EST	#N/A	#N/A	180.25	158.18	164.34	50.86	41.2	33.9
rc_H04793_at	H04793	1840	DKFZP434F091 protein	#N/A	#N/A	23.18	20	41.25	-14.45	-20.45	29
rc_H59617_at	H59617	1964	EST	5.81	0.0115	212.68	209.19	157.42	19.24	21.65	16.88
rc_H97012_at	H97012	2058	EST	3.51	0.03505	171.34	138.12	170.68	27.69	38.46	36.08
rc_H98657_at	H98657	2068	EST	#N/A	#N/A	141.17	131.42	69.63	111.2	84.74	128.92
rc_N23319_at	N23319	2454	EST	#N/A	#N/A	70.62	66.39	49.4	13.74	8.56	21.62
rc_N23868_at	N23868	2459	EST	#N/A	#N/A	79.69	81.67	56.06	20.52	20.19	11.48
rc_N45224_at	N45224	2516	EST	W/A#	#N/A	349.73	360.67	164.87	215.49	223.16	151.06
rc_N48595_at	N48595	2528	EST	#N/A	#N/A	85.77	67.62	51.78	28.84	29.38	8.3
rc_N75541_at	N75541	2692	EST	4.43	0.01059	182.83	131.35	183.41	34.1	15.82	56.07
			ras homolog gene family,								
rc_N90273_s_at	N90273	_	member H	#N/A	#N/A	105.53	96.01	41.89	68.92	59.56	35.69
rc_n93465_s_at	N93465		EST	#N/A	#N/A	803.68	716.56	385.5	624.57	694.14	306.11
rc_R39191_s_at	R39191		KIAA1020 protein	5.18	0.03185	331.72	80.62	590.96	17.46	18.33	16.04
rc_R44793_at	R44793	_	EST	5.4	0.00329	155.86	121.83	125.26	10.1	7.86	16.54
rc_R44817_at	R44817	_	EST	#N/A	#N/A	594.46	602.82	206.15	255.91	249.29	69.09
rc_R44896_at	R44896		KIAA0665 gene product	#N/A	#N/A	67.08	57.13	34.18	19.1	20.75	23.04
rc_R64137_s_at	R64137		EST	#N/A	#N/¥	31.25	24.23	2	2.9	2.65	6.94
rc_R71395_at	R71395		EST	4.12	0.03719	166.03	99.42	190.98	14.99	12.28	14.58
rc_R72087_at	R72087	_	EST	#N/A	W/V#	262.11	302.11	95	201.97	183.76	83.41
rc_R91819_at	R91819	_	EST	12.81	0.00037	467.79	364.2	426.16	11.34	9.35	36.49
rc_T03749_at	T03749	മ	KIAA1089 protein	4.23	0.00776	103	97.55	74.34	-5.18	-6.08	13.69
rc_T25744_s_at	T25744	3092	EST	#N/A	#N/A	72.74	73.3	37.84	15.56	12.65	13.18

· Table 8A. Genes and ESTs expressed only in hepatocellular carcinoma versus normal sample set 2.

				fold		hcc	hcc	pcc			
				change		sample	sample	sample	normal	normal	normal
				in hcc		set 2:	set 2:	set 2:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	set 2	p value	Mean	_	Std Dev	Mean	Median	Std Dev
rc_T62918_at	T62918	3169	EST	5.25	0.00687	136.22	l.	83.63	-12.41	-6.89	17.59
rc_T89731_at	T89731	3245	EST	#N/A	#N/A	63.59	65.07	20.47	5.75	3.83	11.8
			zinc metalloproteinase,								
rc_W32176_s_at	W32176	3498	STE24 (yeast, homolog)	#N/A	#N/A	550.53	614.92	234.79	290.18	277.95	129.45
			rab6 GTPase activating								
			protein (GAP and								
rc_W47388_at	W47388	3536	centrosome-associated)	#N/A	#N/A	97.33	71	59.73	43.93	36.52	48.34
rc_W78057_at	W78057	3600	EST	5.53	0.01231	265.23	222.35	199.24	29.21	29.9	34.33
rc_W80763_at	W80763	3608	EST	4.98	0.01026	147.37	138.37	122.38	16.84	15.48	9.22
rc_W90146_f_at	W90146	3644	EST	3.58	0.00322	82.11	69.02	47.2	9.83	8.63	6.49
rc_Z38299_at	Z38299	3887	EST	3.71	0.0036	140.86	127.16	96.62	30.48	25.94	23.34
rc_Z38404_at	Z38404	3888	EST	#N/A	#N/¥	59.77	56.71	37.29	29.82	30.16	တ
rc_Z38462_at	Z38462	3892	KIAA0938 protein	4.69	0.0142	137.19	116.11	116.16	-0.86	0.53	7.64
rc_Z38688_at	Z38688	3893	EST	#N/A	#N/A	49.85	46.83	42.25	21.38	13.4	29.47
rc_Z38729_at	Z38729	3894	EST	#N/¥	#N/A	77.67	57.81	60.7	-2.4	-5.01	46.96
rc_Z40556_at	Z40556	3921	CGI-96 protein	#N/¥	#N/A	176.19	76.96	285.02	59.65	55.07	16.66
rc_AA021549_at	AA021549	42	EST	3.17	0.00158	100.01	83.02	44.39	31.74	20.12	36.74
rc_AA026270_at	AA026270	26	tyrosyl-tRNA synthetase	#N/A	#N/A	269.96	261.31	191.51	76.85	76.68	45.22
rc_AA055896_at	AA055896	135	collagen, type V, alpha 1	10.87	0.00907	414.16	454.82	330.75	-3.14	5.8	33.88
rc_AA112979_s_at	AA112979	225	vaccinia related kinase 1	#N/A	#N/A	37.93	31.05	16.86	8.54	8.02	2.59
rc_AA134063_at	AA134063	286	EST	#N/A	#N/A	25.71	13.84	34.35	-5.21	-6.17	9
rc_AA150053_at	AA150053	327	EST	#N/¥	#N/¥	270.14	248.87	144.92	101.87	88.37	73.73
rc_AA206914_at	AA206914	428	EST	#N/A	#N/A	89.35	94.1	46.27	66.34	69.2	26.35
rc_AA243133_at	AA243133	525	serine/threonine kinase 15	7.03	0.00005	147.5	162.28	43.03	9.69	12.1	9.8
rc_AA243466_at	AA243466	527	EST	#N/¥	#N/¥	61.94	42.38	37.6	13.66	13.42	9.63
rc_AA243598_at	AA243598	531	EST	#N/¥	#N/A	60.15	62.79	32.67	11.41	13.18	13.43
rc_AA252147_at	AA252147	551	EST	#N/¥	#N/A	95.91	56.69	122.31	3.65	-0.82	22.5
rc_AA255566_at	AA255566	220	EST	#N/A	#N/A	64.28	50.15	52.25	16.18	14.38	13.17

Table 8A. Genes and ESTs expressed only in hepatocellular carcinoma versus normal sample set 2.

				fold)) (ncc	hcc			
				change		sample	sample	sample	normal	normal	normai
				in hcc		set 2:	set 2:	set 2:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID		set 2	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
rc_AA279667_s_at	AA279667	629	EST	#N/A	#N/A	184.99	102.43		8.06	7.61	23.78
rc_AA279943_at	AA279943	635	EST	#N/A	#N/A	137.05	63.54	232.2	4.7	-5.33	11.18
rc_AA290594_at	AA290594	691	EST	#N/A	#N/A	59.19	56.31	23.84	21.4	18.8	23.98
rc_AA290776_s_at	AA290776	693	EST	#N/A	#N/A	524.07	516.6	88.67	441.83	355.04	245.84
rc_AA292765_at	AA292765	712	ZW10 interactor	7.24	0.00498	202.52	192.15	142.78	11.33	18.29	13.27
rc_AA398908_at	AA398908	801	EST	20.72	0.00114	629.56	433.87	551.97	-174.29	-216.08	104.42
rc_AA405098_at	AA405098	855	EST	6.09	0.01224	221.56	130.95	237.73	-4.35	-8.44	30.78
rc_AA406542_at	AA406542	878	EST	Y/N#	W/V#	179.08	84.98	218.93	-1.99	1.49	12.75
rc_AA435738_at	AA435738	1042	EST	#N/A	#N/A	80.97	82	30.96	50.41	51.29	33.08
rc_AA443585_at	AA443585	1077	EST	#N/A	#N/A	200.3	136.72	140.42	118.18	97.38	102.71
			Ts translation elongation								
rc_AA446596_at	AA446596	1092	factor, mitochondrial	#N/A		103.35			72.58	70.64	154.24
rc_AA447777_at	AA447777	1107	EST	#N/A		258.37			133.78	116.63	56.34
rc_AA453757_at	AA453757	1156	EST	#N/A		128.41		40.54	65.66	70.33	40.45
rc_AA459254_at	AA459254	1211	EST	6.22	0.00001	309.74	308.36		51.84	43.51	37.57
			chromosome-associated								
rc_AA459673_at	AA459673	1220	polypeptide C	#N/A	#N/A	32.11	31.27		8.91	6.74	8.86
rc_AA476333_at	AA476333	1282	EST	#N/A	#N/A	52.26	34.54		9.04	14.67	24.04
rc_AA496993_at	AA496993	1405	EST	#N/A	#N/A	91.01	73.62		24.83	12.83	29.07
rc_AA504512_s_at	AA504512	1415	KIAA0943 protein	5.72	0.00384	316.32	322.55	180.22	65.48	28.37	93.94
rc_AA609132_at	AA609132	1479	EST	#N/A	#N/A	67.33	42.61		29.14	23.25	53.79
rc_AA609942_at	AA609942	1494	EST	#N/A	#N/A	89.98	66.8		15.89	14.41	25.58
			Fas-activated .								
rc_F02254_s_at	F02254	1777	serine/threonine kinase	5.1	0.00329		341.06		8	72.97	135.39
rc_H48459_s_at	H48459	1937	KIAA0186 gene product	3.1	0.02325	71.21	49.95	87.89	-29.4	-30.17	6.19
rc_H87790_at	H87790	2018	EST	#N/A	#N/A		287.54		466.07	547.34	192.71
rc_N34017_at	N34017	2494	EST	#N/A	#N/A	39.35	37.49		5.47	7.05	10.01
rc_N35493_at	N35493	2502	EST	W/V#	#N/A	73.6	80.62		19.03	18.75	17

Table 8A. Genes and ESTs expressed only in hepatocellular carcinoma versus normal sample set 2.

				fold		hcc	hcc	DCC DCC			
				change		sample	sample	sample	normal	normal	normal
				in hcc		set 2:	set 2:	set 2:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	set 2	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
rc_N63604_at	N63604	2601	EST	#N/V	#N/A	47.18	32.72	35	16.51	14.36	10.5
rc_N63646_at	N63646	2602	EST	#N/A	#N/A	479.9	367.24	240.56	182.22	137.95	6.06
			SRY (sex-determining								
rc_N69014_s_at	N69014	2642	region Y)-box 22	#N/A	#N/A	193.21	174.83	48.23	116.34	129.47	50.74
rc_N69879_s_at	N69879	2651	drebrin 1	3.15	0.01659	88.78	84.86	61.76	3.69	-2.94	21.49
rc_N69983_at	N69983	2652	EST	#N/A	#N/A	93.25	96.86	49.82	76.2	93.14	54.92
rc_N70330_at	N70330	2656	EST	#N/A	#N/A	108.39	69.74	105.54	33.78	27.33	16.47
rc_N74018_at	N74018	2684	EST	W/A	#N/A	22.65	25.34	10.26	2.34	1.47	10.41
rc_N89670_at	N89670	2709	EST	#N/A	#N/A	65.03	59.18	66.58	3.16	-1.81	43.32
rc_N93000_at	N93000	2727	EST	#N/A	#N/A	77.68	64.15	45.06	17.65	18.66	10.91
rc_N99944_s_at	N99944	2749	EST	3.46	0.00104	211.02	200.61	102.49	60.05	50.12	29.73
rc_R97176_at	R97176	3002	EST	#N/A	#N/A	143.07	152.08	86.96	53.41	58.26	38.91
rc_T16226_at	T16226	3066	EST	7.23	0.00119	323.53	312.1	209.59	33.87	22.78	38.68
rc_T32108_at	T32108	3103	EST	#N/A	#N/	180.81	165.53	68.41	148.09	152.11	92.06
rc_W15275_s_at	W15275	3472	EST	#N/A	W/W#	33.62	31.78	35.23	30.09	24.85	43.25
rc_W31906_at	W31906	3497	secretagogin	6.62	0.00926	474.89	174.52	605.68	42.41	30.95	47.65
rc_W46286_s_at	W46286	3526	EST	3.68	0.00311	154.73	166.08	72.64	23.51	22.85	61.89
			DEAD/H (Asp-Glu-Ala-								
			Asp/His) box polypeptide, Y								
rc_W60097_at	W60097	3556	chromosome	4.82	0.04903	235.42	265.15	189.13	35.34	11.72	84.5
			KDEL (Lys-Asp-Glu-Leu)								
rc \\\\R\\R\\2	W80852	2600	endoplasmic Fenculum	6 97	10000	707	70000				0
יב אספסק מו	70000	6000	Wolf-Hirschhorn syndrome	6.0	6.37 0.00000	104.0	129.90	100.74	11.16	11.92	30.00
rc_AA046745_at	AA046745	113	candidate 1	3.33	0.00648	73.04	72.71	48.97	10.59	12.02	7.33
rc_AA052941_at	AA052941	121	EST	3.36	0.00088	100.81	106.86	44.56	25.66	25.65	13.62
rc_AA058589_f_at	AA058589	144	EST	#N/A	#N/A	44.63	51.66	34.1	-9.37	-10.9	8.66
rc_AA126561_s_at	AA126561	249	stanniocalcin	#N/A	#N/A	51.44	44.19	31.6	7.16	7.73	8.55

Table 8A. Genes and ESTs expressed only in hepatocellular carcinoma versus normal sample set 2.

				fold		hcc	hcc	100			
				change		sample	sample	sample	normai	normal	normal
	,			in hcc		set 2:	set 2:	set 2:	set 2:	set 2:	set 2:
Affy ID	Genbank Seq I	Seq ID	Known Gene Name	set 2	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
			target of myb1 (chicken)								
rc_AA146849_s_at	AA146849	313	homolog	4.72	0.00326	398.05	341.23	244.73	98.86	106.97	86.19
			neighbor of A-kinase								
rc_AA149889_at	AA149889	326	anchoring protein 95	8.55	0.00224	240.81	312.86	143.89	-0.24	8.25	29.83
rc_AA283711_s_at	AA283711	699	ubiquitin carrier protein	#N/A	#N/A	382.91	380.33	210.95	221.7	203.51	93.54
rc_AA284153_at	AA284153	673	EST	#N/A	W/N#	117.98	127.81		53.98	43.58	32.17
rc_AA335191_f_at	AA335191	741	creatine kinase, brain	6.47	0.01462	512.64	199.99	Ψ	43.84	33.21	43.52
1			TNF receptor-associated				-				
rc_AA402642_s_at	AA402642	840	factor 1	#N/A	#N/A	137.67	59.13	211.07	35.93	19.15	31.32
			ATP-binding cassette, sub-								
			family F (GCN20), member								
rc_AA427460_s_at	AA427460	972		#N/A	#N/A	190.92	187.57	78.83	92.5	83.63	49.3
rc_AA431429_at	AA431429	1021	EST	#N/A	#N/A	25.39	21.98	9.32	5.32	4.23	4.43
			v-Ha-ras Harvey rat								
			sarcoma viral oncogene								
rc_AA443316_s_at	AA443316	1075	homolog	3.4	0.00133	138.89	124.06	70.22	40.04	41.12	32.54
rc_AA476260_at	AA476260	1280	EST	#N/A	#N/A	61.23	69.49		-32.66	-15.85	56.91
			ubiquitin-conjugating								
rc_AA487058_at	AA487058	1352	enzyme E2L 3	#N/A	#N/A	245.56	225.48	137.4	315.7	232.85	213.47
rc_AA521149_at	AA521149	1420	EST	3.33	0.00211	113.43	106.74		28.44	29.54	18.61
rc_AA599244_at	AA599244	1448	KIAA0530 protein	#N/A	#N/A	53.83	48.84		7.71	90.9	7.11
rc_AA599850_at	AA599850	1457	EST	3.55	0.03215	122.91	75.32	123.52	-1.23	-2.33	31.86
rc_AA621530_at	AA621530	1526	EST	3.26	0.00298	78.73	75.43	40.45	12.46	15.12	13.43
rc_AA621644_at	AA621644	1528	EST	#N/A	#N/A	83.13	88.29	43.19	71.19	66.84	29.87
rc_C15078_i_at	C15078	1573	EST	#N/A	#N/A	121.71	98.25	100.16	26.22	31.14	60.2
rc_D80710_f_at	D80710	1734	integral type I protein	3.17	0.04549	153.76	74.74	166.28	22.95	28.29	24.59
rc_D80948_f_at	D80948	1738	EST	#N/A	¥N\#	70.05	77.71		41.25		17.48
rc_D81048_at	D81048	1739	EST	W/V#	#N/A	150.18	149.32		86.08	85.08	39.11

Table 8A. Genes and ESTs expressed only in hepatocellular carcinoma versus normal sample set 2.

mal normal		(J)		17.26 9.79	۷,	_			•				67.7 49.99		66.72 64.11			21.3 33.53		11.07 7.26			0.47 30.83			7.36 51.48	
nal norma		_			133.9 15							104.07 15			74.25 6			31.77	_		17.58 1						
norma								'n																			
sample	set 2:	Std Dev		109.02		219.8	Υ-	261.02				99.3	169.31	49.4	380.43			64.7	30.6	39.45	29.3	420.1	87.9	207.7	106.	120.18	
sample	set 2:	Median		122.53	147.93	321.65	176.78	307.06	143.31	94.93	52.26	356.17	208.16	71.59	341.39			100.03	16.41	67.51	57.09	598.82	88.01	473.4	329	134.42	
sample	set 2:	Mean		156.76	143.86	408.05	215.75	285.43	136.58	92.81	56.6	351.55	233.32	77.72	466.88			117.43	31.61	77.08	54.19	730.52	99.7	564.05	336.8	168.18	
		p value		0.00042	#N/A	#N/A	0.00327	0.02674	#N/A	#N/A	#N/A	0.00439	0.0094	#N/A	0.03097			0.00268	#N/A	0.00309	#N/A	0.00358	0.03125	0.00091	0.00012	0.00642	
change	in hcc	set 2		6.29	#N/A	#N/A	3.67	7.5	#N/A	W/V#	#N/A	3.84	3.11	#N/A	4.88			3.36		3.41	#N/A		3.38	5.5	7.04		
•		Known Gene Name	replication factor C	(activator 1) 4 (37kD)	EST	EST	EST	EST	EST	EST	EST	EST	EST	EST	tumor protein D52-like 2	carbohydrate (keratan	suilate Gal-O)	sulfotransferase 1	EST	EST	EST	EST	EST	KIAA0422 protein	EST	EST	cleavage and polyadenylation specific
		Seq ID		1786	1884	1907	1984	2001	2050	2082	2591	2627	2643	2672	2764		į	2791	2802	2807	2810	2867	2945	2956	3001	3062	
		Genbank		F04320	H14617	H26763	H68794	H78211	H95566	H99870	N62487	N67815	N69084	N73278	R06251			R15740	R24507	R27296	R30931	R45994	R70253	R72886	R96924	T15852	
		Affy ID		rc_F04320_s_at	rc_H14617_at	rc_H26763_at	rc_H68794_at	rc_H78211_at	rc_H95566_f_at	rc_H99870_at	rc_N62487_at	rc_N67815_f_at	rc_N69084_I_at	rc_N73278_at	rc_R06251_f_at			rc_R15740_at	rc_R24507_at	rc_R27296_f_at	rc_R30931_at	rc_R45994_f_at	rc_R70253_at	rc_R72886_s_at	rc_R96924_s_at	rc_T15852_f_at	

Table 8A. Genes and ESTs expressed only in hepatocellular carcinoma versus normal sample set 2.

				fold		ည္ပ	ncc	hcc			
				change		sample	sample	sample	normal	normal	normal
!				in hcc		set 2:	set 2:	set 2:	set 2:	set 2:	set 2:
Affy ID	Genbank Seg ID	Seq ID	Known Gene Name	set 2	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
			RNA (guanine-7-)								
rc_T33865_f_at	T33865	3110	methyltransferase	#N/A	#N/A	29.73	32.86	22.11	-0.26	2 33	8.45 7.5
rc_T66935_at	T66935	3179	EST	3.04	0.00123	181 34	189.67	81.40	9 9 9	200	
rc_T95057 f at	T95057	3259	EST	6.46		220 11	188 71	174.46	4 4 2 2	16.24	42.32
rc_W45320_f_at	W45320	3523	KRAB-associated protein 1	10.05		365.22	345.46	127.42	2 - 5	20.01	27.75
AF006041_at	AF006041	1549	death-associated protein 6	#N/A	#N/A	174.22	170.16	27.64	76.37	50.03	112.32
D00596 at	D00596	1590	thymidylate synthetase	7 20		2000	2 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	10.04	9.4.0	20.00	50.31
D38491_at	D38491	1653	KIAA0117 profein	% Y	4.174	47.67	140.11	2,0,0	20.10	20.43	12.43
D63486_at	D63486	1712	KIAA0152 gene product	3.56	_	277.42	248.24	10.12	77.07	20.88	17.43
!			minichromosome	3		1	170:41	03.60	5	95.0	43,40
			maintenance deficient								
D84557_at	D84557	1749	(mis5, S. pombe) 6	3.97		184.48	132.11	125.74	37.22	43 12	28 15
D86957_at	D86957	1754	KIAA0202 protein	3.08	0.02949	91.22	73 14	80 80	147	10.12	6.30
D86972_at	D86972	1755	KIAA0218 gene product	#N/A		68.56	66.54	32.32	34.58	32.05	24.82
			amylase, alpha 2B;							50.10	70.17
D90097_at	D90097	1768	pancreatic	#N/A	W/N#	41.19	37.49	21.85	6.55	11 44	15.08
L29218_at	L29218	2190	CDC-like kinase 2	3.82	0.00035	155,42	142.58	76.28	35.11	41.27	26.41
			RNA-binding protein							į	
L38696_at	L38696	2208	(autoantigenic)	#N/A	#N/A	127.32	114.91	62.34	60.18	58.55	74 77
M11749_at	M11749	2240	Thy-1 cell surface antigen	#N/A	#N/A	83.1	65.86	64.52	26.05	28.95	20.56
M25753_at	M25753	2308	cyclin B1	#N/A	W/V#	44.14	30.96	40.36	9 0	3 03	15.35
			intercellular adhesion						3	3	9
M32334_at	M32334	2333	molecule 2	#N/A	#N/A	95.04	92.33	67.51	42.19	41.31	27.33
,			laminin, gamma 1 (formerly							<u> </u>	3
M55210_at	M55210	2353	LAMB2)	3.47	0.02551	137.63	115.85	102.71	27.07	29.17	12.36
M61916_at	M61916	2372	laminin, beta 1	3.18		75.1	67.4	61.41	7.19	7.98	8.99

Table 8A. Genes and ESTs expressed only in hepatocellular carcinoma versus normal sample set 2.

				fold		hcc	hcc	hcc			
				change		sample	sample	sample	normal	normal	normal
;				in hcc		set 2:	set 2:	set 2:	set 2:	set 2:	set 2:
Affy ID	Genbank Seq	Seq ID	Known Gene Name	set 2	p value	Mean	Median	Std Dev	Mean	_	Std Dev
			stress-induced-							1	
			phosphoprotein 1								
	1		(Hsp70/Hsp90-organizing								
M86752_at	M86752	2412		5.15	0.02881	216.51	248.21	192 98	8 67	20.63	30.03
			replication factor C				!		5	50.03	6.65
M87339_at	M87339	2415	(activator 1) 4 (37kD)	4.59	0.00116	110.39	82.61	79.29	4.26	6 6	16 79
			midkine (neurite growth-					!	1	3	2
M94250_at	M94250	2426	promoting factor 2)	9.86	0.02104	690.32	193.74	1414.43	-155.4	-175.43	101 89
			cytosolic ovarian carcinoma								
S72904_at	S72904	3031		#N/A	¥N/¥	29.33	29.21	18.34	11.53	12.85	7 55
S78187_at	S78187	3036	cell division cycle 25B	4 83	C	143.52	1153	100.13	22.5	5.5	
S78569 at	S78569	3037		V/14#		20.05	- 6	20.13	5.50	Z. I.	20.9
				()	¥15	K2./8	76.91	21.66	6.3	9.7	9.38
	;		I AK (HIV) KNA-binding								
U38847_at	U38847	3357	protein 1	#N/A	#N/A	83.43	70.23	66.3	15.7	17.43	10.2
			diacylglycerol kinase, zeta								
U51477_at	U51477	3384	(104kD)	#N/A	#N/A	73.85	61.64	31.81	36.35	36.29	23.02
			DEAD/H (Asp-Glu-Ala-								10:01
			Asp/His) box polypeptide 17						•		
U59321_at	U59321	3398	(72KD)	3.12	3.12 0.02469	84.5	98.2	70.13	3.1	-1.83	19.73
1166661 at	1 IRREG1	3406	gamma-aminobutyric acid	i		į			:		
n₁ 		5	(GAPS) A receptor, epsilon	3.55	0.0045	97.79	83.66	61.79	16.58	14.81	11.96
1102227 read at	7606011	0460	mumpie endocrine neopiasia		:						
25257 THAZ AL	093237	3402		#N/A	#N/A	84.78	93.3	24.25	45.63	45.39	17.66
A9Z1Ub_at	X92106	3877	bleomycin hydrolase	¥N/¥	#N/A	56.15	48.48	36.93	4.73	3.77	11.78

Table 8A. Genes and ESTs expressed only in hepatocellular carcinoma versus normal sample set 2.

				change		ncc sample	hcc sample	hcc sample	normal	normal	normal
				in hcc		set 2:	set 2:	set 2:	set 2:	set 2:	set 2:
Affy ID	Genbank Seq	Seq ID	Known Gene Name	set 2	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
			tafazzin (cardiomyopathy, dilated 3A (X-linked);								
			endocardial fibroelastosis 2;								
X92762_at	X92762	3828	Barth syndrome)	#N/A	#N/¥	82.96	83.94	15.05	23.4	33.5	24.15
			dual-specificity tyrosine-(Y)-								
			phosphorylation regulated								
Y09216_at	Y09216	3856	kinase 2	#N/A	#N/A	47.87	47.61	18.08	18.99	22.48	13.31
			guanine nucleotide binding								
			protein (G protein), alpha 11								
M69013_at	M69013	2391	(Gq class)	#N/A	#N/A	86.89	70.61	47.65	38.18	47.33	23.06
			RAD23 (S. cerevisiae)								
AD000092_cds7_s_at AD000092	AD000092	1542	homolog A	#N/A	#N/A	97.12	98.23	25.66	37.18	32,35	28.04
			small nuclear								
			ribonucleoprotein 70kD								
X04654_s_at	X04654	3681	polypeptide (RNP antigen)	#N/A	#N/A	122.45	134.9	49.51	42.22	41.24	17.18
			myosin, light polypeptide 1,								
M31211_s_at	M31211	2326	alkali; skeletal, fast	#N/A	#N/A	60.22	49.75	54.83	-2.19	4.38	11.56
			protein kinase, interferon-								
			inducible double stranded								
U50648_s_at	U50648	3379	RNA dependent	#N/A	#N/A	214.34	192.86	122.38	105.38	92.58	43.12
M74715_s_at	M74715	2395	iduronidase, alpha-L-	#N/A	#N/A	122.69	121.95	72.58	41.88	24.48	43.99
			a disintegrin and							! !	
			metalloproteinase domain								
U41767_s_at	U41767	3360	15 (metargidin)	#N/A	#N/A	196.76	147.11	113.93	83.03	66.93	68.33
M12125_at	M12125	2241	tropomyosin 2 (beta)	7.13	0.0004	174.25	183.97	95.24	13.01	16.33	11.64
			sulfotransferase family 1A,								
100001	007001	200	pricion-presenting, interinder	419417	41140	1	9		•		•
UZU488_at	UZ0489	3321		#N/A	#N/A	141.35	126.33	135.57	48.34	54.37	24.69

Table 8B. Genes and ESTs expressed only in normal liver compared to hepatocellular carcinoma.

						hcc	pcc	hcc			
						sample	sample	sample	normal	normal	normal
				hcc fold		set 2:	set 2:	set 2:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq 1D	Known Gene Name	change	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
rc_AA010205_at	AA010205	23	EST	5.71	0.00014	26.95	20.06	32.19	187.55	154.99	92.13
			potassium voltage-gated								
rc_AA013095_s_at	AA013095	ဗ္ဗ	channel, shaker-related	#N/A	W/V#	5.12	7.9	12.98	18.56	15.83	8.24
rc_AA046747_at	AA046747	114	EST	4.77	0.00023	-0.57	3.68	23.81	113.78	88.54	66.41
rc_AA074885_at	AA074885	161	macrophage receptor with	10.88	0.00087	35.67	58.01	44.34	652.03	761.74	300.57
rc_AA099225_at	AA099225	206	EST	6.59	0.00064	10.9	9.75	15.11	212.68	163.45	194.31
rc_AA253410_at	AA253410	564	EST	#N/A	#N/A	3.66	1.48	10.67	49.37	26.82	45.2
rc_AA281796_at	AA281796	650	mannose-P-dolichol utilitzation	#N/A	#N/A	95.74	105.86	45.46	170.88	165.02	41.87
rc_AA282541_at	AA282541	661	EST	#N/A	#N/A	17.21	11.75	13.38	31.31	29.9	13.53
rc_AA285053_at	AA285053	681	EST	5	0.00718	36.49	20.15	49.54	238.16	242.27	169.12
rc_AA287566_at	AA287566	069	KIAA0187 gene product	6.99	0.00023	18.67	14.05	35.71	246.24	201.66	228.64
rc_AA404248_at	AA404248	847	EST	#N/A	#N/A	24.05	30.59	15.83	40.92	35.06	17.49
rc_AA448002_at	AA448002	1113	putative type II membrane	14.14	0	39.9	38.99	13.33	594.13	528.63	282.58
rc_AA460661_at	AA460661	1229	EST	5.46	0.00151	20.05	8.57	39.04	184.62	198.21	108.17
rc_AA487576_at	AA487576	1357	EST	#N/A	#N/A	11.67	2.42	27.75	26.05	25.27	11.13
rc_AA621235_at	AA621235	1517	EST	#N/A	#N/A	62.79	68.63	35.33	114.75	113.36	65.35
rc_F09979_at	F09979	1809	EST .	W/A	#N/A	61.21	6.31	128.69	226.47	116.41	288.21
			butyrobetaine (gamma), 2-								
rc_F10380_at	F10380	1816	oxoglutarate dioxygenase	#N/A	#N/A	43.64	47.09	18.15	106.49	93.71	83.35
rc_H57056_at	H57056	1953	EST	#N/A	#N/A	-1.79	-7.37	11.38	35.07	38.32	17.88
rc_H58673_at	H58673	1959	EST	15.49	0.00002	34.96	26.37	38.53	652.47	677.55	376.36
rc_H59136_at	H59136	1962	EST	6.63	0.00033	33.12	21.17	42.92	250.23	229.94	129.12
H66367_at	H66367	1977	EST	3.84	0.00133	37.14	35.15	26.61	155.38	149.31	70.77
H72650_at	H72650	1994	EST	#N/A	#N/¥	78.97	93.74	40.9	122	125	42.24
rc_H87765_at	H87765	2017	KIAA0626 gene product	3.94	0.00123	10.11	10.07	4.23	94.26	93.78	60.64
M10943_at	M10943	2234	metallothionein 1F (functional)	6.23	0.00007	35.67	28.76	22.4	217.65	186.71	86.73
M30185_at	M30185	2321	cholesteryl ester transfer protein,	3.82	0.00131	-15.66	-12.63	23.86	93.07	86.04	61.35
M63967_at	M63967	2378	aldehyde dehydrogenase 5	3.88	0.00274	40.43	30.04	29.05	164.38	178.74	87.39

Table 8B. Genes and ESTs expressed only in normal liver compared to hepatocellular carcinoma.

						ည	hcc	hcc			
						sample	sample	sample	normal	normal	normal
				hcc fold		set 2:	set 2:	set 2:	set 2:	set 2:	set 2:
Affy ID	Genbank	Sed ID	Known Gene Name	change	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
rc_N22404_at	N22404	2450	EST	3.44	0.02267	56.69	35.82	73.26	193.63	130.09	162.83
rc N34919 at	N34919	2499	EST	#N/A	#N/A	19.32	19.72	14.37	52.96	44.23	24.23
rc_N54604_at	N54604	2570	EST	¥N\A	#N/A	45.27	14.34	81.45	133.06	119.1	109.95
rc_N65959_at	N65959	2612	EST	3.38	0.00785	37.8	28.94	31.45	142.87	149.26	79.26
rc_N67105_at	N67105	2624	EST	4.69	0.00194	12.46	10.45	12.64	143.36	102.9	121.4
rc_N69114_at	N69114	2644	nuclear receptor subfamily 1,	#N/A	#N/A	12.69	5.95	15.01	72.29	73.28	57.34
rc_N74624_at	N74624	2688	collectin sub-family member 10	#N/A	#N/A	39.43	35.17	24.21	71.81	62.09	43.57
N99542 at	N99542		orosomucoid 1	3.53	0.00607	61.09	67.97	39.3	226.06	187.68	146.11
rc_R09053_at	R09053	2783	EST	3.45	0.03074	64.12	36.33	102.03	186.87	204.61	113.19
rc_R73816_at	R73816		EST	7.05	0.01287	35.12	13.76	100.6	462.31	374.67	450.91
			CD5 antigen-like (scavenger								
rc_R99591_at	R99591	3016	receptor cysteine rich family)	7.41	0.00043	124.14	139.76	50.35	1035.39	904.92	691.83
rc_T58756_at	T58756	3156	EST	16.61	0	-1.02	1.06	24.36	390.04	386.76	164.41
T68083_at	T68083	3185	short-chain	#N/A	#N/A	96.34	59.71	104.53	263.22	280.22	136.48
rc_T68711_at	T68711	3188	EST	35.98	0.0003	29.03	-33.95	176.15	1388.67	1074.67	890.91
rc_W48860_at	W48860	3537	EST	#N/A	#N/A	37.25	31.7	27.5	52.69	41.31	21.1
			X-prolyl aminopeptidase								
rc_W78093_at	W78093	3601	(aminopeptidase P) 2,	Y/N#	#N/A	408.58	397.88	102.27	518.77	518.8	211.32
rc_W85890_at	W85890	3623	EST	#N/A	#N/A	60.91	60.47	23.73	70.98	66.52	24.66
rc W90018 f at	W90018		EST	#N/A	#N/A	21.51	1.31	56.9	59.32	53.19	41.68
X54380_at	X54380	3730	pregnancy-zone protein	7.71	0.00069	15.11	8.07	27.07	274.41	255.4	203.47
Z48475_at	Z48475	3943	glucokinase (hexokinase 4)	4.6	0.01693	62.99	51.37	146.72	305.23	239.52	155.98
1	į		Subjecting A (Cys-Cys), inferriber	i	1		,				1
Z49269_at	Z49269	3945	14	7.24	0.01047 138.63	138.63	66.95	201.93	201.93 526.13	532.29	166.67

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					normal	normal	norma
				change		metastatic:	metastatic: metastatic: metastatic:	metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
rc_AA007160_at	AA007160	16	EST	9	0.01035	171.32	175.07	138.03	9.1	8.6	12.54
			diptheria toxin								
			resistance protein								
			required for								
			diphthamide								
			biosynthesis								
			(Saccharomyces)-like								
AA009913_at	AA009913	7		#N/A	#N/A	69.53	81.03	27.69	16.81	18.22	13.51
rc_AA011134_at	AA011134	59	EST	28.79	0.00602	1157.47	566.78	1448.16	-72.57	-51.2	69.3
l			DKFZP434G032								
rc_AA024482_at	AA024482	45	protein	#N/A	#N/A	207.37	118.58	230.63	-1.3	-3.13	13.6
rc_AA026030_at	AA026030	53	EST	11.01	0.01649	566.65	284.32	828.49	3.02	4.66	40.87
			tyrosyl-tRNA								
rc_AA026270_at	AA026270	26	synthetase	#N/A	#N/A	201.1	224.51	50.82	76.85	76.68	45.22
			glutamate-cysteine								
			ligase (gamma-		•						
			glutamylcysteine								
			synthetase),								
rc_AA035540_at	AA035540	2	regulatory (30.8kD)	#N/A	W/W#	39.84	34.37	13.29	13.59	12.27	8.96
rc_AA040465_at	AA040465	92	EST	3.25	0.00146	161.91	125.35	72.19	47.15	45.53	5.48
rc_AA043944_at	AA043944	100	EST	#N/A	#N/A	52.9	29.13	46.43	3.69	3.15	7.26
rc_AA053033_at	AA053033	124	EST	7.83	0.00379	212.61	135.28	160.82	3.41	-1.28	19.74
			cadherin 17, LI								
			cadherin (liver-								
rc_AA053102_s_at	AA053102	125	intestine)	26.63	0.01745	1053.43	972.71	785.51	4.92	4.94	9.04
rc_AA053248_i_at	AA053248	126	EST	7.01	0.00003	2234.44	1595.15	1053.3	341.06	304.8	189.89
rc_AA053660_at	AA053660	128	EST	15.98	0.00003	1573.49	1340	820.5	95.24	79.97	42.99
rc_AA055805_s_at	AA055805	132	EST	42.83	0.00142	1270.03	1026.97	1179.12	-11.11	-10.85	20.27

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					normal	normal	normal
				change		metastatic:	metastatic: metastatic: metastatic:	metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	ame	in metas	p.value	Mean	Median	Std Dev	Mean	Median	Std Dev
			glycoprotein A33								
rc_AAU55811_s_at	AA055811	133	(transmembrane)	6.86	0.02152	236.18	196.53	171.06	14.84	17.82	5./۱
** A A O E E B O A A C C C C C C C C C C C C C C C C C	900000	407	Collagell, type V, alpha	97.07	0770	1000	67.00	Č	;	C L	0000
rc_AAUSS886_at	AAUSSSSB	33	-	18.10	0.00146	540.67	538.43	382	-3.14	2.	33.88
rc_AA084343_at	AA084343	178	EST	W/V#	#N/A	133.86	126.19	19.99	84.58	76.82	41.45
			carcinoembryonic								
			antigen-related cell								
			adhesion molecule 6								
			(non-specific cross								
rc_AA100719_s_at	AA100719	212	reacting antigen)	50.88	0.00081	1405.2	1264.79	1137.97	-17.03	-22.23	16.43
			vaccinia related								
rc_AA112979_s_at	AA112979	225	kinase 1	#N/A	#N/A	25.08	24.98	13.02	8.54	8.02	2.59
			mitotic spindle coiled-								
rc_AA115979_at	AA115979	232	coil related protein	#N/A	#N/A	74.58	89.38	66.52	22.91	13.67	29.42
rc_AA126041_at	AA126041	244	EST	#N/A	#N/A	42.91	33.83	16.2	26.42	28.92	9.81
AA127712_at	AA127712	255	EST	6.59	0.03706	332.45	208.85	296.68	-29.54	-28.71	104.37
			amyloid beta (A4)								
			precursor protein						•		
** A A 4 20 E E 2 # 24	A A 400FF0	090	(protease frexiti-fr,	V/14#	V/1V#	97.05	400	77		07.007	00
10_74120333_1_at	AA 120000	207	AZITEILIEI UISEASE)	¥ / X 4	₹ /NI#	06.70	102.02	74.17	4. 5.	00.10	30.20
rc_AA131162_s_at	AA131162	566	EST	4.68	0.00042	117.43	123.78	39.05	11.86	13.57	19.83
rc_AA134968_at	AA134968	588	EST	12.11	0.00079	322.34	208.47	256.66	10.04	7.96	15.53
rc_AA150053_at	AA150053	327	EST	3.71	0.00102	309.61	304.16	82.48	101.87	88.37	73.73
			i de la companya de l								
rc AA151428 s at	AA151428	335	metalloproteinase 23B	7.15	0.00056	174.77	131.66	104.51	3.23	10.67	24.39
1		}		<u>:</u>							
			serine protease,								
rc_AA156243_at	AA156243	340	umbilical endothelium	41.44	0.00139	1255.4	547.15	1189.26	9.32	11.44	9.39

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					normal	norma	normal
				change		metastatic:	metastatic: metastatic:	metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
rc_AA157857_s_at	AA157857	320	keratin 19	¥N#	#N/A	2728.74	2917.98	1076.95	-13.21	-14.4	15.84
rc_AA159525_at	AA159525	354	EST	49.39	0.00062	1309.05	1107.08	965.67	-32.72	-28.32	20.11
rc_AA161043_at	AA161043	356	tetraspan 1	18.8	0.00015	1477.19	932.02	1467.59	70.82	58.62	42.88
rc_AA171760_at	AA171760	367	EST	17.86	0	645.43	578.38	312.37	28.03	16.24	57.21
•			polyglutamine binding								
rc_AA179787_at	AA179787	380	protein 1	6.44	0.00206	191.33	171.71	138.9	-11.56	-12.46	42.46
rc_AA179845_at	AA179845	381	EST	5.77	0.01414	280.06	335.41	172.62	37.43	37.69	14.87
rc_AA181600_at	AA181600	384	EST	5.38	0.03316	166.88	94.16	153.49	-40.51	-47.81	24.34
rc_AA196790_at	AA196790	421	EST	7.64	0.00287	239.45	275.18	142.37	22.91	26.8	10.54
rc_AA211483_at	AA211483	435	EST	44.07	0.00175	1300.23	1303.61	1051.58	-29.25	-34.99	17.49
rc_AA227926_at	AA227926	460	EST	6.81	0.01701	228.91	120.1	243.92	16.24	14.21	98.9
rc_AA232508_at	AA232508	464	EST	#N/A	#N/A	464	533.98	266.87	170.48	156.89	104.75
			general transcription								
			factor IIIC, polypeptide								
rc AA233290 at	AA233290	469	220kD)	#N/A	#N/A	56.54	43.91	22.15	28.32	34.50	25.36
rc_AA234096_at	AA234096	479	EST	23.72	0.00018	607.06	420.34	366 53	-3.47	173	30.91
rc_AA234346_at	AA234346	480	EST	#N/A	#N/A	36.98	39.47	12.81	6.21	6.79	19.99
rc_AA234362_at	AA234362	481	EST	3.89	0.03524	116.26	75.37	105.77	-1.86	-4.2	16.67
		•	survival of motor				.*			!	
			neuron protein								
rc_AA234365_at	AA234365	482	interacting protein 1	#N/A	W/A	56.37	42.6	34.73	12.96	16.93	12.99
rc_AA234706_at	AA234706	488	EST	#N/A	#N/A	68.33	53.21	21.55	49.66	39.76	45.06
rc_AA235707_at	AA235707	200	EST	9.17	0.00005	189.42	161.88	57.05	-18.19	-19.06	14.8
			ecotropic viral					:			-
rc_AA236533_s_at	AA236533	514	integration site 1	4.01	0.02882	106.15	76.05	78.18	-16.45	-14.04	8.52
rc_AA243173_at	AA243173	526	EST	8.75	0.00003	384.86	482.53	162.08	41.66	40.74	27.31
		!	apoptosis inhibitor 4								
rc_AA252994_at	AA252994	221	(survivin)	3.55	0.00075	152.63	140.53	31.01	50.23	40.59	35.61

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					normal	norma	norma
				change		metastatic:	metastatic: metastatic:	metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
			adaptor-related protein complex 1,								
AA253330 s at	AA253330	562	gamma 1 subunit	3.87	0.00708	219.95	186.12	141.92	47.32	51.59	30.28
rc AA253473 at	AA253473	292	EST	15.23	0.00171	375.2	435.68	216.18	-4.38	-3.19	12.35
rc_AA255566_at	AA255566	570	EST	#N/A	#N/A	63.43	65.2	30.17	16.18	14.38	13.17
rc_AA256642_at	AA256642	582	EST	11.17	0.00035	266.31	275.43	135.85	0.78	-1.34	15.74
i l			WW domain binding								
			protein 4 (formin								
rc_AA258836_at	AA258836	601	binding protein 21)	#N/A	#N/A	41.9	44.58	13.6	26.08	23.64	10.4
rc_AA262943_at	AA262943	611	EST	13.42	0.00234	430.7	207.29	511.01	-1.08	-6.93	19.06
:			neuroblastoma-								
rc_AA281214_s_at	AA281214	643	amplified protein	W/V#	#N/A	130.98	133.63	68.42	68.89	53.91	39.31
rc_AA282505_at	AA282505	629	EST	#N/A	#N/A	461.54	478.83	622.39	41.45	-17	98.17
			putative G protein-								
rc_AA291259_at	AA291259	697	coupled receptor	#N/A	#N\A	112.28	45.1	113.44	1.53	1.88	90.9
AA291456 s at	AA291456	700	EST	3.96	0.03633	1808.4	1273.75	1481.84	671.21	509.58	629.13
rc_AA292765_at	AA292765	712	ZW10 interactor	7.14	0.02623	230.83	166.72	232.16	11.33	18.29	13.27
rc_AA292931_at	AA292931	715	EST	3.97	0.00067	230.65	260.43	79.42	57.32	61.89	18.62
AA295819 s at	AA295819	722	EST	æ	0.01793	230.14	251.43	146.89	-14.93	-20.8	19.72
rc_AA331393_at	AA331393	739	EST	16.73	0.00848	600.02	315.98	598.52	5.08	3.88	9.43
rc_AA335191_f_at	AA335191	741	creatine kinase, brain	47.35	0.00419	3540.65	3971.43	3135.19	43.84	33.21	43.52
			mutY (E. coli)								
rc_AA349792_s_at	AA349792	759	homolog	¥N\#	#N/A	525.17	553.97	245.2	221.5	212.24	98.86
rc_AA372018_at	AA372018	768	EST	14.3	0.00178	363.44	220.03	261.04	-2.44	-3.09	8.36
			differentially								
			expressed in hematopoletic								
AA372630_s_at	AA372630	769	lineages	25.49	0.01743	2094.32	436.62	3873.61	6.67	4.87	7.16

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					normal	normal	normal
				change		metastatic:	metastatic: metastatic:	metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
			DKFZP586B0519								
AA384184_s_at	AA384184	774	protein	3.38	0.01209	476.17	411.64	148.86	181.02	188.54	135.4
			laminin receptor 1								
			(67kD, ribosomal								
rc_AA394121_at	AA394121	778	protein SA)	23.78	0.00099	788.51	677.33	612.74	0.21	-8.38	31.59
rc_AA398908_at	AA398908	801	EST	38.69	0.01089	1678.58	1796.68	1500.48	-174.29	-216.08	104.42
			tight junction protein 3								
rc_AA399226_at	AA399226	803	(zona occludens 3)	3.59	0.02002	89.54	78.97	63.98	-5.01	-6.48	11.33
			tumor suppressor								
			deleted in oral cancer-								
rc_AA401965_at	AA401965	833	related 1	#N/A	#N/A	384.12	271.95	444.06	120.58	93.29	109.41
rc_AA404597_at	AA404597	854	EST	#N/A	W/W#	624.37	495.56	274.8	379.26	336.33	167.43
rc_AA405715_at	AA405715	862	hypothetical protein	4.68	0.00898	152.23	138.92	96.78	24.47	27.3	11.75
rc AA406542 at	AA406542	878	EST	8.27	0.00724	230.18	170.94	206.8	-1.99	1.49	12.75
rc_AA410469_at	AA410469	883	EST	6.3	0.00103	337.03	250.11	264.1	50.51	42.79	60.18
1 I			DKFZP586E1422						:		
rc_AA419217_at	AA419217	923	protein	6.77	0.00045	276.53	215.37	172.25	36.93	36.7	21.88
			anterior gradient 2								
			(Xenepus laevis)								
rc_AA421562_at	AA421562	934	homolog	56.3	0.0041	2556.78	792	3323.39	14.22	15.72	6.54
rc_AA422086_at	AA422086	938	EST	10.71	0.03418	828.27	598.22	800.79	39.48	34.98	23.29
			cytochrome P540								
			family member				-				
rc_AA422150_at	AA422150	939	predicted from ESTs	17.14	0.00108	664.26	606.609	475.91	28.76	27.53	22.47
rc_AA424487_at	AA424487	945	EST	38.41	0.00002	2689.32	1863.02	1900.51	67.92	61.95	46.24
rc_AA424881_at	AA424881	949	EST	6.3	0.00556	158.13	155.45	82.63	-16.85	-22.15	20.49
rc_AA425279_at	AA425279	951	quiescin Q6	6.15	0.00083	221.93	181.8	167.44	18.33	22.33	44.81

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					normal	normal	normal
				change		metastatic: metastatic:	metastatic:	metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Seq ID Known Gene Name	in metas	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
rc AA425401 at	AA425401	954	serine/threonine kinase 24 (Ste20, veast homolog)	3.22	0.00625	246 G	166.4	175 99	76.4	78.33	43.72
rc_AA425852_i_at	AA425852	928	EST	4.8	0.03874	149.8	125.7	128.03	7.02	5.22	4.75
rc AA427460 s at	AA427460	625	ATP-binding cassette, sub-family F (GCN20), member 2	∀/N #	∀ /N#	215.08	135 22	216 QE	20 7	83.63	40 3
AA427468 s at	AA427468	973	claudin 4	84.43	0	5646.4	5344.98	1581.19	72.58	64.85	87.74
rc_AA427636_at	AA427636	926	EST	19.23	0.00145	511.98	500.83	299.69	6.19	3.7	15.84
rc_AA429009_at	AA429009	994	serine protease inhibitor, Kunitz type 1 cisolatin rasistance	30.04	0.00001	1010.32	1100.19	472.23	-2.97	-24.67	62.21
rc_AA429890_s_at	AA429890	1004	associated	12.51	0.00053	1225.72	590.09	992.47	90.05	67.23	59.35
rc_AA430674_at	AA430674	1018	EST	15.11	0.00293	454.82	306.15	378.36	-71.57	-82.03	59.56
rc_AA436616_at	AA436616	1056	EST	3.18	0.04402	79.96	91.35	62.83	-0.73	3.24	15.36
rc_AA442763_at	AA442763	1072	cyclin B2	5.09	0.02168	136.16	109.91	91.52	-14.64	-15.1	13.08
			v-Ha-ras Harvey rat sarcoma viral								
rc_AA443316_s_at	AA443316	1075	oncogene homolog	4.13	0.01729	191.06	173.3	113.42	40.07	41.12	32.54
			subtransferable								
rc_AA443941_at	AA443941	1085	candidate 1	3.57	0.01685	137.02	138.22	83.35	31.09	34.9	16.61
rc_AA447687_at	AA447687	1104	EST	11.42	0.00362	306.28	178.65	244.12	-16.27	-14.45	8.55
rc_AA447991_at	AA447991	1112	EST	4.99	0.00173	279.79	234.63	161.24	64.49	40.73	53,34
rc_AA449456_at	AA449456	1126	EST	6.29	0.00087	847.4	775.81	377.99	160.93	178.76	112.71
rc_AA451877_at	AA451877	1138	EST	8.63	0.00489	239.55	157.3	244.02	-27.28	-27.59	18.28
rc_AA454597_s_at	AA454597	1166	EST	3.63	0.0067	268.15	274.94	167.72	9.99	57.29	23.41

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					norma	normal	normal
				change	-	netastatic:	metastatic: metastatic:	metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
			KIAA0144 gene								
AA454908_s_at	AA454908	1171	product	9.3	0.00539	320.03	253.32	238.5	-33.7	-46.73	73.56
rc_AA457235_at	AA457235	1200	EST	#N/A	#N/A	481.26	138.32	573.73	11.06	17.32	15.26
rc_AA459254_at	AA459254	1211	EST	5.36	0.0259	403.69	194.85	401.21	51.84	43.51	37.57
rc_AA460666_at	AA460666	1231	EST	#N/A	W/V#	56.19	58.13	26.29	-24.55	-17.23	20.98
rc_AA463861_at	AA463861	1251	EST	24.79	96000.0	672.22	311.71	641.54	-22.02	-20.04	16.5
rc_AA464962_at	AA464962	1264	EST	#N/A	#N/A	61.02	56.4	30.98	20.99	14.37	19.64
rc_AA465342_at	AA465342	1271	EST	#N/A	#N/A	113.36	100.15	87.62	30.07	33.06	23.97
rc_AA465660_at	AA465660	1273	LIM domain binding 1	#N/A	#N/A	171.26	118.15	103.39	124.59	105.93	56.71
			tumor necrosis factor								
			receptor superfamily,								
			member 12								
			(translocating chain-								
			association								
rc_AA476749_s_at	AA476749	1286	membrane protein)	#N/A	#N/A	53.23	44.04	18.16	25.5	29.62	11.96
rc_AA477561_at	AA477561	1292	EST	#N/A	#N/A	160.87	104.95	133.7	63.83	76.56	37.87
rc_AA478556_at	AA478556	1303	EST	#N/A	#N/A	172.35	136.55	120.49	143.25	134.62	109.1
rc_AA482546_s_at	AA482546	1336	KIAA0124 protein	4.41	0.00604	181.72	113.91	140.73	38.26	30.26	32.72
			chromosome 6 open								
rc_AA491208_at	AA491208	1388	reading frame 1	#N/A	#N/A	159.88	143.86	80.49	123.37	131.81	47.97
rc_AA599244_at	AA599244	1448	KIAA0530 protein	3.39	0.01246	77.48	78.85	37.98	7.71	90.9	7.11
rc_AA599585_at	AA599585	1454	EST	#N/A	#N/A	66.17	48.91	48.12	-12.47	-17.55	21.82
rc_AA609013_s_at	AA609013	1477	dipeptidase 1 (renal)	10.17	0.00109	1185.55	1222.89	634.13	114.31	98.91	75.22
rc_AA609795_at	AA609795	1492	EST	#N/A	#N/A	74.38	34	77.76	-41.44	45.5	28.82
rc_AA620497_s_at	AA620497	1503	EST	#N/A	#N/A	147.72	165.83	66.02	95.91	76.7	80.33
rc_AA620995_at	AA620995	1512	EST	3.74	0.03414	100.71	80.15	101.95	3.5	1.8	3.77
rc_AA621277_at	AA621277	1520	EST	3.81	0.00194	81.18	74.81	30.84	-0.15	1.98	12.84
AB002304 at	AB002304	1534	KIAA0306 protein	#N/A	#N/A	584.5	621.94	136.64	313.99	298.88	88.6
i			•								

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					normal	norma	normal
				change		metastatic:	metastatic: metastatic:	metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	in metas	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
			KIAA0351 gene								
AB002349_at	AB002349	1537	product	#N/A	#N/A	65.63	52.11	32.26	49.37	46.52	37.93
			lectin, galactoside-								
			binding, soluble, 9								
AB006782_at	AB006782	1541	(galectin 9)	WW#	#N/A	475.47	430.44	192.68	222.25	213.37	51.25
AF003521_at	AF003521	1545	jagged 2	11.26	0.00008	426	330.95	309.91	15.48	-3.6	91.81
C00808 s at	C00808	1553	EST	#N/A	#N/A	122.57	118.32	53.36	91.65	87.87	32.51
C14228 f at	C14228	1567	EST	#N/A	#N/A	39.93	33.15	13.59	-0.51	2.85	8.61
rc_C15078 i at	C15078	1573	EST	#N/A	#N/A	115.08	73.82	91.34	26.22	31.14	60.2
	,		pituitary tumor-								
rc_C21248_at	C21248	1585	transforming 1	3.85	0.00456	100.24	96.81	47.17	-1.7	-11.27	28.49
			phosphatidylinositol								
D13435_at	D13435	1605	glycan, class F	#N/¥	#N/A	80.8	88.58	41.56	34.85	41.76	18.11
			basic transcription								
			element binding								
D14520_at	D14520	1613	protein 2	4.93	0.00004	151.12	135.19	57.24	25.67	17.28	25.67
rc_D20906_at	D20906	1627	EST	5.18	0.02189	210.11	151.67	185.24	14.87	11.71	27.2
			minichromosome								
			maintenance deficient								
			(S. cerevisiae) z								
D21063_at	D21063		(mitotin)	3.83	0.00983	91.18	55.12	60.89	-51.33	-62.63	28.4
D50914_at	D50914	1673	KIAA0124 protein	4.74	0.00752	116.55	91.64	89.27	-17.4	-17.86	16.97
			KIAA0152 gene								
D63486_at	D63486	1712	product	6.33	0.00078	543.91	676.55	287.16	84.6	95.61	45.48
			KIAA0159 gene								
D63880_at	D63880	1715	product	4.26	0.00253	93.03	103.26	41.4	-2.12	-4.45	9.38
			KIAA0170 gene								
D79992_at	D79992	1724	product	#N/A	#N/A	35.23	42.16	14.88	22	18.09	11.9

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					normal	normal	normal
				change		metastatic:	metastatic:	metastatic: metastatic: metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Genbank Seq ID Known Gene Name	in metas	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
			KIAA0175 gene								
D79997_at	D79997	1725	product	#N/A	#N/A	55.25	42.49	53.87	8.57	6.15	13.07
rc D80710 f at	D80710	1734	integral type I protein	7.08	0.00213	253.6	303.7	149.08	22.95	28.29	24.59
rc_D80948_f_at	D80948	1738	EST	#N/A	#N/A	82.4	67.39	42.83	41.25	43.53	17.46
D83735_at	D83735	1747	calponin 2	10.42	0.00001	486.85	436.55	172.25	42.54	43.06	57.58
20,000	000000000000000000000000000000000000000	67.0	trinucleotide repeat containing 11 (THR- associated protein,	u u	200	9000	4 0 0		c c	0 0 1	20
D83/83_at	D83/83	1/48	Z30 KDa subunit)	6.55	0.00176	236.64	156.39	216.64	23.23	19.65	27.84
			minichromosome maintenance deficient								
D84557_at	D84557	1749	(mis5, S. pombe) 6 zinc finger protein 142	#N/A	#N/¥	142.92	125.75	102.81	37.22	43.12	28.15
D87073 at	D87073	1759	(clone pHZ-49)	#N/A	#N/A	40.84	34.37	13.36	33.34	33.07	21.13
D88154_at	D88154	1766	villin-like	4.18	0.00051	117.8	129.16	47.7	23.85	18.99	17.79
rc_F02330_at	F02330	1778	EST	#N/A	W/A	199.08	170.47	83.95	178.42	195.54	58.6
rc_F03811_f_at	F03811	1784	KIAA0440 protein	#N/A	#N/A	638.66	598.46	142.63	235.37	232.6	47.16
rc E04320 s at	F04320	1786	replication factor C	3,63	0.01119	90.37	115 96	49.41	14 92	17.26	0 70
		3	Kell blood group					į) ;
rc_F04531_s_at	F04531	1791	phenotype)	7.79	0.03205	311.05	366.72	262.03	16.22	20.65	13.52
rc_F09394_s_at	F09394	1803	KIAA0715 protein	22.89	0.01753	865.39	696.47	631.83	-49.72	-50.25	35.81
			procollagen-proline, 2- oxoglutarate 4-								
			dioxygenase (proline 4-								
rc_F09788_at	F09788	1808	polypeptide II	4.14	0.00003	104.92	112.31	27.67	19.92	20.29	13.83

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

Canbank Sag ID Known Gene Name In metas p value Mean Median Std Dev Mean Median Std State St					fold					normal	normal	normal
Genbank Seq ID Known Gene Name In metas p value Mean Median Std Dev Mean Median H03629 1834 desmin #NIA #NIA #NIA 52.19 58.52 35.47 -1.96 -2.94 H03629 1874 desmin #NIA #NIA 70.59 62.53 58.16 9.96 8.19 H11760 1878 ET4-like factor 4 (ets) #NIA #NIA 70.59 62.53 58.16 9.96 8.19 H24269 1902 factor 4 (ets) #NIA #NIA 51.79 47.58 24.25 15.19 16.8 H24269 1902 factor 1 #IXA hstone family #IXA hstone family 46.001972 377.04 222.91 315.89 57.02 63.58 H43286 1929 receptor, 1 5.02 0.01972 377.04 222.91 315.89 57.02 63.58 H43286 1926 ribosomal protein L31 #NIA #NIA 47.56 34.17 56.68 4.55 2					change		metastatic:	metastatic:	metastatic:	set 2:	set 2:	set 2:
H03629 1834 desmin #NIA #NIA 52.19 58.52 35.47 -1.96 H03281 1863 EST 6 0.00966 147.11 187.25 71.67 -2.97 H11760 1878 EST 6 0.00966 147.11 187.25 71.67 -2.97 H11760 1878 EST 6 0.00966 147.11 187.25 71.67 -2.97 domain transcription #NIA #NIA 51.79 47.58 24.25 15.19 gamma-aminobutyric acid (GABA) B 70.00147 413.02 424.34 219.27 92.12 H243286 1929 receptor, 1 5.02 0.01972 377.04 222.91 315.96 57.02 H24386 1930 member Y 4.6 0.00147 413.02 424.34 219.27 92.12 H25857 1945 adenylate cyclase 3 3.98 0.0045 140.07 111.99 74.77 31.33 H5709 1966 ribosomal protein L31 #NIA #NIA 47.56 34.17 56.88 4.55 H5873 1961 1 57.98 0.00063 4996.66 4603.55 4107.24 69.89 H5967 2068 EST #NIA #NIA 179.15 192.17 32.25 111.29 mitochondrial 1 7.9 0.00705 212.04 143.89 162.12 -17.21	Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
H1760 1878 EST #NA #NA 70.59 62.53 58.16 9.96 E74-like factor 4 (ets domain transcription transcription factor) H24269 1902 factor) gamma-aminobutyric acid (GABA) B #NA #NA 51.79 47.58 24.25 15.19 gamma-aminobutyric acid (GABA) B #NA #NA 413.02 424.34 219.27 92.12 H2386 1929 receptor, 1 5.02 0.01972 377.04 222.91 315.96 57.02 H24546 1930 member Y 4.6 0.00147 413.02 424.34 219.27 92.12 H55857 1945 adenylate oyclase 3 3.98 0.0045 140.07 111.39 74.77 31.33 H57709 1956 ribosomal protein L31 #N/A #N/A 47.56 34.17 56.08 4.55 solute carrier family 2 (facilitated glucose transporter), member 57.98 0.00063 4996.66 4603.55 4107.24 69.89 H58873 1961 1 57.98 0.00458 116.07 71.39 101 19.24 H78211 2001 EST #N/A #N/A 179.15 192.17 32.25 111.2 creatine kinase, milochondrial 1 7.9 0.00705 212.04 143.89 162.12 -17.21	rc_H03629_s_at	H03629		desmin	W/W#	#N/A	52.19	58.52	35.47	-1.96	-2.94	8.58
H11760 1878 EST #NIA #NIA 70.59 62.53 58.16 9.96 E74-like factor 4 (ets domain transcription domain transcription H24269 1902 factor 1) H24269 1902 factor 1) H24269 1902 factor 1) H24386 1929 receptor, 1 H24386 1920 member Y H24386 1930 member Y H25873 1945 adenylate cyclase 3 H248873 1961 1 H38873 1 111.21	rc_H09281_at	H09281		EST	9	0.00966	147.11	187.25	71.67	-2.97	-0.54	11.7
H24269 1902 factor 4 (ets domain transcription factor) H24269 1902 factor) gamma-aminobutyric acid (GABA) B H43286 1929 receptor, 1 H2386 1929 member Y H53657 1945 adenylate cyclase 3 H57709 1956 ribosomal protein L31 H57709 1956 ribosomal protein L31 H57873 1961 1 H58873 1961 1 H58873 1961 1 H58873 1961 1 H58873 1965	rc_H11760_f_at	H11760		EST	#N/A	#N/A	70.59	62.53	58.16	9.6	8.19	11.54
domain transcription H24269 1902 factor) gamma-aminobutyric acid (GABA) B acid (GABA) B H43286 1929 receptor, 1 H2366 1929 receptor, 1 H2367 1945 adenylate cyclase 3 H236 0.0045 140.07 111.99 H2709 1956 ribosomal protein L31 H3187 H3187 1956 ribosomal protein L31 H3187 H3187 1961 1 H3267 1964 EST H336 0.00063 4996.66 4603.55 4107.24 69.89 H5867 2006 EST HNIA H10.7 71.39 101 19.24 H98657 2068 EST HNIA HNIA 179.15 192.17 32.25 111.2 receptine kinase, mitochondrial 1 J04469 2111 (ubiquitous) H328 212.04 143.89 162.12 -17.21				E74-like factor 4 (ets								
H24269 1902 factor) #N/A #N/A 51.79 47.58 24.25 15.19 gamma-aminobutyric acid (GABA) B H43286 1929 receptor, 1 H23646 1930 member 7 H53657 1945 adenylate cyclase 3 3.98 0.0045 140.07 111.99 74.77 31.33 H57709 1956 ribosomal protein L31 #N/A #N/A 47.56 34.17 56.68 4.55 solute carrier family 2 (facilitated glucose transporter), member 57.98 0.00063 4996.66 4603.55 4107.24 69.89 H58873 1961 1 H58873 1961 1 H58873 1961 1 H58873 1961 1 H78211 2001 EST 6.73 0.02488 211.51 183.81 208.45 -115.95 H98657 2068 EST #N/A #N/A 179.15 192.17 32.25 111.2 creatine kinase, mitochondrial 1 J04469 2111 (ubiquitous) 7.9 0.00705 212.04 143.89 162.12 -17.21				domain transcription								
gamma-aminobutyric acid (GABA) B H43286 1929 receptor, 1 AL2A histone family, H43646 1930 member Y H53657 1945 adenylate cyclase 3 Solute carrier family 2 Kfacilitated glucose transporter), member H58873 1961 1 H78211 2001 EST H98657 2068 EST mitochondrial 1 J04469 2111 (ubiquitous) H43286 1929 receptor, 1 AL2A histone family, H264 1930 member Y AL302 424.34 219.27 92.12 AL303 0.0045 140.07 111.99 74.77 31.33 AL3703 424.34 424.34 219.27 92.12 AL303 0.0045 140.07 111.99 74.77 31.33 AL313 4.17 56.08 4.55 AL313 AL321 56.08 4.55 AL321 2001 EST AL321 2001 ES	rc_H24269_s_at	H24269		factor)	#N/A	W/W#	51.79	47.58	24.25	15.19	16.8	12.36
H43286 1929 receptor, 1 H2A histone family, H43646 1930 member Y H53657 1945 adenylate cyclase 3 3.98 0.0045 140.07 111.99 74.77 31.33 H57709 1956 ribosomal protein L31 #N/A #N/A 47.56 34.17 56.68 4.55 solute carrier family 2 (facilitated glucose transporter), member 4 57.98 0.00063 4996.66 4603.55 4107.24 69.89 H58873 1961 1 57.98 0.00458 116.07 71.39 101 19.24 H78211 2001 EST 6.73 0.02488 211.51 183.81 208.45 -115.95 H98657 2068 EST #N/A #N/A #N/A 179.15 192.17 32.25 111.2 creatine kinase, mitochondrial 1 1 J04469 2111 (ubiquitous) 7.9 0.00705 212.04 143.89 162.12 -17.21				gamma-aminobutyric								
H2846 1930 member Y H53657 1945 adenylate cyclase 3 3.98 0.0045 140.07 111.99 74.77 31.33 H57709 1956 ribosomal protein L31 #N/A #N/A 47.56 34.17 56.68 4.55 solute carrier family 2 (facilitated glucose transporter), member H58873 1961 1 H58873 1961 1 H78211 2001 EST 8.3 0.04588 116.07 71.39 101 19.24 H78257 2068 EST #N/A #N/A 179.15 192.17 32.25 111.2 creatine kinase, mitochondrial 1 J0469 2111 (ubiquitous) 7.9 0.00705 212.04 143.89 162.12 -17.21	H43286 s at	H43286		receptor, 1	5.02	0.01972	377.04	222.91	315.96	57.02	63.58	24.25
H43646 1930 member Y 4.6 0.00147 413.02 424.34 219.27 92.12 H53657 1945 adenylate cyclase 3 3.98 0.0045 140.07 111.99 74.77 31.33 H57709 1956 ribosomal protein L31 #N/A #N/A 47.56 34.17 56.68 4.55 solute carrier family 2 (facilitated glucose transporter), member transporter), member H5967 1964 EST 3.3 0.0058 4996.66 4603.55 4107.24 69.89 H78211 2001 EST 6.73 0.02488 211.51 183.81 208.45 -115.95 H98657 2068 EST #N/A #N/A 179.15 192.17 32.25 111.2 creatine kinase, mitochondrial 1 3.9 0.00705 212.04 143.89 162.12 -17.21	i ì			H2A histone family,	!					!		
H53657 1945 adenylate cyclase 3 3.98 0.0045 140.07 111.99 74.77 31.33 H57709 1956 ribosomal protein L31 #N/A #N/A 47.56 34.17 56.68 4.55 solute carrier family 2 (facilitated glucose transporter), member transporter), member H58873 1961 1 H78211 2001 EST 3.3 0.04588 116.07 71.39 101 19.24 H78211 2001 EST 6.73 0.02488 211.51 183.81 208.45 -115.95 H98657 2068 EST #N/A #N/A 179.15 192.17 32.25 111.2 creatine kinase, mitochondrial 1 J04469 2111 (ubiquitous) 7.9 0.00705 212.04 143.89 162.12 -17.21	rc_H43646_at	H43646	1930	member Y	4.6	0.00147	413.02	424.34	219.27	92.12	91.3	52.41
H57709 1956 ribosomal protein L31 #N/A #N/A 47.56 34.17 56.68 4.55 solute carrier family 2 (facilitated glucose transporter), member transporter), member H58873 1961 1 57.98 0.00063 4996.66 4603.55 4107.24 69.89 H59617 1964 EST 3.3 0.04588 116.07 71.39 101 19.24 H78211 2001 EST 6.73 0.02488 211.51 183.81 208.45 -115.95 H98657 2068 EST #N/A #N/A 179.15 192.17 32.25 111.2 creatine kinase, mitochondrial 1 7.9 0.00705 212.04 143.89 162.12 -17.21	H53657_s_at	H53657	1945	adenylate cyclase 3	3.98	0.0045	140.07	111.99	74.77	31.33	31.74	15.29
(facilitated glucose transporter), member 57.98 0.00063 4996.66 4603.55 4107.24 69.89 H58873 1961 1 3.3 0.04588 116.07 71.39 101 19.24 H78211 2001 EST 6.73 0.02488 211.51 183.81 208.45 -115.95 H98657 2068 EST #NVA #NVA 179.15 192.17 32.25 111.2 creatine kinase, mitochondrial 1 7.9 0.00705 212.04 143.89 162.12 -17.21	rc_H57709_s_at	H57709	1956	ribosomal protein L31	#N/A	#N/A	47.56	34.17	56.68	4.55	2.44	52.46
(facilitated glucose transporter), member 457.98 0.00063 4996.66 4603.55 4107.24 69.89 H58873 1961 1 3.3 0.04588 116.07 71.39 101 19.24 H78211 2001 EST 6.73 0.02488 211.51 183.81 208.45 -115.95 H98657 2068 EST #NVA #NVA 179.15 192.17 32.25 111.2 creatine kinase, mitochondrial 1 7.9 0.00705 212.04 143.89 162.12 -17.21				solute carrier family 2								
H58873 1961 1 57.98 0.00063 4996.66 4603.55 4107.24 69.89 H59617 1964 EST 3.3 0.04588 116.07 71.39 101 19.24 H78211 2001 EST 6.73 0.02488 211.51 183.81 208.45 -115.95 H98657 2068 EST #NI/A #NI/A 179.15 192.17 32.25 111.2 creatine kinase, mitochondrial 1 7.9 0.00705 212.04 143.89 162.12 -17.21				(facilitated glucose								
H59617 1964 EST 3.3 0.04588 116.07 71.39 101 19.24 H78211 2001 EST 6.73 0.02488 211.51 183.81 208.45 -115.95 H98657 2068 EST #N/A #N/A 179.15 192.17 32.25 111.2 creatine kinase, mitochondrial 1 J04469 2111 (ubiquitous) 7.9 0.00705 212.04 143.89 162.12 -17.21	rc H58873 s at	H58873	1961	1	57.98	0.00063	4996.66	4603.55	4107.24	69.83	70.74	58.94
H78211 2001 EST 6.73 0.02488 211.51 183.81 208.45 -115.95 H98657 2068 EST #N/A #N/A 179.15 192.17 32.25 111.2 creatine kinase, mitochondrial 1 7.9 0.00705 212.04 143.89 162.12 -17.21	rc_H59617_at	H59617	1964	EST	3.3	0.04588	116.07	71.39	101	19.24		16.88
H98657 2068 EST #N/A #N/A 179.15 192.17 32.25 111.2 creatine kinase, mitochondrial 1 7.9 0.00705 212.04 143.89 162.12 -17.21	rc_H78211_at	H78211	2001	EST	6.73	0.02488	211.51	183.81	208.45	-115.95	_	70.22
creatine kinase, mitochondrial 1 J04469 2111 (ubiquitous) 7.9 0.00705 212.04 143.89 162.12 -17.21	rc_H98657_at	H98657	2068	EST	#N/A	#N/A	179.15	192.17	32.25	111.2		128.92
creatine kinase, mitochondrial 1 J04469 2111 (ubiquitous) 7.9 0.00705 212.04 143.89 162.12 -17.21												
mitochondrial 1 J04469 2111 (ubiquitous) 7.9 0.00705 212.04 143.89 162.12 -17.21				creatine kinase,								•
	J04469_at	J04469		mitochondrial 1 (ubiquitous)	7.9	0.00705	212.04	143.89	162.12	-17.21	-18.81	12.68

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					norma	normal	normal
				channe		motactatic.	metactatic: metactatic:	motectetic.	c tot 2.	cot 2.	sot 2.
Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	in metas	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
J05257_at	J05257	2118		12.02	0.02099	429.91	300.76	352.56	-21.05	-21.78	30.67
J05272_at	J05272	2119	monophosphate) dehydrogenase 1	#N/A	#N/A	269.89	205	173.64	126.69	106.27	82.73
J05582_s_at	J05582	2121	mucin 1, transmembrane	5.39	0.00056	114	114.74	42.09	-6.01	-4.53	13.68
L07597_at	L07597	2146	ribosomal protein So kinase, 90kD, polypeptide 1	#N/A	#N/A	36.09	29.39	44.43	-12.04	-10.72	11.97
L08044_s_at	L08044	2149	rreroll factor 3 (Intestinal)	21.42	0.01674	2956.22	1618.2	3127.19	107.82	58.55	184.16
L11669_at	L11669	2157	tetracycline transporter-like protein	6.75	0.00101	218.77	261.77	115.8	26.26	25.92	17.48
L23808_at	L23808	2179	metalloproteinase 12 (macrophage elastase)	6.18	0.02195	175.24	161.83	132.75	-9.99	-8.2	8.11
L35035_at	L35035	2201	ribose 5-phosphate isomerase A (ribose 5- phosphate epimerase)	#N/A	#N/A	64.36	69.69	40.9	11.52	12.58	6.43
L35545_at	L35545	2202	endothelial cell protein C/activated protein C receptor	#N/A	#N/A	66.65	55.46	. 68.13	7.75	5.68	11.48
L38696_at	9698ET	2208	RNA-binding protein (autoantigenic)	3.7	0.00093	230.48	161.69	118.85	60.18	58.55	24.77
L41351_at	L41351	2214	protease, serine, 8 (prostasin)	6.34	0.01132	214.13	104.95	189.28	10.88	9.6	22.68

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					normal	normal	normal
				change		metastatic:	metastatic: metastatic: metastatic:	metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank		Seq ID Known Gene Name	in metas	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
L42583_f_at	L42583	2215	keratin 6A	#N/A	#N/A	116.33	111.15	91.3	60.92	51.12	22.52
M12125_at	M12125	2241	2241 tropomyosin 2 (beta)	10.83	0.00191	291.63	158.55	229.08	13.01	16.33	11.64
			thymidine kinase 1,								
M15205_at	M15205	2265	soluble	3.75	0.00159	153.15	150.31	66.27	41.98	35.02	29.02
M16364_s_at	M16364	2269	creatine kinase, brain	12.69	0.03633	683.38	491.19	929.94	-72.18	-70.9	40.37
1			carcinoembryonic antigen-related cell		٠						
			adhesion molecule 6 (non-specific cross								
M18728_at	M18728	2285	reacting antigen) kallikrein 1,	44.82	0.00291	1390.62	1362.73	1031.01	-9.17	-13.17	11.83
			renal/pancreas/salivar								
M25629_at	M25629	2307	· >	#N/A	#N/A	47.43	40.22	29.15	-2.42	2.12	15.6
l			endogenous retroviral								
M27826_at	M27826	2313	protease	26.36	0.00342	993.89	833.56	816.33	5.88	7.04	32.2
			melanoma adhesion								
M29277_at	M29277	2316	molecule	3.91	0.00112	269.54	313.13	82.76	80.09	81.21	48.32
			carcinoembryonic								
			antigen-related cell								
M29540_at	M29540	2317	adhesion molecule 5	36.57	0.0116	1516.55	1083.69	1372.55	-1.09	-3.15	11.75
			transcription factor 3								
	•		(E2A immunoglobulin								
	1	,	ennancer binding					:	!		•
M31523_at	M31523	2329	factors E12/E47)	WW.	W/N#	59.78	62.53	10.63	18.65	21.63	8.94
		•	replication factor C				;			•	1
M87339_at	M87339	2415	(activator 1) 4 (37kD)	4.07	0.00316	93.72	78.1	56.58	4.26	9.92	16.79
			miakine (neurite								
	!		growth-promoting	;		•		,		!	
M94250_at	M94250	2426	factor 2)	10.39	0.01818	442.2	188.32	624.9	-155.4	-175.43	101.89

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					normal	norma	normal
				change		metastatic:	metastatic: metastatic: metastatic:	metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
			capping protein (actin								
M94345_at	M94345	2427	filament), gelsolin-like	22.38	0.00003	503.47	539.15	179.05	-7.51	-10.35	22.75
M94362_at	M94362	2428	lamin B2	#N/A	#N/A	175.16	154.32	75.52	79.2	81.73	34.64
l			pregnancy specific								
			beta-1-glycoprotein								
			4,pregnancy specific	:				1		0	3
M94891_s_at	M94891	2429	beta-1-glycoprotein 7	#N/A	W/N#	221.09	197.74	80.32	178.23	166.98	61.33
			hydroxymethylbilane								
M95623_cds1_at	M95623	2431	synthase	#N/A	#N/A	67.65	72.44	22.29	6.67	0.88	24.92
rc N22015 at	N22015	2448	EST	46.61	0.00025	1225.51	887.65	1106.3	-5.3	-6.84	18.82
rc_N35376_at	N35376	2501	EST	#N/A	#N/A	39.01	35.99	19.81	28.53	29.44	8.2
 			v-myb avian								
			myeloblastosis viral								
rc_N49284_s_at	N49284	2537	oncogene homolog	11.82	0.01981	510.82	523.45	423.41	-36.17	-50.08	50.71
rc N54265 s at	N54265	2563	EST	#N/A	#N/A	45.56	44.98	19.91	17.71	26.43	25.36
rc N54395 at	N54395	2565	EST	#N/A	#N/A	49.95	46.84	48.26	-16.14	-17.71	6.65
l I		•	DEAD/H (Asp-Glu-Ala-								
			Asp/His) box								
rc N62675 s at	N62675	2594	polypeptide 16	3.61	0.04034	109.44	104.65	108.08	6.49	15.91	35.18
rc N63165 at	N63165		EST	#N/A	#N/A	68.04	62.1	44.7	30.07	26.23	13.84
rc_N64616_at	N64616		EST	3.11	0.0074	68.89	75.8	32.12	-0.83	9.77	28.69
rc_N66951_at	N66951	2621	EST	5.54	0.02442	451.16	432.45	381.81	59.83	75.27	32.75
1			solute carrier family 11								
			(proton-coupled								
			divalent metal ion								
			transporters), member								
rc_N72116_s_at	N72116	2668	7	9.01	0.00051	338.43	314.06	196.66	32.57	29.68	20.1
rc N73846 at	N73846	2680	EST	3.27	0.00012	78.37	7.67	20.06	14.43	14.3	17.21

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					normal	normal	normal
				change		metastatic:	metastatic: metastatic: metastatic:	metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
rc_N89670_at	089670	2709	EST	4.26	0.00002	115.98	108.4	29.79	3.16	-1.81	43.32
rc_N92659_at	N92659	2721	EST	#N/¥	#N/A	31.19	37.23	14.14	5.91	4.05	5.63
rc_N92734_at	N92734	2722	EST	#N/A	#N/A	45.63	39.49	14.19	27.31	25.45	10.41
			protein tyrosine								
			phosphatase type IVA,								
rc_N93798_at	N93798	2738	member 3	4.65	0.00118	557.51	523.56	229.03	139.69	122.61	84.93
}			tumor protein D52-like								
rc_R06251_f_at	R06251	2764	7	5.57	0.00037	343.86	381.79	95.11	74.25	66.72	64.11
rc_R06866_s_at	R06866	2774	EST	5.18	0.00187	148.48	114.86	102.01	18.26	15.16	17.11
]]			midline 1 (Opitz/BBB								
rc_R26744_at	R26744	2804	syndrome)	4.32	0.00532	112.54	06	76.53	-0.2	-3.06	24.42
rc_R27296_f_at	R27296	2807	EST	#N/A	#N/A	41.82	39.83	32.72	8.27	11.07	7.26
rc_R33498_s_at	R33498	2820	EST	41.34	0.00001	1839.74	1920.41	1082.84	46.45	33.01	43.64
rc_R36109_at	R36109	2823	EST	#N/A	#N/A	47.54	48.43	19.9	25.67	20.25	34.73
			calcium channel,								
			voltage-dependent,								
rc_R36947_s_at	R36947	2825	beta 3 subunit	4.11	0.00006	101.82	109.62	28.57	-0.61	0.94	37.6
			protein similar to E.coli								
			yhdg and R.								
rc_R38511_s_at	R38511	2832	capsulatus nifR3	5.19	0.00015	131.5	147.54	44.02	21.3	23.75	9.22
rc_R39191_s_at	R39191	2834	KIAA1020 protein	4.69	0.00456	130.93	145.31	62.13	17.46	18.33	16.04
			prominin (mouse)-like								
rc_R40057_at	R40057	2839		#N/A	#N/A	47.6	46.28	36.57	0.83	-0.8	7.91
i			KIAA0552 gene								
rc_R44479_at	R44479	2855	product	4.14	0.0181	97.01	105.95	60.51	7.08	5.99	7.62
rc_R44817_at	R44817	2860	EST	#N/A	#N/¥	600.1	550.42	309.14	255.91	249.29	69.09
			Fc fragment of IgG,								
rc R49047 at	R49047	2878	receptor for (CD16)	#N/A	∀/N#	44.49	36.71	14.37	15.43	14.16	14.13
1											

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					norma	normal	normal
				change	_	metastatic: metastatic:	metastatic:	metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID Kn	Known Gene Name	in metas	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
			ubiquitin specific protease 7 (herpes								ļ :
rc R54935 i at	R54935	2903	virus-associated)	#N/A	#N/A	75.76	81.15	31.57	17.77	4	18.86
rc R55470 at	R55470	2904	EST	3.59	0.00515	256.38	225.69	138.22	75.29	73.42	53.04
E56678 at	R56678	2908	EST	3.81	0.02242	98.37	78.38	75.74	2.67	ស	5.82
rc R59093 at	R59093	2911	EST	#N/A	#N/A	57.79	33.48	73.58	12.26	10.21	7.73
rc_R63925_at	R63925	2929	EST	#N/A	#N/A	70.52	60.93	15.36	49.82	52.73	13.77
R69700 at	R69700	2943	EST	6.71	0.0021	387.34	393.81	94.86	79.33	57.85	129.97
rc R71395 at	R71395	2952	EST	10.42	0.00422	318.75	274.93	227.75	14.99	12.28	14.58
R76363 at	R76363	2962	EST	#N/A	#N/¥	47.81	38.04	24.76	12.67	16.94	13.17
rc R85266 at	R85266	2977	EST	#N/A	#N/A	53.4	54.53	25.44	48.68	39.83	33.9
rc_R91819_at	R91819	2984	EST	8.95	0.0000	263.33	219.91	135.67	11.34	9.35	36.49
I			matrix								
			metalloproteinase 12								
			(macrophage								
rc_R92994_s_at	R92994	2990	elastase)	11.05	0.00248	. 312.14	252.62	248.32	11.43	6.64	11.52
rc_R95966_i_at	R95966	2997	EST	11.22	0.00682	482.68	436.3	446.39	-106.64		127.91
rc_R96924_s_at	R96924	3001	EST	6.18	0.03417	451.59	490.51	339.66	51.01		54.09
S78187 at	S78187	3036	cell division cycle 25B	8.07	0.0000	198.51	218.04	74.52	3.36	-1.2	26.9
rc T03438 s at	T03438	3043	EST	8.18	0.00032	300.09	229.6	218.02	31.03	28.88	15.86
rc T03541 at	T03541	3045	EST	#N/A	#N/A	455.39	418.21	288.45	155.27	155.62	50.93
rc_T15473_at	T15473	3058	muscle specific gene	5.81	0.02404	189.25	139.11	184.39	-5.65	-10.77	15.89
			cleavage and polyadenylation specific factor 4, 30kD								
rc_T16983_s_at	T16983	3074	subunit	5.23	0.00075	268.21	300.53	81.43	65.64	45.67	74.28
rc_T25744_s_at	T25744		EST		W/W	79.78	68.72	52.01	15.56	12.65	13.18

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					normal	normal	normal
				change	•	metastatic:	metastatic: metastatic: metastatic:	metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	in metas	p value	Mean	Medlan	Std Dev	Mean	Median	Std Dev
			protease, serine, 8								
rc_T30193_s_at	T30193	3098	(prostasin)	8.39	0.00043	1912.22	1228.46	1739.5	214.88	175.57	127.28
rc_T30222_at	T30222		EST	#N/A	#N/A	35.41	34.75	27.14	8.47	9.56	17.71
rc_T32108_at	T32108		EST	96.9	0.00723	1095.16	593.52	923.47	148.09	152.11	92.06
rc_T47601_at	T47601		EST	4.05	0.00878	199.79	219.84	62.16	84.5	28.33	122.16
rc_T53404_at	T53404		EST	10.68	0.00582	654.13	475.25	687.49	48.3	9.0	93.06
rc_T66935_at	T66935	3179	EST	3.97	0.00188	253.93	230.32	129.66	8.99	52.94	42.32
rc_T89601_r_at	T89601		EST	W/W	#N/A	839.07	747.51	231.92	410.07	342.22	200.88
rc_T91116_at	T91116		EST	4.01	0.02721	133.54	61.72	126.12	16.62	11.42	13.64
rc_T96060_at	T96060	3263	EST	•••	#N/A	910.76	225.75	1282.67	67.92	70.44	91.72
l			inositol 1,4,5-								
-			triphosphate receptor,								
U01062_at	U01062	3273	type 3	7.41	0	160.46	164.36	23.91	-16.8	-26.61	26.44
•			active BCR-related								
U01147_at	U01147	3275	gene	3.22	0.00103	97.43	84.12	41.43	27.15	22.94	17
			tumor necrosis factor								
			(ligand) superfamily,								
U03398_at	U03398	3282	member 9	W/W#	#N/A	116.17	88.07	59.5	115.08	92.7	93.14
			profease inhibitor 5						-		
U04313_at	U04313	3284	(maspin)	4.54	0.02986	132.77	69.67	115.99	-0.34	-2.59	9.7
			cadherin 17, LI								
			cadherin (liver-								
U07969_s_at	007969 0	3289	intestine)	10.78	0.02002	428.65	383.68	390.23	15.78	12.82	12.06
			chondroitin sulfate								
			proteoglycan 2								
U16306_at	U16306	3312	(versican)	#N/A	#N/A	48.35	56.91	35.99	8.07	4.58	16.58

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					normal	normal	normal
				change		metastatic:	metastatic:	metastatic: metastatic: metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Genbank Seq ID Known Gene Name	in metas	p value	Mean	Median	Std Dev	Mean	Medlan	Std Dev
			laminin, beta 3 (nicein (125kD), kalinin (140kD), BM600		:						
U17760_rna1_at	U17760	3315	(125kD)) sulfotransferase family	3.54	0.01853	103.13	111.96	72.83	6.99	-3.15	21.08
U20499_at	U20499	3321	1A, phenol-preferring, member 3	5.5	0.00299	316.7	231.67	222.02	48.34	54.37	24.69
			epithelial protein up-								
			regulated in carcinoma, membrane								
U21049_at	U21049	3325	associated protein 17	7.53	0.01667	202.38	248.15	119.31	-14.32	-12.21	19.43
U38847_at	U38847	3357	binding protein 1	#N/A	#N/A	72.74	92.99	36.14	15.7	17.43	10.2
			potassium voltage- gated channel, KQT-								
U40990_at	U40990	3359	like subfamily, member 1	3.18	0.00093	128.02	142.31	43.16	40.88	42.64	23.09
			discoldin domain receptor family,								
U48705_rna1_s_at	U48705	3370	member 1	5.94	0.01323	178.04	200.63	102.82	-1.87	-6.25	25.81
			box transcription								
U51095_at	U51095	3382	factor 1	4.76	0.02664	130.81	143.82	93.4	5.83	5.52	8.97
U53786_at	U53786	3390	envoplakin	#N/¥	#N/¥	221.51	73.95	249.37	-20.54	-20.08	16.22
			gamma-aminobutyric acid (GABA) A								
U66661_at	U66661	3406	receptor, epsilon	#N/A	#N/A	55.33	44.93	29.26	16.58	14.81	11.96

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					normal	normal	normal
				change	_	metastatic:	metastatic: metastatic: metastatic:	metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
			DEAD/H (Asp-Glu-Ala- Asp/His) box polypeptide 11								
			(S.cerevisiae CHL1-								
U75968_s_at	U75968	3423	like helicase)	#N/A	#N/A	195.48	155.37	86.8	115.5	102.24	77.72
			O-linked N-								
			acetylglucosamine								
			(GlcNAc) transferase								
			-N-100)								
			acetylglucosamine:pol								
			acet//glucosaminy/							•	
U77413_at	U77413	3427	transferase)	#N/A	#N/A	59.38	59.78	48.05	1.2	5.23	13.8
			pyridoxal (pyridoxine,								
U89606_at	90968N	3452	vitamin B6) kinase	3.58	0.00322	103.6	97.56	58.85	15.19	18.94	24.5
rc_W02695_at	W02695	3467	EST	#N/A	#N/A	129.58	99.52	100.52	30.69	33.06	16.14
			leukemia inhibitory								
			factor (cholinergic								
rc_W46451_s_at	W46451	3529	differentiation factor)	#N/A	#N/¥	120.95	76.95	88.42	36.63	40.09	21.06
rc_W60968_at	W60968	3559	EST	#N/A	#N/A	125.7	144.72	48.22	51.99	55.29	21.11
rc_W67251_s_at	W67251	3570	EST	6.13	0.01463	204.71	182.17	127.82	21.77	23.88	12.17
rc_W73189_at	W73189	3589	EphB2	3.69	0.02909	113.63	144.75	67.73	20.7	23.2	15.44
rc_W78057_at	W78057	3600	EST	90.6	0.0034	397.29	374.78	305.93	29.21	29.9	34.33
rc_W90146_f_at	W90146	3644	EST	6.23	0.01558	170.66	147.78	126.32	9.93	8.63	6.49
rc_W92449_at	W92449	3652	EST	31.67	0.00011	715.17	491.5	459.71	-40.13	-40.74	17.76
			protease inhibitor 5								
rc_W93726_s_at	W93726	3656	(maspin)	16.48	0.00014	355.41	304.26	149.69	-14.2	-14.8	10.59
W95348_at	W95348	3663	HSPC113 protein	10.89	0.01065	555.52	492.63	563.86	26.59	29.36	21.03
rc_W95477_at	W95477	3664	EST	26.51	0.00161	941.08	566.6	1130.33	17.15	18.75	12.83

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					norma	normal	normal
				change		metastatic:	metastatic: metastatic: metastatic:	metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Genbank Seq ID Known Gene Name	In metas	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
			small nuclear ribonucleoprotein								
			70kD polypeptide	:	;	,		!		;	,
X04654_s_at	X04654	3681	(RNP antigen)	#N/A	#N/A	98.11	89.35	38.15	42.22	41.24	17.18
X13956_at	X13956	3701	EST	3.2	0.00321	79.19	75.13	39.53	15.11	18.02	14.55
			H2A histone family,								
X14850_at	X14850	3706	member X	4.11	0.0001	118.41	97.53	52.6	11.6	13.26	30.46
			v-abl Abelson murine leukemla viral								
X16416_at	X16416	3713	oncogene homolog 1	#N/A	#N/A	82.49	90.74	16.7	36.59	38	14.59
X54667 s_at	X54667	3731	cystatin S, cystatin SN	8.53	0.00059	273.96	169.94	217.11	-10.09	-15.68	74.89
X57348_s_at	X57348	3744	stratifin	12.53	0.0013	308.28	241.69	194.79	-63.66	-76.43	44.95
			metalloproteinase 11								
X57766_at	X57766	3745	(stromelysin	#N/A	#N/A	166.25	142.96	124.34	63.38	62.13	25.48
X63629 at	X63629	3762	(placental)	3.02	0.01654	67.22	76.67	29.17	424	-6.82	16.9
3		5				<u>.</u>			_		
X67325_at	X67325	3775		29.6	0.03245	962.87	412.22	1361.55	26.81	48.73	69.77
			sodium channel, nonvoltage-gated 1								
X76180_at	X76180	3795		11.68	0	320.05	268.84	127.86	22.38	23.9	15.02
			cadherin 17, Ll cadherin (liver-								
X83228_at	X83228	3810		10.58	0.02147	342.12	423.87	282.49	-8.87	-6.9	8.55
			FXYD domain- containing ion								
X93036_at	X93036	3830	transport regulator 3	42.36	0.00167	1322.91	783.61	1219	-83.87	-85.84	40.53

Table 9A. Genes and ESTs expressed only in metastatic liver tumor versus normal sample set 2.

				fold					normal	normal normal	normal
				change		metastatic:	metastatic: metastatic: metastatic:	metastatic:	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Genbank Seq ID Known Gene Name	in metas p value	p value	Mean	Median	Std Dev	Mean	Median	Std Dev
			lipocalin 2 (oncogene								
X99133_at	X99133	3842	24p3)	6.27	0.0453		129.1	434.01	-28.39	-19.41	26.24
Y00503_at	Y00503	3849	keratin 19	14.19	0.00217	362.5	427.85	240.73	7.02	10.74	10.98
			HMT1 (hnRNP								
			methyltransferase, S.								
Y10807_s_at	Y10807	3860	cerevisiae)-like 2		0.00124		449.97	142.94	96	90.42	44.52
rc_Z39191_at	Z39191	3901	EST	8.84	0.00011	442.36	371.88	228.18	46.98	49.3	33.31
rc_Z39569_at	Z39569	3909	EST		#N/A		125.78	217.77	-9.57	-12.15	17.32
rc Z41415 at	Z41415	3933	EST		#N/A	199.73	98.98	271.2	10.38	6.64	11.47
ì			SRY (sex-determining								
			region Y)-box 9								
			(campomelic								
			dysplasia, autosomal								
Z46629_at	Z46629	3938	sex-reversal)	#N/A	#N/A	39.68	40.61	13.99	6.21	8.06	9.16

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold change		metastati	metastati metastati c: c: Std	metastati c: Std	normal set 2:	normal set 2:	normal set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_AA001902_at	AA001902	5	KIAA0305 gene product	#N/A	#N/A	14.88	17.06	8.8	29.11	28.6	23.36
rc_AA001903 i at	AA001903	9	EST	#N/A	#N/A	6.64	0.97	14.07	26.52	28.7	13.21
rc_AA004669_at	AA004669	თ	EST	#N/A	#N/A	9.66	10.77	8.65	33.32	25.36	31.12
			copper chaperone for								
rc_AA004707_at	AA004707	9	superoxide dismutase	#N/A	#N/A	217.76	217.72	144.41	502.14	479.38	161.01
rc_AA005202_at	AA005202	12	retinol-binding protein 4, interstitial	3.18	0.00106	43.46	41.24	99.6	163.36	107.5	110.2
			peroxisomal membrane								
rc_AA009719_at	AA009719	20	protein 2 (22kD)	47.12	0.00008	-50.14	-51.69	47.17	1370.32	1503.99	715.62
rc_AA010205_at	AA010205	, 23	EST	7.41	0	14.43	17.64	14.87	187.55	154.99	92.13
rc_AA010360_at	AA010360	54	EST	6.55	0.00027	12.5	14.77	8.62	169.99	135.98	129.2
rc_AA010619_at	AA010619	27	EST	8.55	0.00057	21.58	5.47	42.99	279.66	268.6	154.98
			potassium voltage-gated								
rc AA013095 s at	AA013095	73	channel, shaker-related	₩W.	#W/A	7 84	308	10 74	48 50 50 50 50 50 50 50 50 50 50 50 50 50	15 83	8 24
rc AA015768 at		3 8	EST	15.3	0000	15.51	5 5	11.27	417.05	472.4	248 15
rc_AA016021_at	AA016021	3.5	ubjouitin-like 3	#N/A	#N/A	13.88	16.21	13.21	65.65	51 44	46 44
rc_AA017146_at	AA017146	36	EST	10.1	0.00052	30.35	22.85	50.05	414.24	435.09	193.39
rc_AA018867_at	AA018867	33	EST	42.87	0.00002	45.29	29.28	52.68	1944.56	2160.33	1142.41
rc_AA019715_at	AA019715	41	EST	#N/A	#N/A	8.03	8.03	6.49	15.9	14.58	7.82
			Suppressor of Tv								
rc AA024511 at	AA024511	46	(S.cerevisiae) 3 homolog	#N/A	W/N#	7.82	3.08	12.06	62.54	58.34	27.73
rc_AA024866_at	AA024866	49	EST	#N/A	#N/A	10.89	7.87	8.56	31.16	30.56	14.26

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati	metastati metastati	normal	normal	normal
				change	_	metastati	ຮ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_AA025930_at	AA025930	52	EST	3.59	0.00372	33.24	25.62	26.11	115.2	110.13	45.17
			microvascular endothelial								
AA027766 at	AA027766	28	differentiation gene 1	#N/A	#N/A	16.71	16.37	7.36	25.05	26.19	13.26
AA028976_at	AA028976	63	EST	#N/A	#N/A	9.46	10.28	18.91	72.06	47.28	55.89
rc_AA031360_s_at	AA031360	29	EST	#N/A	#N/¥	13.46	12.87	10.49	26.25	24.36	9.3
rc_AA032250_at	AA032250	73	EST	3.56	0.000	10.56	13.86	9.55	84.44	83.69	50.06
rc_AA034365_at	AA034365	9/	EST	#N/A	#N/¥	119.56	39.46	171.27	216.28	159.86	152.39
rc_AA039616_at	AA039616	06	EST	9.36	0.0000	2.48	-4.83	14.2	238.71	224.42	125.28
rc_AA040087_at	AA040087	95	EST	4.13	0.00123	34.99	27.32	18.99	156.63	148.88	90.44
rc_AA040291_at	AA040291	94	KIAA0669 gene product	3.55	0.00308	12.98	12.72	16.36	101.69	98.94	80.43
			NADH dehydrogenase (ublauinone) 1 beta								
AA041208_at	AA041208	96	subcomplex, 8 (19kD, ASHI)	#N/A	#N/A	234.76	302.34	215.51	448.34	390	234.61
rc_AA043790_at	AA043790	66	KIAA0937 protein	#N/A	W/A	5.63	7.44	12.94	32.16	31.34	10.66
AA044095_at	AA044095	102	EST	#N/A	#N/A	29.41	18.4	35.04	31.85	24.92	38.98
			Autosomal Highly								
AA044842_at	AA044842	105	Conserved Protein	5.21	0.0009	16.66	16.52	8	167.15	159.32	123.77
rc_AA045481_at	AA045481	107	EST	#N/A	#N/A	28.81	21.88	17.14	71.32	63.94	38.49
rc_AA046457_at	AA046457	11	EST	3.5	0.00513	99.77	80.71	27.66	304.54	264.9	233.62
rc_AA046747_at	AA046747	114	EST	4.82	0.00022	-5.19	4.2	10.73	113.78	88.54	66.41
AA047151_at	AA047151	116	EST	7.13	0.00007	17.55	17.5	10.09	188.62	185.41	80.5
rc_AA053917_at	AA053917	131	EST	#N/A	#N/A	-18.24	-11.6	21.61	56.08	38.68	82.71
rc_AA055992_at	AA055992	136	calumenin	3.51	0.00604	80.45	65.8	47.34	276.06	265.13	141.34
AA056319_at	AA056319	139	EST	W/A	#N/A	21.89	17.62	12.89	29.23	26.53	11.96

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastati	metastati	normal	normal	norma
				channe	_	motactati	ز	. S. t.	set 2.	set 2.	set 2.
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	c: Mean	S. Median	Dev S	Mean	Median	Std Dev
rc_AA056482_at	AA056482	141	EST	4.82	0.00199	10.09	19.17	14.96	135.83	132.94	97.88
rc_AA056735_at	AA056735	142	SEC24 (S. cerevisiae) related gene family, member D	#N/A	#N/A	4.59	10.03	14.42	29.84	28.43	10.97
rc_AA074885_at rc_AA075298_at rc_AA076672_at	AA074885 AA075298 AA076672	161 163 172	macrophage receptor with collagenous structure EST	11.05 #N/A #N/A	0.00786 #N/A #N/A	79.55 46.45 86.18	25.58 36.93 87.53	153.64 42.61 60.88	652.03 129.13 122.82	761.74 121.57 105.84	300.57 70.36 54.8
rc_AA084286_at rc_AA084318_at rc_AA086201_at	AA084286 AA084318 AA086201	176 177 185	paternally expressed gene 3 EST EST	#N/A #N/A 5.8	#N/A #N/A 0.00012	-2.06 9.73 21.29	0.32 3.97 24.75	14.88 17.06 14.37	30.7 30.63 177.39	26.84 32.37 182.95	20.69 11.48 95.51
AA092376_at	AA092376	196	15 kDa selenoprotein bone morphogenetic protein	#N/A	#N/A	16.78	14.2	28.1	59.07	57.94	24.97
AA092596_at	AA092596	197	6 HLA-B associated transcript-	3.46	0.02532	30.18	22.69	61.67	148.47	171.15	77.57
AA092716_at	AA092716	198	၉	13.97	0.00009	62.83	63.53	42.33	952.09	817.41	545.31
rc_AA098864_at	AA098864	202	EST	#N/A	W/A#	30.42	31.06	18.38	56.43	52.57	21.3
rc_AA099225_at	AA099225	206	EST	7.33	0.00062	4.37	1.35	6.08	212.68	163.45	194.31
rc_AA099571_at	AA099571	209	MD-2 protein	#N/A	W/A	10.12	4.61	19.11	55.77	62.72	31.71
rc_AA102098_at	AA102098	218	EST	#N/A	#N/A	-1.8	-5.18	15.21	21.79	20.01	6.78
rc_AA102571_at	AA102571	220	EST	W/V#	#N/A	8.7	12.32	15.12	17.15	15.33	7.6
rc_AA112209_s_at AA112209	AA112209	223	acyl-Coenzyme A dehydrogenase, long chain	3.37	0.00084	29.77	28.31	11.33	116	100.18	66.07

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati	metastati metastati	normal	normal	normal
				change		netastati	ដ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Mrnown Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_AA115933_s_at	AA115933	231	KIAA1098 protein	#N/A	#N/A	8.62	6.46	10.77	33.88	34.38	16.63
rc_AA116075_at	AA116075	234	EST	#N/A	#N/A	29.71	23.88	10	62.94	64.79	25.13
rc_AA121140_at	AA121140	235	EST	3.33	0.00058	6.67	5.82	3.73	74.84	83.56	31.9
rc_AA121257_at	AA121257	236	EST	W/V#	#N/A	21.76	21.21	32.49	42.39	43.62	11.55
rc_AA126059 at	AA126059	246	EST	3.08	0.00706	102.34	104.33	40.8	380.92	280.71	316.4
rc_AA127514_at	AA127514	253	EST	3.4	0.00045	11.36	10.76	6.8	74.71	76.5	36.07
l I			schwannomin interacting								
rc_AA127646_at	AA127646	254	protein 1	W/A	#N/A	97.9	-0.26	12.36	44.24	41.48	20.02
l I			sequence-specific single-								
	1	i	stranded-DINA-binding	471477	471477	ì	Č	7000	•	5	
rc_AA128177_at	AA128177	202	protein	#N/A	#WA	11./1	6.05	16.95	44.4	33.5/	33.54
rc_AA129465_f_at	AA129465	263	EST	#N/A	#N/¥	7.9	10.16	24.29	61.62	59.75	34.37
			meningioma expressed antigen 6 (coiled-coil proline-								
rc_AA133214_s_at	AA133214	276	rich)	#N/A	#N/A	3.16	7.46	14.35	65.17	56.11	51.18
			calcitonin receptor-like receptor activity modifying								
rc_AA133215_at	AA133215	277	protein 1	4.55	0.02092	76.1	37.86	72.97	250.94	266.82	64.2
rc_AA133457_at	AA133457	280	EST	#N/A	#N/A	233.92	279.32	161.44	456.09	475.45	114
rc_AA136333_at	AA136333	300	zinc finger protein	#N/A	#N/A	17.23	17.21	5.7	45.55	39.88	25.1
rc_AA136611_at	AA136611	303	EST	#N/A	#N/A	9.05	6.82	8.39	48.23	42.67	13.53
rc_AA136940_at	AA136940	302	EST	#N/A	#N/A	40.81	41.78	20.7	79.13	73.37	41.89
AA143019_at	AA143019	309	EST	6.75	0.00109	-0.4	-5.82	18.62	192.42	176.13	136.81
rc_AA147626_at	AA147626	316	EST	#N/A	#N/A	37.93	20.43	44.09	82.38	75.98	37.45
rc_aa147646_s_at	AA147646	317	DKFZP586A0522 protein	21.82	0	15.59	14.85	24.51	610.52	685.45	288.9
rc_AA148480_s_at AA148480	AA148480	318	monooxygenase 5	19.64	0	18.26	14.26	14.85	521.95	407.11	247.99

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastati	metastati	normal	normal	normal
				change		metastati	ដ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_AA148539_at	AA148539	319	EST	#N/A	#N/A	96.6	9.87	8.65	28.88	25.89	6.73
rc_AA149253_at	AA149253	323	EST	5.12	0.00863	78.65	75.3	61.14	401.77	301.06	333.03
rc_AA150205_at	AA150205	328	EST	#N/A	#N/A	-1.7	-1.72	9.15	8.12	7.44	9.59
rc_AA150284_at	AA150284	329	EST	#N/A	W/A#	28.51	25.35	17.97	41.67	43.94	18.29
rc_AA151243_at	AA151243	334	EST	#N/A	#N/A	1.13	-0.17	14.55	43.61	42.74	11.08
			S-adenosylhomocysteine								
AA157401_at	AA157401	346	hydrolase-like 1	#N/A	#N/A	15.44	13.27	14.06	61.17	65.58	27.48
rc_AA167550_at	AA167550	361	EST	#N/A	#N/A	4.38	7.64	6.98	28.69	26.29	16.06
rc_AA171529_at	AA171529	365	EST	#N/A	#N/A	-1.76	-4.58	6.37	51.3	47.89	33.98
AA174202_at	AA174202	375	EST	#N/A	#N/A	55.99	38.87	72.55	120.99	128.88	62.33
rc_AA179004_at	AA179004	377	EST	14.34	0.00008	-33.2	-28.97	78.62	503.76	495.87	326.16
rc_AA182030_at	AA182030	387	EST	8.32	0.00018	14.05	16.82	12.13	222.23	220.01	117.56
			STAT induced STAT						÷		
rc_AA182568_at	AA182568	388	inhibitor-2	10.92	0.00099	23.5	18.15	21.15	501.87	386.2	478.02
rc_AA187437_at	AA187437	389	EST	W/V#	#N/A	33.59	47.3	26.91	62.23	63	25.01
			protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta								
rc_AA191310_s_at		397	isoform	7.28	0	26.23	29.87	6.93	206.65	209.15	77.34
rc_AA1936/1_ar	AA1936/1	405	KIAAUSBU protein	#N/A	¥/\	40.18	43.2	23.51	64.83	38.29	71.28
AA195179 s at	AA195179	415	eukaryotic translation initiation factor 4A, isoform 2	#N/A	#N/A	30.74	38.24	25.48	85.7	87.87	42 11
rc_AA195463_at	AA195463	416	EST	#N/A	V/N#	5.44	6.92	3.77	51.81	64.76	26.85
rc_AA195515_at	AA195515	417	EST	#N/4	#N/A	7.27	3.56	8.61	51.59	49.91	23.13
מביינים ביינים	/cocs W	<u>t</u>	101	0.44	0.000.0	27.0	44.	47.6	1.761	130.21	100.00

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

A66v ID	Gentant	מיט פיט	SmcN cases among	change		metastati	c: c: Std	c: Std	. set 2:	set 2:	set 2:
	1	2		iii iiiatao		C. MEG	INGCIDE	200	Mail	Median	ora Dav
			intercellular adhesion molecule 1 (CD54), human								
rc_AA197311_s_at	AA197311	422	rhinovirus receptor	6.07	0.00053	-19.49	1.63	43.72	154.69	175.76	83.19
rc_AA199603_at	AA199603	423	EST	#N/A	#N/A	14.97	24.27	28.57	54.95	55.7	19.61
rc_AA211370_at	AA211370	432	EST	#N/A	#N/¥	27.26	29.44	16.5	44.85	45.87	21.25
rc_AA211418_at	AA211418	434	EST	#N/A	#N/A	65.81	70.1	37.84	223.56	214.42	151.4
rc_AA223902_at	AA223902	450	EST	9.91	0.00003	7.98	-3.32	28.42	292.86	294.78	156.98
rc_AA226925_at	AA226925	452	EST	#N/A	#N/A	11.94	9.22	7.55	49.69	48.29	27.49
rc_AA227480_s_at	AA227480	456	pim-2 oncogene	3.31	0.02413	48	62.07	33.49	195.79	162.34	182.76
rc_AA227968_at	AA227968	461	histone deacety/ase 6 epoxide hydrolase 2,	W/W#	#N/A	177.49	137.57	94.86	349.29	340.4	101.81
rc_AA232114_s_at	AA232114	463	cytoplasmic	24.34	0.00007	63.09	46.66	60.38	1455.28	1626.11	664.36
rc_AA233126_at	AA233126	466	EST	#N/A	#N/A	48.86	59.64	33.59	88.56	74.17	35.35
rc_AA233152_at	AA233152	467	EST	12.95	0	-29.09	-28.01	34.42	299.54	291.48	156.26
AA233225_at	AA233225	468	MRS1 protein	#N/A	#N/A	25.16	30.66	26.03	54.1	55.8	22.69
rc_AA233369_at	AA233369	471	histidine ammonia-lyase	9.06	0.0008	49.39	47.92	39.8	425.35	405.81	214.85
rc_AA233763_at	AA233763	472	EST	4.61	0.00004	25.29	36.26	17.49	146.52	139.66	60.53
rc_AA233797_at	AA233797	473	sperm associated antigen 7	#N/A	#N/A	54.72	50.23	11.36	116.14	127.3	54.24
rc_AA233837_at	AA233837	474	EST	4.79	0.0034	18.96	19.45	40.67	214.77	118.28	278.62
		Ç	CCAAT/enhancer binding	3		:	!				
AA234634_r_at AA234687_at	AA234634 AA234687	486 787	protein (C/EBP), deita EST	7.48 4\/\	0.03318 #N/A	158.16 -8.8	49.12 -12.38	223.12 20.12	621.92 61.87	588.94	332.64 57.62
rc_AA234717_at	AA234717	489	EST	W/A#	W/W#	10.99	5.01	20.04	50.22	53.32	31.32
AA234817_at	AA234817	490	EST	6.22	0.00099	31.51	20.97	34.92	222.41	156.99	133.06

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastat	metastati	normal	normal	normal
				change		metastati	ö	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Mnown Gene Name	in metas	p value	c: Mean	Medlan	Dev	Mean	Median	Std Dev
rc_AA234831_at	AA234831	491	EST PTPI 1-associated RhoGAP	3.42	0.00206	23.54	21.62	28.81	112.19	119	49.23
rc_AA235288_at	AA235288	494	1	3.7	0.00643	34.06	30.95	14.36	169.9	113.81	138.05
			golgi autoantigen, golgin			;	į		:		
rc_AA235507_at	AA235507	498	subfamily a, 5	3.28	0.00249	22.14	37.31	26.61	111.91	126.75	58.39
rc_AA242822_at	AA242822	224	EST	¥N\#	∀/N#	9.44	13.66	8.25	27.21	25.96	16.64
rc_AA243654_at	AA243654	532	EST	W/V#	#N/A	29.0	3.93	11.08	69.19	62.85	48.63
AA247453_at	AA247453	533	EST	3.09	0.0015	32.38	37.86	21.04	120.43	133.44	58.12
rc_AA250958_f_at	AA250958	538	EST	#N/A	#N/A	53.41	53.63	22.55	99.74	114.71	55.23
			prostate cancer								
rc_AA251114_at	AA251114	539	overexpressed gene 1	9.9	0.00039	28.47	18.55	28.89	219.81	202.99	87.55
rc_AA251776_at	AA251776	545	Jun D proto-oncogene	#N/A	#N/A	30.8	23.59	32.23	51.25	46.83	15.96
rc_AA251845_at	AA251845	548	EST	#N/A	#N/A	269.35	283.55	60.62	477.47	411.47	377.99
rc_AA253410_at	AA253410	564	EST	#N/A	#N/A	18.46	7.23	42.79	49.37	26.82	45.2
rc_AA255546_at	AA255546	569	EST	4	0.00301	61.04	67.88	31.64	260.34	224.12	142.84
rc_AA255903_at	AA255903	573	CD39-like 4	2.67	0.01687	72.5	39.23	108.92	383.56	374.1	211.92
rc_AA256341_at	AA256341	578	EST	7.37	0.00091	17.81	2.34	28.59	280.57	324.08	170.98
rc_AA256990_at	AA256990	585	EST	#N/A	#N/A	8.43	11.36	27.79	15.63	16.56	68.9
rc_AA257057_s_at	AA257057	586	EST	8.11	0.00379	42.36	16.78	47.02	451.86	462.6	343.05
rc_AA258158_at	AA258158	588	EST	#N/A	W/A	7.91	2.43	17.94	44.84	34.32	35.63
rc_AA258353_at	AA258353	593	EST	5.28	0.00193	71.76	84	37.77	347.7	363.14	106.2
rc_AA259064_at	AA259064	602	EST	13.15	0.00001	15.32	-1.37	28.67	401.93	394.99	178.23
rc_AA278670_at	AA278670	616	EST	#N/A	#N/A	7.4	11.47	12.63	54.24	49.98	28.69
rc_AA278824_at	AA278824	619	EST	#N/A	W/V#	26.85	31.59	11.72	83.48	91.25	30.24
rc_AA278853_at	AA278853	621	EST	#N/A	#N/A	10.28	11.7	21.49	42.68	43.68	17.64
rc_AA279158_i_at	AA279158	623	EST	#N/A	#N/A	20	46.97	19.41	87.9	72.44	38.36

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati	metastati metastati	normal	normal	normal
				change		metastati	ິບ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_AA279341_at	AA279341	625		#N/A	#N/A	67.56	80.37	50.19	132.89	118.11	67.28
rc_AA279916_at	AA279916	633	EST	W/N#	#N/A	61.08	56.18	25.7	115.24	102.89	58.77
			spleen focus forming virus (SFFV) proviral integration								
rc_AA280413_s_at		638	oncogene spi1	4.46	0.02062	64.05	69.15	51.55	339.15	353.53	235.59
rc_AA281545_at	AA281545	645	EST	3.64	0.00002	6.52	-0.81	16.89	87.27	85.27	34.29
-			seven in absentia								
rc_AA281770_at	AA281770	649	(Drosophila) homolog 1 mannose-P-dolichol	3.96	0.00094	7.67	4.72	15.41	103.75	79.4	70.74
rc_AA281796_at	AA281796	650	utilitzation defect 1	3.3	0.04108	65.08	53.58	57.86	170.88	165.02	41.87
rc_AA282541_at	AA282541	661	EST	W/W#	#N/A	7.18	5.97	14.25	31.31	29.9	13.53
rc_AA282956_at	AA282956	664	EST	#N/A	W/A	0.28	-9.07	30.81	59.89	51.54	35.5
rc_AA283066_at	AA283066	999	EST	#N/¥	#N/A	21.18	25.64	13.39	67.44	59.46	35.89
			phosphatidylethanolamine N-								
rc_AA284795_at	AA284795	678	methyltransferase	10.03	0.00019	44.8	62.07	44.12	514.93	591.52	206.4
rc_AA285053_at	AA285053	681	EST	6.95	0.00125	12.65	14.54	23.53	238.16	242.27	169.12
rc_AA286710_at	AA286710	683	lymphocyte adaptor protein	#W/A	#N/A	37.88	39.15	30.32	82.93	86.15	45.58
rc_AA287566_at	AA287566	9	KIAA0187 gene product	9.07	0.00013	4.86	6.24	7.4	246.24	201.66	228.64
rc_AA291293_at	AA291293	698	EST	#N/A	#N/A	17.35	18.07	17.24	33.6	33.3	5.56
AA292440_s_at	AA292440	709	DKFZP566B133 protein	#N/A	#N/A	122.1	125.27	37.73	370.32	318.31	181.37
AA296821_at	AA296821	723	EST	W/V#	#N/W	15.47	10.65	21.91	57.72	71.28	33.61
AA298180_at	AA298180	2 5	EST	 	0.00747	19.6	25.9	18.83	109.91	204.28	213.18
10_AA312940_S_81	A4312840	Ē	LOI	3.2	0.00	76.21	13.70	12.24	300.22	304.30	213.10

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastat	metastat	normal	normal	normal
				change		metastati	ຮ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
			fattv-acid-Coenzyme A								
AA316272 at	AA316272	734	Ilgase, long-chain 3	#N/A	#N/A	34.62	38.08	17.08	71.9	73.01	27.47
AA328684 at	AA328684	737	EST	#N/A	#N/A	49.88	48.15	31.41	115.97	114.66	46.25
rc AA342918 at	AA342918	750	EST	#N/A	#N/A	23.67	31.68	25.77	69.4	73.71	18.13
rc_AA343142_at	AA343142	751	EST	20.87	0.00003	-12.34	-21.46	30.45	610.64	636.83	438.33
			complement component 8.								
rc AA344866 s at	AA344866	752	gamma polypeptide	7.28	0.00206	292.65	305.28	176.61	1845.16	1679.29	561.04
rc_AA363203_s_at		761	EST	#N/A	#N/A	35.7	40.27	34.51	78.45	75.11	47.8
rc AA365691 at		763	EST	#N/A	#N/A	48.01	47.17	25.37	28.69	26.73	13.89
rc_AA381125_at	AA381125	772	EST	15.48	0	17.66	13.82	13.2	412.26	344.45	217.56
AA397841 at	AA397841	780	EST	8.21	0	7.72	3.33	18.47	214.17	189.93	116.41
rc AA397904 at	AA397904	781	EST	#N/A	#N/A	22.74	18.55	19.05	59.75	54.83	32.24
rc_AA397919_at	AA397919	785	EST	#N/A	#N/A	108.63	144.35	84.25	243.79	199.62	185.4
			growth factor recentor-								
rc AA398124 s at	AA398124	787	bound protein 14	7.82	0.0000	3.4	5.86	7.61	189.27	167.23	110.44
rc AA398280 at	AA398280	792	EST	12.43	0.00134	-114.74	-71.05	103.33	433.45	423.73	356.61
rc_AA398386_at	AA398386	793	EST	5.71	0.00007	10.59	16.25	21.59	153.16	164.38	83.94
rc_AA398423_at	AA398423	795	EST	8.26	0.00063	-17.3	-16.19	23.92	230.91	250.5	156.29
rc AA398674 at	AA398674	798	thrombospondin 1	#N/A	#N/A	-27.87	14.49	146.65	137.87	96.14	119.21
rc_AA400030_at	AA400030	806	EST	3.98	0.00088	8.99	12.21	11.35	97.83	115.15	52.04
rc_AA400080_at	AA400080	807	EST	#N/A	#N/A	25.33	23.57	27.54	61.21	60.21	29.91
rc_AA400258_at	AA400258	812	EST	11.89	0.00478	85.31	36.81	139.93	827.48	884.35	562.14

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

Affy ID	Genbank	Seq ID	Known Gene Name	fold change in metas	p value	metastati c: Mean	metastatl metastat c: c: Std Median Dev	metastati c: Std Dev	normal set 2: Mean	normal set 2: Median	normal set 2: Std Dev
•											
			tumor necrosis factor alpha- inducible cellular protein								
			containing leucine zipper domains; Huntingtin								
			Interacting protein L; transcrption factor IIIA-								
AA400333_at	AA400333	815	interacting protein	#N/A	W/V#	27.22	27.33	24.37	62.54	58.6	31.69
rc_AA400934_at	AA400934	824	EST	4.98	0.02013	75.44	67.21	7.77	305.09	307.45	125.76
			calcitonin receptor-like receptor activity modifying								
rc_AA400979_at	AA400979	825	protein 3	6.65	0.01051	48.89	21.04	80.4	276.38	267.3	88.7
rc_AA401091_at	AA401091	826	EST	#N/A	#N/A	31.88	32.59	43.51	30.55	19.82	28.68
rc_AA401562_s_at	AA401562	830	EST	50.45	0.00301	155.46	63.87	317.6	3745.71	3628.4	1635.98
rc_AA401825_at	AA401825	831	EST	#N/A	#N/A	24.3	26.82	18.04	65.22	57.51	46.54
			growth arrest and DNA-								
rc_AA402224_at	AA402224	836	damage-inducible, gamma	14.41	0.00012	37.55	48.88	48.58	749.36	812.2	443.66
rc_AA402610_at	AA402610	839	KIAA0548 protein	#N/A	#N/A	3.02	69.9	13.83	27.54	23.2	17.78
rc_AA402656_at	AA402656	841	EST	12.05	0.00001	-2.56	18.8	40.57	342.11	315.47	205.61
AA404214_at	AA404214	846	EST	W/A	#N/A	35.28	48.54	23.52	99.02	66.71	55.97
rc_AA404248_at	AA404248	847	EST	#N/A	W/V#	11.96	11.18	10.84	40.92	35.06	17.49
rc_AA404352_at	AA404352	820	EST	7	0.00059	26.7	20.02	33.28	213.01	172.11	108
rc_AA405494_at	AA405494	828	EST	#N/A	#N/A	10.03	9.53	7.62	59.95	44.88	50.8
rc_AA405495_at	AA405495	829	EST	W/A	#N/A	26.12	22.63	43.42	79	87.8	30.16
rc_AA405744_at	AA405744	863	EST	W/V#	#N/A	61.18	28.74	58.71	64.39	57.95	35.67
rc_AA406363_at	AA406363	874	EST	#N/A	#N/A	6.85	5.69	15.69	35.62	35.06	13.69

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastati	metastati	normal	normal	normal
				change		metastati	ដ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	D Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_AA406546_at	AA406546	879	EST	#N/A	#N/A	-1.45	-7.89	15.19	46.62	50.65	26.97
rc_AA406610_at	AA406610	880	EST	#N/A	#N/A	5.99	6.04	4.63	35.94	34.84	11.57
rc_AA410255_at	AA410255	882		7.56	0.00043	0.82	4.15	11.49	195.75	236.93	110.49
rc_AA411795_at	AA411795	892	EST	#N/A	#N/A	72.18	53.17	44.28	130.27	131.65	23.71
rc_AA412063_at	AA412063	895		8.26	0.00001	11.36	14.03	19.55	220.12	187.85	149.43
rc_AA412068_at	AA412068	896	EST	#N/¥	#N/A	30.52	29.79	13.4	81.26	74.52	35.68
rc_AA412149 at	AA412149	897	KIAA0480 gene product	V/N#	#N/A	14.07	10.08	14.16	37.43	32.4	15.56
rc_AA412520_at	AA412520	903	EST	#N/A	#N/A	18.84	14.4	14.11	80.29	103.19	41.98
rc AA412700 at	AA412700	904	ubíquitin-conjugating	∀ /N#	- V/N#	139.65	95 44	135.61	275 39	273 98	112 87
1		•	•								
			5-methyltetrahydrofolate- homocysteine								
rc_AA416936_at	AA416936	910	methyltransferase redúctase	4.98	0.00632	82.04	85.81	69.18	427.41	366.53	235.63
rc_AA417078_at	AA417078	916		4.1	0.00414	36.75	35.35	15.12	189.88	171.1	150.02
rc_AA418398_at	AA418398	921		#N/A	#N/A	0.1	-6.02	17.92	30.41	35	20.72
rc_AA419608_at	AA419608	925		9.19	0.00005	51.89	51.37	25.93	524.34	571.05	296.46
rc_AA419622_at	AA419622	926	EST	4.62	0.00386	24.88	17.15	5 8	158.88	162.5	112.57
rc_AA421051_at	AA421051	928	serum-inducible kinase	#N/A	#N/A	42.94	7.14	87.89	51.27	45.65	78
rc_AA421052_at	AA421052	929	branched chain alpha- ketoacid dehydrogenase Kinase	3.52	0.00869	77.76	94.75	43.63	251.45	221.35	109.93
rc_AA421561_at	AA421561	933	Insulin-like growth factor 2 (somatomedin A)	9.98	0.00007	79.46	77.34	41.63	921.91	703.16	679.72

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati	metastati metastati	normal	normal	normal
				change		metastati	ដ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID		in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
AA424307_at	AA424307	944	EST	5.73	l	44.98	21.05	54.01	202.82	194.92	68.07
rc_AA424798_at	AA424798	947	EST	17.45	0.00352	48.63	15.48	171.26	879.91	873.25	489.59
rc_AA425214_at	AA425214	950	EST	#N/A	#N/A	2.71	2.07	4.88	21.4	20.31	10.15
rc_AA426643_at	AA426643	970	EST	#N/A	#N/A	96.6	0.97	18.11	48.26	47.37	23.47
rc_AA427537_at	AA427537	974	DKFZP566J153 protein regulator of G-protein	#N/A	#N/A	183.26	156.56	68.58	259.57	242.97	79.81
rc_AA427579_at	AA427579	975	signalling 14	#W/A	#N/A	13.35	13.28	16.49	34.79	25.25	25.11
rc_AA427819_at	AA427819	980	midline 2	3.44	0.00063	25.98	17.06	14.91	97.03	93.49	31.39
rc_AA428150_at	AA428150	985	EST	5.24	0.00167	41.92	35.06	30.53	213.96	217.27	76.08
rc_AA428325_at	AA428325	988	EST	8.36	0.00002	-0.52	3.28	16.92	194.02	167.37	111.11
rc_AA428900_at	AA428900	992	EST	7.01	0.00037	66.25	66.77	15.35	615.96	619.42	441.72
rc_AA429038_at	AA429038	992	EST	3.29	0.00927	13.39	1.93	28.01	108.66	87.59	86.11
rc_AA429478_at	AA429478	998	EST	3.41	0.02599	55.86	65.19	47.48	192.7	196	89.2
rc_AA429651_at	AA429651	1002	KIAA0871 protein	#N/A	#N/A	15.52	13.25	17.03	44.75	41.91	28.67
rc_AA432166_f_at AA432166	AA432166	1030	succinate dehydrogenase complex, subunit C, integral membrane protein, 15kD	#N/A	Y/N#	10.94	14.1	42.99	33.86	42.75	27.46
rc_AA434225_at	AA434225	1035	1035 serum constituent protein	#N/A	#N/A	1010.84	876.42	674.94	1022.5	746.49	681.49
rc_AA435591_at rc_AA435753_at rc_AA436156_s_at rc_AA436548_at rc_AA436880_at	AA435591 AA435753 AA436156 AA436548 AA436880	1038 1045 1051 1058	kinesin family member 3B EST EST EST EST	3.5 4.71 #N/A #N/A 3.22	0.0001 0.00078 #N/A #N/A 0.00699	3.57 198.97 22.66 5.08 4.71	3.68 193.33 7.78 5.93 9.21	10.34 110.58 34.68 5.2 13.85	75.9 970.79 54.98 40.27 86.89	81.12 830.39 48.35 38.99 68.41	29.32 567.79 38.09 22.22 66.5

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastati	netastati	normal	norma	normal
				change		metastati	ដ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	In metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_AA437295_at	AA437295	1062	1062 ribosomal protein L7a	4.35	0.00347	19.67	20.38	43.07	139.16	140.38	70.9
rc_AA443658_at	AA443658	1079	transmembrane 7 superfamily member 2	9.06	0.00048	4.48	17.91	24.51	276.02	194.73	227.48
rc_AA443934_at	AA443934	1083	GTP-binding protein Rho7	3.09	0.00214	30.32	35.97	13.76	115.87	113.7	82.99
rc_AA446342_at rc_AA447802_at AA447876_at	AA446342 AA447802 AA447876	1088 1108 1109	seven in absentia (Drosophila) homolog 1 EST EST	4.84 #N/A #N/A	0.00015 #N/A #N/A	9.92 15.64 13.05	9.12 17.7 6.78	4.58 13.81 34.07	110.73 21.51 27.08	115.89 21.34 22.86	53.13 7.37 22.46
rc_AA448300_at rc_AA449108_at rc_AA449297_at	AA448300 AA449108 AA449297	1116 1118.	FXYD domain-containing ion transport regulator 1116 (phospholemman) 1118. EST 1121 EST	24.97 #N/A 3.78	0.00001 #N/A 0.00039	118.64 10.9 3.76	81.63 18.13 0.63	70.34 15.28 19.01	2849.54 52.58 91.67	2905.51 57.3 81.15	994.41 23.76 55.17
rc_AA452158_at rc_AA453770_s_at rc_AA454177_i_at rc_AA454667_at	AA452158 AA453770 AA454177 AA454667	1141 1157 1164 1167	ras homolog gene family, member B EST EST EST	28.96 6.04 10.3 #N/A	0.00064 0.00524 0.0008 #N/A	-103.87 46.33 9.16 21.25	-106.99 25.95 14.72 12.77	71.68 53.45 11.39 23.4	1071.9 217.46 324.16 83.02	1164.8 212.4 253.23 75.81	789.64 70.02 258.82 56.63
rc_AA455111_at	AA455111	1173	heterogeneous nuclear 1173 ribonucleoprotein C (C1/C2)	#N/A	#N/A	-31.71	40.39	38.45	38.96	36.83	26.21
rc_AA455261_at	AA455261	1175	1175 chromobox homolog 7	#N/A	#N/A	32.5	45.54	26.51	66.78	80.99	30.15

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

Affy ID	Genbank	Seq ID	Known Gene Name	fold change in metas	p value	metastati c: Mean	metastati metastati c: c: Std Median Dev	metastati c: Std Dev	normal set 2: Mean	normal set 2: Median	set 2: Std Dev
rc_AA455865_at	AA455865	1180	phosphatidylinositol glycan, class B	5.41	0.00004	11.68	8.67	10.65	133.15	134.74	63.3
rc_AA455896_s_at	AA455896	1181	glypican 1	3.46	0.00887	16.1	4.35	40.39	120.52	137.84	66.93
rc_AA455987_at	AA455987	1183	EST	5.36	0.00029	20.54	17.51	15.24	128.55	130.64	17.07
	7		butyrobetaine (gamma), 2- oxoglutarate dioxygenase (gamma-butyrobetaine	i L		9	5	8	1	į	3
rc_AA455988_at	AA455988	1 7 7 8	hydroxylase) DAD22 (6. goznadaja)	15.54	0.00001	10.13	11.88	8.38	354.42	375.91	141.08
rc_AA456075_at	AA456075	1186		#N/A	#N/A	33.34	38.35	32.93	90.47	66.92	66.03
rc_AA456080_at	AA456080	1187	EST	#N/A	#N/A	32.35	17.59	33.21	27.76	26.18	12.38
20 AAAES447 04	A A A E C 4 4 7	7100	general transcription factor	200	9000	3	1	Ġ	7	0	70
1C_A4430147_at	AA430 147	0 9	YIII	4.23	0.00088	10.4) 	9.08	102.1	89.95	03.84
rc_AA456289_at	AA456289	1189	EST .	15.31	0.00004	18.07	17.84	39.22	512.64	542.52	303.15
rc_AA456326_at	AA456326	1191	EST	3.35	0.00489	17.08	2.74	30.38	111.5	102.17	68.09
rc_AA456612_at	AA456612	1195	EST	#N/#	¥N\¥	164.11	136.36	117.01	254.26	266.45	84.11
AA456687_at	AA456687	1197	EST	3.08	0.01189	17.88	37.03	53.32	130.65	118.55	65.44
rc_AA456845_at	AA456845	1198	KIAA0680 gene product	#N/A	W/N#	23.95	17.11	17.99	67.15	63.46	49.27
rc_AA458652_at	AA458652	1202		8.26	0.00001	19.3	18.21	17.18	203.23	218.67	53.52
rc_AA459005_at	AA459005	1210	EST	#N/¥	#N/A	-3.57	12.22	40.05	49.76	42.58	28.85
rc_AA459256_at	AA459256	1212	lectin, mannose-binding, 1	3.01	0.00094	3.83	8.1	8.32	65.91	63.36	39.92
rc_AA460661_at	AA460661	1229	EST	7.02	0.00053	-1.52	-6.03	15.81	184.62	198.21	108.17
rc_AA461448_at	AA461448	1240	EST	#N/A	#N/A	1.74	4.19	22.52	58.65	56.06	32.42

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati	metastati metastati	normal	normal	normal
			•	change		metastati	ij	C: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Sed ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc AA463729 at	AA463729	1250	EST	4.07	0.00676	19.31	19.05	13.37	150.62	116.86	156.67
rc_AA463876_at	AA463876	1252	EST	3.31	0.00109	9.81	11.89	10.39	73.95	73.76	46.64
rc AA464606 at	AA464606	1261		#N/A	#N/A	24.35	19.03	39.62	59.55	36.75	57.76
rc_AA465381_at	AA465381	1272	EST	#N/A	#N/A	88.83	36.24	130.22	102.73	113.07	52.43
rc_AA465720_at	AA465720	1274	EST	#N/A	#N/A	11.5	21.33	37.22	93.06	108.97	43.26
rc_AA470153_at	AA470153	1275	solute carrier family 21 (organic anion transporter), member 9	13.26	0.00315	47.49	48.57	116.54	726.75	713.23	297.62
					•	1	;	9	i i	į	! (
rc_AA478104_at rc_AA478441_at	AA478104 AA478441	1296	binding protein) catheosin F	#N/A	#N/A 0.00752	-7.07 53.85	-11.44 67.48	23.2 43.52	62.06 243.44	243.61	56.07 69.17
rc_AA479148_at	AA479148	1311	EST	38.05	0	6.2	1.32	14.38	895.91	847.72	362.53
AA479266_at	AA479266	1312	EST	#N/A	#N/A	18.04	21.7	25.73	42.53	38.32	18.46
rc_AA479488_at	AA479488	1313	S-adenosylhomocysteine hydrolase-like 1	4	0.0269	75.18	60.93	59.8	241.1	222.96	112.87
rc_AA479961_at	AA479961	1320	EST	#N/A	#N/A	33.49	28.45	10.58	88.13	89.35	36.9
rc. AA479968 s at	AA479968	1321	arylsulfatase A	9.01	0.00224	37.97	20.36	45.8	331.32	312.63	97.49
rc_AA480991_s_at	AA480991		EST	8.59	0.00156	48.08	25.74	51.03	444.29	309.38	367.89
rc_AA480997_l_at	AA480997	1324		#N/A	#N/A	9	20.58	9. 9.	68.53	55.82	63.6
rc_AA481057_f_at	AA481057	1325	EST	#N/A	#N/A	16.3	18.55	8.1	33.83	37.89	23.22

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

			fold			metastati metastat	metastati	normal	normal	normal
			change		metastati		c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID Known Gene Name	in metas	p value	c: Mean	Medlan	Dev	Mean	Median	Std Dev
rc_AA486407_at	AA486407	1347 EST	#N/A	#N/A	33.22	47.88	28.61	81.72	97.02	55.07
rc_AA486567_at	AA486567	1350 EST	လ	0.00002	4.65	2.5	21.62	131.53	98.76	95.59
rc_AA486794_at	AA486794	1351 EST	#N/A	#N/A	49.57	52.25	18.73	78.8	72.55	31.84
rc_AA487195_at	AA487195	1354 EST	#N/A	#N/A	8.73	7.94	9.21	21.04	14.67	16.52
rc_AA487503_at	AA487503	1356 EST	8.85	0.00012	13.8	17.99	8.76	220.45	255.47	119.11
rc_AA487576_at	AA487576	1357 EST	#N/¥	#N/A	-12.17	-14.87	17.17	26.05	25.27	11.13
rc_AA489009_at	AA489009	1366 EST	#N/A	#N/A	15.19	18.01	8.67	59.19	45.15	41.42
rc_AA490882_s_at	AA490882	1381 EST	3.29	0.00319	20.67	13.84	27.06	100.67	98.47	54.46
rc_AA490890_at	AA490890	1382 EST	3.02	0.00007	20.26	21.34	9.23	75.61	65.02	33.37
rc_AA490947_at	AA490947	1383 EST	#N/A	#N/A	34.15	32	21.49	56.24	38.75	49.85
rc_AA490964_at	AA490964	1384 EST	#N/A	#N/A	20.3	17.53	11.39	47.7	41.84	25.18
rc_AA495803_at	AA495803	1392 EST	#N/A	#N/A	95.29	83.46	90.72	94.07	93.85	37.65
		_			•		1	;	:	;
rc_AA495924_at	AA495924		#N/A	#N/A	4.16	3.28	2.95	35.69	34.43	19.93
rc_AA496053_at	AA496053		3.28	0.00095	5.36	2.22	17.58	81.79	94.01	42.77
rc_AA496927_at	AA496927	1402 EST	#N/A	#N/¥	24.89	26.85	9.47	58.2	58.42	17.68
rc_AA496936_at	AA496936	1403 EST	#N/A	#N/A	17.71	9.86	20.19	30.24	34.4	14.77
rc_AA504324_at	AA504324	1412 EST	#N/A	#N/A	45.99	38.81	31.27	74.31	72.05	31.59
rc_AA521290_at	AA521290	1421 EST	4.53	0.0148	46.54	22.84	63.63	166.84	174.65	58.28
rc_AA598412_at	AA598412	1425 EST	#N/A	#N/A	-2.4	-5.93	29.83	29	52.53	29.41
rc_AA598453_s_at	AA598453	1429 EST	#N/A	#N/A	7.27	7.06	9.67	67.15	54.25	41.65
		lectin, galactoside-binding.								
rc_AA598685_at	AA598685	1435 soluble, 8 (galectin 8)	#N/A	#N/A	16.45	11.35	11.87	55.9	55.08	42.18
rc_AA599107_at	AA599107	1443 EST	#N/A	#N/A	53.34	9	88.85	77.28	58.08	40.75
		endothelin converting								
rc_AA599199_at	AA599199	1444 enzyme 1	#N/A	#N/A	187.77	108.97	225.55	695.29	680.26	375.12
rc_AA599214_at	AA599214	1446 EST	#N/A	#N/A	10.94	7.36	12.27	34.58	36	14.54

				fold			metastati metastati	metastati	normal	normal	normal
				change		metastati	ដ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_AA599365_at	AA599385	1449	1449 decorin	#N/A	#N/A	36.41	34.43	21.53	83.84	84.81	43.41
rc_AA600248_at	AA600248	1461	EST	#N/A	#N/¥	59.11	59.91	32.47	80.55	71.14	61.42
rc_AA608546_at	AA608546	1463	1463 EST	12.52	0.00003	-19.59	-29.07	29.39	310.07	300.44	189.6
rc_AA608723_at	AA608723	1467	EST	#N/A	#N/A	17.44	. 15.29	13.31	66.54	70.38	20.94
rc AA609316 at	AA609316	1481	FGF-like-domain multiple 5	7 07	0000	300	2		7366	07. 900	9
rc_AA609519_at	AA609519	1482		. c	00000	20.00	00.00	22.20	264 62	27.072	40F 22
rc_AA609715_at	AA609715	1488		#N/A	#N/A	-1.49	-3.92	10.63	29.09	33.14	17.26
rc_AA620965_at	AA620965	1511	NOT3 (negative regulator of transcription 3, yeast) 1511 homolog	#N/A	#N/A	4.34	8.96	16.51	48.05	40.77	32.06
			similar to Caenorhabditis								
rc_AA621209_at	AA621209	1516	elegans protein C42C1.9	6.34	0.00144	22.77	19.95	46.78	214.61	167.05	138.24
rc_AA621235_at	AA621235	1517		3.44	0.0021	26.29	24.68	23.17	114.75	113.36	65.35
			catenin (cadherin- associated protein), alpha-								
rc_AA621315_at	AA621315	1521		#N/A	#N/A	191.28	141.04	182.69	313.23	281.93	134.57
rc_AA621796_at	AA621796	1531	1531 kinesin family member 3B	4.44	0.00032	21.81	23.64	8.64	128.01	124.81	70.04
AB000114_at	AB000114	1532	osteomodulin	#N/A	#N/A	-2.62	-0.81	29.14	31.94	25.4	20.87
AF000573_ma1_at AF000573	AF000573	1543	homogentisate 1,2- dioxygenase (homogentisate oxidase)	13.76	0.00002	9.05	13.23	17.33	380.3	348.9	256.4

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	fold change in metas	p value	metastati c: Mean	metastati metastati c: c: Std Median Dev	metastati c: Std Dev	normal set 2: Mean	normal set 2: Median	normal set 2: Std Dev
D12485_at	D12485	1600	phosphodiesterase Vnucleotide pyrophosphatase 1 (homologous to mouse Ly- 41 antigen)	4.57	0.00008	-2.69	-0.53	9.86	101.7	90.07	46.62
D12620 s at	D12620	1601	cytochrome P450, subfamily IVF, polypeptide 2,cytochrome P450, subfamily IVF, polypeptide 3 (leukotriene B4 omega hydroxylase)	35.09	0.00015	41.08	36.71	10.11	604.7	631.98	249.32
 D13243_s_at	D13243	1602	pyruvate kinase, liver and RBC	20.22	o	-35.85	-34.85	51.7	579.28	445.53	502
D13814_s_at D14012_s_at	D13814 D14012	1611 1612	angiotensin receptor 1611 1,angiotensin receptor 1B 1612 HGF activator	3.12 12.76	0.00101	13.86 160.15	10.01 216.05	12.82 107.03	79.69 1705.96	75.71 1963.23	45.03 794.42
D14664_at	D14664	1616	KIAA0022 gene product	8.98	0.00011	14.15	13.51	9.07	233.08	248.97	111.44
D14686_at	D14686	1617	aminomethyltransferase (glycine cleavage system protein T)	#N/A	#N/A	76.93	90.12	29.68	171.07	190.08	34.32
D14695_at	D14695	1618	KIAA0025 gene product; MMS-inducible gene	6.48	0	28.53	28.21	12	196.04	197.12	77.25

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

Seq ID Known Gene Name
1620 associated) homolog
1622 histidine ammonia-lyase
1622 histidine ammonia-lyase
basic transcription element 1647 binding protein 1
regucalcin (senescence 1648 marker protein-30) 1661 EST 1662 EST 1664 EST
1668 hyaluronan-binding protein 2
potassium inwardly- rectifying channel, subfamily 1669 J, member 8
potassium inwardly- rectifying channel, subfamily 1670 J, member 11 1687 EST

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold		metastati	metastati c:	metastati metastati c: c: Std	normal set 2:	normal set 2:	normal set 2:
Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
			Sec23 (S. cerevisiae)								
D57823_at	D57823	1690		4.43	0	13.37	13.08	8.38	94.25	92.78	30.56
D57916_s_at	D57916	1691	EST	#N/A	#N/A	67.05	42.08	79.49	126.25	103.85	69.38
rc_D59294_at	D59294		EST	W/V#	#N/A	1.31	0.89	6.58	22.83	20.84	14.1
rc_D59554_f_at	D59554		EST	6.7	0	6.09	9.79	34.83	184.48	158.33	79.55
rc_D60769_s_at	D60769		KIAA0096 protein	4.31	0.00142	13.44	13.91	10.95	119.96	107.2	86.36
D61991_at	D61991		EST	4.84	0.00005	22.03	21.01	10.8	131.66	150.48	90.09
D62103_s_at	D62103		EST	4.11	0.0263	96.52	111.02	79.07	349.4	258.95	229.11
D63160_at	D63160	1709	ficolin (collagen/fibrinogen domain-containing fectin) 2 (hucolin)	4.01	0.00391	51.13	46.11	30.07	219.26	228.53	125.06
			Zic family member 1 (odd-								
D76435_at	D76435	1716	paired Drosophila homolog)	#N/A	#N/A	7.52	9.44	7.51	28.48	22.05	16.54
ບ/ຮບ11_at	D/8011	۱/۱/	dihydropyrimidinase	21.37	0.00003	22.34	11.34	31.83	640.3	680.03	206.48
		!	sterol-C5-desaturase (fungal ERG3, delta-5-desaturase)-	i							
D85181_at D85433_at	D85181 D85433	1750 like 1751 EST	like EST	9.56 #N/A	0.00005 #N/A	31.54 45.14	25.11 48.1	23.09 33.75	350.04 45.46	388.34 44.56	151.37 22.01
D86983_at	D86983	1758	p53-responsive gene 2	#N/A	#N/A	44.18	43.24	14.93	56.19	, 23	16.12
D87075_at	D87075	1760	solute carrier family 23 (nucleobase transporters), member 1	4.15	0.00067	5.77	-0.83	26.24	119.77	104.75	72.62

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastat	metastati	normal	normal	normal
Affy ID	Genbank	Seq ID	Known Gene Name	change in metas	p value	metastati c: Mean	c: Median	c: Std Dev	set 2: Mean	set 2: Median	set 2: Std Dev
D90042_at	D90042	1767	N-acetyltransferase 2 (arylamine N- 1767 acetyltransferase)	7.06	0	5.13	18.92	32.5	167.38	176.16	66.7
D90282_at rc_F04611_at rc_F04677_at	D90282 F04611 F04677	1769 1792 1794	carbamoyl-phosphate synthetase 1, mitochondrial EST EST	27.29 23.96 #N/A	0.00002 0.00018 #N/A	8.24 42.65 138.06	12.24 18.88 123.28	8.02 62.74 34.39	712.98 1011.12 355.75	819.32 1040.46 310.97	415.69 589.37 168.21
rc_F04944_s_at rc_F09350_at rc_f09687_s_at rc_F09729_at rc_F09979_at rc_F10149_at	F04944 F09350 F09687 F09729 F10149	1795 1801 1806 1809 1810	acyl-Coenzyme A oxidase EST EST EST EST EST EST dual specificity phosphatase 6	4.01 4.79 #N/A #N/A 4.36 #N/A 8.13	0.00242 0.00088 #N/A #N/A 0.02555 #N/A	40.92 13.91 12.72 9.35 6.98 111.86	33.99 -6.46 8.26 20.58 6.51 108.46	28.07 33.97 28.12 23.17 20.72 60.06	191.04 147.64 58.85 55.49 226.47 257.05	192.25 130.28 57.03 55.78 116.41 276.87	99.98 79.24 31.82 27.37 288.21 165.09
rc_F10380_at rc_F10381_s_at rc_F10418_at rc_F10874_f_at	F10380 F10381 F10418 F10874	1816 1817 1818	butyrobetaine (gamma), 2- oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) KIAA0541 protein EST	#N/A #N/A #N/A 4.19	#N/A #N/A #N/A 0.00025	36.92 22.16 44.91 233.85	34.01 25.03 44.45 209.96	13.56 8.75 22.72	106.49 .64.94 .64.3	93.71 71.82 52.54 990.04	83.35 26.24 31.96 477.31

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

Affy ID	Genbank	Seq ID	Known Gene Name	fold change in metas	p value	metastatí c: Mean	metastati metastati c: c: Std Median Dev	metastati c: Std Dev	normal set 2: Mean	normal set 2: Median	normal set 2: Std Dev
rc_F13624_at	F13624	t 1825 n	breast cancer anti-estrogen 1825 resistance 3	#N/A	#N/A	27.76	19.2	32.49	8.06	73.79	59.27
rc_F13782_s_at	F13782	1827 LIM	.IM binding domain 2	4.17	0.00109	-0.64	5.61	22.4	100.8	119.01	55.07
rc_H01059 i at	H01059	s ((1830 th	solute carrier family 16 (monocarboxylic acid transporters), member 4	#N/A	#N/A	9.13	. 9.22	13.53	32.73	34.27	21.05
rc_H02855_at rc_H03348_at	H02855 H03348	1832 E	EST claudin 1	5.96	0.00458	5.06	1.15	14.13	261.57	93.25	407.93
rc_H05970_at	H05970		EST	#N/A	#N/A	9.16	12.81	14.19	68.16	65.08	40.19
rc_H09331_f_at rc_H09353_at	H09331 H09353		EST EST	#N/A 23.06	#N/A 0.00094	313.2 45.11	309.79 18.95	122.67 65.29	512.04 782.6	486.42 824.74	149.27 226.28
rc_H10661_at	H10661		EST	4.54	0.00276	31.29	18.75	28.5	132.09	124.86	64.37
rc_H11739_s_at	H11739	9 () d	glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)	10.33	0.00023	-21.2	-37.69	28.32	290.05	210.37	244.67
rc_H12593_at rc_H16098_at rc_H17472_s_at H19089_at rc_H19504_f_at	H12593 H16098 H17472 H19089	1885 1885 1888 1894 1895	1880 zinc-finger protein 265 1885 EST 1888 EST 1894 EST 1895 EST	10.72 #N/A #N/A #N/A 3.13	0.0056 #N/A #N/A #N/A 0.04948	39.96 45.29 12.2 76.83	-9.15 37.73 9.54 44.82 49.48	111.74 26.92 8.57 89.14 64.05	515.58 87.28 31.08 76.54 227.6	506.07 94.49 31.66 74.4 221.91	224.5 38.15 13.28 40.21 125.23

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold change		metastati	metastati metastati c: c: Std	metastati c: Std	normal set 2:	normal set 2:	normal set 2:
Affy ID	Genbank Seq ID	Sed ID	Known Gene Name	In metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_H20543_at	H20543	1897	DKFZP586B1621 protein	31.03	0.00074	62.11	36.98	80.24	1684.92	1680.81	731.79
H20627_at	H20627	1898	EST	#N/A	W/A#	30.59	30.04	23.84	79.8	87.46	43.37
rc_H24081_at	H24081	1901	KIAA1035 protein	#N/A	#N/A	19.72	18.46	5.69	24.15	27.08	9.52
rc_H25124_at	H25124	1903	EST	3.65	0.00004	20.47	14.4	12.59	95.09	85.36	34.91
rc_H29568_at	H29568	1914	EST	11.45	0.00058	232.54	140.09	218.85	2206.49	1884.76	783.84
rc_H30270_at	H30270	1915	EST	17.09	0.00001	61.64	60.29	25.01	1224.59	1332.66	695.76
H39627_at	H39627	1920	EST	#N/A	#N/A	73.92	101.48	54.09	155.43	158.44	39.98
			cytochrome P450, subfamily				,				
H46990_at	H46990	1933	1933 IIE (ethanol-inducible)	3.2	0.00095	-0.27	-6.33	16.23	72.1	71.1	37.01
rc_H47838_at	H47838	1936	carboxypeptidase Bz (plasma)	16.74	0.00002	-26.99	-41.82	25.87	401.55	412.78	188.81
		. •	ATP-binding cassette, sub-								
rc_H49417_s_at	H49417	1939		W/N#	#N/A	16.93	17.31	8.56	62.68	54.75	48.37
rc_H52251_at	H52251	1942	EST	#N/A	#N/A	25.41	22.3	15.29	33.86	34.48	19,95
rc_H53829_at	H53829	1946	EST	#N/A	#N/A	44.31	40.52	36.62	6.66	98.22	46.1
			4-nitrophenyiphosphatase domain and non-neuronal								
rc_H56584_at rc_H56965_at	H56584 H56965	1951	SNAP25-like 1 EST	9.5 #N/A	o \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	1.95	10.13	31.43	223.03	233.37	105.28
i I)	i)		

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati	metastati metastati	normal	normal	normal
				change		metastati	ដ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	In metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
			protein phosphatase 2								
			(formerly 2A), regulatory								
A. 02053L1 42	00000	0		6		90	0	44.04	404	90 004	62 67
16_105/6D_51	000/01	1828	isolorm formyttetrahydrofolate	3.02	0.00123	41.30	20.05	4	131.12	130.30	22.07
rc h58602 c of	HEREOS	1060		21.71	c	286	7 Y	. 181	1886 60	1520 43	1120 25
וה ווספספל פי מו	760001	200	denyal oyer lase	t :	>	-2.00	5.4	- - -	60.000	250.40	160.00
rc_H60317_at	H60317		EST	#N/A	¥N/¥	18.86	22.34	11.81	38.92	39.1	18.67
H61002_at	H61002	1967	EST	#N/A	W/V#	68.96	23.38	102.25	88.87	93.79	36.34
H66367_at	H66367	1977	EST	6.68	0.0001	-5.44	-2.13	18.66	155.38	149.31	70.77
rc H68239 f at	H68239	1983.	EST	#N/A	#N/A	26.96	17.94	15.81	92.99	66.18	51.67
i i			v-Ki-ras2 Kirsten rat								
			sarcoma 2 viral oncogene								
rc_H69138_at	H69138	1986	homolog	9.76	0.00142	42.88	30.87	38.35	328.51	313.13	218.8
rc_H69565_at	H69565	1987	EST	4.11	0.00002	15.45	16.92	9.4	92.6	94.91	42.92
rc H70485 at	H70485		EST	#N/A	#N/A	113.44	81.62	63.73	232.9	256.86	107.1
rc H70554 at	H70554		EST	10.99	0	-11.73	-19.98	33.09	292.66	288.78	153.17
rc H70627 s at	H70627		EST	#N/A	#N/A	17.89	17.62	8.85	42.72	41.34	11.7
H72650 at	H72650	1994	EST	#N/A	#N/A	81.21	98.79	41.38	122	125	42.24
rc H73535 s at	H73535	1996	EST	68.9	0.00202	154.24	97.36	149.45	912.39	956.58	383.35
rc H77494 at	H77494	1999	EST	#N/A	W/A	9.65	6.64	15.53	42.67	47.73	27.54
rc_H79820_at	H79820	2004	EST	3.25	0.01466	10.64	7	22.28	113.3	113.19	92.96
rc_H81070_f_at	H81070	2006	RNA helicase-related protein	25.74	0.00126	93.43	62.01	121.29	2044.42	2051.11	615.84
rc H81964 s at	H81964	2008	SEC14 (S. cerevislae)-like 1	W/N#	WW#	9.95	15.7	12.54	29.9	21.14	20.56
rc_H82424_at	H82424	2009	EST	#N/A	#N/A	41.99	48.17	21.1	65.11	69.41	36.73

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastati	metastati	normal	normal	normal
	٠			change		metastati	ដ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_H82735_s_at	H82735	2010	NOT3 (negative regulator of transcription 3, yeast) homolog	#N/A	#N/A	-1.13	6.14	29.78	58.77	54.86	35.76
rc_H82966_s_at rc_H83109_f_at	H82966 H83109	2011 2012	apolipoprotein B (including Ag(x) antigen) EST	3.42 16.55	0.00769	0.2 2.74	1.43	15.26 21.21	100.93 417.46	77.36 421.97	96.78 224.35
rc_H87765_at	H87765	2017	2017 KIAA0626 gene product protein phosphatase 1,	3.86	0.00131	5.2	7.91	19.6	94.26	93.78	60.64
rc_H89980_at	H89980	2026		31.13	0.00006	12.16	13.82	12.3	990.48	1005.21	755.6
rc_H90417_s_at	H90417	2028		4.17	0.015	14.23	-10.79	70.02	191.04	154.37	125.5
rc_H93381_at	H93381	2036	EST	24.23	0	80.9	-0.69	28.81	621.48	640.77	214.25
			proline synthetase co- transcribed (bacterial								
rc_H93562_at	H93562	2038		3.17	0.00113	20.83	14.13	20.46	89.3	84.36	37.72
rc_H93745_s_at	H93745	2040	GS2 gene	#N/A	#N/A	4.52	8.01	8.31	47.92	46.53	28.87
rc_H95079_at	H95079	2046	EST	#N/A	#N/A	7.05	11.03	7.33	39.79	33.3	29.08
rc_H95089_at	H95089	2047		#N/A	#N/A	13.05	13.54	4.03	31.99	31.89	13.19
rc_H95358_at	H95358	2049	EST	3.17	0.00182	-5.85	-5.95	11.57	74.74	72.66	42.36
rc_H95978_at	H95978	202		8.55	0.00046	12.28	14.38	10.71	240.91	246.43	147.67
rc_H96392_at	H96392	2053		#N/A	#N/A	12.6	9.93	33.15	35.98	53.46	42.74
rc_H96897_at	H96897	2056	KIAA0336 gene product	#N/A	#N/A	35.22	19.98	42.05	48.46	50.39	33.36
rc_H97587_s_at	H97587	2060		#N/A	#N/A	-5.07	-3.35	14.02	39.65	36.54	21.7
rc_H97670_at	H97670	2061	EST	#N/A	#N/¥	23.31	29.71	31.35	101.35	128.08	56.78

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold					normal	normal	normal
				change		metastatic	metastatic metastatic metastatic set 2:	metastatic	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Genbank Seq ID Known Gene Name	In metas p value : Mean	p value	: Mean	: Median	: Std Dev Mean	Mean	Median	Std Dev
rc_H98083_at	H98083	2067	2067 EST	5.09	0.00025 11.73	11.73	11.11	3.97	121.51	104.88	70.52
rc_H99393_s_at	H99393	2076 end	endothelin receptor type 3.43	3.43	0.00093 4.63	4.63	9.33	11.96	79.18	70.67	42.71
			apolipoprotein A-								
J00098_cds1_s_at	100098	2086	= 50	#N/A	#N/A	96.71	29.74	269.46	9836.26	8356.89	8217.05
J02943_at	J02943	2090	globulin	18.98	0.00087 57.44	57.44	39.79	44.72	880.54	924.99	144.24
77 0 070001	0,000	Č	Ö	3	0000	100	6	; ;	000	770	70
303242_S_81	303242	7607			0.00042 40.37	40.37	43.32	55.55	00.871	17.23	5.5
			(facilitated glucose								
J03810_at	J03810	2099	2099 transporter), member 2 21.99	21.99	0.00004 21.12	21.12	16.81	24.34	571.66	593.24	118.08
J04056_at	J04056	2104	carbonyl reductase 1	5.19	0.00001	9.77	22.83	29.45	145.33	139.19	73.11

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold change		metastati	metastati metastati c: c: Std	metastati c: Std	normal set 2:	normal set 2:	normal set 2:
Affy ID	Genbank	Sed ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
J04093_s_at J05037_at	J04093 J05037	2106 2116	2106 UDP glycosyltransferase 1 2116 serine dehydratase	18.92 16.24	0 0.00015	8.62 12.71	8.7 32.78	12.9 67.98	462.51 626.47	511 497.97	215.46 306.18
J05158_at	J05158	2117	carboxypeptidase N, polypeptide 2, 83kD	8.52	0	2.27	-7.78	21.43	209.63	218.19	81.01
K02100_at	K02100	2123	ornithine 2123 carbamoyitransferase	10.24	0.00009	6.1	3.97	11.14	253.26	300.99	126.18
K02402_at	K02402	2125	coagulation factor IX (plasma thromboplastic component, Christmas disease, hemophilia B)	28.81	0.00001	10.4	2.94	28.08	742.92	734.01	215.88
K02766_at	K02766	2126	2126 complement component 9	21.24	0	23.15	14.02	21.18	652.66	656.14	320.1
K03192_f_at	K03192	2127	cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 6	. 69.95	0	3.07	9.83	30.14	1767.25	1790.36	741.7
K03192_f_at	K03192	2127	cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 6	69.92	0	-1.32	-6.49	12.52	1087.08	1034.79	451.92

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold change		metastati	metastati metastati c: c: Std	metastati c: Std	normal set 2:	normal set 2:	normal set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
L00389_f_at	L00389	2132	cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2	#N/A	#N/A	69.38	86.39	64.81	222.59	184.81	121.16
L00972_at	L00972	2133	2133 cystathionine-beta-synthase	7.19	0.00008	30.44	29.08	21.44	268.9	253.33	153.24
L04751_at	L04751	2138	cytochrome P450, subfamily IVA, polypeptide 11	36.79	0.00004	32.39	23.29	32.64	1164.28	1183.4	334.08
L07956_at	L07956	2148	glucan (1,4-alpha-), branching enzyme 1 (glycogen branching enzyme, Andersen disease, glycogen storage disease type IV)	5.6	0.00029	19.13	18.57	16.75	166.17	184.57	75.67
L09717_at	L09717	2153	lysosomal-associated membrane protein 2	4.06	0.00034	16.78	9.78	21.83	115.12	111.26	57.66
L11244_s_at	L11244	2155	complement component 4- binding protein, beta	43.33	0	0.49	-8.84	36.95	1147.16	1114.71	441.14
L11244_s_at	L11244	2155	complement component 4- binding protein, beta	43.33	0	-13.27	-16.78	12.92	292.9	341.12	114.93
L11931_at	L11931	2159		7.27	0.00041	-18.81	-31.65	26.43	188.25	181.11	114.89

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				ploj			metastati metastati	metastati	normal	normal	normal
:				change		metastati	ដ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	In metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
L13689_at	L13689	2164	murine leukemia viral (bmi- 2164 1) oncogene homolog	#N/A	#N/A	32.33	34.76	18.57	63.42	77.84	36.39
L19871_at	L19871	2172	activating transcription factor 3	#N/A	#N/A	72.2	34	78.72	98.22	85.66	61.41
L26336_at L27050_at	L26336 L27050	2185 heat 2186 apoli	heat shock 70kD protein 2 apolipoprotein F	#N/A 10.26	#N/A 0.00026	15.67 -23.8	14.08 -20.7	10.72	31.12 258.1	33.86 252.65	10.1 124.08
L27841_at L32140_at	L27841 L32140	2187 2192	pericentriolar material 1 afamin	#N/A 17.31	#N/A 0.00003	58.75 9.44	58.95 16	40.61 10.75	90.06 426.89	82.7i 464.97	28.43 221.11
L32179_at	L32179	2193	arylacetamide deacetylase (esterase)	23.83		22.94	24.96	16.06	688.97	675.71	305.75
L32961_at	L32961	2194	4-aminobutyrate aminofransferase	#N/A	#N/A	15.64	7.44	15.63	76.44	79.62	26.55
L33799_at	L33799	2196	procollagen C- endopeptidase enhancer	#N/A	#N/A	87.45	73.5	89.14	230.54	248.1	130.08
L34081_at	L34081	2199	bile acid Coenzyme A: amino acid N- acyltransferase (glycine N- choloyltransferase)	11.96	0.00008	60.9	4.41	14.12	314.27	330.42	174.43
L41067_at	L41067	2213	nuclear factor of activated T-cells, cytoplasmic 3	4.96	0.00473	57.54	60.41	36.65	261.77	228.95	119.65

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastati	metastati	normal	normal	normal
			•	change		metastati	ö	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
10071	-	9	nucle		9	1		:			
L4100/	L4 100/	2213	cells, cytopiasmic 3	4.90	0.00473	30.25	13.66	32.44	/3.8/	7.38	20.79
L44424_at	L44424	2216	UMP-CMP kinase	#N/A	#N/A	23.79	18.2	26.85	57.57	43.3	36.92
L48516_at	L48516	2220	paraoxonase 3	22.21	0.00004	36.05	28.85	37.25	896.92	896.69	337.05
M10058_at	M10058	2230	asialoglycoprotein receptor 1 metallothionein 1F	23.96	0	-47.64	-42.75	75.52	591.6	603.68	188.25
M10943_at	M10943	2234		3.88	0	53.15	52.73	8.81	217.65	186.71	86.73
M11437_cds1_at	M11437	2238	kininogen	18.38	0.00006	20.84	10.7	36.84	535.53	539.53	186.97
			anglogenin, ribonuclease,								
M11567_rna1_at	M11567	2239		32.25	0.0001	2.5	-18.19	58.03	1019.17	968.25	273.9
M12625_at	M12625	2245		4.55	0.01584	110.15	128.06	73.94	447.22	425.61	138.52
			protein C (inactivator of coagulation factors Va and								
M12712_s_at	M12712	2246		7.37	0.01866	107.12	177.74	113.63	646.94	628.19	326.15
M12759_at	M12759	2247		#N/A	#N/A	27.23	21.91	28.99	97.65	103.06	53.91
			kallikrein B plasma,								
M13143_at	M13143	2249	(Fletcher factor) 1	10.39	0.00019	38.55	37.19	32.81	402.05	441.15	122.27
			coagulation factor VII				-				
M13232 s. at	M13232	2251	(serun	υ 0	0.00014	43.46	42 50	18 46	248 65	275 82	20.04
10 - 2 - 3 - 1 M	141 1020	777		e.	500.0	1.0 1.0	47.33	10.40	740.03	70.017	40.07
M13699_at	M13699	2253	2253 cèruloplasmin (ferroxidase)	15.85	0.00012	36.21	37.43	44.51	688.88	638.74	329.28

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	fold change in metas	p value	metastatl c: Mean	metastati metastati c: c: Std Median Dev	metastati c: Std Dev	normal set 2: Mean	normal set 2: Median	normal set 2: Std Dev
M14091_at	M14091	2257	2257 thyroxin-binding globulin	10.66	0.00024	1.76	2.84	6.6	269,26	284.66	119.28
			glutathione S-transferase A2,glutathione S-transferase		;			:			;
M14777_s_at	M14777	2263 A3	A3 ovruvate kinase, liver and	#N/#	#N/#	-24.81	-27.52	27.54	2842.35	2790.19	1048.69
M15465_s_at	M15465	2266	RBC	6.1	0.00069	3.06	3.32	11.38	158.56	132.57	102.11
M15656_at	M15656	2268		96.66	0	-44.61	-66.97	59.8	2911.78	2539.75	1883.04
M16594_at	M16594	2272	2272 glutathione S-transferase A2	73.21	0	-3.62	-9.74	18.15	.1602.11	1787.28	655.41
M16967_at	M16967	2275	coagulation factor V 2275 (proaccelerin, labile factor)	5.56	0.00047	22.71	26.49	30.11	204.85	248.05	88.92
M16973_at	M16973	2276	complement component 8, beta polypeptide	22.75	0.00001	20.03	23.43	31.9	686.99	714.82	203.16
M16974_s_at	M16974	2277		49.47	0.00046	28.24	-6.62	84.02	1843.82	1920.94	524.62
M17466_at	M17466	2279	coagulation ractor All (Hageman factor)	9.76	0.00285	94.21	63.47	93.18	706.11	724.27	261.46
M20218_at	M20218	2288	coagulation factor XI (plasma thromboplastin antecedent)	6.4	0.00004	38.74	45.83	14.62	247.85	259.47	69.46
M20786_at	M20786	2290	2290 alpha-2-plasmin inhibitor	16.95	0.00709	58.96	-14.12	171	1074.45	1132.06	620.06

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastati	metastati	normal	normal	normal
				change	_	metastati	ដ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
M22324_at	M22324	2295	alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13, p150)	#N/A	#N/A	224.68	25.21	471.53	365.81	363.02	134.32
M23234_s_at	M23234	2299	ATP-binding cassette, sub- family B (MDR/TAP), member 4	10.05	0	-4.37	-11.49	29.05	255.03	242.93	112.08
M24283_at	M24283	2303	intercellular adhesion molecule 1 (CD54), human rhinovirus receptor acyl-Coenzyme A	3.19	0.04985	77.88	34.05	69.45	207.07	183.74	121.4
M26393_s_at M29194_at	M26393 M29194	2309 2315		16.27 12.18	0.00007	16.81 18.97	12.39 11.91	48.16 30.61	677.3 352.8	775.54 332.28	358.47 87.49
M30185_at	M30185	2321	cholesteryl ester transfer protein, plasma	3.83	0.0013	-37.15	-29.18	28.09	93.07	86.04	61.35
M30257_s_at M30269_at	M30257 M30269	2322 2323	vascular cell adhesion molecule 1 nidogen (enactin)	3.11	0.00064	17.33	13.46 26.36	10.06 14.57	78.1 96.8	82.04 94.16	35.74 42.52

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastat	metastati	normal	normal	normal
Affy ID	Genbank	Seq ID	Known Gene Name	change in metas	p value	metastati c: Mean	c: Median	c: Std Dev	set 2: Mean	set 2: Median	set 2: Std Dev
M33317_f_at	M33317	2338	cytochrome P450, subfamily IIA (phenobarbital-inducible), 2338 polypeptide 7	32.63	0	44.53	35.06	29.77	1613.89	1437.34	1086.43
M61853_at	M61853	2369	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 18	7.82	0.00024	12.17	12.44	4.36	191.94	204.27	91.68
M61854_s_at	M61854	2370	cytochrome P450, subfamily IIC (mephenytoin 4- hydroxylase)	3.3	0.04185	52.7	55.56	44.01	321.6	166.36	430.71
M63967_at	M63967	2378	2378 aldehyde dehydrogenase 5	4.04	0.00058	34.59	36.64	5.46	164.38	178.74	87.39
M64174_at	M64174	2379	Janus kinase 1 (a protein tyrosine kinase)	#N/A	#N/A	10.42	10.81	15.82	59.51	59.38	27.77
M64554_rna1_at	M64554	2380	. coagulation factor Alli, b 2380 polypeptide	5.87	0.00011	-4.73	-4.91	7.92	137.26	136.8	72.05
M64590_at	M64590	2381	glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)	6.41	0.00002	14.28	17.87	8.65	152.26	127.72	82.96

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastati	metastati	normal	normal	normal
				change		metastati	ၓ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank Seq ID	Sed IL	Known Gene Name	In metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
M64929_at	M64929	2383	protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), alpha 2383 isoform	#N/A	#N/A	64.63	38.82	95.31	106.38	88.13	67.95
M65134_s_at	M65134	2385	2385 complement component 5	12.01	0.00012	2.31	3.66	7.43	303.27	337.95	151.33
M68516_rna1_at	M68516	2387		20.54	0	-1.34	-11.78	20.54	466.81	481.06	119.75
M68840_at	M68840	2388	monoamine oxidase A	3.96	0.01396	42.09	28.9	45.52	182	201.64	94.09
M69177_at M74719_at	M69177 M74719	2392 2396		11.64 #N/A	0.00001 #N/A	21.97 8.97	20.41 15.15	20.83	322.15 46.89	340.27 44.78	94 12.66
M75106_at	M75106	2397	carboxypepiidase bz (plasma)	40.63	0	19.77	30.19	22.24	1170.81	1124.59	329.77
M76665_at	M76665	2398		19.22	0.00004	33.41	17.51	23.86	628.97	670.88	196.22
M83216_s_at	M83216	2407	~ -	4.27	0.00037	7.89	2.98	12.17	105.21	109.38	55.62
M83772_at	M83772	2409		19.54	0	6.88	-0.95	15.39	504.14	595.51	245.03
M86873_s_at	M86873	2414	plasminogen,plasminogen- like	17.54	0	-3.92	-8.08	6.71	410.11	403.69	218.51

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

Affy ID	Genbank	Seq ID	Known Gene Name	fold change In metas	p value	metastati c: Mean	metastati metastati c: c: Std Median Dev	metastati c: Std Dev	normal set 2: Mean	normal set 2: Medlan	normal set 2: Std Dev
M88163_at	M88163	2416	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1	3.37	0.00098	17.39	17.52	7.25	84.41	91.86	41.42
M88338_at	M88338	2417		#N/A	#N/A	134.22	128.76	53.79	155.51	140.27	70.28
M88468_at	M88468	2418	mevalonate kinase (mevalonic aciduria) methylmalonate-	#N/A	#N/A	89.85	108.13	54.23	214.81	260.33	86.76
M93405_at	M93405	2424		23.06	0	16.51	27.77	20.66	679.66	734.58	307.25
M94065_at	M94065	2425	ainyaroorotate dehydrogenase	6.47	0.00013	30.26	20.14	17.64	202.13	183.44	86.43
M95767_at	M95767	2432	2432 chitobiase, di-N-acetyl-	4.94	0.00004	26.01	37.13	21.53	173.07	153.03	92
			CD36 antigen (collagen type I receptor, thrombospondin								
M98399_s_at	M98399	2437		W/N#	#N/A	4.71	4.58	5.51	47.65	38.28	35.2
rc_N22404_at	NZ1626 N22404	2445	EST	4/N#:	#N/A 0.01152	30.59	24.63 23.97	25.09 55.32	59.18 193.63	130.09	33.30 162.83
rc_N22434_at	N22434	2451		4.37	0.01725	100.96	66.55	110.62	334.51	328.98	150.7
rc_N22938_s_at rc_N24879_at	N22938 N24879	2453 2460	serum amyloid A4, constitutive EST	35.39 9.44	0.000128	163.4 6.2	145.31 5.49	160.24 23.52	4244.44 280.93	3330.35 337.77	2358.25 165.77

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati	metastati metastati	normal	normal	normal
				change	•	metastati	ຮ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq (D	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_N24973_at	N24973	2462	EST	#N/A	#N/A	30.46	28.45	11.29	56.57	59.09	22.87
rc_N25262_at	N25262	2465	EST	#N/A	#N/A	31.16	28.04	9.03	64.13	64.97	18.29
rc_N27524_at	N27524		EST	3.13	0.00216	14.18	22.08	20.51	87.67	98.26	42.62
N27670 at	N27670	2474	progesterone membrane binding protein	6.15	0.00321	38.66	15.48	47.19	252.94	292.34	133.48
I			Į.								
			monooxygenase								
rc_N29353_at	N29353	2477	(kynurenine 3-hydroxylase)	4.78	0.00019	-4.7	-5.88	13.94	109.79	101.27	53.38
rc N29543 at	N29543		EST	#N/A	#N/A	11.66	9.07	5.04	59.21	51.22	30.43
rc_N29740_at	N29740		EST	#N/A	#N/A	48.71	27.45	46.9	80.01	77.9	37.18
rc_N31952_at	N31952	2490	EST	3.13	0.01481	36.21	27.5	25.04	133.49	147.66	83.03
rc_N32071_at	N32071		EST	8.75	0.00006	40.89	43.12	15.37	421.21	488.49	238.4
rc_N34804_at	N34804	2497	DKFZP434J214 protein	8.08	0.00028	6.9	5.94	33.73	344.08	176.4	532.11
rc_N34919_at	N34919	2499	EST	#N/A	#N/A	7.39	œ	6.82	52.96	44.23	24.23
rc_N35247_at	N35247	2500	EST	#N/A	#N/A	39.9	33.56	15.03	117.08	116.14	57.05
rc_N36085_at	N36085	2505	EST	#N/A	#N/A	20.98	19.21	13.89	58.28	28	22.95
N40320_at	N40320	2514	EST	7.56	0.01584	99.72	83.43	128.45	558.37	595.16	250.67
rc_N45320_at	N45320	2519	EST	#N/A	#N/A	11.39	11.26	7.06	50.75	36	39.19
rc_N45998_at	N45998	2520	EST	3.14	0.00337	28.42	22.62	13.52	99.42	110.53	49.55
rc_N47469_at	N47469	2522	EST	3.34	0.00329	20.35	13.91	20.65	104.74	99.87	61.84
rc_N48155_at	N48155	2525	EST	#N/A	#N/A	17.08	16.77	14.66	97.37	54.69	99.7
			adantor-related protein								
rc N48315 at	N48315	2527	complex 2, mu 1 subunit	5.3	0.0149	62.03	30.66	52.29	368.37	331.28	260.93
rc_N48674_at	N48674	2530	EST	4.06	0.00028	2.7	4.57	10.52	94.61	72.82	54.62
rc_N50038_at	N50038	2541	EST	#N/A	#N/A	0.25	5.19	45.95	47.04	41.45	16.56

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

			fold			metastati metastat	metastati	normal	normal	normal
			change	•	metastati	ដ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_N51117_at	N51117	ES	9.68	0.00081	8.23	4.5	11.88	327.53	296.4	266.42
rc_N52845_at	N52845	2554 EST	5.53	0.00088	28.56	30.14	14.95	219.38	230.31	149.67
rc_N53757_at	N53757	2560 EST	3.97	0.00255	99.49	80.7	56.09	365.45	324.21	118.42
		secreted phosphoprotein 2,								
rc_N54053_at	N54053	2561 24kD	60.39	0.00087	44.3	-18.16	166.47	2749.73	2790.77	1230.33
rc_N54311_at	N54311		4.82	0.00183	9.77	9.36	25.17	160.29	130.17	124.7
rc_N54604_at	N54604	2570 EST	3.72	0.00741	2.36	2.08	35.23	133.06	119.1	109.95
		cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMP-N-acetylneuraminate								-
rc_N54792_at rc_N55272_at	N54792 N55272	2571 monooxygenase) 2574 EST	3.23 #N/A	0.00099 #N/A	28.36	27.42	6.39	110.19 45.08	77.69	87.32
l l		į								
N57464_at	N57464	2576 protein (C/EBP), delta	14.69	0.00018	22.28	11.43	38.78	429.29	442.58	169.83
rc_N57934_s_at	N57934	formiminotransferase 2577 cyclodeaminase	13.81	0.00171	806.55	477.9	939.39	9051.2	6373.16	8542.52
rc_N59089_at	N59089	2581 EST	4.74	0.00055	38.4	36.58	24.6	215.54	167.6	133.64
rc_N59532_s_at	N59532	2585 protein T)	6.73	0.00005	12.43	2.55	17.66	196.37	155.84	122.13
rc_N59543_at rc_N59550_at	N59543 N59550	2587 PDZ domain containing 1 2588 EST	9.96 25.56	0.00052	1.2 19.9	-2.89 2.53	17.29 65.91	303.49 855.88	259.23 774.72	225.96 358.3

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold change		metastati	metastati metastati c: c: Std	metastati c: Std	normal set 2:	normal set 2:	normal set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	In metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_N62523_at	N62523	2592 h	hepatic leukemia factor	5.02	0.00087	9.04	6.67	16.46	144.8	148.62	85.03
rc_N62922_at	N62922	2596 E	EST	#N/A	#N/A	14.92	14.15	2.75	54.94	52.4	18.93
rc_N63047_at	N63047	2597 E	EST	#N/A	#N/A	4.13	0.93	9.72	14.78	15.63	8.24
			cell division cycle 42 (GTP-			6		1	6		3
rc_N63172_at	N63698	2599 0	Dinding protein, 25KU) FST	#N# 7 92	#N/A	26.88 19.14	33.1 18.14	24.75 12.14	221.25	212.4	122.32
rc_N64017_at	N64017	2606 E	EST	5.27	0.00022	5.45	8.71	8.71	122.34	135.27	55.58
rc_N64436_at	N64436	2609 E	EST	3.51	0.00441	24.46	20.38	21.08	119.24	133.44	20.66
rc_N65959_at	N65959	2612 E	EST	5.43	0.00044	3.51	3.25	22.24	142.87	149.26	79.26
rc N66130 at	N66130		progesterone membrane binding protein	3.98	0.0106	29.02	21.05	33.88	172.14	181.78	114.84
rc_N66613_at	N66613	2617 E	EST	#N/A	#N/A	25.61	22.34	26.39	62.58	50.13	51.99
rc_N67009_s_at rc_N67105_at	N67009 N67105	2622 ft 2624 E	prion protein (p27-30) (Creutzfeld-Jakob disease, Gerstmann-Strausler- Scheinker syndrome, fatal familial insomnia)	3.55 5.01	0.00956 0.00176	25.95 -0.75	11.35	38.17 16.38	122.85 143.36	124.39 102.9	65.69 121.4
rc_N67876_s_at	N67876	insuli 2628 (som:	insulin-like growth factor 1 (somatomedin C)	8.89	0.00042	11.81	15.88	8.82	267.41	145.79	238.35

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati	metastati metastati	normal	normal	normal
				change		metastati	ၓ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
		- •	activating transcription factor 4 (tax-responsive enhancer			•					
rc_N67974_at	N67974		element B67)	#N/A	#N/A	2.67	-0.08	15.97	82.1	74.13	59.47
rc_N68133_at	N68133	2633	EST	W/A	#N/A	2.35	-5.53	16.59	58.69	37.21	57.82
			betaine-homocysteine								
rc_N68596_s_at	N68596		methyltransferase	40.99	0	-6.75	-13.81	19.15	1061.81	1013.27	574.42
rc_N68871_at	N68871		EST	#N/A	W/A	4.3	4.02	8.66	34.08	36.71	14.33
rc_N70305_at	N70305	2655	EST	4.41	0.00078	-13.99	-13.48	10.76	105.8	97.72	72.15
rc_N70358_s_at	N70358	2657	growth hormone receptor kidney- and liver-specific	34.35	0	20.93	29.26	36.06	1449.57	1157.97	1115.22
rc_N71542_at	N71542	2665	gene	21.05	0	-14.76	-18.28	14.3	471.65	486.43	226.63
rc_n71935_s_at	N71935	2667	multiple PDZ domain protein	16.28	0	12.84	19.17	14.1	410.92	422.1	218.42
rc_N72200_at	N72200	5669	EST	#N/A	W/V#	12.93	14.15	14.26	57.8	56.14	30.12
rc_N73561_at	N73561		EST	12.96	0.00011	17.04	4.48	25.06	516.79	458.57	393.69
rc_N73883_at	N73883	2682	EST	9.35	0	18.47	23.48	17.67	256.78	276.41	95.34
rc N74025 at	N74025	2685	delodinase, iodothyronine,	22 79	-	-7 6A	6	15.05	527 67	717 68	256 00
rc_N74422_at	N74422		EST	30.32	0	23.57	28.41	36.93	1063.07	1094.48	371.26
			collectin sub-family member								
rc_N74624_at	N74624	2688	10 (C-type lectin)	#N/A	#N/A	33.8	34.24	5.13	71.81	62.09	43.57
rc_N75072_at	N75072	2689	EST	3.73	0.00379	5.14	6.21	15.5	104.12	104.99	81.79
N75120_at	N75120		EST	#N/#	#N/¥	20.59	23.42	10.65	61.42	58.88	13.84
rc_N76086_r_at	N76086	2692	EST	#N/A	W/N#	8.23	7.19	6.54	55.55	55.02	35.47

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

			fold			metastati metastati	metastati	norma	normal	normal
			change		metastati	ដ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank Seq ID	Seq ID Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_N80129_i_at	N80129	2703 metallothionein 1L	66.48	0.00415	179.8	104.5	643.06	10421.47	6358.88	9618.38
N87590_at	N87590	2707 EST	#N/A	#N/A	1.04	-3.72	9.99	64.67	59.2	35.53
rc_N91882_at	N91882	2720 alpha2,3-sialytransferase	14.52	0.00024	-0.18	0.18	34.36	512.3	550.51	320.62
rc_N93191_at	N93191	2730 EST	3.25	0.00232	174.54	168.53	56.36	659.95	565.08	409.15
rc_N93403_at	N93403	2734 EST	#N/A	#N/A	4.44	7.63	11.8	48.84	38.39	30.93
rc_N93470_at	N93470	2736 EST	#N/A	#N/A	14.01	8.69	17.09	77.86	66.84	70.45
rc_N93764_at	N93764	2737 EST	5.92	0.0109	113.46	68.13	96.98	771.74	792.59	504.88
N94146_at	N94146	2739 EST	8.05	0	28.92	34.7	14.14	258.82	265.55	101,53
N99542_at	N99542	2747 orosomucoid 1	8.41	0.00001	6.74	10.14	21.89	226.06	187.68	146.11
rc_R02365_f_at rc_R05309_f_at	R02365 R05309	glucose-6-phosphatase, catalytic (glycogen storage disease type I, von Gierke 2755 disease) *	17.17 3.72	0.00124 0.0008	0.92 21.94	-5.3 13.92	9.39 18.75	768.72 96.81	444.03 100.54	841.02 31.73
		SEC24 (S. cerevisiae) related gene family, member		:						
rc_R05490_at	R05490	2761 B	3.03	0.00317	5.87	3.49	12.23	75.28	78.17	48.59
rc_R06002_s_at	R06002		10.15	0.00003	10.52	8.26	20.8	292.89	264.17	160.28
rc_R06271_s_at	R06271	2766 EST	6.14	0.00063	23.1	18.95	21.07	208.75	221.65	107.72
rc_R06273_f_at	R06273		#N/A	W/A#	138	103.77	75.66	235.98	183.78	122.56
rc_R06543_at	R06543		#N/A	#N/A	61.75	61.42	88.77	163.57	144.04	96.98
rc_R06746_at	R06746		15.77	0.0000	13.37	6. O-	39.24	455.48	410.16	191.35
rc_R06860_at	R06860		#N/A	#N/A	84.61	75.89	71.35	104.51	116.59	44.71

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati	metastati	normal	normal	normal
!				change		metastati	ដ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Sed ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Medlan	Std Dev
		Ö	glucokinase (hexokinase 4)								
rc_R06977_f_at	R06977		regulatory protein	6.1	0.00049	-47.7	-38.97	37.79	152.22	150.69	87.15
rc_R08564_at	R08564	-	plasminogen-like	60.18	0.00091	69.78	24	105.91	2485.63	2384.62	531.43
rc_R09053_at	R09053		EST	5.9	0.0002	6.45	17.17	35.01	186.87	204.61	113.19
rc_R10287_at	R10287		EST	11.2	0.0003	7.46	4.94	35.03	376.82	434.91	198.74
rc_R10684_at	R10684		EST	5.51	0.00741	28.67	1.31	62.39	217.05	221.32	122.94
rc_R12472_at	R12472	2789 E	ST	55.18	0.00011	32.21	3.13	76.26	2002.79	1930.03	1097.37
rc_R12579_at	R12579		EST	3.5	0.00137	54.49	37.84	26.65	198.7	194.59	92.03
R19808_at	R19808		ST	#N/A	#N/A	9.95	12.2	25.55	27.53	25.43	10.61
rc_R31104_f_at	R31104		ST	#N/A	#N/A	-6.45	0.74	37.65	32.27	26.77	13.57
R31641_at	R31641	2814 E	EST	9.36	0.00011	29.02	21.83	31.18	350.89	330.68	166.29
rc_R33146_at	R33146		ST	7	0.00043	3.32	2.1	10.76	179.67	195.02	107
50 D34360 of	00000			i	1		1		1		
1C_N3430Z_8I	704207		NAAUSZ/ gene product	5.4	0.04615	621.7	353.73	689.66	2107.55	2121.04	1000.75
rc_R39238_at	R39238	2836 sy le	synaptojanin 1 lecithin-cholesterol	#N/A	#N/A	16.06	16.03	9.94	26.8	23.84	16.46
rc_R40395_s_at	R40395	2841 ac	acyltransferase	37.33	0.00032	0.98	-46.23	77.82	1192.03	1230.66	281.28
rc_R40556_s_at	R40556	2843 ES	EST	3.57	0.00184	8.98	8.28	11.75	91.55	95.59	58.66
		ָס	crystallin, zeta (quinone								
rc_R40946_f_at	R40946	2845 re	reductase)	6.14	0.00156	18.65	19.52	14.3	205.48	220.3	137.27
rc_R43174_s_at	R43174		paraoxonase 1	74.04	0.00038	47.94	-8.83	119.68	2926.85	3104.07	1318.41
		ಕ	downregulated in renal cell								
rc_R43347_at	R43347		carcinoma	#N/A	#N/A	36.93	32.68	30.41	105.66	100.62	28.62
rc_R43365_at	R43365		EST	5.37	0.00103	5.57	6.67	12.18	150.58	112.8	122.96
rc_R43910_at	R43910		EST	5.71	0	23.41	24.6	11.1	156.7	166.34	52.21
rc_R45480_i_at	R45480		cyclin K	#N/A	#N/A	27.21	17.36	21.39	71.04	79.77	50.88
rc_R49602_at	. R49602	2885 ES	EST	36.5	0.00001	19.25	9.65	26.41	970.39	905.54	322.69
rc_R51831_at	R51831		ST	5.03	0.00761	5.89	2.5	44.67	221.54	195.97	179.99

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

			fold			metastati metastati	metastati	norma	norma	norma
			change	-	metastati	ដ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_R52822_i_at	R52822	2896 EST	12.79	0.00001	10.78	0.35	28.51	380.07	441.17	180.12
rc_R53044_at	R53044	2898 KIAA0981 protein	#N/A	#N/A	17.84	25.74	11.45	48.77	44.34	18.43
rc_R53891_at	R53891		#N/A	#N/A	9.88	5.59	10.68	66.28	52.16	49.21
rc_R59312_at	R59312	2913 EST	#N/¥	#N/A	34.37	35.83	22.13	94.44	91.55	36.35
rc_R59722_at	R59722	2916 EST	19.74	0.00016	18.78	4.94	51.34	628.69	642.78	316.88
rc_R60959_at	R60959	2919 EST	#N/A	#N/¥	31.21	23.86	17.79	72.94	69.87	45.25
rc_R62519_f_at	R62519		10.83	0.00243	73.01	104.54	56.5	707.38	751.42	357.22
R63545_at	R63545	2927 EST	5.4	0.00202	2.58	9.54	17.4	157.98	128.33	139.55
rc_R63734_at	R63734		#N/A	#N/A	13.28	17.42	12.17	42.74	39.66	18.51
R64534_at	R64534	2934 EST	W/W#	#N/A	12.11	14.54	5.77	40.32	40.98	17.27
		kynurenine 3- monooxygenase								
rc_R65593_s_at	R65593	2935 (kynurenine 3-hydroxylase)	21.27	0.00007	28.84	18.5	43.46	704.58	812.38	352.86
rc_R67970_s_at	R67970	2940 carboxylase	9.45	0.00212	85.44	59.33	76.67	655.11	692.66	267.95
rc_R70319_at	R70319		#N/A	#N/A	5.34	2.91	8.92	29.23	29.18	10.78
rc_R70791_at	R70791	2949 EST	#N/A	#N/A	127.11	110.15	41.83	73.19	57.2	56.17
		differentially expressed in								
R71459_at	R71459		#N/A	#N/A	16.9	11.46	16.47	37.42	30.98	20.83
rc_R73468_at	R73468		W/V#	#N/A	9.97	10.43	69.6	38.29	44.82	17.14
rc_R73816_at	R73816	2961 EST	11.53	0.00259	-26.88	-30.68	10.09	462.31	374.67	450.91
R77539_at	R77539	2965 EST	#N/A	#N/A	5.91	14.55	25.48	70.5	59.8	31.72
rc_R78713_s_at	R78713		#N/A	#N/A	0.27	-1.59	8.92	70.57	57.33	56.37
•										

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastat	metastati	normal	norma	normal
				change		metastati	ö	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
			phosphatidylserine								
R82229_at	R82229	2975 d	lecarboxylase	3.08	0.03455	84.63	80.61	67.01	228.19	232.06	58.38
rc_R91060_at	R91060	2981 E	ST	#N/A	#N/A	59.14	37.15	56.04	85.88	61.99	68.99
rc_R93507_at	R93507	2991 E	ST	#N/A	#N/A	19.53	20.08	Ξ	67.62	67.56	44.22
rc_R93714_at	R93714	2992 fe	etuin B	10.42	0.00043	-60.74	-65.14	57.99	280.62	301.36	203.86
rc_R93908_at	R93908	2994 E	ST	5.8	0.02699	66.75	29.54	129.46	348.58	301.29	173.81
rc_R94674_s_at	R94674	2996 E	ST	10.76	0.00008	0.91	4.15	14.66	269.49	288.56	148.06
rc_R96822_at	R96822	3000 E	3000 EST	8.25	0.00008	16.45	17.01	30.67	250.81	257.18	131.85
		0 2	ytochrome P450, subfamily								
rc_R97419_at	R97419	3004 h	VIIIB (steroi 12-aipna- 1 hydroxylase), polypeptide 1	65.07	0.0039	152.16	-3.42	302.56	4114.39	3837.4	1458.43
rc_R97804_at	R97804	3008 E	ST		#N/A	144.46	187.67	95.8	193.05	201.89	61.84
R98073_at	R98073	3009 E	ST		0	-4.33	-9.52	11.43	1161.51	1291.95	564.26
rc_R98105_at	R98105	3011 E	ST	#N/A	W/A	132.16	97.16	141.15	373.83	342.91	215.89
rc_R98413_at	R98413	3012 E	ST		0.00007	38.74	28.05	21.96	402.49	443.47	212.95
rc_R98624_at	R98624	3013 E	ST		0	15.01	4.48	22.97	686.81	542.22	466.97
rc_R99014_at	R99014	3015 E	ST		#N/A	26.99	17.82	29.49	49.82	52.35	18
			CD5 antigen-like (scavenger								
rc_R99591_at	R99591	3016 rece	eceptor cysteine rich family)	9.52	0.00006	87.08	72.59	28.25	1035.39	904.92	691.83
S62539_s_at	S62539	3022 11	3022 insulin receptor substrate 1	3.7	0.01307	28.26	13.05	40.92	132.59	97.52	103.35

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	fold change in metas	p value	metastati c: Mean	metastati metastati c: c: Std Median Dev	metastati c: Std Dev	normal set 2: Mean	normal set 2: Median	normal set 2: Std Dev
	S68287	3025	aldo-keto reductase family 1, member C4 (chlordecone reductase; 3-alpha hydroxysteroid dehydrogenase, type I; dihydrodiol dehydrogenase 4)	24.11	o	6.23	6.37	9.75	510.59	569.32	165.14
S69232_at	S69232	3027	electron-transferring- 3027 flavoprotein dehydrogenase	6.9	0.00017	2.73	6.4	4.29	113.33	103.27	60.93
S70004_at	S70004	3029 glyco	glycogen synthase 2 (liver)	96.6	0.00001	-0.03	4.28	11.42	225.1	212.32	102.76
S72370_at	S72370	3030	3030 pyruvate carboxylase	5.31	0.00075	3.83	5.81	23.1	113.03	118.49	50.19
S77410_at	S77410	3035	3035 anglotensin receptor 1	10.4	0	18.77	17.34	10.85	266.59	284.37	98.14
S82240_at	S82240	3039	member E	#N/A	#N/A	19.9	6.78	30.8	75.14	74.07	40.43
rc_T16306_at	1088/9 T16306	3068	catnepsin r EST	5.29 #N/A	90008 #N/A	17.98 24.23	14.06 23.64	12.92 24.91	156.33 58.82	180.88 63.62	79.67 22.35
	1		protein tyrosine phosphatase type IVA,	:							
rc_T40895_at rc_T46901_at	T40895 T46901	3117	member 1 FST	#N/A 77.28	#N/A 0000	1575.59	2039.82	1098.29	4148.86	2440.28	4169.52
rc_T48075 f_at rc_T50773_s_at	T48075 T50773		hemoglobin, alpha 1 apolipoprotein C-IV	32.56 #N/A	0.00172 #N/A	246.19 94.77	164.89 43.61	271.65 169.6	7193.85 8473.97	5199.28 6484.47	6317.01 7036.85

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold		motoctofi	metastati metastati	metastati c. Std	normal	normal	normal
Affy ID	Genbank Seq ID	Seq (D	Known Gene Name	in metas	p value	c: Mean	C: Median	Dev	Set 2: Mean	Set 2: Median	Set 2: Std Dev
rc_T51617_at rc_T51930_at	T51617 T51930	3138 3139	solute carrier family 22 (extraneuronal monoamine transporter), member 3 EST	17.67	0.00018	29.08 8.27	19.44 9.41	56.17 5.97	669.34 325.48	725.25 218.59	402.58 298.12
rc_T56281_f_at T57140_s_at rc_T58756_at	T56281 T57140 T58756	3151 3152 3156	RNA helicase-related protein paraoxonase 3 EST	32.34 28.8 13.39	0.00002 0 0.00013	71.16 -1.37 7.38	62.87 -7.55 -19.91	44.81 22.26 46.26	2132.07 825.16 390.04	2146.52 979.66 386.76	824.76 487.32 164.41
rc_T58775_at	T58775	3157	small inducible cytokine subfamily A (Cys-Cys), member 16	21.18	0.00006	11.93	-0.59	34.83	577.14	540.96	205.27
rc_T59148_s_at	T59148	3158	carbamoyl-phosphate synthetase 1, mitochondrial ketohexokinase	88.89	0	17.1	2.26	49.29	3384.09	3845.28	2295.81
rc_T61256_s_at	T61256	3162	(fructokinase)	13.59	0.00425	55.8	29.78	120.62	752.99	846.1	315.74
rc_161654_T_at rc_T64933_r_at	161654 T64933	3166	apolipoprotein A-I EST	4 X # #	4/2 # # #	66.98 1.58	-33.89 10.35	208.52 17.94	9388.4 52.88	4297.02 40.46	12058.3 54 68
rc_T65443_s_at	T65443	3175	EST	#N/A	#N/¥	10.45	9.99	13.16	70.03	75.01	29
rc_T66189_s_at rc_T67520_at	T66189 T67520	3178 3182	glutaryl-Coenzyme A dehydrogenase EST	8.61 #N/A	0.00003 #N/A	17.08 52.46	20.49 49.25	23.82 28.02	269.19 105.56	301.13 113.95	136.96 38.23
rc_T67705_s_at	T67705	3183	3183 asialoglycoprotein receptor 2	31.6	0.00705	168.64	37.91	284.26	2403.76	2437.4	683.22

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastati	metastati	normal	norma	normal
				change		metastati	ម	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank Seq ID		Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_T67931_at	T67931	3184 p	fibrinogen, B beta 3184 polypeptide	49.55	0	-22.74	-22.4	23.54	1187.95	1000.67	692.18
		Ø	short-chain								
T68083_at	T68083	3185 d	ehydrogenase/reductase 1	4.03	0.01593	65.11	47.59	67.87	263.22	280.22	136.48
T68510_at	T68510	3187 E	3187 EST	3.87	0.00617	0.88	-1.97	11.33	113.31	94.26	103.92
rc_T68711_at	T68711	3188 E	EST	37.65	0.00036	19.73	-26.69	95.05	1388.67	1074.67	890.91
rc_T68855_at	T68855	3189 E	ST	34.04	0	8.38	6.98	6	800.27	911.26	406.27
rc_T69020_s_at	T69020	3193 EST	ST	5.39	0.00383	32.69	17.15	46.31	202.05	208.64	90.05
rc_T69164_at	T69164	3195 E	ST	4.38	0.00548	34.31	17.81	. 30.85	173.2	167.2	85.34
		E 🗢	mannose-binding lectin (protein C) 2, soluble								
rc_T69284_s_at	T69284	3196 (3196 (opsonic defect)	36.53	0	9.82	0.32	17.14	1147.2	618.07	972.57
rc_T69305_at	T69305	3197 E	ST	#N/A	#N/A	-107.09	-119.3	45.51	4052.6	4262.37	3025.26
į		α.	period (Drosophila) homolog								
T69384_at	T69384	3198 1		5.88	0.01219	37.94	19.8	90.03	232.84	205.78	126.44
rc_T71978_at	T71978	3205 E	EST	4.39	0.0017	41.46	58.86	43.93	218.38	208.73	89.39
rc T72171 s at	T72171	3206 th	nyroxin-binding globulin	10.41	0.00163	5.48	-20.52	54.58	492.89	371.71	454.89
rc_T72502_at	T72502	3208 E	ST	8.87	0.0000	24.11	24.41	28.19	308.87	271.27	179.15
rc_T72906_at	T72906	3210 E	3210 EST	7.56	0.00062	4.88	3.04	14.04	233.73	199.26	211.99
rc_T73442_at	T73442	3213 E	ST	94.41	0	28.55	25.96	25.95	3170.29	3275.73	1073.74

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastati	metastati	normal	norma	norma
Q 784	100	2		change		metastati	_ອ ີ :	c: Std	set 2:	set 2:	set 2:
	Genoank	Oi bac	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_T73739_s_at	173739	3214	alanine-glyoxylate aminotransferase (oxalosis I; hyperoxaluria I; glycolicaciduria; serine- pyruvate aminotransferase)	16.18	0.00277	1891.22	896.45	2229.6	26094.38	15281.08	25947.4
rc_T74542_s_at	T74542	3215	UDP glycosyltransferase 2 3215 family, polypeptide B10	32.36	0.00004	27.96	25.04	64.23	1374.78	1445.94	869.3
rc_T74608_at	T74608	. 3216	hydroxyacid oxidase (glycolate oxidase) 1	14.03	0	-3.14	-1.78	23.12	360.97	328.7	194.85
rc_T82323_at	T82323	3231	immunoglobulin superfamily, member 4	10.14	0	14.47	5.07	19.91	264.33	229.92	135.46
T83397_at rc_T84084_at	T83397 T84084	3233 3234	phytanoyl-CoA hydroxylase (Refsum disease) EST	63.6 #N/A	0 #N/A	-17.97 21.47	4.64 21.35	35.51 9.96	1404.6 68.96	1421.69 66.69	605.99 27.4
rc_T84491_at	T84491 T86482	3235	CUG triplet repeat,RNA- binding protein 2 transferrin	#N/A 11.15	#N/A 0.00006	32.84 7.6	34.93 9.41	8.15 12.34	79.08 316.82	80.41 197.03	33.03 302.36
rc_T87224_at rc_T90037_at rc_T90520_at rc_T91161_at	T87224 T90037 T90520 T91161	3241 3246 3249 3253	est est est	#N/A 3.99 8.67 3.48	#N/A 0.0016 0.00072 0.00002	584.24 23.17 9.05 9.95	451.54 25.82 -7.07 2.64	184.49 23.62 25.65 11.55	909.33 150.67 306.39 77.85	851.86 107.18 362.5 70.8	431.47 126.19 204.34 30.28

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati	metastati metastati	normal	norma	normal
				change		metastati	ຮ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	7	Known Gene Name	In metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
T95813_f_at	T95813	3262	3262 KIAA1051 protein	38.38	0.00008	56.83	42.22	56.86	2271.29	1809.29	1537.82
U00115_at	U00115		B-cell CLL/lymphoma 6 (zinc 3272 finger protein 51)	5.18	0.00045	16.17	10.31	26.94	132:13	133.88	32.06
U01120_at	U01120	3274	glucose-6-phosphatase, catalytic (glycogen storage disease type I, von Gierke disease)	13.41	0.00147	83.05	45.5	91.8	878.33	693.43	495.6
U02388_at	U02388	3278	cytochrome P450, subfamily IVF, polypeptide 2	9.38	0.00001	4.93	-3.43	18.14	207.48	207.15	90.12
U03056_at	003056	3280	3280 hyaluronoglucosaminidase 1	6.64	0	12.68	11.77	4.73	139.32	137.21	43.97
U05861_at	U05861	3285	aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid dehydrogenase)	23.22	0.00002	47.98	44.41	21.91	1070.69	962.74	359.01
U06641_s_at U06863_at	U06641 U06863	3287 3288	UDP glycosyltransferase 2 3287 family, polypeptide B15 3288 follistatin-like 1	24.32 3.09	0.00001	56.39 43.48	62.92	54.9 14.83	1762.46 141.97	1615.25 149.4	1206.06 59.45

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastati	metastati	normal	norma	normal
Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	change in metas	p value	metastati c: Mean	c: Median	c: Std Dev	set 2: Mean	set 2: Median	set 2: Std Dev
U08006_s_at	900800	3290	complement component 8, 3290 alpha polypeptide	16	0.00111	47.06	31.92	47.52	633.01	661.72	102.98
U08198_rna1_at	U08198	3292	complement component 8, gamma polypeptide	19.71	0	-29.27	-38.32	47.54	544.28	630.51	234.87
U08854_s_at	U08854	3293	UDP glycosyltransferase 2 3293 family, polypeptide B15	7.38	0.00005	10.72	6.45	10.71	181.08	184.97	91.81
U11313_at	U11313	3297	sterol carrier protein 2	5.44	0.00187	17.39	0.82	35.86	181.8	228.15	99.25
U12778_at	U12778	3301	acyl-Coenzyme A dehydrogenase, short/branched chain	5.68	0.00116	5.23	6.16	7.33	147.06	158.14	91.5
U13061_ma1_at	U13061	3302	sulfotransferase family 2A, dehydroeplandrosterone (DHEA) -preferring, member 1	11.32	0.00048	9.86	7.49	19.46	369.12	431.45	213.83
U15174_at	U15174	3310	BCL2/adenovirus E1B 19kD- 3310 Interacting protein 3	#N/A	W/A	41.72	11.86	49.01	129.19	138.02	68.72
U15932_at U17989_at	U15932 U17989	3311	dual specificity phosphatase 5 nuclear autoantigen	#N/A #N/A	#N/A #N/A	47.94 14.21	27.05 12.72	47.87 6.13	86.73 44.22	86.97	38.45 19.09

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold change		metastati	metastati metastati c: c: Std	metastati c: Std	normal set 2:	normal set 2:	normal set 2:
Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
U19495_s_at	U19495	3319 s	3319 stromal cell-derived factor 1	4.59	0.00011	7.17	5.76	5.65	103.81	114.61	50.36
U19523_at	U19523	3320 14	GTP cyclohydrolase 1 (dopa- 3320 responsive dystonia)	5.25	0.00029	12.84	12.26	15.75	136.86	142.71	66.64
U20530_at	U20530	3322 24kD	secreted phosphoprotein 2, 24kD	16.93	0	12.63	11.54	9.93	383.92	421.24	128.02
U20938_at	U20938	3324 d	dehydrogenase	3.92	0.00053	99.9	6.08	7.12	90.66	97.02	44.64
U22029_f_at	U22029	3327 p	cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 7	71.98	0	5.05	10.11	21.51	1968.7	1339.04	1937.45
U22662_at U31342_at U32576_ma1_at	U22662 U31342 U32576	3329 1 3344 n 3347 a	nuclear receptor subfamily 1, group H, member 3 nucleobindin 1 apolipoprotein C-IV	#N/A #N/A 18.59	#N/A #N/A 0.00005	5.71 77.59 311.97	14.46 66.2 318.75	20.18 40.03 271.42	63.21 183.59 1299.4	58.72 197.29 1145.33	37.5 58.86 698.02
U32989_at	U32989	3348 tr	3348 tryptophan 2,3-dioxygenase	10.07	0.02825	166.12	22.7	333.99	527.61	473.11	268.8

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

Affy ID	Genbank	Seq ID	Known Gene Name	fold change In metas	p value	metastati c: Mean	metastati metastati c: c: Std Median Dev	metastati c: Std Dev	normal set 2: Mean	normal set 2: Medlan	normal set 2: Std Dev
U37055_rna1_s_at	U37055	3353	macrophage stimulating 1 (hepatocyte growth factor- like),macrophage stimulating, pseudogene 9	18.28	0	-7.37	-38.2	47.48	549.49	626.51	217.69
U37143_at U37547_at	U37143 U37547	3354 3355	cytochrome P450, subfamily IIJ (arachidonic acid epoxygenase) polypeptide 2 apoptosis inhibitor 1	#N/A #N/A	W/N#	33.79 29.52	28.24 19.51	31.46 48.74	116.06 93.6	131.46 112.45	48.68 52.27
U39226_at	U39226	3358	myosin VIIA (Usher syndrome 1B (autosomal recessive, severe))	#N/A	#N/A	33.54	31.07	8.59	53.24	50.47	20.86
U46689_at	U46689	3366	aldehyde dehydrogenase 10 (fatty aldehyde dehydrogenase)	3.5	0.01292	31.22	25.36	49.19	124.41	136.16	53.23
U48707_at U49082_at	U48707 U49082	3371 3373	protein phosphatase 1, regulatory (inhibitor) subunit 1A transporter protein	14.22	0.00088	-1.33	-1.45 46.71	20.92 56.13	319.97 563.34	310.24 515.31	125.51 179.82

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati	metastati metastati	normal	normal	normal
Affy ID	Genbank Seq ID	Seq IC	Known Gene Name	change in metas	p value	metastati c: Mean	c: Median	c: Std Dev	set 2: Mean	set 2: Median	set 2: Std Dev
U49248_at	U49248	3374	ATP-binding cassette, subfamily C (CFTR/MRP), member 2	7.06	0.00067	30.01	26.03	36.14	231.96	249.25	2.18
U50929_at	U50929	3380	betaine-homocysteine methyltransferase	36.91	0	8.63	2.82	20.35	898.57	865.9	313.61
U51010_s_at	U51010	3381	nicounamide iv- methyltransferase	27.79	0.00366	105.25	43.72	204.23	1589.66	1590.62	536.04
U56814_at	U56814	3393	3393 deoxyribonuclease I-like 3	29.43	0.00003	5.04	11.75	22.3	853.78	1073.24	434.79
U57094_at	U57094	3394		#N/A	#N/A	30.85	31.58	23.86	93.06	93.79	50.75
U59111_at	U59111	3397	dematan supnate proteoglycan 3	#N/A	#N/A	32.34	26.73	15.11	68.69	64.44	32.48
U59423_at	U59423	3399	MAD (mothers against decapentaplegic, Drosophila) homolog 1	#N/A	#N/A	17.46	16.81	10.17	60.5	51.09	37.25
U60061_at	U60061	3400	fasciculation and elongation protein zeta 2 (zygin II)	#N/A	#N/A	61.44	29.18	68.3	55.02	66.29	38.2
U66672_at	U66672	3407	ATP-binding cassette, sub- 3407 family A (ABC1), member 5	#N/A	#N/A	78.03	41.24	72.76	105.45	97.64	60.15

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastati	metastati	normal	normal	normal
				change		metastati	ຮ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
U68233_at	U68233	3412	nuclear receptor subfamily 1, group H, member 4	6.76	0.00022	19.94	8.6	29.99	198.25	233.6	83.71
U69141_at	U69141	3414	glutaryl-Coenzyme A dehydrogenase	3.06	0.00053	35.13	27.91	13.89	108.36	119.26	34.82
U70732_ma1_at	U70732	3415	glutamic-pyruvate transaminase (alanine aminotransferase)	27.63	0	-47.95	-65.21	50.88	696.22	732.8	284.7
U70732_rna1_at	U70732	3415	glutamic-pyruvate transaminase (alanine aminotransferase)	27.63	0	-1.44	3.98	66.42	201.88	218.68	136.17
U72515_at	U72515	3416	putative protein similar to nessy (Drosophila)	#N/A	#N/A	45.44	58.93	45.12	137.35	138.01	55.38
U73514_at	U73514	3419		3.79	0.01392	9.85	-22.7	56.91	159.74	161.9	127.8
U77396_at	U77396	3426	LPS-induced TNF-alpha factor	4.47	0.00108	30.53	33.74	31.54	169.83	141.36	87.43
U77594_at U79716_at	U77594 U79716	3428 3437	retinoic acld receptor responder (tazarotene induced) 2	11.95 3.51	0.00527	94.59 14.44	122.86	71.01	838.98	864.02	313.87
U80226_s_at	U80226	3439	4-aminobutyrate aminotransferase	#N/A	#N/A	39.69	51.46	20.33	86.94	91.76	24.15

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

Affy ID	Genbank	Seq ID	Known Gene Name	fold change in metas	p value	metastati c: Mean	metastati metastati c: c: Std Median Dev	metastati c: Std Dev	normal set 2: Mean	normal set 2: Median	normal set 2: Std Dev
U81607_at	U81607	3440	A kinase (PRKA) anchor protein (gravin) 12 solute carrier family 9	#N/A	#N/A	18.75	8.46	50.91	82.7	78.31	62.79
U82108_s_at	U82108	3441	(sodium/hydrogen (sodium/hydrogen) (sochanger), isoform 3 regulatory factor 2	3.19	0.01545	58.61	78.15	43.49	130.34	122.39	73.74
U83461_at U85193_at	U83461 U85193	3444 3447	solute carrier family 31 (copper transporters), member 2 nuclear factor I/B	#/N/A #/N/A	#N/A	24.64 21.84	21.28 23.61	13.16 4.44	51.79 72.71	48.53 68.69	20.85 32.02
U90544_at	U90544	3454	solute carrier family 17 (sodium phosphate), member 2	6.42	0.00023	-3.14	-5.18	19.12	157.41	168.92	63.8
U95090_at	U95090	3464	nephrosis 1, congenital, Finnish type (nephrin)	14.01	0.00018	40.49	30.15	38.71	554.93	539.41	183.55
U95090_at W02027_s_at W03796_at rc_W15417_at	U95090 W02027 W03796 W15417	3464 3465 3468 3473	nephrosis 1, congenital, Finnish type (nephrin) EST EST KIAA0699 protein	14.01 #N/A 8.3 #N/A	0.00018 #N/A 0.0032 #N/A	4.97 7.28 8.13 30.82	5.87 2.64 -19.16 20.85	18.32 14.09 75.11 38.03	188.83 30.56 336.51 83.24	201.08 28.52 383.56 81.29	88.01 12.47 190.14 49.83
W16686_at	W16686	3476	basic helix-loop-helix domain containing, class B, 2	#N/A	#N/A	46.29	-6.45	123.94	100.9	83.13	79.01

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

					fold			metastati metastati	metastati	normal	norma	normal
					change		metastati	ິວ	c: Std	set 2:	set 2:	set 2:
	Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
i	W27503_at	W27503	3486	3486 KIAA0679 protein	#N/A	#N/A	17.31	17.31	21.95	27.71	27.51	5.28
	W28235_at	W28235	3487 EST	EST	#N/A	#N/A	95.97	150.37	81.4	271.36	307.26	108.42
	W28824_at	W28824	3493	EST	15.8	0.00006	-1.99	-5.59	17.64	441.67	509.29	251
				Kreisler (mouse) maf-related								
	W36290 s at	W36290	3501	leucine zipper homolog	3.94	0.02718	48.52	10.45	73.21	157.7	156.24	65.15
	W38778_s_at	W38778	3507	EST	#N/A	#N/A	-55.97	-63.87	44.35	78.01	37.07	137.01
	rc_W42429_at	W42429	3509	EST	#N/A	W/W#	98.32	80.07	52.23	252.63	300.68	162.35
	rc_W45560_at	W45560	3525	EST	5.06	0.00996	86.81	62.95	81.92	369.61	354.89	158.02
	rc_W48860_at	W48860	3537	EST	#N/A	#N/A	36.89	39	14.08	52.69	41.31	21.1
	,			CD36 antigen (collagen type I receptor, thrombospondin receptor)-like 2 (lysosomal integral membrane protein								
	W52581_at	W52581	3543		3.08	0.00091	10.92	8.89	10.63	71.35	58.02	37.28
	W58520_at	W58520	3552	nucleoporin 88kD	#N/A	#N/A	24.77	26.75	16.56	81.88	87.47	37.77
	rc_W58756_at	W58756	3554	EST	12.17	0.00087	93.37	88.97	71.48	1363.71	1064.26	1032.27
	rc_W60186_at	W60186	3557	EST	3.24	0.00228	19.15	26.5	27.35	101.92	109.68	47.85
	rc_W63741_at	W63741	3566	EST	#N/A	#N/A	-11.85	-13.73	14.25	28.54	17.1	44.58
	rc_W67147_at	W67147	3568	deleted in liver cancer 1	9.74	0.00002	16.09	9.11	24.66	282.59	235.29	169.33
	rc_W67199_at	W67199	3569		3.09	0.01528	30.05	35	12.16	123.27	117.99	90.47
	rc_W70131_at	W70131	3577	EST	#N/A	#N/A	108.21	30.68	183.05	118.49	100.66	53.4
	rc_W72044_at	W72044	3580	3580 insulin induced gene 1	24.58	0.00001	41.6	36.28	36.46	1133.09	940.16	723.6
	rc_W72079_at	W72079	3581	EST	6.36	0.00641	46.78	17.94	66.71	261.7	214.62	175.87

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastati	metastati	normal	normal	normal
Affy ID	Genbank Seq ID	Seq 10	Known Gene Name	change In metas	p value	metastati c: Mean	c: Medlan	c: Std Dev	set 2: Mean	set 2: Median	set 2: Std Dev
			oxidative 3 alpha								
			nydroxysteroid dehydrogenase; retinol								
rc_W72382_at	W72382	3584		W/A#	#N/A	37.21	6.21	66.91	3403.46	3255.54	1538.23
rc_W72471_at	W72471		EST .	#N/A	#N/A	17.93	13.32	10.61	71.51	76.9	29.33
rc_W72972_at	W72972	3587	EST	5.61	0.00939	44.7	26.44	80.59	277.4	270.63	183.07
rc_W73382_at	W73382	3591	EST	#N/A	#N/A	62.97	39.05	67.26	87.32	89.49	28.17
rc_W79422_s_at	W79422		fumarylacetoacetate	14.94	0.00059	-18.4	-19.27	33.52	467.37	554.19	306.71
W81053_at	W81053			4.91	0.00164	-21.38	-13.04	24.17	135.84	109.34	113.36
rc_W85765_at	W85765			3.83	0.00379	3.6	1.46	7.87	108.99	77.01	109.58
rc_W85847_at	W85847	3619	EST	7.28	0.00024	4.15	5.29	9.26	187.31	160.02	130.73
rc_W85886_at	W85886	3621	EST	3.46	0.00814	-6.09	-2.4	11.46	99.92	68.44	97.4
			protein C inhibitor								
rc_W86431 s at	W86431	3627		14.94	0.00152	3.16	5,55	12 03	606 44	305 34	590 7
rc_W86600_at	W86600	3628		32.14	0	12.67	7.49	15.61	792.37	807.74	313.83
			homogentisate 1,2-								
			dioxygenase (homogentisate								
rc_W87454_at	W87454	3632	oxid	7.93	0.00149	11.36	5.83	39.02	336.07	275.03	315.24
			STAT Induced STAT								
rc_W87480_at	W87480	3633		3.24	0.01063	31.91	26.07	30.44	129.06	119.73	80.94
			protein Z, vitamin K-								
12 00000000	000000	9		0		i	. !	1			
rc_w8/606_s_at	W8/606	3635	glycoprotein	9.23	0.00085	2.53	-1.74	9.98	268.59	280.44	184.7
rc W88946 at	W88946	3639		58.26	c	2.16	22 43	000	4747 EA	4004 77	200
1 2 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1	010001		acylical siciase	20.20	> :	7.10	-24.13	59.6	1717.04	1821.77	207.22
rc_W90018_f_at	W90018	3642	EST	∀Z#	#N/A	-2.1	4.12	13.16	59.32	53.19	41.68

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastati	metastati	normal	normal	norma
				change		metastati	ដ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	U)	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
rc_W90396_at	W90396	3645	3645 EST	#N/A	#N/A	16.1	15.26	11.11	23.65	22.93	10.28
rc_W92148_s_at	W92148	3650	kininogen	51.09	0.00376	220.31	42.96	427.59	3697.54	4015.04	1444.99
. 00000000		0	dual specificity phosphatase					:	!		
rc_w84842_i_at	W8484Z	3661	01	7.23	0.00137	19.36	16.05	11.9	250.16	281.49	160.43
rc_W95041_at	W95041	3662		12.79	0.00001	99.9	5.17	3.55	291.2	298.05	115.81
X02160_at	X02160	3671	insulin receptor	5.29	0.0001	10.06	8.21	10.89	77.32	65.71	45.53
X02176 s at	X02176	3672	3672 complement component 9	9.61	0.00004	47.28	46.34	28.54	507.56	507.21	261.45
l l			protein C (inactivator of								
X02750_at	X02750	3673	Coagulation factors valand	7.04	0.00079	55.79	52.95	30.08	373.11	367.46	95.74
X06562_at	X06562	3686	3686 growth hormone receptor	10.87	0.00001	10.46	6.89	15.53	291.31	314.9	160.29
X07618_s_at	X07618	3691	cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolising), polypeptide 7a (pseudogene)	35.79	0.00065	59.61	12.32	101.97	1429.98	1631.04	671.55
X07618_s_at	X07618	3691	cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolising), polypeptide 7a 3691 (pseudogene)	. 35.79	0.00065	40.81	38.21	14.35	609.22	605.91	330.02

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	fold change In metas	p value	metastati c: Mean	metastati metastati c: c: Std Median Dev	metastati c: Std Dev	normal set 2: Mean	normal set 2: Median	set 2: Std Dev
X07619_s_at	X07619	3692	cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolising), polypeptide 7a (pseudogene)	4.96	0.00004	32.26	33.56	10.88	177.56	206.15	77.69
X07732_at	X07732	3693	hepsin (transmembrane protease, serine 1)	28.21	0	-8.34	1.	39.24	678.15	672.42	183.61
X07767_at X12662_ma1_at	X07767 X12662	3694 3697	protein kinase, cAMP- dependent, catalytic, alpha arginase, liver	5.94 20.59	0.00028	16.15	19.43 10.15	11.48	152.58 486.71	160.88 479.11	73.73 199.71
X13227_at	X13227	3698	3698 D-amino-acid oxidase	4.81	0.0002	25.1	33.95	26.2	166.22	147.21	77.49
X13930 <u>f</u> at X14787_at	X13930 X14787	3700 3704	cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 6 thrombospondin 1	38.52 3.69	0 0.01115	52.66 21.81	64.02	31.42	2408.66 143.24	1948.18 86.81	1843.46 166.32
X14813_at X15393_ma1_at	X14813 X15393	3705 3707	acetyl-Coenzyme A acyltransferase 1 (peroxisomal 3-oxoacyl- Coenzyme A thiolase) motilin	11.61 #N/A	0.0002 #N/A	59.4 70.16	71.51 55.83	42.45 27.07	712.58 113.93	704.45 117.96	258.91 26.14

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold change		metastati	metastati metastati c: c: Std	metastati c: Std	normal set 2:	normal set 2:	normal set 2:
Affy ID	Genbank Seq ID	Seq IC	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
X15422_at	X15422	3708	mannose-binding lectin (protein C) 2, soluble 3708 (opsonic defect)	8.29	0.00015	2.28	2.69	7.25	208.25	221.14	123.22
X16260_s_at	X16260	3710	inter-alpha (globulin) inhibitor, H1 polypeptide hepatocyte growth factor	44.65	0.00933	40.4	36.54	29	1261.99	1133	523.31
X16323_at	X16323	3711		#N/A	#N/A	10.65	6.56	6.59	32.58	30.52	9.66
X16663_at	X16663	3714	hematopoletic cell-specific 3714 Lyn substrate 1	#N/A	#N/A	48.32	28.69	56.44	81.51	83.53	33.75
X17094_at	X17094	3717	paired basic amino acid cleaving enzyme (furin, membrane associated receptor protein)	8.5	0	-1.85	7.01	25.41	190.11	216.35	74.11
X53414_at	X53414	3728	alanine-glyoxylate aminotransferase (oxalosis I; hyperoxaluria I; glycolicaclduria; serine- pyruvate aminotransferase)	13.87	0.00003	138.92	110.29	. 69.06	1856.57	1888.79	846.06
X54380_at	X54380	3730	3730 pregnancy-zone protein	8.44	0.00059	4.93	3.19	19.26	274.41	255.4	203.47

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

Affy ID	Genbank Seq ID	Seq ID	Known Gene Name	fold change in metas	p value	metastati c: Mean	metastati metastati c: c: Std Median Dev	metastati c: Std Dev	normal set 2: Mean	normal set 2: Median	normal set 2: Std Dev
X56411_rna1_at	X56411	3737	alcohol dehydrogenase 4 3737 (class II), pi polypeptide	25.14	0.00144	55.53	11.29	102.45	991.98	943.64	448.31
X57025_at X60673_s_at	X57025 X60673	3742 3752	insulin-like growth factor 1 (somatomedin C) adenylate kinase 3	4.72 8.3	0.00087	5.88 23.02	10.95 32.17	10.22 44.24	120.82 331.58	100.54 324.75	85.16 164.03
X63359_at	X63359	3759	UDP glycosyltransferase 2 3759 family, polypeptide B10	13.66	0.00051	55.28	48.57	41.25	669.93	732.6	161.42
X63417_at	X63417	3760	3760 protein	#N/A	#N/A	. 28.85	27.75	24.56	68.08	56.34	33.18
X64877_at	X64877	3766	3766 H factor (complement)-like 3	14.6		14.6	7.51	21.01	387.8	402.95	151.23
X64877_s_at	X64877	3766	3766 H factor (complement)-like 3	12.33	0	6.14	8.26	14.25	262.65	268.29	84.84
X65727_cds2_s_at	X65727	3768	glutathione S-transferase A2,glutathione S-transferase A3	73.64	0	21.03	17.39	15.18	2162.22	2183.18	1435.52
X65962_s_at	X65962	3769	cytochrome P450, subfamily IIC (mephenytoin 4- hydroxylase)	5.47	0.00014	36.73	31.48	11.66	247.79	149.39	208.59
X76105_at	X76105	3794	3794 death-associated protein .	3.02	0.00944	30.12	33.72	31.36	108.68	118.36	56.75

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastati metastati	metastati	normal	normal	normal
				change	_	metastati	ၓ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Sed ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
X78992_at	X78992	3802	butyrate response factor 2 3802 (EGF-response factor 2)	4.69	0.01995	64.86	31.76	66.31	318.26	336.95	207.43
X79981_at	X79981	3806	cadherin 5, VE-cadherin (vascular epithelium)	#N/A	#N/A	45.01	41.07	11.65	80.92	80.1	8.57
X86401_s_at	X86401	3815	glycine amidinotransferase (L-arginine:glycine amidinotransferase)	22.7	. 0	19.17	9.16	19.13	646	721.34	274.64
X90999_at	66606X	3820	hydroxyacyl glutathione hydrolase; glyoxalase 2	5.27	0.00047	16.15	26.83	26.47	170.37	179.54	76.98
X91148_at	X91148	3821		5.91 #N/A	0.00045 #N/A	15.37	3.85	31.49	173.77	189.11	83.82
X92475_at X94563_xpt2_r_at	X92475 X94563	3824	ITBA1 gene	#N/A 3.52	#N/A 0.00928	56.74 76.79	63.84 66.4	25.6 52.64	66.2 274.91	63.72 244.92	20.36 177.63
X95190_at	X95190	3832	acyl-Coenzyme A oxidase 2, branched chain	12.81	0	-80.53	-76.73	37.81	285.88	349.39	119.31
X97160_ma1_at	X97160	3838	transcription factor binding 3838 to IGHM enhancer 3	#N/A	#N/A	61.31	49.54	30.41	75.26	66.36	29.46

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic fiver tissue.

Affy ID	Genbank	Seq ID	Known Gene Name	fold change in metas	p value	metastati c: Mean	metastati metastati c: c: Std Median Dev	metastati c: Std Dev	normal set 2: Mean	normal set 2: Medlan	normal set 2: Std Dev
X98337_s_at Y00097_s_at	X98337 Y00097	3840 3844	complement factor H related 3,complement factor H- related 4 annexin A6	13.5 3.4	0.00001	18.76 19.43	22.2 16.39	33.33 33.67	411.51	375.08 104.75	169.37 39.99
Y00317_at	Y00317	3845	UDP glycosyltransferase 2 3845 family, polýpeptide B4	18.34	0.00001	-9.82	-11.91	20.96	456.09	477.28	257.07
Y00317_at	Y00317	3845	UDP glycosyltransferase 2 3845 family, polypeptide B4	18.34	0.00001	11.31	14.85	7.33	231.32	282.35	122.76
Y00339_s_at	Y00339	3847	3847 carbonic anhydrase II	6.89	0	6.23	-1.39	18.22	168.76	178.44	69.52
Y10659_at	Y10659	3859		4.22	0.00061	18.27	12.85	25.15	123.23	134.47	49.24
Y10659_at	Y10659	3859		4.22	0.00061	15.82	16.3	16.79	81.75	89.09	37.01
Y12711_at	Y12711	3861	3861 progesterone binding protein	14.83	0.00285	26.37	16.12	99.79	1061.83	935.43	829.85
Z28339_at	Z28339	3875	aldo-keto reductase family 1, member D1 (delta 4-3- ketosteroid-5-beta- reductase)	24.66	0	3.67	3.48	<u>بې</u>	527.72	552.17	156.66
Z29481_at	Z29481	3877	3-hydroxyanthranilate 3,4- 3877 dioxygenase	6.39	0.00029	546.48	440.33	293.12	2012.12	1797.38	944.18

Table 9B. Genes and ESTs expressed only in normal liver tissue compared to metastatic liver tissue.

				fold			metastatl	metastati metastati	normal	normal	norma
				change		metastati	ដ	c: Std	set 2:	set 2:	set 2:
Affy ID	Genbank	Seq ID	Known Gene Name	in metas	p value	c: Mean	Median	Dev	Mean	Median	Std Dev
		_	nuclear receptor subfamily								
Z30425_at	Z30425	3878	I, group I, member 3	26.64	0	5.66	7.49	8.02	181.6	192.48	76.65
rc_Z38161_at	Z38161	3884	EST	4.38	0.0011	11.84	12.14	6.32	111.16	107.62	80.11
rc_Z38192_s_at	Z38192	3885	EST	3.35	0.00184	-0.28	4.75	17.86	87.12	87.23	52.58
rc_Z38910_at	Z38910		EST	#N/A	#N/A	, 89.0	2.75	12.7	35.49	32.21	23.55
rc_Z39394_at	Z39394	3904 E	EST	#N/A	#N/A	10.11	10.43	11.1	24.06	22.96	11.11
rc_z39622_s_at	Z39622		EST	4.4	0.00001	19.65	21.87	11.97	110.87	115.21	36.19
rc_Z39833_at	Z39833		GTP-binding protein	16.89	0.00034	35.79	41.07	84.59	957.61	1080.1	674.72
rc_Z39976_at	Z39976	3915	EST	5.76	0.00012	13.09	7.15	18.64	165.45	151.05	98.9
rc_Z40259_s_at	Z40259	3919 E	EST	8.18	0.00002	14.39	8.61	11.98	218.4	223.24	122.06
			ariadne, Drosophila,								
rc_z41271_s_at	Z41271	3930	homolog of	#N/A	#N/A	51.96	64.49	36.28	145.09	126.18	57.57
rc_Z41356_at	Z41356	3932	EST	#N/A	W/A#	4.46	15.94	28.44	82.7	48.14	71.73
rc_Z41634_at	Z41634		ST	#N/A	#N/A	16.4	16.07	ო	51.19	48.49	33
		•	flavin containing								
Z47553_at	247553	3939 r	monooxygenase 5	6.17	0.00011	4.86	1.26	8.96	141.98	165.57	59.33
Z48054_at	Z48054	3941	3941 peroxisome receptor 1	#N/A	#N/A	46.89	51.87	23.55	78.16	80.88	26.87
		Ų.	glucokinase (hexokinase 4)								
Z48475_at	248475	3943	regulatory protein	13.84	0	-42.61	-53.52	23.46	305.23	239.52	155.98
Z48633_at	Z48633	3944	EST	#N/A	#N/A	-5.51	-6.39	13.15	36.84	40.63	26.33
	٠	<i>0, 0,</i>	small inducible cytokine subfamily A (Cvs-Cvs).								
Z49269_at	Z49269	3945 1	member 14	18.46	0.00001	1.88	-25.63	41.94	526.13	532.29	166.67
Z49878_at	Z49878	3946	methyltransferase	13.96	0.00021	44.63	45.34	41.76	615.57	626.09	196.31

WO 02/29103 PCT/US01/30589

-286-

What is claimed is:

5

15

30

- 1. A method of diagnosing liver cancer in a patient, comprising:
- (a) detecting the level of expression in a tissue sample of two or more genes from Tables 3-9; wherein differential expression of the genes in Tables 3-9 is indicative of liver cancer.
- 2. A method of detecting the progression of liver cancer in a patient, comprising:
- (a) detecting the level of expression in a tissue sample of two or more genes from Tables 3-9; wherein differential expression of the genes in Tables 3-9 is indicative of liver cancer progression.
 - 3. A method of monitoring the treatment of a patient with liver cancer, comprising:
 - (a) administering a pharmaceutical composition to the patient;
 - (b) preparing a gene expression profile from a cell or tissue sample from the patient; and
 - (c) comparing the patient gene expression profile to a gene expression from a cell population selected from the group consisting of normal liver cells,
- 20 hepatocellular carcinoma and metastatic liver carcinoma.
 - 4. A method of treating a patient with liver cancer, comprising:
 - (a) administering to the patient a pharmaceutical composition, wherein the composition alters the expression of at least one gene in Tables 3-9;
- 25 (b) preparing a gene expression profile from a cell or tissue sample from the patient comprising tumor cells; and
 - (c) comparing the patient expression profile to a gene expression profile selected from the group consisting of normal liver cells, hepatocellular carcinoma and metastatic liver carcinoma

5. A method of diagnosing hepatocellular carcinoma in a patient, comprising:

-287-

WO 02/29103 PCT/US01/30589

- (a) detecting the level of expression in a tissue sample of two or more genes from Tables 3-9; wherein differential expression of the genes in Tables 3-9 is indicative of hepatocellular carcinoma.
- 5 6. A method of detecting the progression of hepatocellular carcinoma in a patient, comprising:
 - (a) detecting the level of expression in a tissue sample of two or more genes from Tables 3-9; wherein differential expression of the genes in Tables 3-9 is indicative of hepatocellular carcinoma progression.

- 7. A method of monitoring the treatment of a patient with hepatocellular carcinoma, comprising:
 - (a) administering a pharmaceutical composition to the patient;
- (b) preparing a gene expression profile from a cell or tissue sample from the patient; and
 - (c) comparing the patient gene expression profile to a gene expression from a cell population comprising normal liver cells or to a gene expression profile from a cell population comprising hepatocellular carcinoma cells or to both.
- 20 8. A method of treating a patient with hepatocellular carcinoma, comprising:
 - (a) administering to the patient a pharmaceutical composition, wherein the composition alters the expression of at least one gene in Tables 3-9;
 - (b) preparing a gene expression profile from a cell or tissue sample from the patient comprising hepatocellular carcinoma cells; and
- 25 (c) comparing the patient expression profile to a gene expression profile from an untreated cell population comprising hepatocellular cells.

WO 02/29103

-288-

9. A method of diagnosing a metastatic liver tumor in a patient, comprising:

PCT/US01/30589

(a) detecting the level of expression in a tissue sample of two or more genes from Tables 3-9; wherein differential expression of the genes in Tables 3-9 is indicative of metastatic liver cancer.

5

10

- 10. A method of detecting the progression of a metastatic liver cancer in a patient, comprising:
- (a) detecting the level of expression in a tissue sample of two or more genes from Tables 3-9; wherein differential expression of the genes in Tables 3-9 is indicative of a metastatic liver cancer progression.
- A method of monitoring the treatment of a patient with a metastatic liver cancer, comprising:
 - (a) administering a pharmaceutical composition to the patient;
- 15 (b) preparing a gene expression profile from a cell or tissue sample from the patient; and
 - (c) comparing the patient gene expression profile to a gene expression from a cell population comprising normal liver cells or to a gene expression profile from a cell population comprising metastatic liver tumor cells or to both.

- 12. A method of treating a patient with a metastatic liver tumor, comprising:
- (a) administering to the patient a pharmaceutical composition, wherein the composition alters the expression of at least one gene in Tables 3-9;
- (b) preparing a gene expression profile from a cell or tissue sample from25 the patient comprising metastatic liver tumor cells; and
 - (c) comparing the patient expression profile to a gene expression profile from an untreated cell population comprising metastatic liver tumor cells.
- 13. A method of differentiating metastatic liver cancer from hepatocellular30 carcinoma in a patient, comprising:

-289-

WO 02/29103 PCT/US01/30589

- (a) detecting the level of expression in a tissue sample of two or more genes from Tables 3-9; wherein differential expression of the genes in Tables 3-9 is indicative of metastatic liver cancer rather than hepatocellular carcinoma.
- 14. A method of screening for an agent capable of modulating the onset or progression of liver cancer, comprising:
 - (a) preparing a first gene expression profile of a cell population comprising liver cancer cells, wherein the expression profile determines the expression level of one or more genes from Tables 3-9;
- (b) exposing the cell population to the agent;

5

10

- (c) preparing second gene expression profile of the agent-exposed cell population; and
- (d) comparing the first and second gene expression profiles.
- 15 15. The method of claim 14, wherein the liver cancer is a hepatocellular carcinoma.
 - 16. The method of claim 14, wherein the liver cancer is a metastatic liver cancer.
- 20 17. A composition comprising at least two oligonucleotides, wherein each of the oligonucleotides comprises a sequence that specifically hybridizes to a gene in Tables 3-9.
 - 18. A composition according to claim 17, wherein the composition comprises at least 3 oligonucleotides.
 - 19. A composition according to claim 17, wherein the composition comprises at least 5 oligonucleotides.
- 20. A composition according to claim 17, wherein the composition comprises at 30 least 7 oligonucleotides.

WO 02/29103

-290-

PCT/US01/30589

- 21. A composition according to claim 17, wherein the composition comprises at least 10 oligonucleotides.
- 22. A composition according to any one of claims 17-21, wherein the oligonucleotides are attached to a solid support.
 - 23. A composition according to claim 22, wherein the solid support is selected from a group consisting of a membrane, a glass support, a filter, a tissue culture dish, a polymeric material, a bead and a silica support.

10

- 24. A solid support comprising at least two oligonucleotides, wherein each of the oligonucleotides comprises a sequence that specifically hybridizes to a gene in Tables 3-9.
- 25. A solid support according to claim 24, wherein the oligonucleotides are covalently attached to the solid support.
 - 26. A solid support according to claim 24, wherein the oligonucleotides are non-covalently attached to the solid support.
- 27. A solid support according to claim 24, wherein the support comprises at least about 10 different oligonucleotides in discrete locations per square centimeter.
 - 28. A solid support according to claim 24, wherein the support comprises at least about 100 different oligonucleotides in discrete locations per square centimeter.

- 29. A solid support according to claim 24, wherein the support comprises at least about 1000 different oligonucleotides in discrete locations per square centimeter.
- 30. A solid support according to claim 24, wherein the support comprises at least about 10,000 different oligonucleotides in discrete locations per square centimeter.
 - 31. A computer system comprising:

10

25

-291-

(a) a database containing information identifying the expression level in liver tissue of a set of genes comprising at least two genes in Tables 3-9; and

- (b) a user interface to view the information.
- 5 32. A computer system of claim 31, wherein the database further comprises sequence information for the genes.
 - 33. A computer system of claim 31, wherein the database further comprises information identifying the expression level for the set of genes in normal liver tissue.

34. A computer system of claim 31, wherein the database further comprises information identifying the expression level of the set of genes in liver cancer tissue.

- 35. A computer system of claim 34, wherein the liver cancer tissue comprises hepatocellular carcinoma cells.
 - 36. A computer system of claim 34, wherein the liver cancer tissue comprises metastatic liver cancer cells.
- 20 37. A computer system of any of claims 31-36, further comprising records including descriptive information from an external database, which information correlates said genes to records in the external database.
 - 38. A computer system of claim 37, wherein the external database is GenBank.
 - 39. A method of using a computer system of any one of claims 31-36 to present information identifying the expression level in a tissue or cell of at least one gene in Tables 3-9, comprising:
- (a) comparing the expression level of at least one gene in Tables 3, 4, 5, 6, 8 or 3-9 in the tissue or cell to the level of expression of the gene in the database.

-292-

- 40. A method of claim 39, wherein the expression level of at least two genes are compared.
- 41. A method of claim 39, wherein the expression level of at least five genes are 5 compared.
 - 42. A method of claim 39, wherein the expression level of at least ten genes are compared.
- 10 43. A method of claim 39, further comprising displaying the level of expression of at least one gene in the tissue or cell sample compared to the expression level in liver cancer.

FIGURE 1




FIGURE 2A




FIGURE 2B





FIGURE 2C



(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 11 April 2002 (11.04.2002)

PCT

(10) International Publication Number WO 02/029103 A3

(51) International Patent Classification⁷: C12Q 1/68, G06F 19/00

(21) International Application Number: PCT/US01/30589

(22) International Filing Date: 2 October 2001 (02.10.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/237,054

2 October 2000 (02.10.2000) U


- (71) Applicant (for all designated States except US): GENE LOGIC, INC. [US/US]; 708 Quince Orchard Road, Gaithersburg, MD 20878 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): HORNE, Darci

[US/US]; 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). ALVARES, Christopher [US/US]; 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). PERES-DA-SILVA, Supriya [US/US]; 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). VOCKLEY, Joseph, G. [US/US]; 708 Quince Orchard Road, Gaithersburg, MD 20878 (US).

- (74) Agents: CARROLL, Lawrence, J. et al.; Morgan, Lewis & Bockius LLP, 1111 Pennsylvania Avenue, NW, Washington, DC 20004 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,

[Continued on next page]

(54) Title: GENE EXPRESSION PROFILES IN LIVER CANCER



(57) Abstract: The present invention identifies the global changes in gene expression associated with liver cancer by examining gene expression in tissue from normal liver, metastatic malignant liver and hepatocellular carcinoma. The present invention also identifies expression profiles which serve as useful diagnostic markers as well as markers that can be used to monitor disease states, disease progession, drug toxicity, druge efficacy and drug metabolism.

WO 02/029103 A3



SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau
- (88) Date of publication of the international search report: 4 September 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

THIS PAGE BLANK (USPTO)

PCT/US 01/30589

-4-							
A CLASSII IPC 7	C12Q1/68 G06F19/00		•				
According to	According to International Patent Classification (IPC) or to both national classification and IPC						
	SEARCHED						
	Minimum documentation searched (classification system followed by classification symbols)						
Documentat	ion searched other than minimum documentation to the extent that sa	ch documents are included in t	the fields searched				
Electronic da	ata base consutted during the international search (name of data bas	e and, where practical, search	terms used)				
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT						
Category °	Citation of document, with indication, where appropriate, of the rela	vant passages	Relevant to daim No.				
X	WO 99 13334 A (DEUTSCHES KREBSFORSCH; NEHRBASS DIRK (DE); BANNASCH PETER (DE); KL) 18 March 1999 (1999-03-18) see whole doc. esp. claims e.g. 6						
X	EP 0 857 780 A (SUMITOMO ELECTRIC 1-43 INDUSTRIES) 12 August 1998 (1998-08-12) see whole doc. esp. claims and p.2, 1.55ff.						
	-	/ 					
X Furth	ner documents are listed in the continuation of box C.	X Palent family member	s are listed in annex.				
*Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance with the application but cited to understand the principle or theory underlying the invention filing date "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered to work an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is somblined with one or more other such document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.		conflict with the application but niche or theory underlying the vance; the claimed invention all or cannot be considered to when the document is taken alone vance; the claimed invention volve an inventive step when the h one or more other such docu—					
later th		& document member of the sa					
	odual completion of the international search January 2003	Pate of mailing of the inter	nauxuau search report				
Name and n	nailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NI 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Mueller, F					

Internati Application No
PCT/US 01/30589

	PCT/US 01/30589		7 30303
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category •	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
X	DARABI A ET AL: "DIFFERENTIAL GENE EXPRESSION IN EXPERIMENTAL HEPATOCELLULAR CARCINOMA INDUCED BY WOODCHUCK HEPATITIS B VIRUS" CANCER LETTERS, NEW YORK, NY, US, vol. 95, no. 1-2, 1995, pages 153-159, XP000978529 ISSN: 0304-3835 the whole document		1-43
X			1-43

Inte: nal application No. rcT/US 01/30589

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: see FURTHER INFORMATION sheet PCT/ISA/210
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable dalms.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: claims 1-43 (partially)
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim(s) 1,2 as fas as an in vivo method is concerner are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. Although claims 3-14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: INVENTION 1 claims 1-43 (patially)

method of diagnosing liver cancer by detecting expression of gene collagen, type v,alpha and subject-matter as defined by the wording of claims 1-43 restricted to the mentioned gene sequence (Genbank AA055896)

2. Claims: INVENTION 2-3953 claims 1-43 (partially)

ibid. for sequences listed in tables 3-9 for each sequence separately

h nation on patent family members

Internat	Application No
PCT/us	01/30589

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9913334	Α	18-03-1999	DE 1	9739360 A	01-04-1999
EP 0857780	A	12-08-1998	WO	9710333 A	20-03-1997
WO 9939200	A	05-08-1999	AU	2480799 A	16-08-1999

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:	
☐ BLACK BORDERS	
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES	
FADED TEXT OR DRAWING	
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING	
☐ SKEWED/SLANTED IMAGES	
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS	
☐ GRAY SCALE DOCUMENTS	
LINES OR MARKS ON ORIGINAL DOCUMENT	
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY	

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER: _____

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.